
<html lang="en"     class="pb-page"  data-request-id="30520579-5999-451a-ae45-f37d01d6ff71"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;article:article:10.1021/acs.jmedchem.5b01273;wgroup:string:ACHS website Group;issue:issue:10.1021/jmcmar.2016.59.issue-8;website:website:acspubs;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="dc.Title" content="AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective" /></meta><meta name="dc.Creator" content="Samuel H.  Myers" /></meta><meta name="dc.Creator" content="Valerie G.  Brunton" /></meta><meta name="dc.Creator" content="Asier  Unciti-Broceta" /></meta><meta name="dc.Description" content="Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of cancer. It has not been until recently, however, that targeting AXL has come under the spotlight because of ..." /></meta><meta name="Description" content="Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of cancer. It has not been until recently, however, that targeting AXL has come under the spotlight because of ..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="November 20, 2015" /></meta><meta name="dc.Type" content="review-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.5b01273" /></meta><meta name="dc.Language" content="EN" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="© 2015 American Chemical Society" /></meta><meta name="citation_fulltext_world_readable" content=""/></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01273" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.5b01273" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.5b01273" /></link>
        
    
    

<title>AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.5b01273" /></meta><meta property="og:title" content="AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0011.jpeg" /></meta><meta property="og:description" content="Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of cancer. It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance. The entry of the first AXL-branded inhibitor in clinical trials in 2013 marked an important milestone for the clinical validation of AXL as an anticancer target. Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clinical development have AXL as either a prominent secondary or even the primary target. Through this review, the chemical and biological properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.5b01273"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.5b01273">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-14/achre4.2021.54.issue-14/20210720/achre4.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-29/aamick.2021.13.issue-29/20210728/aamick.2021.13.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-14/acncdm.2021.12.issue-14/20210721/acncdm.2021.12.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-7/amlcef.2021.3.issue-7/20210705/amlcef.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-29/acsodf.2021.6.issue-29/20210727/acsodf.2021.6.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-29/ascecg.2021.9.issue-29/20210726/ascecg.2021.9.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-29/ancham.2021.93.issue-29/20210727/ancham.2021.93.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-29/bichaw.2021.60.issue-29/20210727/bichaw.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-27/cgeabj.2021.99.issue-27/20210726-01/cgeabj.2021.99.issue-27.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-7/cgdefu.2021.21.issue-7/20210707/cgdefu.2021.21.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-14/esthag.2021.55.issue-14/20210720/esthag.2021.55.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-29/iecred.2021.60.issue-29/20210728/iecred.2021.60.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-14/inocaj.2021.60.issue-14/20210719/inocaj.2021.60.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-29/jafcau.2021.69.issue-29/20210728/jafcau.2021.69.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-29/jacsat.2021.143.issue-29/20210728/jacsat.2021.143.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-7/jamsef.2021.32.issue-7/20210707/jamsef.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-29/langd5.2021.37.issue-29/20210727/langd5.2021.37.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-7/mpohbp.2021.18.issue-7/20210705/mpohbp.2021.18.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.5b01273&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.5b01273&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.5b01273&amp;href=/doi/10.1021/acs.jmedchem.5b01273" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2016</span><span class="cit-fg-volume">, 59</span><span class="cit-fg-issue">, 8</span><span class="cit-fg-pageRange">, 3593-3608</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/59/8" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.5b01198" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Perspective</span><a href="/doi/10.1021/acs.jmedchem.5b01457" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective</span></h1><h2 class="article_header-subtitle"><span class="hlFld-SubTitle">Miniperspective</span></h2><ul class="loa non-jats-loa"><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Samuel+H.++Myers">Samuel H. Myers</a></span></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Valerie+G.++Brunton">Valerie G. Brunton</a></span></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor"><a href="/action/doSearch?field1=Contrib&amp;text1=Asier++Unciti-Broceta">Asier Unciti-Broceta</a></span><span class="author-xref-symbol "><sup>*</sup></span></span></li><span class="comma-separator"></span></ul><div class="affiliations"><div class="view-affs"><span class="title">View Author Information</span><i class="caret-icon icon-angle-down"></i></div><div class="all-aff-infos hlFld-Affiliation"><div class="aff-info" id="aff1"><span class="aff-text">Edinburgh Cancer Research UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div><div class="corresp-info"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#cf8ebca6aabde19aa1aca6bba6e28dbda0acaabbae8fa6a8a2a2e1aaabe1aeace1baa4"><span class="__cf_email__" data-cfemail="8acbf9e3eff8a4dfe4e9e3fee3a7c8f8e5e9effeebcae3ede7e7a4efeea4ebe9a4ffe1">[email protected]</span></a>. Phone: (0044)1316518702.</div></div></div><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01273&amp;href=/doi/10.1021%2Facs.jmedchem.5b01273" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2016</span></span><span class="cit-volume">, 59</span><span class="cit-issue">, 8</span><span class="cit-pageRange">, 3593–3608</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">November 10, 2015</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>14 August 2015</li><li><span class="item_label"><b>Published</b> online</span>20 November 2015</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 28 April 2016</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.5b01273" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.5b01273</a></div><div class="article_header-article-copyright"><strong>Copyright © 2015 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/page/rightslinkno.jsp">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"><a href="/page/policy/authorchoice_termsofuse.html"><img src="/pb-assets/images/programsLogos/OA_Icons_Ac-1612971054130.svg" alt="ACS AuthorChoice" /></img><span>ACS AuthorChoice</span></a></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.5b01273"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">21154</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">115</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.5b01273" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;AXL Inhibitors in Cancer: A Medicinal Chemistry Perspective&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Samuel&quot;,&quot;last_name&quot;:&quot;H. Myers&quot;},{&quot;first_name&quot;:&quot;Valerie&quot;,&quot;last_name&quot;:&quot;G. Brunton&quot;},{&quot;first_name&quot;:&quot;Asier&quot;,&quot;last_name&quot;:&quot;Unciti-Broceta&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2015&quot;,&quot;month&quot;:&quot;11&quot;,&quot;day&quot;:&quot;20&quot;,&quot;issue&quot;:&quot;8&quot;,&quot;volume&quot;:&quot;59&quot;,&quot;pages&quot;:&quot;3593-3608&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.5b01273&quot;},&quot;abstract&quot;:&quot;Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of cancer. It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance. The entry of the first AXL-branded inhibitor in clinical trials in 2013 marked an important milestone for the clinical validation of AXL as an anticancer target. Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clinical development have AXL as either a prominent secondary or even the primary target. Through this review, the chemical and biological properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01273&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01273" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01273&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01273" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.5b01273&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01273" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.5b01273&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.5b01273&amp;href=/doi/10.1021/acs.jmedchem.5b01273" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.5b01273" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.5b01273" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (4 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.5b01273&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.5b01273%26sid%3Dliteratum%253Aachs%26pmid%3D26555154%26genre%3Darticle%26aulast%3DMyers%26date%3D2016%26atitle%3DAXL%2BInhibitors%2Bin%2BCancer%253A%2BA%2BMedicinal%2BChemistry%2BPerspective%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D59%26issue%3D8%26spage%3D3593%26epage%3D3608%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=290896" title="Cells">Cells</a>,</li><li><a href="/action/doSearch?ConceptID=292528" title="Inhibitors">Inhibitors</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292258" title="Cancer">Cancer</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/59/8" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/jmcmar.2016.59.issue-8/20160428/jmcmar.2016.59.issue-8.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="f_tgr1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">Dysregulation of the AXL receptor tyrosine kinase has been associated with many types of cancer. It has not been until recently, however, that targeting AXL has come under the spotlight because of ever accumulating evidence of its strong correlation with poor prognosis and drug resistance. The entry of the first AXL-branded inhibitor in clinical trials in 2013 marked an important milestone for the clinical validation of AXL as an anticancer target. Nevertheless, to weigh the current contribution and potential future impact of AXL inhibition in the clinic, it is fundamental to recognize that several kinase inhibitors approved or in clinical development have AXL as either a prominent secondary or even the primary target. Through this review, the chemical and biological properties of the main inhibitors targeting AXL (either intentionally or unintentionally) will be discussed, along with the prospects and challenges to translate AXL inhibitors into a bona fide therapeutic option.</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i1">1 Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_61261" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_61261" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Receptor tyrosine kinases (RTKs) are multidomain transmembrane proteins that function as sensors for extracellular ligands. Ligand receptor binding induces receptor dimerization and activation of their intracellular kinase domain, leading to the recruitment, phosphorylation, and activation of multiple downstream signaling cascades.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> To date, 58 RTKs have been identified in the human genome, which regulate a broad range of cellular processes, including cell survival, growth, differentiation, proliferation, adhesion, and motility.<a onclick="showRef(event, 'ref1 ref2'); return false;" href="javascript:void(0);" class="ref ref1 ref2">(1, 2)</a></div><div class="NLM_p last">In 1991 Bryan and co-workers were the first to report the discovery of an unidentified transforming gene, eventually named <i>AXL</i>, from two patients with chronic myeloid leukemia (CML).<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> The AXL protein (also known as UFO, ARK, and TYRO7) was later classified as a RTK belonging to the TAM (<u class="uu">T</u>YRO3, <u class="uu">A</u>XL, and <u class="uu">M</u>ER) subfamily. Since then, overexpression or overactivation of the AXL protein has been correlated with the promotion of multiple tumorigenic processes. High levels of AXL expression have been associated with poor prognosis in different cancers such as glioblastoma multiforme,<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> breast<a onclick="showRef(event, 'ref5'); return false;" href="javascript:void(0);" class="ref ref5">(5)</a> and lung<a onclick="showRef(event, 'ref6'); return false;" href="javascript:void(0);" class="ref ref6">(6)</a> cancer, osteosarcoma,<a onclick="showRef(event, 'ref7'); return false;" href="javascript:void(0);" class="ref ref7">(7)</a> and acute myeloid leukemia.<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> In addition, it has been demonstrated that abnormal activation of AXL signaling is one prominent mechanism by which tumor cells undergo epithelial–mesenchymal transition (EMT)<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> and develop drug resistance to both targeted therapies<a onclick="showRef(event, 'ref10 ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref10 ref11 ref12">(10-12)</a> and chemotherapy.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> EMT is a process consisting of multiple biochemical changes by which polarized epithelial cells gain a mesenchymal cell phenotype, leading to increased migration and invasive properties. In cancer, EMT biomarkers are a hallmark of invading cells and consequently cancer metastases.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9, 10)</a> Accumulating evidence supporting the role of AXL in cancer together with the first entry of a selective AXL inhibitor in clinical trials<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> has brought AXL inhibitors to the center of pharma interests. As some excellent articles have recently reviewed the biological role of AXL in cancer,<a onclick="showRef(event, 'ref16 ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19">(16-19)</a> the aim of this review is to complement them by focusing on the most significant medicinal chemistry developments and challenges found on the pharmacological targeting of AXL kinase activity with small molecules.</div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">2 The AXL/GAS6 Axis</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_46577" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_46577" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3">2.1 Structure of AXL and Its Major Ligand GAS6</h3><div class="NLM_p">Proteins within the TAM family contain a β-stranded N terminal lobe consisting of two immunoglobulin (Ig) like domains and two fibronectin type III (FTIII) repeats which comprise the extracellular region. This is connected via a transmembrane region to a helical C terminal lobe that contains an intracellular kinase domain<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a). TAM family members TYRO3 (aka BRT, DTK, RSE, SKY, and TIF) and MER (aka MERTK, RP38, and TYRO12) can bind to two vitamin K-dependent extracellular ligands, protein S and the growth arrest specific protein 6 (GAS6). Of these two ligands, AXL has been shown to bind only GAS6, a secreted protein of 75 kDa (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>a).<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The affinity of TAM proteins for the ligand GAS6 is different, following the ranking of affinity AXL > TYRO3 > MER. AXL possesses around 10-fold superior affinity for GAS6 than MER.<a onclick="showRef(event, 'ref17'); return false;" href="javascript:void(0);" class="ref ref17">(17)</a> Apart from protein S and GAS6, additional extracellular ligands for TAM receptors have been recently discovered such as TUBBY, TULP-1, and galectin-3,<a onclick="showRef(event, 'ref20 ref21'); return false;" href="javascript:void(0);" class="ref ref20 ref21">(20, 21)</a> while evidence so far suggest that AXL can only be activated by GAS6 and TULP-1.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0002.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) AXL kinase and its extracellular ligand GAS6. (b) Types of AXL activation: (1) GAS6 ligand-dependent activation of AXL; (2) ligand independent activation of AXL; (3) heterophilic activation of AXL with a non-TAM family protein; (4) heterophilic activation of AXL with MER or TYRO3; (5) transcellular ligand independent activation of AXL. (c) Downstream AXL signaling pathways upon classical GAS6-mediated activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec2_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i4" class="anchor-spacer"></div><h3 class="article-section__title" id="_i4">2.2 Receptor Activation and Downstream Signaling</h3><div class="NLM_p">AXL can be activated by a variety of mechanisms (<a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>b), the most common being the ligand dependent activation in which AXL binds with GAS6 to form a dimer complex consisting of two AXL molecules bound to two GAS6 molecules. Other activation mechanisms can occur such as ligand independent activation,<a onclick="showRef(event, 'ref22'); return false;" href="javascript:void(0);" class="ref ref22">(22)</a> which tends to happen when AXL is greatly overexpressed or under oxidative stress, e.g., ligand independent AXL activation in vascular smooth muscle cells.<a onclick="showRef(event, 'ref23'); return false;" href="javascript:void(0);" class="ref ref23">(23)</a> Heterophilic activation of AXL with either TYRO3 or MER has been hypothesized. While there is no evidence yet of AXL/MER interactions,<a onclick="showRef(event, 'ref24'); return false;" href="javascript:void(0);" class="ref ref24">(24)</a> it has been recently shown that AXL and TYRO3 heterodimerize or coexist in the same molecular complex in chronic lymphocytic leukemia B-cells.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> GAS6-independent heterophilic dimerization with non-TAM kinases such as VEGFR1 has also been observed,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> which represents an alternative resistance mechanism developed in response to anti-VEGFR1 therapy. Lastly, transcellular homophilic binding of the extracellular domains of AXL has been proven, where the extracellular binding of the AXL protein causes cell aggregates leading to increased AXL kinase activity.<a onclick="showRef(event, 'ref27'); return false;" href="javascript:void(0);" class="ref ref27">(27)</a> Under physiological conditions, maximal stimulation of TAM RTKs including AXL is achieved in the presence of the specific protein ligand and an extracellular lipid moiety, the lipid phosphatidylserine (PtdSer). While PtdSer is an abundant phospholipid ubiquitously present in the membrane of all cells, it is mostly found in the inner layer, pointing its polar head toward the cytoplasm, due to the action of a class of enzymes called flippases.<a onclick="showRef(event, 'ref28'); return false;" href="javascript:void(0);" class="ref ref28">(28)</a> PtdSer becomes available to activate TAM receptors only when externalized on the cell membranes in apoptotic cells, aggregating platelets, exosomes and invading virus envelopes.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div><div class="NLM_p last">Dimer formation promotes autophosphorylation of tyrosine residues on the intracellular region of AXL, most prominently on Y779, Y821, and Y866.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> The phosphorylated kinase domain then activates downstream proteins by cross-phosphorylation, and various signaling cascades take place. The main signaling pathways activated by the GAS6/AXL axis are shown in <a class="ref internalNav" href="#fig1" aria-label="Figure 1">Figure 1</a>c. AXL activation causes phosphorylation of GRB2, which subsequently activates the RAS-RAF-MEK-ERK pathway leading to cancer cell proliferation.<a onclick="showRef(event, 'ref29'); return false;" href="javascript:void(0);" class="ref ref29">(29)</a> AXL also phosphorylates PI3K, thus leading to increased levels of phosphatidylinositol trisphosphate and resulting in recruitment and activation of AKT. AKT is then responsible for the activation of multiple prosurvival proteins, such as IKK, MDM2, or mTOR, and the inactivation of proapoptotic signals such as the BCL-2 family member BAD. Direct AXL-mediated phosphorylation of SRC or through crosstalk with other RTK and the subsequent activation of FAK leads to the promotion of migration and invasiveness.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> As mentioned, apart from downstream pathways, AXL has also been shown to exhibit crosstalk with numerous RTK such as VEGFR,<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> EGFR,<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> and MET,<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> which highlights the complexity of the regulatory role of the AXL receptor and underlines the plausible involvement of AXL in different mechanisms of drug resistance observed in some cancers. In addition, AXL and other TAM proteins play a significant role in inflammatory processes;<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a> this is due to the phosphorylation of AXL causing the upregulation of SOCS proteins and STAT-1.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a> The importance and implications of the TAM family in inflammatory events and disease will be further discussed in the last section of this review.</div></div><div id="sec2_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5">2.3 AXL in Cancer</h3><div class="NLM_p">Overexpressed levels of AXL have been found in numerous cancer types and in most cases high AXL expression correlates with a poorer patient prognosis. <i>AXL</i> gene expression is mediated by SP1/SP3 transcription factors and modulated by CpG methylation of its promoter.<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> In addition, the expression of the AXL receptor is post-transcriptionally regulated by two specific microRNAs, miR-34a and miR-199a/b, the expression of which is suppressed by promoter methylation in several solid tumors (e.g., non-small-cell lung cancer (NSCLC), colorectal cancer, breast cancer).<a onclick="showRef(event, 'ref34'); return false;" href="javascript:void(0);" class="ref ref34">(34)</a></div><div class="NLM_p">In NSCLC, interest in AXL as a potential oncology target has risen in recent years due to the involvement of AXL upregulation in resistance to EGFR-targeted therapy<a onclick="showRef(event, 'ref10'); return false;" href="javascript:void(0);" class="ref ref10">(10)</a> along with evidence of AXL crosstalk with EGFR.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> EGFR-driven tumors are typically treated with erlotinib (structure not disclosed), a potent EGFR inhibitor; however, these tumors can develop resistance with one major cause of this thought to be associated with AXL overexpression.<a onclick="showRef(event, 'ref35'); return false;" href="javascript:void(0);" class="ref ref35">(35)</a> It has been demonstrated that continuous EGFR inhibition ultimately induces GAS6 upregulation, hence causing increased AXL activity. These data are further supported by increased levels of AXL, GAS6, and protein S being found in over 50% of NSCLC cell lines, with AXL and MER being the most phosphorylated RTKs in NSCLC cells.<a onclick="showRef(event, 'ref36'); return false;" href="javascript:void(0);" class="ref ref36">(36)</a> AXL upregulation tends to correlate with lymph node metastasis and poorer patient survival.<a onclick="showRef(event, 'ref37'); return false;" href="javascript:void(0);" class="ref ref37">(37)</a> In vitro knockdown studies have shown that inhibition of <i>AXL</i> causes a decrease in the growth of NSCLC cells and a significant reduction of migration and invasiveness.<a onclick="showRef(event, 'ref38'); return false;" href="javascript:void(0);" class="ref ref38">(38)</a></div><div class="NLM_p">AXL is generally expressed at low concentrations in healthy breast tissue, while in the advanced stages of breast cancer levels of AXL expression are significantly increased, particularly in ER+ cells,<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> and correlate with a highly invasive phenotype.<a onclick="showRef(event, 'ref40'); return false;" href="javascript:void(0);" class="ref ref40">(40)</a> In breast cancers, overactivation of AXL signaling is further enhanced by the progesterone receptor B through upregulation of GAS6 and it has been reported that HER2 can also activate AXL signaling.<a onclick="showRef(event, 'ref41'); return false;" href="javascript:void(0);" class="ref ref41">(41)</a> Lorens and co-workers showed that RNAi knockdown of <i>AXL</i> in triple negative breast cancer models reduces tumor growth and metastases in mice.<a onclick="showRef(event, 'ref42'); return false;" href="javascript:void(0);" class="ref ref42">(42)</a> Other studies have also shown the importance of AXL inhibition in breast cancer cell migration.<a onclick="showRef(event, 'ref43'); return false;" href="javascript:void(0);" class="ref ref43">(43)</a> The pathological role of AXL in breast cancer is also evidenced by its association with resistance to lapatinib (structure not disclosed) in HER2+ breast cancer.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><div class="NLM_p">Several studies have found high levels of phosphorylated AXL and GAS6 in many glioblastoma cell lines, which are biomarkers that generally correlate with poorer prognosis and cancer recurrence.<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> In vivo studies have shown that tumor growth is significantly reduced in tumors that have AXL inhibited, showing a less invasive phenotype with an increased overall survival of the animals.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Keating et al. also found that <i>AXL</i> mRNA levels and protein expression are elevated in astrocytic patient samples and cell lines.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> RNAi-mediated silencing of AXL RTK expression led to a significant increase in chemosensitivity of astrocytic cells (including glioblastoma cells) in response to temozolomide, carboplatin, and vincristine treatment (structures not disclosed), suggesting scope for combination therapy with a variety of traditional cytotoxic agents.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a></div><div class="NLM_p">In prostate cancer there has been shown to be a direct correlation between the malignancy of the disease and GAS6/AXL expression in undifferentiated metastatic human prostatic cancer cells, which leads to activation of AKT and MAPK phosphorylation.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a></div><div class="NLM_p last">Originally discovered in AML (acute myeloid leukemia), AXL has therefore been long proposed as a therapeutic target for this disease. AML cells induce secretion of GAS6 by bone marrow–derived stromal cells which then activates AXL, stimulating cell survival and drug resistance.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> It has been shown that inhibition of AXL in AML results in the improvement of clinically relevant indicators, suggesting AXL inhibitors could be used on their own or in combination therapy to treat AML.</div></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i6">3 AXL Inhibitors</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_28221" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_28221" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">While a wide range of kinase inhibitors that target the AXL RTK have been described in the literature (see list in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), in most cases AXL was not the intended primary target but a secondary consequence of the similarities among the kinase domains of AXL and other RTK such as MET or MER. Consequently, many of those inhibitors often exhibit less potency for AXL than against its main target. Inhibitors falling into this category are cabozantinib (<b>2</b>)<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> and bosutinib (<b>8</b>),<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> drugs approved by the FDA for the treatment of medullary thyroid cancer and CML, respectively, or the drug candidate foretinib (<b>1</b>).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Interestingly, the opposite case has also been described, e.g., the MET-branded inhibitor BMS-777607 (<b>5</b>),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> the potency of which is 3-fold greater against AXL than against MET in vitro. The first inhibitor reported to be purposely developed as an AXL selective inhibitor was BGB324 (<b>17</b>),<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> which also holds the questionable honor of being considered the first AXL inhibitor to enter clinical trials.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a></div><div class="NLM_p">It is important to note that much of the kinase inhibition data available in the literature were generated in vitro using the corresponding recombinant proteins. While cell-free assays provide a practical screening tool for in-house drug discovery programs, reported biochemical data need to be used with caution due to the lack of correlation with cell activity. Consequently, inhibitory activity in cells (rather than biochemical data) represents the optimal data source to directly compare the potency of different inhibitors. Unfortunately, the activity of kinase inhibitors in cells is not always reported. Biochemical and cell activity data (when available) of the main AXL inhibitors reported to date are compiled in <a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>.</div><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Summary of the Main AXL Inhibitors and Their Target Kinases</div></div></div><div class="scrollable-table-wrap"><table class="table" border="0"><colgroup><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col><col align="left" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">compd</th><th class="colsep0 rowsep0" align="center">drug (code name)</th><th class="colsep0 rowsep0" align="center">primary target</th><th class="colsep0 rowsep0" align="center">AXL inhibition</th><th class="colsep0 rowsep0" align="center">developer/sponsor</th><th class="colsep0 rowsep0" align="center">phase of development<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>1</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Foretinib (XL880, GSK1363089)</td><td class="colsep0 rowsep0" rowspan="2" align="left">MET, VEGFR2, AXL, RON</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 11 nM <a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a></td><td class="colsep0 rowsep0" align="left">GSK</td><td class="colsep0 rowsep0" rowspan="2" align="left">Phase II, active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) < 100 nM <a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>2</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Cabozantinib (XL184, BMS-907351, marketed as Cometriq)</td><td class="colsep0 rowsep0" rowspan="2" align="left">VEGFR2, MET, MEK, KIT, RET, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 7 nM <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Exelixis Inc./various, including NCI and Memorial Sloan Kettering Cancer Center</td><td class="colsep0 rowsep0" align="left">Approved for medullary thyroid cancer</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 42 nM <a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a></td><td class="colsep0 rowsep0" align="left">Phase II and III for different solid tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>3</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Merestinib (LY2801653)</td><td class="colsep0 rowsep0" rowspan="2" align="left">MET, MST1R, DDR1, TIE1, MER, TYRO3, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 11 nM <a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Eli Lilly and Co.</td><td class="colsep0 rowsep0" rowspan="2" align="left">Phase I, active, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 2 nM <a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>4</b></td><td class="colsep0 rowsep0" align="left">MGCD265</td><td class="colsep0 rowsep0" align="left">MET, AXL, VEGFR2,</td><td class="colsep0 rowsep0" align="left">Data for AXL not reported</td><td class="colsep0 rowsep0" align="left">Mirati Therapeutics</td><td class="colsep0 rowsep0" align="left">Phase I, active, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>5</b></td><td class="colsep0 rowsep0" align="left">ASLAN002 (BMS-777607)</td><td class="colsep0 rowsep0" align="left">AXL, RON, MET, TYRO3, MER, FLT3</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 1.1 nM <a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></td><td class="colsep0 rowsep0" align="left">Bristol-Myers Squibb/Aslan Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">Phase I, active, not recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>6</b></td><td class="colsep0 rowsep0" align="left">NPS-1034</td><td class="colsep0 rowsep0" rowspan="2" align="left">AXL, DDR1, FLT3, KIT, MEK, MET, ROS1, and TIE1</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 10 nM <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td><td class="colsep0 rowsep0" align="left">NeoPharm</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) < 0.5 μM <a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>7</b></td><td class="colsep0 rowsep0" align="left">LDC1267</td><td class="colsep0 rowsep0" align="left">MET, AXL, TYRO3</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 19 nM <a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></td><td class="colsep0 rowsep0" align="left">Lead Discovery Centre</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>8</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Bosutinib (SKI-606, marketed as Bosulif)</td><td class="colsep0 rowsep0" rowspan="2" align="left">BCR-ABL, ABL, SRC, YES, MEK, AXL, BMX</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 0.56 μM <a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td><td class="colsep0 rowsep0" align="left">Pfizer</td><td class="colsep0 rowsep0" align="left">Approved for CML with resistance to treatment</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 0.34–1.65 μM <a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a></td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phase II and III for different CML stages</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>9</b></td><td class="colsep0 rowsep0" align="left">Gilteritinib (ASP2215)</td><td class="colsep0 rowsep0" align="left">FLT3 and mutants, ALK, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) < 1 nM <a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a></td><td class="colsep0 rowsep0" align="left">Astellas Pharma Global</td><td class="colsep0 rowsep0" align="left">Phase I/II, active, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>10</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">SGI-7079</td><td class="colsep0 rowsep0" rowspan="2" align="left">MET, MER, YES, RET, FLT3, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 58 nM <a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Tolero Pharmaceuticals/Astex Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) < 1 μM <a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>11</b></td><td class="colsep0 rowsep0" align="left">TP-0903</td><td class="colsep0 rowsep0" rowspan="2" align="left">Aurora A and B, JAK2, ALK, ABL, AXL, MER</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 27 nM <a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Huntsman Cancer Institute/Tolero Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 222 nM <a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a></td><td class="colsep0 rowsep0" align="left"> </td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>12</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Crizotinib (PF-02341066, marketed as Xalkori)</td><td class="colsep0 rowsep0" rowspan="2" align="left">ALK, MET, RON, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 294 nM <a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Pfizer/Further clinical sponsors include NCI, EORTC, etc.</td><td class="colsep0 rowsep0" align="left">Approved for NSCLC</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phase II/III for different solid tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>13</b></td><td class="colsep0 rowsep0" align="left">Amuvatinib (MP470)</td><td class="colsep0 rowsep0" align="left">KIT, PDGFR1, FLT3, RET, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) < 1 μM <a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a></td><td class="colsep0 rowsep0" align="left">Astex Pharmaceuticals</td><td class="colsep0 rowsep0" align="left">Phase II, development discontinued</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>14</b></td><td class="colsep0 rowsep0" align="left">UNC2025</td><td class="colsep0 rowsep0" align="left">MER, FLT3, AXL, TYRO3</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 1.6 nM <a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a></td><td class="colsep0 rowsep0" align="left">University of North Carolina</td><td class="colsep0 rowsep0" align="left">Preclinical</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>15</b></td><td class="colsep0 rowsep0" align="left">S49076</td><td class="colsep0 rowsep0" rowspan="2" align="left">MET and mutants, AXL, MER, FGFRs</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 7 nM <a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Institut de Recherches Internationales Servier</td><td class="colsep0 rowsep0" rowspan="2" align="left">Phase I, active, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) = 56 nM<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>16</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">Sunitinib (SU11248, marketed as Sutent)</td><td class="colsep0 rowsep0" rowspan="2" align="left">KIT, FLT3, PDGFR, VEGFR2, AXL</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 9 nM <a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Pfizer/Further clinical sponsors include NCI, Baylor Breast Care Center, M.D. Anderson Cancer Center, etc.</td><td class="colsep0 rowsep0" align="left">Approved for renal cell carcinoma, imatinib-resistant gastrointestinal stromal tumor, and metastatic pancreatic neuroendocrine tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">Phase II/III for different solid tumors</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"><b>17</b></td><td class="colsep0 rowsep0" rowspan="2" align="left">BGB324 (R428)</td><td class="colsep0 rowsep0" rowspan="2" align="left">AXL (selective)</td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in vitro) = 14 nM <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td><td class="colsep0 rowsep0" rowspan="2" align="left">Rigel Pharmaceuticals/BerGen BIO</td><td class="colsep0 rowsep0" rowspan="2" align="left">Phase I/II, active, recruiting</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left"> </td><td class="colsep0 rowsep0" align="left">IC<sub>50</sub> (in cells) < 30 nM <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a></td></tr></tbody></table></div></div><div class="NLM_p">Since the discovery of allosteric AXL inhibitors has not yet been reported, all kinase inhibitors described in this review are ATP-competitive inhibitors having either type I or type II binding modes. Type I inhibitors bind to the ATP site of the kinase in its active conformation (aspartate–phenylalanine–glycine (DFG) motif oriented toward the active site or DFG-in), being the most common mode of binding. Both type I and type II inhibitors typically contain an adenine-mimicking heterocyclic moiety that binds to the hinge region of the ATP site. However, type II inhibitors adopt an extended conformation via interactions with DFG residues of the activation loop to enter an allosteric region (adjacent to the ATP binding site) that is only accessible in the inactive DFG-out conformation of the kinase.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a> Therefore, while the complex formed by type II inhibitors and the inactive conformation of the kinase impede substrate-enzyme binding (=enzymatic competition), ATP molecules and type II inhibitors bind to different conformations of the kinase catalytic site. The type II binding mode is generally attributed to provide inhibitors that display superior selectivity profile. However, such a general assumption has been disputed by some authors.<a onclick="showRef(event, 'ref54'); return false;" href="javascript:void(0);" class="ref ref54">(54)</a></div><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i8" class="anchor-spacer"></div><h3 class="article-section__title" id="_i8">3.1 Type II Kinase Inhibitors</h3><div class="NLM_p">Compound <b>1</b> is a MET/VEGFR2 inhibitor (IC<sub>50</sub> = 0.4 and 0.9 nM in cell-free assays, respectively) in clinical development (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>). Cocrystallization of <b>1</b> with the MET kinase domain shows that the inhibitor occupies both the ATP binding site and an adjacent pocket of the inactive conformation of the kinase.<a onclick="showRef(event, 'ref55'); return false;" href="javascript:void(0);" class="ref ref55">(55)</a> After validation of its safety in healthy volunteers during phase I,<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a><b>1</b> went on to stage II clinical trials for lung, papillary renal carcinoma, hepatocellular carcinoma, and refractory gastric cancer. All trials but one have now been completed.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> No phase III trials have yet been initiated. While the anticancer properties of compound <b>1</b> are attributed to MET and VEGFR2 inhibition, <b>1</b> inhibits other kinases such as AXL at the low nanomolar level (IC<sub>50</sub> = 11 nM in cell free assay).<a onclick="showRef(event, 'ref51'); return false;" href="javascript:void(0);" class="ref ref51">(51)</a> Inhibitor <b>1</b> has been reported to lead to almost complete inhibition of AXL phosphorylation in lapatinib-resistance breast cancer cells at 100 nM and to restore sensitivity to lapatinib (structure not disclosed) in treated cells.<a onclick="showRef(event, 'ref44'); return false;" href="javascript:void(0);" class="ref ref44">(44)</a></div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0003.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of type II kinase inhibitors in clinical and preclinical development that target the AXL RTK.<a onclick="showRef(event, 'ref49 ref51 ref52 ref59 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref49 ref51 ref52 ref59 ref60 ref61 ref62">(49, 51, 52, 59-62)</a> The hinge-binding heterocycles are displayed at the left side of the structures. The chemically related structural motifs that connect the “head” heterocycle with the terminal phenyl ring (in red) are highlighted in blue. Note that all compounds but <b>4</b> present a fluoro atom at the para position of the terminal phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p"><b>2</b> is an extremely potent VEGFR2 inhibitor (IC<sub>50</sub> = 0.035 nM, in cell-free assays) that also inhibits a wide number of kinases, including MET, KIT, RET, and AXL, in the low nanomolar range.<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> In 2012 the FDA gave approval for its use in medullary thyroid cancer with orphan drug status.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> A number of clinical trials sponsored by different parties are ongoing for a wide variety of indications, including NSCLC and cancers of prostate, kidney, breast, pancreas, and ovaries.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> This orally available drug inhibits the kinase activity of human recombinant MET and AXL with IC<sub>50</sub> = 1.3 and 7 nM, respectively, i.e., 35- to 200-fold lower potency than for its main target VEGFR2 in biochemical assays. On the basis of the cell-free inhibition data of <b>2</b>, this compound could in principle be considered a selective VEGFR2 inhibitor. In cells, however, <b>2</b> inhibits phosphorylation of VEGFR2, MET, and AXL at much closer concentrations (IC<sub>50</sub> values of 1.9, 7.8, and 42 nM, respectively),<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> which delineates the limitations of relying only on biochemical data to evaluate and rank on- and off-target activities. A phase II study (NCT01639508) with inhibitor <b>2</b> is currently ongoing in patients with advanced NSCLC whose tumors present one of the following gene changes: RET, ROS1, NTRK fusion or increased MET or AXL activity.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a> A randomized, open-label phase III study of <b>2</b> versus everolimus (structure not disclosed) in patients with advanced renal cell carcinoma has just been reported (NCT01865747).<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> The study concluded that progression-free survival was longer with inhibitor <b>2</b> than everolimus (structure not disclosed) for patients that had relapsed after VEGFR-targeted therapy and highlighted the multitargeting capabilities of the drug as partly responsible for its excellent response rate.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>, the chemical structures of inhibitors <b>1</b> and <b>2</b> are almost identical. Significant structural similarities are also found in related kinase inhibitors such as LY2801653 (<b>3</b>),<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> MGCD265 (<b>4</b>),<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a><b>5</b>,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> NPS-1034 (<b>6</b>),<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and LDC1267 (<b>7</b>)<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> (see chemical moieties highlighted in blue and red in <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), which may explain why all these compounds strongly inhibit a common subset of RTKs, including MET, VEGFR2, MER, and AXL. Inhibitor <b>3</b> is a potent MET inhibitor that targets several RTKs (MST1R, MER, TYRO3, AXL, etc.) at the low nanomolar range both in biochemical assays and in cells (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> Eli Lilly and Co. has recently completed phase I trials for inhibitor <b>3</b> in healthy volunteers and is currently recruiting for a safety study in patients with advanced cancer in combination with cisplatin, cetuximab, gemcitabine, and ramucirumab (structures not disclosed).<a onclick="showRef(event, 'ref59'); return false;" href="javascript:void(0);" class="ref ref59">(59)</a> The goal of this phase I study is to find the recommended phase II dose of <b>3</b> that may be safely given to patients with selected advanced cancers in combination with chemotherapy and/or immunotherapy. Another related drug candidate, <b>4</b>, a potent inhibitor of MET, VEGFR-2, and other RTKs (IC<sub>50</sub> = 1–10 nM, in biochemical assays),<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> also entered several phase I studies with healthy volunteers and patients with advanced malignancies under the sponsorship of Mirati Therapeutics. A trial is active and recruiting to evaluate the safety of daily doses of the drug in advanced cancer patients. Preliminary results of this study reported that a NSCLC patient with <i>AXL</i> gene amplification responded very well (∼50% lesion reduction) after just four daily doses of <b>4</b>,<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> indicating that certain <i>AXL</i> abnormalities may be clinically relevant oncogenic drivers in NSCLC.</div><div class="NLM_p"><b>5</b> is a drug candidate developed by Bristol Myers-Squibb that strongly inhibits MET, AXL, and MER RTKs. X-ray crystal structure of <b>5</b> complexed with the MET kinase domain shows that the inhibitor binds at the ATP pocket of the MET kinase with the activation loop in a DFG-out (inactive) conformation (see <a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> The 2-aminopyrimidine core anchors the inhibitor to the hinge region via two hydrogen bonds, whereas the central phenyl ring and 2-pyridone group interact by π-stacking and H-bonding with the phenylalanine and glutamate residues, respectively, of the DGF motif (<a class="ref internalNav" href="#fig3" aria-label="Figure 3">Figure 3</a>). Analogous mode of binding was observed for inhibitors <b>1</b> and <b>3</b>. While <b>5</b> was rationally designed to inhibit MET (IC<sub>50</sub> = 3.9 nM, in biochemical assays), its inhibitory potency against AXL is actually higher (IC<sub>50</sub> = 1.1 nM, in biochemical assays),<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> meaning that <b>5</b> is the most potent in vitro inhibitor that has the AXL kinase as its primary target. This compound went through phase I and II clinical trials for advanced or metastatic solid tumors. While the results have not yet been reported, Aslan Pharmaceuticals is now sponsoring a new phase I study in cancer patients to identify the maximum tolerated dose of <b>5</b>.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0004.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of <b>5</b> bound to the inactive conformation of MET kinase domain (left panel)<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and main binding interactions of the inhibitor (right panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Besides the above-mentioned drugs and clinical candidates, two additional structurally related inhibitors targeting AXL have recently been reported, <b>6</b><a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> and <b>7</b>.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Both compounds contain some of the key features found in other previously mentioned AXL inhibitors, i.e., the central phenyl ring and the terminal <i>p</i>-fluorophenyl moiety in this case connected through a carboxamidopyrazole linker (<a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), groups that are likely to be involved in type II binding.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> While these compounds are still in preclinical development, they have displayed remarkable activities against chemoresistant cell lines and metastasis. Compound <b>6</b>, developed by NeoPharm, shows significant inhibitory activity against multiple RTK including AXL, DDR1, FLT3, KIT, MEK, MET, ROS1, and TIE1. IC<sub>50</sub> against human recombinant MET and AXL was 48 and 10 nM, respectively.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a><b>6</b> demonstrated inhibition of AXL signaling in NSCLC cells with acquired resistance to EGFR-tyrosine kinase inhibitors. Significantly, treatment of these resistant cell lines with <b>6</b> restored the sensitivity of the cells to gefitinib and erlotinib (structures not disclosed), resulting in induction of cell death.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a> Inhibitor <b>7</b> inhibits the three members of the TAM family in cells at low nanomolar levels. Treatment of wild-type natural killer (NK) cells with <b>7</b> efficiently enhanced antimetastatic NK cell activity in vivo.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i9" class="anchor-spacer"></div><h3 class="article-section__title" id="_i9">3.2 Type I Kinase Inhibitors</h3><div class="NLM_p">Inhibitor <b>8</b> is used in the clinic for the treatment of adult patients with CML after resistance or intolerance to prior therapy due to its capacity to inhibit most imatinib-resistant forms of the BCR-ABL fusion protein. However, <b>8</b> is a promiscuous kinase inhibitor that also inhibits other proteins such as SRC, ABL, MEK, and BMX with IC<sub>50</sub> = 1–10 nM.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Through screening of chemical libraries in the search for inhibitors of AXL signaling, Zhang et al. discovered that <b>8</b> also inhibits GAS6-mediated tyrosine phosphorylation of AXL in Hs578T breast cancer cells (IC<sub>50</sub> = 0.34 μM, similar levels to those found for SRC inhibition in the same cell line) and inhibited cell motility and invasiveness.<a onclick="showRef(event, 'ref66'); return false;" href="javascript:void(0);" class="ref ref66">(66)</a> In this respect, the inhibitory properties of compound <b>8</b> can be considered unique, since it targets both receptor and nonreceptor tyrosine kinases that are dysregulated in many types of cancer. Studies by Yuan et al.<a onclick="showRef(event, 'ref50'); return false;" href="javascript:void(0);" class="ref ref50">(50)</a> have shown that <b>8</b> mediates inhibition of AXL signaling in hepatocellular carcinoma cells and decreases their invasiveness by suppressing the expression of the EMT-inducing transcription factor SLUG, further suggesting that the distinct polypharmacological properties of <b>8</b> may become beneficial in the treatment of various cancer indications and, in particular, metastasis.</div><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig2" aria-label="Figures 2">Figures 2</a> and <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a>, the chemical similarities between the structures of compound <b>8</b> and inhibitors <b>1</b> and <b>2</b> are remarkable. The three inhibitors contain a 6-methoxyquinoline core with substitutions on the positions C4 and C7 of the heterocycle. Inhibitor <b>1</b> can be considered a hybrid molecule between <b>2</b> and <b>8</b>, since it has a morpholinopropyloxy group at the C7 position, like <b>8</b>, and it shares with <b>2</b> the same substituted fluorophenyloxy motif at the C4 position of the quinoline. While all three compounds contain a central phenyl group that, in principle, could π-stack with the Phe of the inactivation loop of the enzyme, compound <b>8</b> lacks the key cyclopropyl-1,1-dicarboxamide linkage and the terminal <i>p</i>-fluorophenyl group required to access the hydrophobic pocket of the DFG-out conformation of kinases. According to the cocrystal structure of <b>8</b> with the ABL kinase domain (<a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>),<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> compound <b>8</b> is a type I kinase inhibitor. Interestingly, compound <b>8</b> shares some structural similarities with other inhibitors of the AXL RTK, such as gilteritinib (<b>9</b>),<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> SGI-7079 (<b>10</b>),<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a> and TP-0903 (<b>11</b>)<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> (see <a class="ref internalNav" href="#fig4" aria-label="Figure 4">Figure 4</a>). Although there is not yet any X-ray structural information or biochemical assay addressing the mode of binding of <b>9</b>–<b>11</b> to AXL or related kinases, based on their structures they are likely to be type I inhibitors. The differences in AXL activity among these compounds could become useful to initiate novel medicinal chemistry campaigns.</div><figure id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0005.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of multikinase type I inhibitors <b>8</b>–<b>11</b> and cocrystal structure of <b>8</b> bound to the active conformation of ABL kinase (reproduced from  <cite>Trends in Pharmacological Sciences</cite>, Vol. <em>36</em>, <contrib-group>Wu, P.; Nielsen, T. E.; Clausen, M. H.</contrib-group>FDA-approved small-molecule kinase inhibitors, pp 422–439, Copyright <span class="NLM_year">2015</span>, with permission from Elsevier<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a>). Shared chemical motifs are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Compound <b>9</b> is a highly potent inhibitor of FLT3 (including mutant forms) and AXL with subnanomolar IC<sub>50</sub>.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> The compound exhibits potent antileukemic activity against AML with either or both FLT3-ITD and FLT3-D835 mutations.<a onclick="showRef(event, 'ref69'); return false;" href="javascript:void(0);" class="ref ref69">(69)</a> Under the sponsorship of Astellas Pharma, <b>9</b> is currently undergoing clinical trials (phase I/II) to assess its safety and tolerability, including the maximum tolerated dose alone and in combination with chemotherapy, in subjects with relapsed or treatment-refractory AML.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div><div class="NLM_p"><b>10</b> is a relatively potent AXL inhibitor (IC<sub>50</sub> = 58 nM, in cell-free assays) in preclinical development that also targets MET, MER, YES, RET, and FLT3 at a similar concentration range.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a><b>10</b> inhibits GAS6-stimulated AXL signaling in inflammatory breast cancer cells (IC<sub>50</sub> < 1 μM), resulting in decreased cell proliferation and invasion.<a onclick="showRef(event, 'ref70'); return false;" href="javascript:void(0);" class="ref ref70">(70)</a> Byers et al. at the MD Anderson Cancer Center identified AXL as a potential therapeutic target for overcoming EGFR inhibitor resistance associated with the mesenchymal phenotype and demonstrated that treatment with inhibitor <b>10</b> sensitized lung cancer cells to erlotinib (structure not disclosed), particularly in an acquired resistance setting.<a onclick="showRef(event, 'ref9'); return false;" href="javascript:void(0);" class="ref ref9">(9)</a></div><div class="NLM_p"><b>11</b> is an AXL-branded inhibitor developed by Bearss and co-workers at the Huntsman Cancer Institute<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> that is currently under preclinical development by Tolero Pharmaceuticals. The compound, which was rationally designed using a homology model of the AXL active site, inhibits AXL with an IC<sub>50</sub> = 27 nM (biochemical assays) but also other kinases such as Aurora A and B, JAK2, ALK, and ABL at even lower concentrations. In fact, cell cycle studies have revealed that the inhibitor induced strong cell cycle arrest by inhibition of Aurora A and B.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Recent studies have shown that <b>11</b> is effective in inducing apoptosis of B-cell chronic lymphocytic leukemia (CLL) cells as a single agent at nanomolar concentrations and found a synergistic effect with BTK inhibitors.<a onclick="showRef(event, 'ref25'); return false;" href="javascript:void(0);" class="ref ref25">(25)</a> In the same work they demonstrated that CLL B-cells not only express constitutively active AXL but also increased levels of TYRO3, although AXL was found to be the predominant TAM RTK regulating CLL B-cell survival.</div><div class="NLM_p">Crizotinib (<b>12</b>,<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> see <a class="ref internalNav" href="#fig5" aria-label="Figure 05">Figure 05</a>) is a clinically approved orally bioavailable inhibitor of RTKs including MET, ALK, and AXL (IC<sub>50</sub> = 8, 20, and 294 nM, respectively, in biochemical assays). Pfizer developed this ATP-competitive inhibitor through a structure-based drug design strategy using the MET kinase domain for cocrystallization experiments.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a><b>12</b> potently inhibits cancer cell growth of cell lines harboring fusion variants and activating mutations of ALK<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> and also exhibits antiangiogenic properties.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> Clinical studies of <b>12</b> in ALK-rearranged NSCLC rapidly demonstrated significant activity and clinical benefit,<a onclick="showRef(event, 'ref75 ref76'); return false;" href="javascript:void(0);" class="ref ref75 ref76">(75, 76)</a> which led to its early approval by the FDA in 2011.<a onclick="showRef(event, 'ref77'); return false;" href="javascript:void(0);" class="ref ref77">(77)</a> In a recent phase III clinical study of patients with ALK-rearranged NSCLC with metastasis in the brain, treatment with <b>12</b> was associated with systemic and intracranial disease control at 12 weeks of therapy.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> However, following this period, acquired resistance to <b>12</b> was commonly observed, leading to the development of preexisting or new intracranial metastatic lesions.<a onclick="showRef(event, 'ref78'); return false;" href="javascript:void(0);" class="ref ref78">(78)</a> Clinical studies of <b>12</b> against several cancers with ALK rearrangements or mutations including metastatic NSCLC, anaplastic large cell lymphoma, myofibroblastic tumor, and neuroblastoma are currently ongoing under different sponsorships.<a onclick="showRef(event, 'ref77 ref55'); return false;" href="javascript:void(0);" class="ref ref77 ref55">(77, 55)</a></div><div class="NLM_p">Amuvatinib (<b>13</b>)<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> is a promiscuous type I kinase inhibitor targeting KIT, PDGFR1, FLT3, RET, and AXL developed by Astex Pharmaceuticals. In MDA-MB-231 cells, it has been shown that this compound inhibits phosphorylation of AXL at 1 μM.<a onclick="showRef(event, 'ref79'); return false;" href="javascript:void(0);" class="ref ref79">(79)</a> Inhibition of AXL using <b>13</b> reversed EMT in murine breast cancer stem cells, reducing self-renewal and restoring sensitivity to chemotherapy.<a onclick="showRef(event, 'ref80'); return false;" href="javascript:void(0);" class="ref ref80">(80)</a> After phase I evaluation in patients with solid tumors,<a onclick="showRef(event, 'ref81'); return false;" href="javascript:void(0);" class="ref ref81">(81)</a><b>13</b> entered a phase II clinical trial in patients with NSCLC in combination with standard of care chemotherapy (platinum and etoposide, structures not disclosed). Despite favorable safety and preliminary clinical activity in the first stage of this phase II, Astex Pharmaceuticals announced discontinuation of its clinical development in 2012.</div><figure id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0006.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of type I AXL inhibitors <b>12</b>–<b>17</b>. Shared chemical motifs between compounds <b>15</b> and <b>16</b> are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">UNC2025 (<b>14</b>)<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> is a promising preclinical candidate developed by Wang and co-workers at the University of North Carolina. It is a dual MER/FLT3 type I inhibitor (IC<sub>50</sub> < 1 nM, in cell-free assays for both kinases) that blocks AXL kinase activity with an in vitro IC<sub>50</sub> of 1.6 nM.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> In animal models, oral administration of <b>14</b> resulted in target inhibition in bone marrow leukemia cells.<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> This compound derives from a previous MER/FLT3 inhibitor, UNC1062 (<b>35</b>,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> see <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), which was shown to reduce activation of MER-mediated downstream signaling in melanoma cells, inducing apoptosis in culture and inhibiting invasion.<a onclick="showRef(event, 'ref84'); return false;" href="javascript:void(0);" class="ref ref84">(84)</a> On the basis of the remarkable capacity of <b>14</b> and some of its early derivatives to target AXL, its development program will be the focus of further discussions in following sections.</div><div class="NLM_p">S49076 (<b>15</b>)<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> is an ATP-competitive inhibitor of MET, AXL, MER, and FGFRs (<a class="ref internalNav" href="#fig5" aria-label="Figure 05">Figure 05</a>) that targets AXL at low nanomolar levels both in vitro (IC<sub>50</sub> = 7 nM) and in cells (IC<sub>50</sub> = 56 nM, in murine embryonic fibroblasts engineered to express human AXL). The molecule was designed using a structure-based approach in the search for potent and selective MET inhibitors and its mode of binding inferred by X-ray resolution of cocrystal complexes of <b>15</b> analogs with MET.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a> Its chemical structure closely resembles that of sunitinib (<b>16</b>),<a onclick="showRef(event, 'ref86'); return false;" href="javascript:void(0);" class="ref ref86">(86)</a> a potent multitargeted RTK inhibitor approved for the treatment of different cancer indications that also inhibits AXL at the low nanomolar range (IC<sub>50</sub> = 9 nM).<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a><b>15</b> displays potent antiproliferative properties in MET- and FGFR2-dependent gastric cancer cells and inhibits migration of lung carcinoma cells. <b>15</b> potently inhibits phosphorylation of MET, AXL, and FGFRs in tumor xenograft models. Combination of inhibitor <b>15</b> with bevacizumab (structure not disclosed) in xenograft models of colorectal cancer resulted in near total suppression of tumor growth, and remarkably, <b>15</b> alone induced arrest of tumor growth in bevacizumab-resistant tumors. A phase I dose-escalation study of <b>15</b> (oral administration) is currently undergoing in patients with advanced solid tumors to establish its safety profile.<a onclick="showRef(event, 'ref85'); return false;" href="javascript:void(0);" class="ref ref85">(85)</a></div><div class="NLM_p last"><b>17</b> was the first kinase inhibitor to be intentionally designed to target the AXL RTK (see <a class="ref internalNav" href="#fig5" aria-label="Figure 05">Figure 05</a>).<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> It inhibits AXL in an ATP-competitive manner in the low nanomolar range (IC<sub>50</sub> = 14 nM) and displays significant selectivity (>40-fold) toward MER and TYRO3 (TAM family members) and other kinases including ABL and MET,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> thus formally being the only selective AXL inhibitor reported to date. Hollande et al. showed that <b>17</b> is able to block AXL-dependent events in cells, including AKT phosphorylation, invasiveness of breast cancer cells, and the production of proinflammatory cytokines. Oral treatment with <b>17</b> in mouse xenograft models demonstrated a dose-dependent reduction of the EMT transcriptional regulator SNAIL and extended survival (>35%) in a MDA-MB-231 intracardiac mouse model of breast cancer metastasis.<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> Additionally, combination with cisplatin (structure not disclosed) enhanced reduction of liver micrometastases in a murine model. Originally developed by Rigel Inc.,<a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a> it was licensed to BerGen BIO in 2011 which is currently conducting two phase I clinical trials,<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> one of which received FDA orphan-drug designation for the treatment of AML. These trials are aimed at evaluating the safety and tolerability of the drug in AML and NSCLC patients when administered as a single agent and in combination with cytarabine and erlotinib (structures not disclosed), respectively.<a onclick="showRef(event, 'ref56'); return false;" href="javascript:void(0);" class="ref ref56">(56)</a></div></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10">3.3 Discovery of Dual MET/AXL Inhibitor <b>5</b></h3><div class="NLM_p">As discussed above, compound <b>5</b> is a MET inhibitor showing 3-fold greater potency for AXL than for MET in biochemical assays. The development of this drug candidate, which shares significant similarities with other type II kinase inhibitors such as <b>1</b> or <b>3</b> (see <a class="ref internalNav" href="#fig2" aria-label="Figure 2">Figure 2</a>), was carried out at Bristol Myers-Squibb. Encouraged by the potent inhibitory properties of pyrrolo[2,1-<i>f</i>][1,2,4]triazine-based compounds,<a onclick="showRef(event, 'ref88'); return false;" href="javascript:void(0);" class="ref ref88">(88)</a> Schroeder, Borzilleri, and co-workers utilized this scaffold in the search for MET inhibitors. In silico modeling followed by library synthesis and in vitro screening led to potent MET inhibitors with poor pharmacokinetic properties.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Subsequent investigations focused on the substitution of the pyrrolotriazine scaffold by a pyrrolopyrimidine, which led to potent MET inhibitors <b>18</b> and <b>19</b> (see <a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> While the malonamide derivative <b>19</b> inhibited the target with superior potency, the <i>N</i>-acylurea, <b>18</b>, showed higher antiproliferative activity in a MET-driven human gastric carcinoma cell line (GTL-16 cells).<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> The substitution of the malonamide group by a conformationally constrained 3-carboxamido-2-pyridone ring led to a dramatic increment in MET inhibition and superior antiproliferative activity in MET-dependent GTL-16 cells.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> 2-Pyridone derivative <b>20</b><a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> also inhibited FLT3 and VEGFR2 at low nanomolar concentration and demonstrated good in vivo efficacy in a GLT-16 xenograft model.</div><figure id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0007.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Development of the ATP-competitive (type II), orally available, dual MET/AXL inhibitor <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">The success with the 2-pyridone fragment motivated the team to explore it on derivatives containing a 2-aminopyridine scaffold instead of the pyrrolopyridine one. <i>N</i>-Acylureas containing the 2-aminopyridine scaffold had previously demonstrated good inhibitory properties against MET but also potent inhibition of cytochrome P450 (CYP) isozymes.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Novel derivative <b>21</b>,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> which displayed high inhibition of MET kinase activity, served as a starting point for SAR studies. On the basis of the X-ray structure of derivative <b>20</b>,<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> it was hypothesized that substitutions at the C3 position of the pyridine group could provide access to the ribose pocket of the ATP binding site. Different groups were therefore introduced in that position aiming to improve potency, solubility, and CYP inhibition profile. Introduction of an <i>N</i>-methylpiperazinylmethyl moiety at C3 provided a soluble derivative (derivative <b>22</b>,<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a><a class="ref internalNav" href="#fig6" aria-label="Figure 6">Figure 6</a>) with good on-target potency but low activity in cells. Substitutions by smaller, more rigid groups such as aminopropargyl, hydroxypropargyl, or unsubstituted propargyl groups led to a slight increase of MET inhibitory properties and superior antiproliferative activity in MET-dependent GLT-16 cells. Further optimization of DMPK properties resulted in inhibitor <b>5</b>, an orally available type II inhibitor with excellent half-life that inhibits AXL with an IC<sub>50</sub> = 1.1 nM (biochemical assays).<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a></div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i11" class="anchor-spacer"></div><h3 class="article-section__title" id="_i11">3.4 Medicinal Chemistry Campaigns for the Discovery of <b>14</b> and Related Compounds</h3><div class="NLM_p">Overexpression of the MER RTK is strongly associated with acute lymphoblastic leukemia (ALL). While MER is not expressed in normal human T lymphocytes at any stage of development, it is found ectopically expressed in over 50% of pediatric T-cell ALL.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Compound <b>52</b> (<b>26</b>,<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a><a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>), a polysubstituted purine derivative originally developed in Schultz’ lab, is a weak inhibitor of MER (IC<sub>50</sub> = 11.3 μM), the complex of which was cocrystallized with the MER protein and the structure resolved by Dhe-Paganon and co-workers.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> This information was used by Wang and co-workers to create a docking model for MER inhibition.<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> On the basis of this model, they proposed a trisubstituted pyrazolopyrimidine scaffold to search for novel MER inhibitors (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Preliminary SAR studies found that compounds <b>27</b> and <b>28</b>,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> both containing a 4-aminocyclohexylmethyl group in R<sub>2</sub>, displayed nanomolar activity against MER, with the trans isomer having 3-fold superior potency than the cis one. Given the similarities of MER with other members of the TAM subfamily, compounds were also screened against AXL and TYRO3. As shown in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>, compounds <b>27</b> and <b>28</b> displayed slightly lower activity for AXL than for MER. Exploration of different alkylamino groups in the position R<sub>3</sub> of the ring showed that the larger the alkyl group, the higher the selectivity of the compound for MER. Introduction of the small methylamino group at R<sub>3</sub> generated highly potent AXL inhibitors such as compound <b>29</b>,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> the only compound of the series with higher affinity for AXL than MER. Among the range of aromatic substituents explored at the R<sub>1</sub> position, a 4-piperazinylphenyl group was found to be optimal for AXL inhibition (see compounds <b>29</b> and <b>31</b> in <a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> The trans isomers were found to be the most active ones across the libraries, with the most potent MER inhibitor (compound <b>31</b>, IC<sub>50</sub> = 0.15 nM, in cell-free assays) possessing a phenylpropylamino group in R<sub>3</sub>. All compounds were found to be ATP competitive inhibitors. Due to its lower molecular weight, UNC569 (<b>32</b>,<a onclick="showRef(event, 'ref95'); return false;" href="javascript:void(0);" class="ref ref95">(95)</a> with IC<sub>50</sub> = 2.9 and 37 nM for MER and AXL, respectively) was the inhibitor chosen for further PD/PK analysis, showing inhibition of MER phosphorylation in cells (IC<sub>50</sub> = 141 nM in human pre-B leukemia 697 cells) and good oral bioavailability (57%).</div><figure id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0008.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Medicinal chemistry campaigns for the discovery of TAM inhibitor <b>14</b> and related compounds by Wang and co-workers.<a onclick="showRef(event, 'ref82 ref83 ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref95 ref96 ref97">(82, 83, 95-97)</a> MER-compound <b>52</b> cocrystal structure was adapted from Huang et al.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> from <i>Journal of Structural Biology</i>, Elsevier, under the Creative Commons License Deed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">From this point two distinct medicinal chemistry campaigns were followed. A new family of potent MER inhibitors was developed by using a pseudo-ring replacement strategy (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>).<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> From the new derivatives generated, compound <b>33</b><a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> was the most potent against AXL (IC<sub>50</sub> = 38 nM in biochemical assays), while the MER-targeting lead compound of the series, UNC2250 (<b>34</b>),<a onclick="showRef(event, 'ref96'); return false;" href="javascript:void(0);" class="ref ref96">(96)</a> displayed good selectivity and PK profile, potent inhibition of MER phosphorylation in cells, and antiproliferative activity in a NSCLC cell line. Following studies on that scaffold led to UNC2881<a onclick="showRef(event, 'ref97'); return false;" href="javascript:void(0);" class="ref ref97">(97)</a> (structure not disclosed), a potent highly selective MET inhibitor that demonstrated inhibition of platelet aggregation in collagen-stimulated human platelet-rich plasma. In parallel, optimization studies on the scaffold of inhibitor <b>32</b> proceeded toward increasing MER selectivity and DMPK properties (<a class="ref internalNav" href="#fig7" aria-label="Figure 7">Figure 7</a>). Studies resulted in the MER inhibitor <b>35</b>,<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> which shows high selectivity (>75-fold) over other TAM kinases, and the drug candidate <b>14</b>,<a onclick="showRef(event, 'ref82'); return false;" href="javascript:void(0);" class="ref ref82">(82)</a> a dual MER/FLT3 inhibitor with subnanomolar potency (but low selectivity over AXL and TYRO3) that displays excellent oral bioavilability (100%) and the capacity to inhibit MER phosphorylation in vivo in leukemic blasts of mouse bone marrow.</div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12">3.5 Discovery of AXL-Selective Inhibitor <b>17</b></h3><div class="NLM_p">As mentioned before, <b>17</b> is the most selective AXL inhibitor reported to date and the first one to progress to clinical trials based on its AXL inhibitory properties.<a onclick="showRef(event, 'ref15'); return false;" href="javascript:void(0);" class="ref ref15">(15)</a> The number of studies reported in the literature with this drug candidate is limited to biological studies.<a onclick="showRef(event, 'ref12 ref53 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref12 ref53 ref98 ref99">(12, 53, 98, 99)</a> Apart from the original patent published by Rigel Inc. in 2010,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> no other chemical report has yet become public. The patent application is thus the only source available to shed some light on how <b>17</b> was developed and review the structural requirements for the AXL inhibition activity of this interesting multicyclic [1,2,4]triazole-based compound.</div><figure id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0009.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Synthesis of the specific AXL inhibitor <b>17</b> from commercial starting materials <b>36</b> and <b>39</b>.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">As shown in <a class="ref internalNav" href="#fig8" aria-label="Figure 8">Figure 8</a>, the strategy to prepare inhibitor <b>17</b> consists of the generation of the polycyclic synthons <b>38</b> and <b>41</b> (by five- and six-step synthetic processes, respectively) from commercial starting materials, followed by a cyclocondensation reaction to form the central triazole of <b>17</b>.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> This relatively straightforward strategy enabled Holland et al. to replace the pyrrolidine group on the cycloheptan ring of intermediate <b>37</b><a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> with different moieties. SAR analyses showed that an amino group was required in that position for inhibiting AXL (<a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a>), with dialkylated and cyclic amines providing the highest AXL inhibition activities.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> When the amino group was masked as a carbamate, affinity for AXL was significantly reduced. It is also notable that halogens or amino groups functionalized with large cyclic structures were not well tolerated at that position. Twenty-six out of 56 compounds based on scaffold I exhibited submicromolar IC<sub>50</sub> values, showing the versatile potency of the scaffold. Three derivatives based on scaffold II were also synthesized, while only the one shown in <a class="ref internalNav" href="#fig9" aria-label="Figure 9">Figure 9</a> exhibited AXL inhibition at the submicromolar range.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></div><figure id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0010.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical scaffolds investigated by Holland et al. in the search for specific AXL inhibitors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">After the publication of the highly focused patent application that describes <b>17</b> and derivatives,<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a> the same team at Rigel Pharmaceuticals Inc. filed divisional patent applications for new AXL inhibitors.<a onclick="showRef(event, 'ref100 ref101'); return false;" href="javascript:void(0);" class="ref ref100 ref101">(100, 101)</a> The protected structures also contain the central triazole group representative of this unique class of compounds, while the chemical variety of substituents used in each of those patents have been significantly expanded. It is therefore likely to expect that the discovery of novel selective AXL inhibitors will be reported at some point in the future.</div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13">3.6 General Considerations with Regard to the Use of Current AXL Inhibitors in Cancer Treatment</h3><div class="NLM_p">The interest of Pharma and the research community in AXL inhibitors as anticancer agents has dramatically increased over the past 10 years. Given the amount of evidence supporting the role of AXL in cancer and the increasing number of AXL-targeting candidates entering clinical trials, it is likely that such interest will continue to rise in the years to come. After a review of the state-of-the-art, however, it seems clear that the main barrier that could potentially block the generation of clinically useful AXL inhibitors is their selectivity profile. The majority of inhibitors of AXL kinase activity also inhibit other protein kinases, preferentially RTKs. This is due to the considerable similarities among the intracellular kinase domains of RTKs,<a onclick="showRef(event, 'ref102'); return false;" href="javascript:void(0);" class="ref ref102">(102)</a> which are very significant not only within the members of the TAM subfamily (TYRO3, AXL, and MER), but also among other RTKs such as MET, FLT3, RON, and Aurora A/B.<a onclick="showRef(event, 'ref67 ref71 ref103 ref104'); return false;" href="javascript:void(0);" class="ref ref67 ref71 ref103 ref104">(67, 71, 103, 104)</a> Consequently, the discovery of ATP-competitive kinase inhibitors displaying cross-reactivity for multiple RTKs has been and will continue to be a widespread phenomenon, whereas selectivity over other groups of kinases should be expected.<a onclick="showRef(event, 'ref105'); return false;" href="javascript:void(0);" class="ref ref105">(105)</a> Due to the complexity of cancer pathology, a certain level of promiscuity may actually become an advantage in cases where inhibiting more than one target can lead to a synergistic effect for treatment. For instance, this may be one of the reasons behind the remarkable clinical response mediated by the VEGFR2/MET/AXL inhibitor <b>2</b> in patients with advanced renal cell carcinoma.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> However, in other cases a poor selectivity profile will result in the inhibition of kinases that are essential for physiological functions and, consequently, in severe side effects.<a onclick="showRef(event, 'ref106'); return false;" href="javascript:void(0);" class="ref ref106">(106)</a> This issue may become a challenging one, since an AXL inhibitor will rarely be employed in the clinic on its own, and drug combinations usually lead to incremental adverse effects.</div><div class="NLM_p">Interestingly, across the list of inhibitors described in this article (<a class="ref internalNav" href="#tbl1" aria-label="Table 1">Table 1</a>), something can be concluded: contrary to the general assumption, type II kinase inhibitors provided no benefit in terms of selectivity over type I inhibitors. A potential way to improve the selectivity profile of AXL inhibitors would be to focus on the development of either allosteric or irreversible inhibitors.<a onclick="showRef(event, 'ref107 ref108'); return false;" href="javascript:void(0);" class="ref ref107 ref108">(107, 108)</a> Nonetheless, the unique properties of inhibitor <b>17</b> proves that ATP-competitive inhibitors with adequate selectivity profile and AXL potency can certainly be generated.</div><div class="NLM_p last">Due consideration to the immunoregulatory role of AXL, MER, and TYRO3 is also essential to understand the limitations of a potential anti-AXL therapy. Studies by Lu and Lemke reported that TAM triple knockout mice develop broad-spectrum autoimmunity and a severe lymphoproliferative disorder.<a onclick="showRef(event, 'ref109'); return false;" href="javascript:void(0);" class="ref ref109">(109)</a> Bosurgi et al. showed that ablation of AXL and MER signaling in mice favors a tumor-promoting environment in the colon by increasing production of proinflammatory cytokines and reducing clearance of apoptotic neutrophils in the intestines.<a onclick="showRef(event, 'ref110'); return false;" href="javascript:void(0);" class="ref ref110">(110)</a> On the other hand, the role of TAM receptors in diminishing the innate immune response makes their inhibition an attractive mechanism to reverse the immunosuppressive tumor microenvironment.<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a> Furthermore, it has been demonstrated that tumor-macrophage cross-talk is responsible for stimulating the macrophage secretion of GAS6 in the tumor microenvironment, which in turn foster tumor growth by activation of TAM RTKs, particularly AXL.<a onclick="showRef(event, 'ref111'); return false;" href="javascript:void(0);" class="ref ref111">(111)</a> Consequently, while chronic inhibition of TAM family members, particularly MER, could eventually result in autoimmune side effects,<a onclick="showRef(event, 'ref19 ref24'); return false;" href="javascript:void(0);" class="ref ref19 ref24">(19, 24)</a> the benefit provided by the temporary use of AXL inhibitors for cancer treatment would considerably overcome the associated risks. To minimize detrimental autoimmune responses, it may be particularly useful to generate further AXL inhibitors with selectivity over the other TAM members MER and TYRO3, the role of which seems to be more important in immunoregulation.<a onclick="showRef(event, 'ref19'); return false;" href="javascript:void(0);" class="ref ref19">(19)</a></div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i14">4 Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02552" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02552" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">The shift of the Pharma industry and the medical community toward personalized cancer medicine and genotype-guided therapeutic intervention is causing an ever-increasing need for both single- and multitargeted inhibitors.<a onclick="showRef(event, 'ref112'); return false;" href="javascript:void(0);" class="ref ref112">(112)</a> While the number of treatable patients can significantly decrease with the use of drugs that selectively target proteins involved in specific cancer types, the effectiveness and safety of these targeted therapies can be far greater. However, since cancer survival and progression are typically driven in most malignancies by more than one protein or signaling pathway, the clinical use of targeted monotherapies normally becomes insufficient to fully control or eliminate the disease.<a onclick="showRef(event, 'ref113'); return false;" href="javascript:void(0);" class="ref ref113">(113)</a> Furthermore, resistance mechanisms typically arise to both chemotherapeutics and targeted therapies through mutations or activation of additional proteins or signaling pathways.<a onclick="showRef(event, 'ref114'); return false;" href="javascript:void(0);" class="ref ref114">(114)</a> Due to their pathological and etiological complexity, pharmacological interventions based on combination strategies will be essential to effectively treat those cancers.<a onclick="showRef(event, 'ref113 ref114'); return false;" href="javascript:void(0);" class="ref ref113 ref114">(113, 114)</a> However, the shortage of highly selective targeted agents against many relevant oncotargets is limiting the development of drug combinations with acceptable safety profiles. As more and more proteins involved in neoplasia and/or chemoresistance mechanisms are uncovered and their roles elucidated, the need for targeted inhibitors becomes ever greater.</div><div class="NLM_p">The prominent role of AXL in the survival, spread, and mechanisms of drug resistance in different solid and blood cancers strongly supports the choice of AXL inhibition as an anticancer strategy, especially for advanced disease.<a onclick="showRef(event, 'ref16 ref17 ref18 ref19 ref115'); return false;" href="javascript:void(0);" class="ref ref16 ref17 ref18 ref19 ref115">(16-19, 115)</a> Consequently, various drug candidates targeting AXL are currently under clinical development, and more are expected to come. Preliminary clinical evidence in a NSCLC patient with <i>AXL</i> gene amplification receiving treatment with AXL/MET inhibitor <b>4</b> has shown that <i>AXL</i> abnormalities may be clinically relevant oncogenic drivers in certain forms of NSCLC.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> These particular cancer types could represent the primary clinical indication for AXL-targeted monotherapy. However, since cases where AXL is the main driver of the cancer are rare, AXL inhibitors would be most beneficial as combination partners. For example, strong evidence indicates that AXL inhibition could significantly benefit anti-EGFR, anti-HER2, or anti-VEGFR therapies.<a onclick="showRef(event, 'ref26 ref35 ref44'); return false;" href="javascript:void(0);" class="ref ref26 ref35 ref44">(26, 35, 44)</a> AXL inhibitors also have the potential to impact cancer metastasis, but translating this into clinical trials is currently problematic. Therefore, at the moment AXL inhibitors show more promise in the treatment of resistant disease. AXL upregulation is one prominent mechanism whereby chemoresistance develops in different cancers,<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13, 14)</a> therefore strongly indicating that AXL inhibitors could synergize in the clinic with standard-of-care chemotherapeutics such as cisplatin (structure not disclosed). If AXL targeting drugs with adequate selectivity profile are developed and synergistic drug combinations established, they could provide cancer patients with new therapeutic options to fight the latest and most aggressive forms of cancer.</div><div class="NLM_p last">As reviewed in this article, there are currently just a few drug candidates that have AXL as its primary target and only one reported clinical candidate can be considered as a selective AXL inhibitor. One of the challenges we face for the de novo design of AXL inhibitors is the lack of crystallographic data for the kinase domain of the AXL RTK. Given the growing demand for small molecule inhibitors targeting AXL activity, this limitation will certainly be addressed in the near future. Nonetheless, until this information becomes available, ligand-based approaches provide one useful route to develop AXL inhibitors with improved properties. This comprehensive review of the state-of-the-art is an effort to promote and facilitate medicinal chemistry activities in such a direction.</div></div><div class="NLM_back"><div class="article_supporting-info" id=""></div><div class="testing" data-doi="10.1021/acs.jmedchem.5b01273" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_41718" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_41718" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Asier Unciti-Broceta</span> - <span class="hlFld-Affiliation affiliation">Edinburgh Cancer Research
UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span>; 
    <span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#e3a2908a8691cdb68d808a978acea1918c80869782a38a848e8ecd8687cd8280cd9688"><span class="__cf_email__" data-cfemail="c786b4aea2b5e992a9a4aeb3aeea85b5a8a4a2b3a687aea0aaaae9a2a3e9a6a4e9b2ac">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Samuel H. Myers</span> - <span class="hlFld-Affiliation affiliation">Edinburgh Cancer Research
UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Valerie G. Brunton</span> - <span class="hlFld-Affiliation affiliation">Edinburgh Cancer Research
UK Centre, MRC Institute of Genetics and Molecular Medicine, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, U.K.</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>All authors have given approval to the final version of the manuscript.</p></li><li></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="bio" rid="ath1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="biographies">Biographies</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_14571" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_14571" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><figure id="ath1" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Samuel H. Myers</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=BIO-d3660e2224-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Samuel H. Myers</b> received his M.Chem. in Chemistry from The University of Huddersfield (U.K.) in 2013. He is currently a doctoral student at the Institute of Genetic and Molecular Medicine at the University of Edinburgh (U.K.) under the supervision of Dr. Asier Unciti-Broceta. His research focuses on the development and optimization of novel small molecule kinase inhibitors.</p></figure></div><div class="bio" rid="ath2"><figure id="ath2" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Valerie G. Brunton</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=BIO-d3660e2229-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Valerie G. Brunton</b> received her Ph.D. in Pharmacology from the University of Aberdeen (U.K.) in 1990. After postdoctoral work in the field of preclinical drug development and cancer biology, she joined the University of Edinburgh (U.K.) in 2007, where she has been Professor of Cancer Therapeutics since 2013.</p></figure></div><div class="bio" rid="ath3"><figure id="ath3" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Asier Unciti-Broceta</h2><div class="figure-bottom-links"><div class="download-hi-res-img"></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=BIO-d3660e2234-autogenerated"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><b>Asier Unciti-Broceta</b> received his Ph.D. in Medicinal Chemistry from the Universidad of Granada (Spain) in 2004. After postdoctoral work in the fields of cell delivery and chemical biology in the School of Chemistry of the University of Edinburgh (U.K.), he joined the Institute of Genetics and Molecular Medicine (U.K.) in 2010, where he is a Reader and Head of the Innovative Therapeutics Lab at the Edinburgh Cancer Research UK Centre.</p></figure></div><div class="ack" id="ACK-d3660e2242-autogenerated"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i19">Acknowledgment</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_35320" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_35320" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank Scottish Power and CRUK for funding. A.U.-B. thanks the IGMM for an Academic Fellowship.</p></div><div class="postAsapNotesSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="postAsapNotesSection">Note Added After ASAP Publication</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_02063" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_02063" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="first last">The version of this paper that was published ASAP November 20, 2015, contained errors in Figure 2. The corrected version was reposted February 11, 2016.</p></div><div id="" class="NLM_sec NLM_sec_level_1"><div id="ac_i20" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i20"> </h2><div class="NLM_p last"><table summary="" class="NLM_def-list" id="dl1"><div id="ac_i21" class="anchor-spacer"></div><h2 class="article-section__title section__title" id="_i21"> Abbreviations Used</h2><tr><td class="NLM_term">RTK</td><td class="NLM_def"><p class="first last">receptor tyrosine kinase</p></td></tr><tr><td class="NLM_term">TAM</td><td class="NLM_def"><p class="first last">TYRO3, AXL, and MER</p></td></tr><tr><td class="NLM_term">GAS6</td><td class="NLM_def"><p class="first last">growth arrest-specific 6</p></td></tr><tr><td class="NLM_term">EMT</td><td class="NLM_def"><p class="first last">epithelial–mesenchymal transition</p></td></tr><tr><td class="NLM_term">CML</td><td class="NLM_def"><p class="first last">chronic myeloid leukemia</p></td></tr><tr><td class="NLM_term">PtdSer</td><td class="NLM_def"><p class="first last">phosphatidylserine</p></td></tr><tr><td class="NLM_term">CpG</td><td class="NLM_def"><p class="first last">cytosine–phosphate–guanine</p></td></tr><tr><td class="NLM_term">RNAi</td><td class="NLM_def"><p class="first last">RNA interference</p></td></tr><tr><td class="NLM_term">ER+</td><td class="NLM_def"><p class="first last">estrogen receptor-positive</p></td></tr><tr><td class="NLM_term">DFG</td><td class="NLM_def"><p class="first last">aspartate–phenylalanine–glycine</p></td></tr><tr><td class="NLM_term">ATP</td><td class="NLM_def"><p class="first last">adenosine triphosphate</p></td></tr><tr><td class="NLM_term">NSCLC</td><td class="NLM_def"><p class="first last">non-small-cell lung carcinoma</p></td></tr><tr><td class="NLM_term">IC<sub>50</sub></td><td class="NLM_def"><p class="first last">half maximal inhibitory concentration</p></td></tr><tr><td class="NLM_term">FDA</td><td class="NLM_def"><p class="first last">Food and Drug Administration</p></td></tr><tr><td class="NLM_term">NK</td><td class="NLM_def"><p class="first last">natural killer</p></td></tr><tr><td class="NLM_term">AML</td><td class="NLM_def"><p class="first last">acute myeloid leukemia</p></td></tr><tr><td class="NLM_term">CYP</td><td class="NLM_def"><p class="first last">cytochrome P450</p></td></tr><tr><td class="NLM_term">ALL</td><td class="NLM_def"><p class="first last">acute lymphoblastic leukemia</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">DMPK</td><td class="NLM_def"><p class="first last">drug metabolism and pharmacokinetic</p></td></tr><tr><td class="NLM_term">AACR</td><td class="NLM_def"><p class="first last">American Association for Cancer Research</p></td></tr></table></div></div><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_38486" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_38486" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 115 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. F.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase family of the human genome</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5548</span><span class="NLM_x">–</span> <span class="NLM_lpage">5557</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1203957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11114734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5548-5557&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=S.+F.+Lin&title=The+protein+tyrosine+kinase+family+of+the+human+genome&doi=10.1038%2Fsj.onc.1203957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine kinase family of the human genome</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Lin, Su-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5548-5557</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the sequencing of the human genome is completed by the Human Genome Project, the anal. of this rich source of information will illuminate many areas in medicine and biol.  The protein tyrosine kinases are a large multigene family with particular relevance to many human diseases, including cancer.  A search of the human genome for tyrosine kinase coding elements identified several novel genes and enabled the creation of a nonredundant catalog of tyrosine kinase genes.  Ninety unique kinase genes can be identified in the human genome, along with five pseudogenes.  Of the 90 tyrosine kinases, 58 are receptor type, distributed into 20 subfamilies.  The 32 nonreceptor tyrosine kinases can be placed in 10 subfamilies.  Addnl., mouse orthologs can be identified for nearly all the human tyrosine kinases.  The completion of the human tyrosine kinase family tree provides a framework for further advances in biomedical science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KhPd82OXhLVg90H21EOLACvtfcHk0liB4Hm3ZQYDJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D&md5=007f1f4a2d4ada11c5c9ea77d586816d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203957%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DS.%2BF.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520family%2520of%2520the%2520human%2520genome%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5548%26epage%3D5557%26doi%3D10.1038%2Fsj.onc.1203957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group">Ségaliny, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellez-Gabriel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymann, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymann, D.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span> <span class="citation_source-journal">J. Bone Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1016/j.jbo.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.jbo.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=26579483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-12&author=A.+I.+S%C3%A9galinyauthor=M.+Tellez-Gabrielauthor=M.-F.+Heymannauthor=D.+Heymann&title=Receptor+tyrosine+kinases%3A+Characterisation%2C+mechanism+of+action+and+therapeutic+interests+for+bone+cancers&doi=10.1016%2Fj.jbo.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span></div><div class="casAuthors">Segaliny Aude I; Tellez-Gabriel Marta; Heymann Marie-Francoise; Heymann Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn">2212-1366</span>.
    </div><div class="casAbstract">Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment.  In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche.  As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed.  These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours.  The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl42y4bB4mnvYfW6udTcc2eauJxJxQ8Rrkbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D&md5=57563bfe33ca5752242d56cc24546c1c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jbo.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbo.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A9galiny%26aufirst%3DA.%2BI.%26aulast%3DTellez-Gabriel%26aufirst%3DM.%26aulast%3DHeymann%26aufirst%3DM.-F.%26aulast%3DHeymann%26aufirst%3DD.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520Characterisation%252C%2520mechanism%2520of%2520action%2520and%2520therapeutic%2520interests%2520for%2520bone%2520cancers%26jtitle%3DJ.%2520Bone%2520Oncol.%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.jbo.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group">O’Bryan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogswell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5016</span><span class="NLM_x">–</span> <span class="NLM_lpage">5031</span><span class="refDoi"> DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le+Beauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0liB4Hm3ZQYDJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group">Hutterer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockhammer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-07-0862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18172262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=130-138&author=M.+Huttererauthor=P.+Knyazevauthor=A.+Abateauthor=M.+Reschkeauthor=H.+Maierauthor=N.+Stefanovaauthor=T.+Knyazevaauthor=V.+Barbieriauthor=M.+Reindlauthor=A.+Muiggauthor=H.+Kostronauthor=G.+Stockhammerauthor=A.+Ullrich&title=Axl+and+growth+arrest-specific+gene+6+are+frequently+overexpressed+in+human+gliomas+and+predict+poor+prognosis+in+patients+with+glioblastoma+multiforme&doi=10.1158%2F1078-0432.CCR-07-0862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme</span></div><div class="casAuthors">Hutterer, Markus; Knyazev, Pjotr; Abate, Ariane; Reschke, Markus; Maier, Hans; Stefanova, Nadia; Knyazeva, Tatjana; Barbieri, Verena; Reindl, Markus; Muigg, Armin; Kostron, Herwig; Stockhammer, Guenther; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The receptor tyrosine kinase Axl has recently been identified as a crit. element in the invasive properties of glioma cell lines.  However, the effect of Axl and its ligand growth arrest-specific gene 6 (Gas6) in human gliomas is still unknown.  Exptl. Design: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin-embedded glioma specimens by means of reverse transcription-PCR and immunohistochem.  The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients.  RESULTS: Axl and Gas6 were detectable in gliomas of malignancy grades WHO 2 to 4.  Moderate to high Axl mRNA expression was found in 61%, Axl protein in 55%, Gas6 mRNA in 81%, and Gas6 protein in 74% of GBM samples, resp.  GBM patients with high Axl expression and Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an assocn. with poorer overall survival.  Comparative immunohistochem. studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes.  Addnl., Axl/Gas6 coexpression was obsd. in glioma cells and tumor vessels.  In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons.  CONCLUSIONS: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients.  Our results indicate that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-54ka16GPkrVg90H21EOLACvtfcHk0lgtJMZHcG36SA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCn&md5=45d8887803613422b9e704b803ee757c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0862%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DM.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DAbate%26aufirst%3DA.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DKnyazeva%26aufirst%3DT.%26aulast%3DBarbieri%26aufirst%3DV.%26aulast%3DReindl%26aufirst%3DM.%26aulast%3DMuigg%26aufirst%3DA.%26aulast%3DKostron%26aufirst%3DH.%26aulast%3DStockhammer%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAxl%2520and%2520growth%2520arrest-specific%2520gene%25206%2520are%2520frequently%2520overexpressed%2520in%2520human%2520gliomas%2520and%2520predict%2520poor%2520prognosis%2520in%2520patients%2520with%2520glioblastoma%2520multiforme%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D130%26epage%3D138%26doi%3D10.1158%2F1078-0432.CCR-07-0862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saso, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, N. T.</span><span> </span><span class="NLM_article-title">TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6525</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-0967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-0967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6516-6525&author=X.+Wangauthor=H.+Sasoauthor=T.+Iwamotoauthor=W.+Xiaauthor=Y.+Gongauthor=L.+Pusztaiauthor=W.+A.+Woodwardauthor=J.+M.+Reubenauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=G.+N.+Hortobagyiauthor=M.+C.+Hungauthor=N.+T.+Ueno&title=TIG1+promotes+the+development+and+progression+of+inflammatory+breast+cancer+through+activation+of+Axl+kinase&doi=10.1158%2F0008-5472.CAN-13-0967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-0967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-0967%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSaso%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DTIG1%2520promotes%2520the%2520development%2520and%2520progression%2520of%2520inflammatory%2520breast%2520cancer%2520through%2520activation%2520of%2520Axl%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6516%26epage%3D6525%26doi%3D10.1158%2F0008-5472.CAN-13-0967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">re6</span><span class="refDoi"> DOI: 10.1126/scisignal.2004652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscisignal.2004652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24065147" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=re6&author=M.+J.+Niederstauthor=J.+A.+Engelman&title=Bypass+mechanisms+of+resistance+to+receptor+tyrosine+kinase+inhibition+in+lung+cancer&doi=10.1126%2Fscisignal.2004652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004652%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DBypass%2520mechanisms%2520of%2520resistance%2520to%2520receptor%2520tyrosine%2520kinase%2520inhibition%2520in%2520lung%2520cancer%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26spage%3Dre6%26doi%3D10.1126%2Fscisignal.2004652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span> </span><span class="NLM_article-title">Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bbrc.2013.05.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=493-500&author=J.+Hanauthor=R.+Tianauthor=B.+Yongauthor=C.+Luoauthor=P.+Tanauthor=J.+Shenauthor=T.+Peng&title=Gas6%2FAxl+mediates+tumor+cell+apoptosis%2C+migration+and+invasion+and+predicts+the+clinical+outcome+of+osteosarcoma+patients&doi=10.1016%2Fj.bbrc.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DYong%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DT.%26atitle%3DGas6%252FAxl%2520mediates%2520tumor%2520cell%2520apoptosis%252C%2520migration%2520and%2520invasion%2520and%2520predicts%2520the%2520clinical%2520outcome%2520of%2520osteosarcoma%2520patients%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D493%26epage%3D500%26doi%3D10.1016%2Fj.bbrc.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0lg-5L7eTDb0hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudikote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardnell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulks, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=I.+I.+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.CCR-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0lg-5L7eTDb0hA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.CCR-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group">Cichoń, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szentpetery, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caley, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadakis, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span> </span><span class="NLM_article-title">The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4185</span><span class="NLM_x">–</span> <span class="NLM_lpage">4192</span><span class="refDoi"> DOI: 10.1038/onc.2013.388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2013.388" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=4185-4192&author=M.+A.+Cicho%C5%84author=Z.+Szentpeteryauthor=M.+P.+Caleyauthor=E.+S.+Papadakisauthor=I.+C.+Mackenzieauthor=C.+H.+Brennanauthor=E.+A.+O%E2%80%99Toole&title=The+receptor+tyrosine+kinase+Axl+regulates+cell-cell+adhesion+and+stemness+in+cutaneous+squamous+cell+carcinoma&doi=10.1038%2Fonc.2013.388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.388%26sid%3Dliteratum%253Aachs%26aulast%3DCicho%25C5%2584%26aufirst%3DM.%2BA.%26aulast%3DSzentpetery%26aufirst%3DZ.%26aulast%3DCaley%26aufirst%3DM.%2BP.%26aulast%3DPapadakis%26aufirst%3DE.%2BS.%26aulast%3DMackenzie%26aufirst%3DI.%2BC.%26aulast%3DBrennan%26aufirst%3DC.%2BH.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26atitle%3DThe%2520receptor%2520tyrosine%2520kinase%2520Axl%2520regulates%2520cell-cell%2520adhesion%2520and%2520stemness%2520in%2520cutaneous%2520squamous%2520cell%2520carcinoma%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D4185%26epage%3D4192%26doi%3D10.1038%2Fonc.2013.388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0lhyQGGrNL8vaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group">Brand, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrigan, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braverman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimple, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to cetuximab therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5164</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=AXL+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.CAN-14-0294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.CAN-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehdev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkhiri, A.</span><span> </span><span class="NLM_article-title">ABL regulation by AXL promotes cisplatin resistance in oesophageal cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-12-3151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=331-340&author=J.+Hongauthor=D.+Pengauthor=Z.+Chenauthor=V.+Sehdevauthor=A.+Belkhiri&title=ABL+regulation+by+AXL+promotes+cisplatin+resistance+in+oesophageal+cancer&doi=10.1158%2F0008-5472.CAN-12-3151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3151%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSehdev%26aufirst%3DV.%26aulast%3DBelkhiri%26aufirst%3DA.%26atitle%3DABL%2520regulation%2520by%2520AXL%2520promotes%2520cisplatin%2520resistance%2520in%2520oesophageal%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D331%26epage%3D340%26doi%3D10.1158%2F0008-5472.CAN-12-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group">Hong, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lay, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, S. E.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.canlet.2008.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18502572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2008&pages=314-324&author=C.+C.+Hongauthor=J.+D.+Layauthor=J.+S.+Huangauthor=A.+L.+Chengauthor=J.+L.+Tangauthor=M.+T.+Linauthor=G.+M.+Laiauthor=S.+E.+Chuang&title=Receptor+tyrosine+kinase+AXL+is+induced+by+chemotherapy+drugs+and+overexpression+of+AXL+confers+drug+resistance+in+acute+myeloid+leukemia&doi=10.1016%2Fj.canlet.2008.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</span></div><div class="casAuthors">Hong, Chih-Chen; Lay, Jong-Ding; Huang, Jhy-Shrian; Cheng, Ann-Lii; Tang, Jih-Luh; Lin, Ming-Tseh; Lai, Gi-Ming; Chuang, Shuang-En</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-324</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">By using a novel profiling anal. of protein tyrosine kinases differentially expressed in the sensitive and refractory leukemia from the same patients we found that AXL was up-regulated in drug-resistant leukemia.  Furthermore, AXL could be induced by chemotherapy drugs in the acute myeloid leukemia U937 cells and this induction was dependent on the CCWGG methylation status of the AXL promoter.  In U937 cells ectopically over-expressing AXL, addn. of exogenous Gas6 induced AXL phosphorylation and activation of the Akt and ERK1/2 survival pathways.  The Gas6-AXL activation pathway of drug resistance was assocd. with increased expression of Bcl-2 and Twist.  These results show that up-regulation of AXL by chemotherapy might induce drug resistance in acute myeloid leukemia in the presence of Gas6 stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZUB9br3lBSrVg90H21EOLACvtfcHk0lhyQGGrNL8vaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt70%253D&md5=03facdf77393a8a82c8554664234a6d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DLay%26aufirst%3DJ.%2BD.%26aulast%3DHuang%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26aulast%3DTang%26aufirst%3DJ.%2BL.%26aulast%3DLin%26aufirst%3DM.%2BT.%26aulast%3DLai%26aufirst%3DG.%2BM.%26aulast%3DChuang%26aufirst%3DS.%2BE.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520AXL%2520is%2520induced%2520by%2520chemotherapy%2520drugs%2520and%2520overexpression%2520of%2520AXL%2520confers%2520drug%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D268%26spage%3D314%26epage%3D324%26doi%3D10.1016%2Fj.canlet.2008.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group">Sheridan, C.</span><span> </span><span class="NLM_article-title">First Axl inhibitor enters clinical trials</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span><span class="refDoi"> DOI: 10.1038/nbt0913-775a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt0913-775a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=775-776&author=C.+Sheridan&title=First+Axl+inhibitor+enters+clinical+trials&doi=10.1038%2Fnbt0913-775a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnbt0913-775a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0913-775a%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFirst%2520Axl%2520inhibitor%2520enters%2520clinical%2520trials%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fnbt0913-775a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">Targeting Axl and Mer kinases in cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">–</span> <span class="NLM_lpage">1773</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-11-0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21933973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1763-1773&author=A.+Vermaauthor=S.+L.+Warnerauthor=H.+Vankayalapatiauthor=D.+J.+Bearssauthor=S.+Sharma&title=Targeting+Axl+and+Mer+kinases+in+cancer&doi=10.1158%2F1535-7163.MCT-11-0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Axl and Mer Kinases in Cancer</span></div><div class="casAuthors">Verma, Anupam; Warner, Steven L.; Vankayalapati, Hariprasad; Bearss, David J.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1763-1773</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play an important role in signal transduction in both normal and malignant cells.  The mammalian TAM RTK family includes 3 closely related members: Tyro-3, Axl, and Mer.  Overexpression or ectopic expression of the TAM receptors has been detected in a wide array of human cancers.  Growth arrest-specific gene 6 has been identified as the major ligand for these TAM RTKs, and its binding to the receptors has been shown to promote proliferation and survival of cancer cells in vitro.  Abnormal expression and activation of Axl or Mer can provide a survival advantage for certain cancer cells.  Inhibition of Axl and Mer may enhance the sensitivity of cancer cells to cytotoxic agents and would potentially be a therapeutic strategy to target cancer cells.  This review elucidates the role of Axl and Mer in normal cellular function and their role in oncogenesis.  In addn., we review the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer.  Mol Cancer Ther; 10(10); 1763-73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogR8epfrv2ArVg90H21EOLACvtfcHk0ljnM4hhrNu_DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrfJ&md5=5048fdf6f6874a61bfbc6576db18d61c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0116%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DTargeting%2520Axl%2520and%2520Mer%2520kinases%2520in%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1763%26epage%3D1773%26doi%3D10.1158%2F1535-7163.MCT-11-0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">AXL kinase as a novel target for cancer therapy</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">9546</span><span class="NLM_x">–</span> <span class="NLM_lpage">9563</span><span class="refDoi"> DOI: 10.18632/oncotarget.2542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.18632%2Foncotarget.2542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=9546-9563&author=X.+Wuauthor=X.+Liuauthor=S.+Koulauthor=C.+Y.+Leeauthor=Z.+Zhangauthor=B.+Halmos&title=AXL+kinase+as+a+novel+target+for+cancer+therapy&doi=10.18632%2Foncotarget.2542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2542%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAXL%2520kinase%2520as%2520a%2520novel%2520target%2520for%2520cancer%2520therapy%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D9546%26epage%3D9563%26doi%3D10.18632%2Foncotarget.2542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlinhauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Axl kinase as a key target for oncology: focus on small molecule inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2148</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-1083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-13-1083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2141-2148&author=C.+Feneyrollesauthor=A.+Spenlinhauerauthor=L.+Guietauthor=B.+Fauvelauthor=B.+Dayd%C3%A9-Cazalsauthor=P.+Warnaultauthor=G.+Chev%C3%A9author=A.+Yasri&title=Axl+kinase+as+a+key+target+for+oncology%3A+focus+on+small+molecule+inhibitors&doi=10.1158%2F1535-7163.MCT-13-1083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors</span></div><div class="casAuthors">Feneyrolles, Clemence; Spenlinhauer, Aurelia; Guiet, Lea; Fauvel, Benedicte; Dayde-Cazals, Benedicte; Warnault, Pierre; Cheve, Gwenael; Yasri, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2141-2148</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells.  As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways.  Its overexpression/overactivation has been underlined in several conditions, esp. cancers, and in both chemotherapy and targeted therapy sensitivity loss.  In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition.  We esp. focus on small mol. inhibitors, their structure, inhibition profile, and development stages.  Mol Cancer Ther; 13(9); 2141-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRn5-b7gNJkLVg90H21EOLACvtfcHk0ljnM4hhrNu_DA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO&md5=6c569ae44113e6cae2f59e8ba462a787</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-1083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-1083%26sid%3Dliteratum%253Aachs%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DSpenlinhauer%26aufirst%3DA.%26aulast%3DGuiet%26aufirst%3DL.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DWarnault%26aufirst%3DP.%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAxl%2520kinase%2520as%2520a%2520key%2520target%2520for%2520oncology%253A%2520focus%2520on%2520small%2520molecule%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2141%26epage%3D2148%26doi%3D10.1158%2F1535-7163.MCT-13-1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span> </span><span class="NLM_article-title">The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span><span class="refDoi"> DOI: 10.1038/nrc3847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnrc3847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25568918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=769-785&author=D.+K.+Grahamauthor=D.+DeRyckereauthor=K.+D.+Daviesauthor=H.+S.+Earp&title=The+TAM+family%3A+phosphatidylserine+sensing+receptor+tyrosine+kinases+gone+awry+in+cancer&doi=10.1038%2Fnrc3847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer</span></div><div class="casAuthors">Graham, Douglas K.; DeRyckere, Deborah; Davies, Kurtis D.; Earp, H. Shelton</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">769-785</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematol. and epithelial malignancies.  Rather than functioning as oncogenic drivers, their induction in tumor cells predominately promotes survival, chemoresistance and motility.  The unique mode of maximal activation of this RTK family requires an extracellular lipid-protein complex.  For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages.  This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization.  In tumors, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumor cell and favor an anti-inflammatory, immunosuppressive microenvironment.  Thus, TAM kinase inhibition could stimulate antitumor immunity, reduce tumor cell survival, enhance chemosensitivity and diminish metastatic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8tV8-04ed7Vg90H21EOLACvtfcHk0ljq1lJww4QwRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7jK&md5=b92c6d091b711b586ed1bfe02a3d6345</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc3847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3847%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26atitle%3DThe%2520TAM%2520family%253A%2520phosphatidylserine%2520sensing%2520receptor%2520tyrosine%2520kinases%2520gone%2520awry%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D769%26epage%3D785%26doi%3D10.1038%2Fnrc3847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group">Caberoy, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span> </span><span class="NLM_article-title">Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3898</span><span class="NLM_x">–</span> <span class="NLM_lpage">3910</span><span class="refDoi"> DOI: 10.1038/emboj.2010.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Femboj.2010.265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3898-3910&author=N.+B.+Caberoyauthor=Y.+Zhouauthor=W.+Li&title=Tubby+and+tubby-like+protein+1+are+new+MerTK+ligands+for+phagocytosis&doi=10.1038%2Femboj.2010.265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.265%26sid%3Dliteratum%253Aachs%26aulast%3DCaberoy%26aufirst%3DN.%2BB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubby%2520and%2520tubby-like%2520protein%25201%2520are%2520new%2520MerTK%2520ligands%2520for%2520phagocytosis%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3898%26epage%3D3910%26doi%3D10.1038%2Femboj.2010.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group">Caberoy, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigcas, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span> </span><span class="NLM_article-title">Galectin-3 is a new MerTK-specific eat-me signal</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">227</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1002/jcp.22955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1002%2Fjcp.22955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21792939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFartLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=2012&pages=401-407&author=N.+B.+Caberoyauthor=G.+Alvaradoauthor=J.-L.+Bigcasauthor=W.+Li&title=Galectin-3+is+a+new+MerTK-specific+eat-me+signal&doi=10.1002%2Fjcp.22955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Galectin-3 is a new MerTK-specific eat-me signal</span></div><div class="casAuthors">Caberoy, Nora B.; Alvarado, Gabriela; Bigcas, Jo-Lawrence; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">227</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-407</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Phagocytosis of apoptotic cells and cellular debris is a crit. process of maintaining tissue and immune homeostasis.  Defects in the phagocytosis process cause autoimmunity and degenerative diseases.  Phagocytosis ligands or "eat-me" signals control the initiation of the process by linking apoptotic cells to receptors on phagocyte surface and triggering signaling cascades for cargo engulfment.  Eat-me signals are traditionally identified on a case-by-case basis with challenges, and the identification of their cognate receptors is equally daunting.  Here, we identified galectin-3 (Gal-3) as a new MerTK ligand by an advanced dual functional cloning strategy, in which phagocytosis-based functional cloning is combined with receptor-based affinity cloning to directly identify receptor-specific eat-me signal.  Gal-3 interaction with MerTK was independently verified by co-immunopptn.  Functional analyses showed that Gal-3 stimulated the phagocytosis of apoptotic cells and cellular debris by macrophages and retinal pigment epithelial cells with MerTK activation and autophosphorylation.  The Gal-3-mediated phagocytosis was blocked by excessive sol. MerTK extracellular domain and lactose.  These results suggest that Gal-3 is a legitimate MerTK-specific eat-me signal.  The strategy of dual functional cloning with applicability to other phagocytic receptors will facilitate unbiased identification of their unknown ligands and improve our capacity for therapeutic modulation of phagocytic activity and innate immune response.  J. Cell. Physiol. 227: 401-407, 2012. © 2011 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvCbQdt3DRLVg90H21EOLACvtfcHk0ljq1lJww4QwRw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFartLnE&md5=3cf8e16295c5bedcfe4ad5fd11e814dd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjcp.22955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.22955%26sid%3Dliteratum%253Aachs%26aulast%3DCaberoy%26aufirst%3DN.%2BB.%26aulast%3DAlvarado%26aufirst%3DG.%26aulast%3DBigcas%26aufirst%3DJ.-L.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DGalectin-3%2520is%2520a%2520new%2520MerTK-specific%2520eat-me%2520signal%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2012%26volume%3D227%26spage%3D401%26epage%3D407%26doi%3D10.1002%2Fjcp.22955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group">Heiring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, Y. A.</span><span> </span><span class="NLM_article-title">Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">6952</span><span class="NLM_x">–</span> <span class="NLM_lpage">6958</span><span class="refDoi"> DOI: 10.1074/jbc.M311750200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1074%2Fjbc.M311750200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=6952-6958&author=C.+Heiringauthor=B.+Dahlbackauthor=Y.+A.+Muller&title=Ligand+recognition+and+homophilic+interactions+in+Tyro3%3A+structural+insights+into+the+Axl%2FTyro3+receptor+tyrosine+kinase+family&doi=10.1074%2Fjbc.M311750200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311750200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311750200%26sid%3Dliteratum%253Aachs%26aulast%3DHeiring%26aufirst%3DC.%26aulast%3DDahlback%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DY.%2BA.%26atitle%3DLigand%2520recognition%2520and%2520homophilic%2520interactions%2520in%2520Tyro3%253A%2520structural%2520insights%2520into%2520the%2520Axl%252FTyro3%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D6952%26epage%3D6958%26doi%3D10.1074%2Fjbc.M311750200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group">Konishi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korshunov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, B. C.</span><span> </span><span class="NLM_article-title">Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">28766</span><span class="NLM_x">–</span> <span class="NLM_lpage">28770</span><span class="refDoi"> DOI: 10.1074/jbc.M401977200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1074%2Fjbc.M401977200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=28766-28770&author=A.+Konishiauthor=T.+Aizawaauthor=A.+Mohanauthor=V.+A.+Korshunovauthor=B.+C.+Berk&title=Hydrogen+peroxide+activates+the+Gas6-Axl+pathway+in+vascular+smooth+muscle+cells&doi=10.1074%2Fjbc.M401977200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M401977200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M401977200%26sid%3Dliteratum%253Aachs%26aulast%3DKonishi%26aufirst%3DA.%26aulast%3DAizawa%26aufirst%3DT.%26aulast%3DMohan%26aufirst%3DA.%26aulast%3DKorshunov%26aufirst%3DV.%2BA.%26aulast%3DBerk%26aufirst%3DB.%2BC.%26atitle%3DHydrogen%2520peroxide%2520activates%2520the%2520Gas6-Axl%2520pathway%2520in%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D28766%26epage%3D28770%26doi%3D10.1074%2Fjbc.M401977200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0li-3W-aunIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Targeted Axl inhibition primes Chronic Lymphocytic Leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2115</span><span class="NLM_x">–</span> <span class="NLM_lpage">2126</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-14-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25673699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2115-2126&author=S.+Sinhaauthor=J.+Boysenauthor=M.+Nelsonauthor=C.+Secretoauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=C.+Lesnickauthor=T.+D.+Shanafeltauthor=N.+E.+Kayauthor=A.+K.+Ghosh&title=Targeted+Axl+inhibition+primes+Chronic+Lymphocytic+Leukemia+B+cells+to+apoptosis+and+shows+synergistic%2Fadditive+effects+in+combination+with+BTK+inhibitors&doi=10.1158%2F1078-0432.CCR-14-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors</span></div><div class="casAuthors">Sinha, Sutapa; Boysen, Justin; Nelson, Michael; Secreto, Charla; Warner, Steven L.; Bearss, David J.; Lesnick, Connie; Shanafelt, Tait D.; Kay, Neil E.; Ghosh, Asish K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2115-2126</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches.  We previously found that Axl receptor tyrosine kinase (RTK) plays a crit. role in CLL B-cell survival.  Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clin. trial to treat patients with CLL.  Exptl. Design: Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated.  Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs).  Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells.  Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to det. any synergistic/additive effects of the combination.  Results: CLL B cells overexpress Tyro3, but not MER.  Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells.  TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges.  Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis.  A marked redn. of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition.  Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis.  Conclusions: Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.  Clin Cancer Res; 21(9); 2115-26. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCcdSntQPu7Vg90H21EOLACvtfcHk0li-3W-aunIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D&md5=2d7554e400d1d5e4bee347f43dea2762</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1892%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DLesnick%26aufirst%3DC.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Axl%2520inhibition%2520primes%2520Chronic%2520Lymphocytic%2520Leukemia%2520B%2520cells%2520to%2520apoptosis%2520and%2520shows%2520synergistic%252Fadditive%2520effects%2520in%2520combination%2520with%2520BTK%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2115%26epage%3D2126%26doi%3D10.1158%2F1078-0432.CCR-14-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group">Ruan, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazlauskas, A.</span><span> </span><span class="NLM_article-title">Axl is essential for VEGF-A-dependent activation of PI3K/Akt</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1038/emboj.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Femboj.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22327215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1692-1703&author=G.+X.+Ruanauthor=A.+Kazlauskas&title=Axl+is+essential+for+VEGF-A-dependent+activation+of+PI3K%2FAkt&doi=10.1038%2Femboj.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is essential for VEGF-A-dependent activation of PI3K/Akt</span></div><div class="casAuthors">Ruan, Guo-Xiang; Kazlauskas, Andrius</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1692-1703</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here, the authors report that vascular endothelial growth factor A (VEGF-A) engages the phosphatidylinositol 3-kinase (PI3K)/Akt kinase pathway by a previously unknown mechanism that involves 3 protein tyrosine kinases.  Upon VEGF-A-dependent activation of VEGF receptor-2 (VEGFR-2), and subsequent TSAd-mediated activation of Src family kinases (SFKs), SFKs engaged receptor tyrosine kinase Axl via its juxtamembrane domain to trigger ligand-independent autophosphorylation at a pair of YXXM motifs that promoted assocn. with PI3K and activation of Akt.  Other VEGF-A-mediated signaling pathways were independent of Axl.  Interfering with Axl expression or function impaired VEGF-A- but not bFGF-dependent migration of endothelial cells.  Similarly, Axl-null mice respond poorly to VEGF-A-induced vascular permeability or angiogenesis, whereas other agonists induce a normal response.  Thus, these results elucidated the mechanism by which VEGF-A activates PI3K/Akt, and identified previously unappreciated potential therapeutic targets of VEGF-A-driven processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtunGB7l3o5rVg90H21EOLACvtfcHk0li-3W-aunIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGnt7s%253D&md5=f9db8bd5f1453b20e2fe1898cdf3a4d9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DG.%2BX.%26aulast%3DKazlauskas%26aufirst%3DA.%26atitle%3DAxl%2520is%2520essential%2520for%2520VEGF-A-dependent%2520activation%2520of%2520PI3K%252FAkt%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26spage%3D1692%26epage%3D1703%26doi%3D10.1038%2Femboj.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span> </span><span class="NLM_article-title">The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1128/MCB.15.2.614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1128%2FMCB.15.2.614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=7823930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlansL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=614-625&author=P.+Bellostaauthor=M.+Costaauthor=D.+A.+Linauthor=C.+Basilico&title=The+receptor+tyrosine+kinase+ARK+mediates+cell+aggregation+by+homophilic+binding&doi=10.1128%2FMCB.15.2.614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding</span></div><div class="casAuthors">Bellosta, Paola; Costa, Mario; Lin, Debby A.; Basilico, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">614-25</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The ARK (AXL, UFO) receptor is a member of a new family of receptor tyrosine kinases whose extracellular domain contains combination of fibronectin type III and Ig motifs similar to those found in many cell adhesion mols.  ARK mRNA is expressed at high levels in the mouse brain, prevalently in the hippocampus and cerebellum, and this pattern of expression resembles that of adhesion mols. that are capable of promoting cell aggregation through homophilic or heterophilic binding.  We report here the ability of the murine ARK receptor to mediate homophilic binding.  Expression of the ARK protein in Drosophila S2 cells induces formation of cell aggregates consists of ARK-expressing cells, and aggregation leads to receptor activation, with an increase in receptor phosphorylation.  Homophilic binding does not require ARK tyrosine kinase activity, since S2 cells expressing a receptor in which the intracellular domain was deleted were able to undergo aggregation as well as cells expressing the wild-type ARK receptor.  Similar results were obtained with NIH 3T3 and CHO cells expressing high levels of ARK, although in this case ARK expression appeared to be accompanied by constitutive activation.  The purified recombinant extracellular domain of ARK can induce homotypic aggregation of coated fluorescent beads (Covaspheres), and this protein can also function as a substrate for adhesion by S2 and NIH 3T3 cells expressing ARK.  The results suggest that ARK represents a new cell adhesion mol. that through its homophilic interaction may regulate cellular functions during cell recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5IlXBp2I7bVg90H21EOLACvtfcHk0li-3W-aunIZPQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlansL4%253D&md5=405989ab8dc7a9be50cd2bd1e82a722a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.2.614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.2.614%26sid%3Dliteratum%253Aachs%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DD.%2BA.%26aulast%3DBasilico%26aufirst%3DC.%26atitle%3DThe%2520receptor%2520tyrosine%2520kinase%2520ARK%2520mediates%2520cell%2520aggregation%2520by%2520homophilic%2520binding%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D614%26epage%3D625%26doi%3D10.1128%2FMCB.15.2.614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group">Hankins, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldridge, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, T. R.</span><span> </span><span class="NLM_article-title">Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution</span> <span class="citation_source-journal">Traffic</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1111/tra.12233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1111%2Ftra.12233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25284293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFansLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=35-47&author=H.+M.+Hankinsauthor=R.+D.+Baldridgeauthor=P.+Xuauthor=T.+R.+Graham&title=Role+of+flippases%2C+scramblases+and+transfer+proteins+in+phosphatidylserine+subcellular+distribution&doi=10.1111%2Ftra.12233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution</span></div><div class="casAuthors">Hankins, Hannah M.; Baldridge, Ryan D.; Xu, Peng; Graham, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-47</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is well known that lipids are heterogeneously distributed throughout the cell.  Most lipid species are synthesized in the endoplasmic reticulum (ER) and then distributed to different cellular locations in order to create the distinct membrane compns. obsd. in eukaryotes.  However, the mechanisms by which specific lipid species are trafficked to and maintained in specific areas of the cell are poorly understood and constitute an active area of research.  Of particular interest is the distribution of phosphatidylserine (PS), an anionic phospholipid that is enriched in the cytosolic leaflet of the plasma membrane.  PS transport occurs by both vesicular and non-vesicular routes, with members of the oxysterol-binding protein family (Osh6 and Osh7) recently implicated in the latter route.  In addn., the flippase activity of P4-ATPases helps build PS membrane asymmetry by preferentially translocating PS to the cytosolic leaflet.  This asym. PS distribution can be used as a signaling device by the regulated activation of scramblases, which rapidly expose PS on the extracellular leaflet and play important roles in blood clotting and apoptosis.  Here, the authors discuss recent advances made in the study of phospholipid flippases, scramblases, and PS-specific lipid transfer proteins, as well as how these proteins contribute to subcellular PS distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRw8_NcmXSSbVg90H21EOLACvtfcHk0liBjFOuC0CjbQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFansLzO&md5=830e3a821330aab6777080e4cedca6e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Ftra.12233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftra.12233%26sid%3Dliteratum%253Aachs%26aulast%3DHankins%26aufirst%3DH.%2BM.%26aulast%3DBaldridge%26aufirst%3DR.%2BD.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DT.%2BR.%26atitle%3DRole%2520of%2520flippases%252C%2520scramblases%2520and%2520transfer%2520proteins%2520in%2520phosphatidylserine%2520subcellular%2520distribution%26jtitle%3DTraffic%26date%3D2015%26volume%3D16%26spage%3D35%26epage%3D47%26doi%3D10.1111%2Ftra.12233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group">Stenhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafizi, S.</span><span> </span><span class="NLM_article-title">Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">319</span><span class="NLM_x">, </span> <span class="NLM_fpage">871</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2004.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bbrc.2004.05.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2004&pages=871-878&author=J.+Stenhoffauthor=B.+Dahlbackauthor=S.+Hafizi&title=Vitamin+K-dependent+Gas6+activates+ERK+kinase+and+stimulates+growth+of+cardiac+fibroblasts&doi=10.1016%2Fj.bbrc.2004.05.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DStenhoff%26aufirst%3DJ.%26aulast%3DDahlback%26aufirst%3DB.%26aulast%3DHafizi%26aufirst%3DS.%26atitle%3DVitamin%2520K-dependent%2520Gas6%2520activates%2520ERK%2520kinase%2520and%2520stimulates%2520growth%2520of%2520cardiac%2520fibroblasts%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D319%26spage%3D871%26epage%3D878%26doi%3D10.1016%2Fj.bbrc.2004.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group">Vazquez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cufí, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveras-Ferraros, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Garcia, V. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corominas-Faja, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuyàs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonavia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Castillo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrajón-Catalán, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch-Barrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, J. A.</span><span> </span><span class="NLM_article-title">IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="refDoi"> DOI: 10.1038/srep02560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsrep02560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23994953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC3sbksFentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=2560&author=A.+Vazquez-Martinauthor=S.+Cuf%C3%ADauthor=C.+Oliveras-Ferrarosauthor=V.+Z.+Torres-Garciaauthor=B.+Corominas-Fajaauthor=E.+Cuy%C3%A0sauthor=R.+Bonaviaauthor=J.+Visaauthor=B.+Martin-Castilloauthor=E.+Barraj%C3%B3n-Catal%C3%A1nauthor=V.+Micolauthor=J.+Bosch-Barreraauthor=J.+A.+Menendez&title=IGF-1R%2Fepithelial-to-mesenchymal+transition+%28EMT%29+crosstalk+suppresses+the+erlotinib-sensitizing+effect+of+EGFR+exon+19+deletion+mutations&doi=10.1038%2Fsrep02560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations</span></div><div class="casAuthors">Vazquez-Martin Alejandro; Cufi Silvia; Oliveras-Ferraros Cristina; Torres-Garcia Violeta Zenobia; Corominas-Faja Bruna; Cuyas Elisabet; Bonavia Rosa; Visa Joana; Martin-Castillo Begona; Barrajon-Catalan Enrique; Micol Vicente; Bosch-Barrera Joaquim; Menendez Javier A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using non-small cell lung carcinoma (NSCLC) cells harboring the erlotinib-sensitizing Epidermal Growth Factor Receptor (EGFR) exon 19 mutation delE746-A750, we developed erlotinib-refractory derivatives in which hyperactive Insulin-like Growth Factor-1 Receptor (IGF-1R) signaling associated with enrichment in epithelial-to-mesenchymal transition (EMT)-related morphological and transcriptional features.  We then explored whether an IGF-1R/EMT crosstalk was sufficient to promote erlotinib refractoriness in the absence of second-site EGFR mutations, MET and AXL hyperactivation.  Transforming Growth Factor-beta1 (TGFβ1)-induced mesenchymal trans-differentiation was sufficient to impede erlotinib functioning in the presence of drug-sensitive delE746-A750 EGFR mutation.  Pharmacological blockade of IGF-1R fully prevented the TGFβ1's ability to activate an EMT protein signature [E-cadherin low/vimentin high].  The sole presence of erlotinib was capable of rapidly activate an IGF-1R-dependent, vimentin-enriched mesenchymal-like phenotype in delE746-A750-mutated epithelial cells.  Even if transient, NSCLC cells' intrinsic plasticity to undergo crosstalk between IGF-1R and EMT signaling pathways can sufficiently eliminate the erlotinib-sensitizing effect of highly prevalent EGFR mutations and suggests the urgent need for dual IGF-1R/EMT-targeting strategies to circumvent erlotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdsob6YTymuIIRAdBLKY41fW6udTcc2eahY1IbTC4nArntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbksFentw%253D%253D&md5=cbf7bc50267fcc3cb753509fd7e80dab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fsrep02560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep02560%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Martin%26aufirst%3DA.%26aulast%3DCuf%25C3%25AD%26aufirst%3DS.%26aulast%3DOliveras-Ferraros%26aufirst%3DC.%26aulast%3DTorres-Garcia%26aufirst%3DV.%2BZ.%26aulast%3DCorominas-Faja%26aufirst%3DB.%26aulast%3DCuy%25C3%25A0s%26aufirst%3DE.%26aulast%3DBonavia%26aufirst%3DR.%26aulast%3DVisa%26aufirst%3DJ.%26aulast%3DMartin-Castillo%26aufirst%3DB.%26aulast%3DBarraj%25C3%25B3n-Catal%25C3%25A1n%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DV.%26aulast%3DBosch-Barrera%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DIGF-1R%252Fepithelial-to-mesenchymal%2520transition%2520%2528EMT%2529%2520crosstalk%2520suppresses%2520the%2520erlotinib-sensitizing%2520effect%2520of%2520EGFR%2520exon%252019%2520deletion%2520mutations%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D2560%26doi%3D10.1038%2Fsrep02560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group">Salian-Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierman, M. E.</span><span> </span><span class="NLM_article-title">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.mce.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.mce.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23648337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2013&pages=92-100&author=S.+Salian-Mehtaauthor=M.+Xuauthor=M.+E.+Wierman&title=AXL+and+MET+crosstalk+to+promote+gonadotropin+releasing+hormone+%28GnRH%29+neuronal+cell+migration+and+survival&doi=10.1016%2Fj.mce.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span></div><div class="casAuthors">Salian-Mehta, Smita; Xu, Mei; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">92-100</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The membrane tyrosine kinase receptors, AXL and MET, are implicated in GnRH neuron migration and/or survival.  We hypothesized that the receptors with their ligands, GAS6 and HGF, resp. may cross-talk in GnRH neuronal function.  In NLT GnRH neuronal cells, MET co-immunopptd. with AXL, although HGF or GAS6 did not transphosphorylate AXL or MET, resp.  Co-expression of a kinase dead AXL blocked HGF activation of MET and indirectly AKT and p38MAPK.  Silencing of AXL decreased HGF's ability to phosphorylate MET and activate AXL's downstream effectors, p38MAPK and AKT.  HGF/MET signaling modulated neuron migration dependent and independent of AXL co-expression and p38MAPK.  Conversely, AXL's control of GnRH neuronal survival was dependent on HGF/MET signaling.  Together, these data support that the importance of membrane tyrosine kinase receptor crosstalk to regulate neuronal cell-specific developmental functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFg8H1UC0HerVg90H21EOLACvtfcHk0lgk3t0AtRCL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D&md5=de528dce1d3a19fe4392b25017d3cbb0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalian-Mehta%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DAXL%2520and%2520MET%2520crosstalk%2520to%2520promote%2520gonadotropin%2520releasing%2520hormone%2520%2528GnRH%2529%2520neuronal%2520cell%2520migration%2520and%2520survival%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D374%26spage%3D92%26epage%3D100%26doi%3D10.1016%2Fj.mce.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuniga, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldstone, M. B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptors are pleiotropic inhibitors of the innate immune response</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.cell.2007.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18083102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1124-1136&author=C.+V.+Rothlinauthor=S.+Ghoshauthor=E.+I.+Zunigaauthor=M.+B.+A.+Oldstoneauthor=G.+Lemke&title=TAM+receptors+are+pleiotropic+inhibitors+of+the+innate+immune+response&doi=10.1016%2Fj.cell.2007.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptors are pleiotropic inhibitors of the innate immune response</span></div><div class="casAuthors">Rothlin, Carla V.; Ghosh, Sourav; Zuniga, Elina I.; Oldstone, Michael B. A.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1136</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The activation of Toll-like receptors (TLRs) in dendritic cells (DCs) triggers a rapid inflammatory response to pathogens.  However, this response must be tightly regulated because unrestrained TLR signaling generates a chronic inflammatory milieu that often leads to autoimmunity.  We have found that the TAM receptor tyrosine kinases-Tyro3, Axl, and Mer-broadly inhibit both TLR and TLR-induced cytokine-receptor cascades.  Remarkably, TAM inhibition of inflammation is transduced through an essential stimulator of inflammation-the type I interferon receptor (IFNAR)-and its assocd. transcription factor STAT1.  TLR induction of IFNAR-STAT1 signaling upregulates the TAM system, which in turn usurps the IFNAR-STAT1 cassette to induce the cytokine and TLR suppressors SOCS1 and SOCS3.  These results illuminate a self-regulating cycle of inflammation, in which the obligatory, cytokine-dependent activation of TAM signaling hijacks a proinflammatory pathway to provide an intrinsic feedback inhibitor of both TLR- and cytokine-driven immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCPRBPKbiNrVg90H21EOLACvtfcHk0lgk3t0AtRCL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D&md5=32511c20288ef6f92b60d9a6bc94637d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DOldstone%26aufirst%3DM.%2BB.%2BA.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptors%2520are%2520pleiotropic%2520inhibitors%2520of%2520the%2520innate%2520immune%2520response%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1124%26epage%3D1136%26doi%3D10.1016%2Fj.cell.2007.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group">Mudduluru, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgayer, H.</span><span> </span><span class="NLM_article-title">The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation</span> <span class="citation_source-journal">Biosci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1042/BSR20080046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1042%2FBSR20080046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18522535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVaktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=161-176&author=G.+Mudduluruauthor=H.+Allgayer&title=The+human+receptor+tyrosine+kinase+Axl+gene-promoter+characterization+and+regulation+of+constitutive+expression+by+Sp1%2C+Sp3+and+CpG+methylation&doi=10.1042%2FBSR20080046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation</span></div><div class="casAuthors">Mudduluru, Giridhar; Allgayer, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Bioscience Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-176</span>CODEN:
                <span class="NLM_cas:coden">BRPTDT</span>;
        ISSN:<span class="NLM_cas:issn">0144-8463</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Axl is a receptor tyrosine kinase which promotes anti-apoptosis, mitogenesis, invasion, angiogenesis and metastasis, and is highly expressed in cancers.  However, the transcriptional regulation of this important gene has never been characterized.  The present study was initiated to characterize the promoter, cis-acting elements and promoter methylation driving expression of Axl.  The 2.4 kb sequence upstream of the translational start site, and sequential 5'-deletions were cloned and revealed a minimal GC-rich region (-556 to +7) to be sufficient for basal Axl promoter activity in Rko, HCT116 and HeLa cells.  Within this minimal region, five Sp (specificity protein)-binding sites were identified.  Two sites (Sp a and Sp b) proximal to the translation start site were indispensable for Axl promoter activity, whereas mutation of three addnl. upstream motifs (Sp c, Sp d and Sp e) was of addnl. relevance.  Gel-shift assays and chromatin immunopptn. identified that Sp1 and Sp3 bound to all five motifs, and mutation of all motifs abolished binding.  Mithramycin, which inhibits binding of Sp factors to GC-rich sites, dramatically reduced Axl promoter activity and Axl, Sp1 and Sp3 expression.  In Drosophila Schneider SL2-cells, exogenous expression of Sp1/Sp3 increased Axl promoter activity.  Use of Sp1/Sp3 siRNAs (small interfering RNAs) significantly reduced Axl promoter activity and protein levels in Rko and HeLa cells.  Methylation-bisulfite sequencing detected methylated CpG sites within three Sp motifs (Sp a, Sp b and Sp c) and GC-rich flanking sequences, and demethylation by 5-aza-2'-deoxycytidine up-regulated Axl and Sp3 expression in low-Axl-expressing Colo206f/WiDr cells, but not in high-Axl-expressing Rko cells.  The results of the present study suggest that Axl gene expression in cancer cells is (1) constitutively driven by Sp1/Sp3 bound to five core promoter motifs, and (2) restricted by methylation within/around Sp-binding sites.  This might enhance the understanding and treatment of essential mechanisms assocd. with cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolVG5cjhmrXrVg90H21EOLACvtfcHk0lgk3t0AtRCL-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVaktL0%253D&md5=88baae37d4c3089ec66dcd4663fa47ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2FBSR20080046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20080046%26sid%3Dliteratum%253Aachs%26aulast%3DMudduluru%26aufirst%3DG.%26aulast%3DAllgayer%26aufirst%3DH.%26atitle%3DThe%2520human%2520receptor%2520tyrosine%2520kinase%2520Axl%2520gene-promoter%2520characterization%2520and%2520regulation%2520of%2520constitutive%2520expression%2520by%2520Sp1%252C%2520Sp3%2520and%2520CpG%2520methylation%26jtitle%3DBiosci.%2520Rep.%26date%3D2008%26volume%3D28%26spage%3D161%26epage%3D176%26doi%3D10.1042%2FBSR20080046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group">Mudduluru, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceppi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarswamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgayer, H.</span><span> </span><span class="NLM_article-title">Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2888</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span><span class="refDoi"> DOI: 10.1038/onc.2011.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2011.13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=2888-2899&author=G.+Mudduluruauthor=P.+Ceppiauthor=R.+Kumarswamyauthor=G.+V.+Scagliottiauthor=M.+Papottiauthor=H.+Allgayer&title=Regulation+of+Axl+receptor+tyrosine+kinase+expression+by+miR-34a+and+miR-199a%2Fb+in+solid+cancer&doi=10.1038%2Fonc.2011.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.13%26sid%3Dliteratum%253Aachs%26aulast%3DMudduluru%26aufirst%3DG.%26aulast%3DCeppi%26aufirst%3DP.%26aulast%3DKumarswamy%26aufirst%3DR.%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DPapotti%26aufirst%3DM.%26aulast%3DAllgayer%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520Axl%2520receptor%2520tyrosine%2520kinase%2520expression%2520by%2520miR-34a%2520and%2520miR-199a%252Fb%2520in%2520solid%2520cancer%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D2888%26epage%3D2899%26doi%3D10.1038%2Fonc.2011.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group">Zhang, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+F.+Zhangauthor=J.+C.+Leeauthor=L.+P.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Q.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0lg3Phq9J6Yp9A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BF.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macneill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.cell.2007.11.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+Macneillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.+L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer&doi=10.1016%2Fj.cell.2007.11.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacneill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203%26doi%3D10.1016%2Fj.cell.2007.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group">Shieh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Expression of axl in lung adenocarcinoma and correlation with tumor progression</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1593/neo.05640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1593%2Fneo.05640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1058-1064&author=Y.+S.+Shiehauthor=C.+Y.+Laiauthor=Y.+R.+Kaoauthor=S.+G.+Shiahauthor=Y.+W.+Chuauthor=H.+S.+Leeauthor=C.+W.+Wu&title=Expression+of+axl+in+lung+adenocarcinoma+and+correlation+with+tumor+progression&doi=10.1593%2Fneo.05640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1593%2Fneo.05640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05640%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DKao%26aufirst%3DY.%2BR.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DExpression%2520of%2520axl%2520in%2520lung%2520adenocarcinoma%2520and%2520correlation%2520with%2520tumor%2520progression%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1058%26epage%3D1064%26doi%3D10.1593%2Fneo.05640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hongo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallop, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, L.</span><span> </span><span class="NLM_article-title">Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3442</span><span class="NLM_x">–</span> <span class="NLM_lpage">3455</span><span class="refDoi"> DOI: 10.1038/onc.2009.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2009.212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=3442-3455&author=Y.+Liauthor=X.+Yeauthor=C.+Tanauthor=J.+A.+Hongoauthor=J.+Zhaauthor=J.+Liuauthor=D.+Kallopauthor=M.+J.+Ludlamauthor=L.+Pei&title=Axl+as+a+potential+therapeutic+target+in+cancer%3A+role+of+Axl+in+tumor+growth%2C+metastasis+and+angiogenesis&doi=10.1038%2Fonc.2009.212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.212%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DHongo%26aufirst%3DJ.%2BA.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKallop%26aufirst%3DD.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DPei%26aufirst%3DL.%26atitle%3DAxl%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520cancer%253A%2520role%2520of%2520Axl%2520in%2520tumor%2520growth%252C%2520metastasis%2520and%2520angiogenesis%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D3442%26epage%3D3455%26doi%3D10.1038%2Fonc.2009.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group">Berclaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altermatt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span> </span><span class="NLM_article-title">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1023/A:1011126330233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1023%2FA%3A1011126330233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11484958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=819-824&author=G.+Berclazauthor=H.+J.+Altermattauthor=V.+Rohrbachauthor=I.+Kiefferauthor=E.+Dreherauthor=A.+C.+Andres&title=Estrogen+dependent+expression+of+the+receptor+tyrosine+kinase+axl+in+normal+and+malignant+human+breast&doi=10.1023%2FA%3A1011126330233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span></div><div class="casAuthors">Berclaz G; Altermatt H J; Rohrbach V; Kieffer I; Dreher E; Andres A C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-24</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Axl, a member of a family of receptor tyrosine kinases characterized by an extracellular domain resembling cell adhesion molecules and an intracellular conserved tyrosine kinase domain has been reported to induce cell proliferation and transformation.  In mice, axl is expressed in the normal mammary gland and over-expressed in aggressive mammary tumors.  PATIENTS AND METHODS:  We have investigated the expression of axl immunohistochemically in 23 normal human breast samples and in 111 consecutive breast carcinomas.  Expression of axl was correlated with tumour characteristics (lymph node involvement, stage, grade) and immunohistochemical expression of ER, PR, Ki-67 and c-erbB-2.  RESULTS:  In normal tissue, axl localizes to the membrane of breast epithelial cells.  Axl protein shows membrane associated staining in high correlation (P = 0.004) with the expression of the estrogen receptor (ER).  Axl expression was found in a subset of breast carcinomas and was also correlated with high significance (P < 0.0001) with the presence of ER.  CONCLUSION:  Our results suggest that axl may serve as a mediator of estrogen stimulation preventing the completion of the breast epithelial life cycle and that estrogen induced axl expression may give a survival signal to cancerous cells, preventing them from dying through apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4jH3dLUflJ91QT_1O5WBYfW6udTcc2eb68LSFRzby4Lntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D&md5=36a9041a5d19646e01b47ea4886e182e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011126330233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011126330233%26sid%3Dliteratum%253Aachs%26aulast%3DBerclaz%26aufirst%3DG.%26aulast%3DAltermatt%26aufirst%3DH.%2BJ.%26aulast%3DRohrbach%26aufirst%3DV.%26aulast%3DKieffer%26aufirst%3DI.%26aulast%3DDreher%26aufirst%3DE.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26atitle%3DEstrogen%2520dependent%2520expression%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520normal%2520and%2520malignant%2520human%2520breast%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D819%26epage%3D824%26doi%3D10.1023%2FA%3A1011126330233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group">Meric, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Expression profile of tyrosine kinases in breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11839650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFegurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=361-367&author=F.+Mericauthor=W.+P.+Leeauthor=A.+Sahinauthor=H.+Zhangauthor=H.+J.+Kungauthor=M.+C.+Hung&title=Expression+profile+of+tyrosine+kinases+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of tyrosine kinases in breast cancer</span></div><div class="casAuthors">Meric, Funda; Lee, Wei-Ping; Sahin, Aysegul; Zhang, Haixia; Kung, Hsing-Jien; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins.  Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior.  Thus, TKs are being actively pursued as therapeutic targets.  The purpose of this study was to det. the expression pattern of TKs in breast cancer.  Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were detd. by digestion with a panel of restriction enzymes.  Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines.  The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines.  Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells.  Several kinases were differentially expressed among the cell lines.  Similar TK profiles were found using RNA from human breast tumors.  We conclude that there is significant variability in the TK expression pattern of breast cancers.  This variability should be considered when selecting TK inhibitors to treat patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW5sVLEPxNrVg90H21EOLACvtfcHk0ljid_lb7kpDug"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFegurw%253D&md5=c110703426c511054849ea0d679b712e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeric%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DExpression%2520profile%2520of%2520tyrosine%2520kinases%2520in%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitok, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periaswamy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span> </span><span class="NLM_article-title">Phosphoproteomic analysis of Her2/neu signaling and inhibition</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9773</span><span class="NLM_x">–</span> <span class="NLM_lpage">9778</span><span class="refDoi"> DOI: 10.1073/pnas.0603948103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0603948103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=16785428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvVajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9773-9778&author=R.+Boseauthor=H.+Molinaauthor=A.+S.+Pattersonauthor=J.+K.+Bitokauthor=B.+Periaswamyauthor=J.+S.+Baderauthor=A.+Pandeyauthor=P.+A.+Cole&title=Phosphoproteomic+analysis+of+Her2%2Fneu+signaling+and+inhibition&doi=10.1073%2Fpnas.0603948103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic analysis of Her2/neu signaling and inhibition</span></div><div class="casAuthors">Bose, Ron; Molina, Henrik; Patterson, A. Scott; Bitok, John K.; Periaswamy, Balamurugan; Bader, Joel S.; Pandey, Akhilesh; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9773-9778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Her2/neu (Her2) is a tyrosine kinase belonging to the EGF receptor (EGFR)/ErbB family and is overexpressed in 20-30% of human breast cancers.  The authors sought to characterize Her2 signal transduction pathways further by using MS-based quant. proteomics.  Stably transfected cell lines overexpressing Her2 or empty vector were generated, and the effect of an EGFR and Her2 selective tyrosine kinase inhibitor, PD168393, on these cells was characterized.  Quant. measurements were obtained on 462 proteins by using the SILAC (stable isotope labeling with amino acids in cell culture) method to monitor three conditions simultaneously.  Of these proteins, 198 showed a significant increase in tyrosine phosphorylation in Her2-overexpressing cells, and 81 showed a significant decrease in phosphorylation.  Treatment of Her2-overexpressing cells with PD168393 showed rapid reversibility of the majority of the Her2-triggered phosphorylation events.  Phosphoproteins that were identified included many known Her2 signaling mols. as well as known EGFR signaling proteins that had not been previously linked to Her2, such as Stat1, Dok1, and δ-catenin.  Importantly, several previously uncharacterized Her2 signaling proteins were identified, including Axl tyrosine kinase, the adaptor protein Fyb, and the calcium-binding protein Pdcd-6/Alg-2.  The authors also identified a phosphorylation site in Her2, Y877, which is located in the activation loop of the kinase domain, is distinct from the known C-terminal tail autophosphorylation sites, and may have important implications for regulation of Her2 signaling.  Network modeling, which combined phosphoproteomic results with literature-curated protein-protein interaction data, was used to suggest roles for some of the previously unidentified Her2 signaling proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnr6Plokluo7Vg90H21EOLACvtfcHk0liOdRxxLnUXYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvVajtro%253D&md5=0f091b606ed216f61981865c0b720f34</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0603948103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0603948103%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DH.%26aulast%3DPatterson%26aufirst%3DA.%2BS.%26aulast%3DBitok%26aufirst%3DJ.%2BK.%26aulast%3DPeriaswamy%26aufirst%3DB.%26aulast%3DBader%26aufirst%3DJ.%2BS.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DPhosphoproteomic%2520analysis%2520of%2520Her2%252Fneu%2520signaling%2520and%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D9773%26epage%3D9778%26doi%3D10.1073%2Fpnas.0603948103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friera, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atchison, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pali, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasaga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogenberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nör, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Multiple roles for the receptor tyrosine kinase axl in tumor formation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">9294</span><span class="NLM_x">–</span> <span class="NLM_lpage">9303</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-05-0993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=9294-9303&author=S.+J.+Hollandauthor=M.+J.+Powellauthor=C.+Franciauthor=E.+W.+Chanauthor=A.+M.+Frieraauthor=R.+E.+Atchisonauthor=J.+McLaughlinauthor=S.+E.+Swiftauthor=E.+S.+Paliauthor=G.+Yamauthor=S.+Wongauthor=J.+Lasagaauthor=M.+R.+Shenauthor=S.+Yuauthor=W.+Xuauthor=Y.+Hitoshiauthor=J.+Bogenbergerauthor=J.+E.+N%C3%B6rauthor=D.+G.+Payanauthor=J.+B.+Lorens&title=Multiple+roles+for+the+receptor+tyrosine+kinase+axl+in+tumor+formation&doi=10.1158%2F0008-5472.CAN-05-0993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0993%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPowell%26aufirst%3DM.%2BJ.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DFriera%26aufirst%3DA.%2BM.%26aulast%3DAtchison%26aufirst%3DR.%2BE.%26aulast%3DMcLaughlin%26aufirst%3DJ.%26aulast%3DSwift%26aufirst%3DS.%2BE.%26aulast%3DPali%26aufirst%3DE.%2BS.%26aulast%3DYam%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLasaga%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DM.%2BR.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHitoshi%26aufirst%3DY.%26aulast%3DBogenberger%26aufirst%3DJ.%26aulast%3DN%25C3%25B6r%26aufirst%3DJ.%2BE.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DMultiple%2520roles%2520for%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520tumor%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D9294%26epage%3D9303%26doi%3D10.1158%2F0008-5472.CAN-05-0993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group">Gjerdrum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Høiby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glackin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1149&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+H%C3%B8ibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0liOdRxxLnUXYQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DH%25C3%25B8iby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1149%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-08-4490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+M.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL&doi=10.1158%2F0008-5472.CAN-08-4490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4490%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878%26doi%3D10.1158%2F0008-5472.CAN-08-4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group">Vajkoczy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelle, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrndt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Tengg-Kobligk, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelsbacher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">5799</span><span class="NLM_x">–</span> <span class="NLM_lpage">5804</span><span class="refDoi"> DOI: 10.1073/pnas.0510923103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0510923103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5799-5804&author=P.+Vajkoczyauthor=P.+Knyazevauthor=A.+Kunkelauthor=H.+H.+Capelleauthor=S.+Behrndtauthor=H.+von+Tengg-Kobligkauthor=F.+Kiesslingauthor=U.+Eichelsbacherauthor=M.+Essigauthor=T.+A.+Readauthor=R.+Erberauthor=A.+Ullrich&title=Dominant-negative+inhibition+of+the+Axl+receptor+tyrosine+kinase+suppresses+brain+tumor+cell+growth+and+invasion+and+prolongs+survival&doi=10.1073%2Fpnas.0510923103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510923103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510923103%26sid%3Dliteratum%253Aachs%26aulast%3DVajkoczy%26aufirst%3DP.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DKunkel%26aufirst%3DA.%26aulast%3DCapelle%26aufirst%3DH.%2BH.%26aulast%3DBehrndt%26aufirst%3DS.%26aulast%3Dvon%2BTengg-Kobligk%26aufirst%3DH.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DEichelsbacher%26aufirst%3DU.%26aulast%3DEssig%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DT.%2BA.%26aulast%3DErber%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DDominant-negative%2520inhibition%2520of%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%2520suppresses%2520brain%2520tumor%2520cell%2520growth%2520and%2520invasion%2520and%2520prolongs%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D5799%26epage%3D5804%26doi%3D10.1073%2Fpnas.0510923103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group">Keating, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulcahy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzberg, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorburn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1307</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-09-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20423999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslektrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1298-1307&author=A.+K.+Keatingauthor=G.+K.+Kimauthor=A.+E.+Jonesauthor=A.+M.+Donsonauthor=K.+Wareauthor=J.+M.+Mulcahyauthor=D.+B.+Salzbergauthor=N.+K.+Foremanauthor=X.+Liangauthor=A.+Thorburnauthor=D.+K.+Graham&title=Inhibition+of+Mer+and+Axl+receptor+tyrosine+kinases+in+astrocytoma+cells+leads+to+increased+apoptosis+and+improved+chemosensitivity&doi=10.1158%2F1535-7163.MCT-09-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity</span></div><div class="casAuthors">Keating, Amy K.; Kim, Grace K.; Jones, Ashley E.; Donson, Andrew M.; Ware, Kathryn; Mulcahy, Jean M.; Salzberg, Dana B.; Foreman, Nicholas K.; Liang, Xiayuan; Thorburn, Andrew; Graham, Douglas K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1298-1307</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Astrocytomas account for the majority of malignant brain tumors diagnosed in both adult and pediatric patients.  The therapies available to treat these neoplasms are limited, and the prognosis assocd. with high-grade lesions is extremely poor.  Mer (MerTK) and Axl receptor tyrosine kinases (RTK) are expressed at abnormally high levels in a variety of malignancies, and these receptors are known to activate strong antiapoptotic signaling pathways that promote oncogenesis.  In this study, the authors found that Mer and Axl mRNA transcript and protein expression were elevated in astrocytic patient samples and cell lines.  ShRNA-mediated knockdown of Mer and Axl RTK expression led to an increase in apoptosis in astrocytoma cells.  Apoptotic signaling pathways including Akt and extracellular signal-regulated kinase 1/2, which have been shown to be activated in resistant astrocytomas, were downregulated with Mer and Axl inhibition, whereas poly(ADP-ribose) polymerase cleavage was increased.  Furthermore, Mer and Axl shRNA knockdown led to a profound decrease of astrocytoma cell proliferation in soft agar and a significant increase in chemosensitivity in response to temozolomide, carboplatin, and vincristine treatment.  The authors' results suggest Mer and Axl RTK inhibition as a novel method to improve apoptotic response and chemosensitivity in astrocytoma and provide support for these oncogenes as attractive biol. targets for astrocytoma drug development.  Mol Cancer Ther; 9(5); 1298-307.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPZlqtANWfZbVg90H21EOLACvtfcHk0li2nPo2G1y3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslektrY%253D&md5=04e8a0c70eba12c28f58a989131ab885</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0707%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BK.%26aulast%3DJones%26aufirst%3DA.%2BE.%26aulast%3DDonson%26aufirst%3DA.%2BM.%26aulast%3DWare%26aufirst%3DK.%26aulast%3DMulcahy%26aufirst%3DJ.%2BM.%26aulast%3DSalzberg%26aufirst%3DD.%2BB.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DThorburn%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DInhibition%2520of%2520Mer%2520and%2520Axl%2520receptor%2520tyrosine%2520kinases%2520in%2520astrocytoma%2520cells%2520leads%2520to%2520increased%2520apoptosis%2520and%2520improved%2520chemosensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1298%26epage%3D1307%26doi%3D10.1158%2F1535-7163.MCT-09-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group">Sainaghi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamasco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G. C.</span><span> </span><span class="NLM_article-title">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/jcp.20265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1002%2Fjcp.20265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=15605394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=36-44&author=P.+P.+Sainaghiauthor=L.+Castelloauthor=L.+Bergamascoauthor=M.+Gallettiauthor=P.+Bellostaauthor=G.+C.+Avanzi&title=Gas6+induces+proliferation+in+prostate+carcinoma+cell+lines+expressing+the+Axl+receptor&doi=10.1002%2Fjcp.20265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span></div><div class="casAuthors">Sainaghi, Pier Paolo; Castello, Luigi; Bergamasco, Luca; Galletti, Margherita; Bellosta, Paola; Avanzi, Gian Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Axl is a Tyr kinase receptor and although it is expressed in malignancy such as leukemia, colon cancer, melanoma, endometrial, prostate and thyroid cancers, its role was not completely elucidated yet and appears to be complex.  The ligand of Axl, Gas6, is a 75 KDa multimodular protein with an N-terminal γ-carboxy-glutamic acid that is essential for binding.  Gas6 has a mitogenic effect on several normal cell lines.  The receptor Axl is expressed in primary prostate carcinoma and in prostate cancer cell lines as such as PC-3 and DU 145.  We demonstrated a mitogenic activity detd. by Gas6/Axl interaction in these undifferentiated metastatic human prostatic cancer cell lines.  This effect is proportional to Axl expression, not due to inhibition of apoptosis, and induces AKT and MAPK phosphorylation.  However, only MEK phosphorylation seems to be essential for growth signaling.  Our results suggest that Axl overexpression and activation by Gas6 could be involved in progression of prostate neoplastic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNkOPWaojibVg90H21EOLACvtfcHk0li2nPo2G1y3tw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D&md5=21e2ec8a6dab885ea9dcfed641c71f9c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20265%26sid%3Dliteratum%253Aachs%26aulast%3DSainaghi%26aufirst%3DP.%2BP.%26aulast%3DCastello%26aufirst%3DL.%26aulast%3DBergamasco%26aufirst%3DL.%26aulast%3DGalletti%26aufirst%3DM.%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DG.%2BC.%26atitle%3DGas6%2520induces%2520proliferation%2520in%2520prostate%2520carcinoma%2520cell%2520lines%2520expressing%2520the%2520Axl%2520receptor%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D36%26epage%3D44%26doi%3D10.1002%2Fjcp.20265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witzkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0liVfMBI4yKdJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitzke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group">Hart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boer, R. H.</span><span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0liVfMBI4yKdJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R. H.</span><span> </span><span class="NLM_article-title">Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1093/carcin/bgt372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1093%2Fcarcin%2Fbgt372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=769-775&author=H.+J.+Leeauthor=Y.+M.+Jengauthor=Y.+L.+Chenauthor=L.+Chungauthor=R.+H.+Yuan&title=Gas6%2FAxl+pathway+promotes+tumor+invasion+through+the+transcriptional+activation+of+Slug+in+hepatocellular+carcinoma&doi=10.1093%2Fcarcin%2Fbgt372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgt372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgt372%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DJeng%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DChung%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DR.%2BH.%26atitle%3DGas6%252FAxl%2520pathway%2520promotes%2520tumor%2520invasion%2520through%2520the%2520transcriptional%2520activation%2520of%2520Slug%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26spage%3D769%26epage%3D775%26doi%3D10.1093%2Fcarcin%2Fbgt372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2&doi=10.1158%2F1078-0432.CCR-10-0574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0lj8CvUrQ8Mekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-10-0574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0lj8CvUrQ8Mekw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckrodt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apatira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+Axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-2997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520Axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.CAN-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lh-ePnnrgaElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0lh-ePnnrgaElQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> (accessed Sep 30,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+%28accessed+Sep+30%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-11-0264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lhknw968KsTwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308%26doi%3D10.1158%2F1535-7163.MCT-11-0264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainwaring, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donskov, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltola, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Géczi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman-Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span> </span><span class="NLM_article-title">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="refDoi"> DOI: 10.1056/NEJMoa1510016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1510016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=26406150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1814&author=T.+K.+Choueiriauthor=B.+Escudierauthor=T.+Powlesauthor=P.+N.+Mainwaringauthor=B.+I.+Riniauthor=F.+Donskovauthor=H.+Hammersauthor=T.+E.+Hutsonauthor=J.+L.+Leeauthor=K.+Peltolaauthor=B.+J.+Rothauthor=G.+A.+Bjarnasonauthor=L.+G%C3%A9cziauthor=B.+Keamauthor=P.+Marotoauthor=D.+Y.+Hengauthor=M.+Schmidingerauthor=P.+W.+Kantoffauthor=A.+Borgman-Hageyauthor=C.+Hesselauthor=C.+Scheffoldauthor=G.+M.+Schwabauthor=N.+M.+Tannirauthor=R.+J.+Motzer&title=Cabozantinib+versus+everolimus+in+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa1510016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span></div><div class="casAuthors">Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J.-L.; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Geczi, L.; Keam, B.; Maroto, P.; Heng, D. Y. C.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1814-1823</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cabozantinib is an oral, small-mol. tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiol. of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.  This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.  We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily.  The primary end point was progression- free survival.  Secondary efficacy end points were overall survival and objective response rate.  Median progression-free survival was 7.4 mo with cabozantinib and 3.8 mo with everolimus.  The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001).  The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001).  A planned interim anal. showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary for the interim anal.  Adverse events were managed with dose redns.; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus.  Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.  Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvjc8n5w4zbVg90H21EOLACvtfcHk0lhknw968KsTwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D&md5=09927cde8f581f4ff2060679df1ff5b8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510016%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DDonskov%26aufirst%3DF.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DPeltola%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DB.%2BJ.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DG%25C3%25A9czi%26aufirst%3DL.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DD.%2BY.%26aulast%3DSchmidinger%26aufirst%3DM.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBorgman-Hagey%26aufirst%3DA.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DG.%2BM.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DCabozantinib%2520versus%2520everolimus%2520in%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1814%26doi%3D10.1056%2FNEJMoa1510016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group">Yan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peek, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidler, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konicek, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manro, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlik, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walgren, R. A.</span><span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.+H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+MET%2C+MST1R%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0lglSUdYGukaNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.%2BH.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520MET%252C%2520MST1R%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1790</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-1790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1538-7445.AM2012-1790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis&doi=10.1158%2F1538-7445.AM2012-1790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1790%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1790%26doi%3D10.1158%2F1538-7445.AM2012-1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0lglSUdYGukaNQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group">Paolino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choidas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pranjic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uribesalgo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langdon, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fededa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterleitner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penninger, J. M.</span><span> </span><span class="NLM_article-title">The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">507</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span><span class="refDoi"> DOI: 10.1038/nature12998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnature12998" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=507&publication_year=2014&pages=508-512&author=M.+Paolinoauthor=A.+Choidasauthor=S.+Wallnerauthor=B.+Pranjicauthor=I.+Uribesalgoauthor=S.+Loeserauthor=A.+M.+Jamiesonauthor=W.+Y.+Langdonauthor=F.+Ikedaauthor=J.+P.+Fededaauthor=S.+J.+Croninauthor=R.+Nitschauthor=C.+Schultz-Fademrechtauthor=J.+Eickhoffauthor=S.+Menningerauthor=A.+Ungerauthor=R.+Torkaauthor=T.+Gruberauthor=R.+Hinterleitnerauthor=G.+Baierauthor=D.+Wolfauthor=A.+Ullrichauthor=B.+M.+Kleblauthor=J.+M.+Penninger&title=The+E3+ligase+Cbl-b+and+TAM+receptors+regulate+cancer+metastasis+via+natural+killer+cells&doi=10.1038%2Fnature12998"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature12998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12998%26sid%3Dliteratum%253Aachs%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DWallner%26aufirst%3DS.%26aulast%3DPranjic%26aufirst%3DB.%26aulast%3DUribesalgo%26aufirst%3DI.%26aulast%3DLoeser%26aufirst%3DS.%26aulast%3DJamieson%26aufirst%3DA.%2BM.%26aulast%3DLangdon%26aufirst%3DW.%2BY.%26aulast%3DIkeda%26aufirst%3DF.%26aulast%3DFededa%26aufirst%3DJ.%2BP.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DNitsch%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DTorka%26aufirst%3DR.%26aulast%3DGruber%26aufirst%3DT.%26aulast%3DHinterleitner%26aufirst%3DR.%26aulast%3DBaier%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DD.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DKlebl%26aufirst%3DB.%2BM.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520E3%2520ligase%2520Cbl-b%2520and%2520TAM%2520receptors%2520regulate%2520cancer%2520metastasis%2520via%2520natural%2520killer%2520cells%26jtitle%3DNature%26date%3D2014%26volume%3D507%26spage%3D508%26epage%3D512%26doi%3D10.1038%2Fnature12998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group">Sholl, L.</span><span> </span><span class="NLM_article-title">Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring <i>AXL</i> Amplification</span>. Presented at the IASLC 16th World Conference on Lung Cancer, Denver, CO,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>3611.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Sholl&title=Evaluation+of+the+MET%2FAxl+Receptor+Tyrosine+Kinase+%28RTK%29+Inhibitor+MGCD265+in+a+Patient+with+Metastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+Harboring+AXL+Amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSholl%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520the%2520MET%252FAxl%2520Receptor%2520Tyrosine%2520Kinase%2520%2528RTK%2529%2520Inhibitor%2520MGCD265%2520in%2520a%2520Patient%2520with%2520Metastatic%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520Harboring%2520AXL%2520Amplification%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group">Messoussi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyronnet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bougrin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">16223</span><span class="NLM_x">–</span> <span class="NLM_lpage">16239</span><span class="refDoi"> DOI: 10.3390/molecules191016223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.3390%2Fmolecules191016223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=16223-16239&author=A.+Messoussiauthor=L.+Peyronnetauthor=C.+Feneyrollesauthor=G.+Cheveauthor=K.+Bougrinauthor=A.+Yasri&title=Structural+elucidation+of+the+DFG-Asp+in+and+DFG-Asp+out+states+of+TAM+kinases+and+insight+into+the+selectivity+of+their+inhibitors&doi=10.3390%2Fmolecules191016223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191016223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191016223%26sid%3Dliteratum%253Aachs%26aulast%3DMessoussi%26aufirst%3DA.%26aulast%3DPeyronnet%26aufirst%3DL.%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DCheve%26aufirst%3DG.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DStructural%2520elucidation%2520of%2520the%2520DFG-Asp%2520in%2520and%2520DFG-Asp%2520out%2520states%2520of%2520TAM%2520kinases%2520and%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D16223%26epage%3D16239%26doi%3D10.3390%2Fmolecules191016223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1038/leu.2008.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+M%C3%BCllerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells&doi=10.1038%2Fleu.2008.334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0lhXiInDaM8zVA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485%26doi%3D10.1038%2Fleu.2008.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheburkin, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kéri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">AXL is a potential target for therapeutic intervention in breast cancer progression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1905</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-07-2661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1905-1915&author=Y.+X.+Zhangauthor=P.+G.+Knyazevauthor=Y.+V.+Cheburkinauthor=K.+Sharmaauthor=Y.+P.+Knyazevauthor=L.+Orfiauthor=I.+Szabadkaiauthor=H.+Daubauthor=G.+K%C3%A9riauthor=A.+Ullrich&title=AXL+is+a+potential+target+for+therapeutic+intervention+in+breast+cancer+progression&doi=10.1158%2F0008-5472.CAN-07-2661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DKnyazev%26aufirst%3DP.%2BG.%26aulast%3DCheburkin%26aufirst%3DY.%2BV.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DKnyazev%26aufirst%3DY.%2BP.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAXL%2520is%2520a%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520breast%2520cancer%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1905%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-07-2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0ljL5cbXFB2U6g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAXL+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAXL%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group">Annesley, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P.</span><span> </span><span class="NLM_article-title">The biology and targeting of FLT3 in pediatric leukemia</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="refDoi"> DOI: 10.3389/fonc.2014.00263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.3389%2Ffonc.2014.00263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25295230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC2M7os1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=263&author=C.+E.+Annesleyauthor=P.+Brown&title=The+biology+and+targeting+of+FLT3+in+pediatric+leukemia&doi=10.3389%2Ffonc.2014.00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The Biology and Targeting of FLT3 in Pediatric Leukemia</span></div><div class="casAuthors">Annesley Colleen E; Brown Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite remarkable improvement in treatment outcomes in pediatric leukemia over the past several decades, the prognosis for high-risk groups of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as for relapsed leukemia, remains poor.  Intensification of chemotherapy regimens for those at highest risk has improved success rates, but at the cost of significantly increased morbidity and long-term adverse effects.  With the success of imatinib in Philadelphia-chromosome-positive leukemia and all-trans retinoic acid in acute promyelocytic leukemia, the quest to find additional molecularly targeted therapies has generated much excitement over recent years.  Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3).  FLT3 aberrations are among the most frequently identified transforming events in AML, and have significant clinical implications in both high-risk pediatric AML and in certain high-risk groups of pediatric ALL.  Therefore, the successful targeting of FLT3 has tremendous potential to improve outcomes in these subsets of patients.  This article will give an overview of the molecular function and signaling of the FLT3 receptor, as well as its pathogenic role in leukemia.  We review the discovery of targeting FLT3, discuss currently available FLT3 inhibitors in pediatric leukemia and results of clinical trials to date, and finally, consider the future promise and challenges of FLT3 inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuFK2u7sSOZJdYoSR9eyvsfW6udTcc2eaiWohvqG6NFLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7os1eluw%253D%253D&md5=b263d4c239232c8eb102fa9cada4be4c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00263%26sid%3Dliteratum%253Aachs%26aulast%3DAnnesley%26aufirst%3DC.%2BE.%26aulast%3DBrown%26aufirst%3DP.%26atitle%3DThe%2520biology%2520and%2520targeting%2520of%2520FLT3%2520in%2520pediatric%2520leukemia%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D263%26doi%3D10.3389%2Ffonc.2014.00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saso, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, N. T.</span><span> </span><span class="NLM_article-title">TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6525</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-0967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-0967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6516-6525&author=X.+Wangauthor=H.+Sasoauthor=T.+Iwamotoauthor=W.+Xiaauthor=Y.+Gongauthor=L.+Pusztaiauthor=W.+A.+Woodwardauthor=J.+M.+Reubenauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=G.+N.+Hortobagyiauthor=M.+C.+Hungauthor=N.+T.+Ueno&title=TIG1+promotes+the+development+and+progression+of+inflammatory+breast+cancer+through+activation+of+Axl+kinase&doi=10.1158%2F0008-5472.CAN-13-0967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-0967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-0967%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSaso%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DTIG1%2520promotes%2520the%2520development%2520and%2520progression%2520of%2520inflammatory%2520breast%2520cancer%2520through%2520activation%2520of%2520Axl%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6516%26epage%3D6525%26doi%3D10.1158%2F0008-5472.CAN-13-0967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group">Mollard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1021/ml200198x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200198x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=907-912&author=A.+Mollardauthor=S.+L.+Warnerauthor=L.+T.+Callauthor=M.+L.+Wadeauthor=J.+J.+Bearssauthor=A.+Vermaauthor=S.+Sharmaauthor=H.+Vankayalapatiauthor=D.+J.+Bearss&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+novel+AXL+kinase+inhibitors&doi=10.1021%2Fml200198x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fml200198x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200198x%26sid%3Dliteratum%253Aachs%26aulast%3DMollard%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCall%26aufirst%3DL.%2BT.%26aulast%3DWade%26aufirst%3DM.%2BL.%26aulast%3DBearss%26aufirst%3DJ.%2BJ.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520AXL%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D907%26epage%3D912%26doi%3D10.1021%2Fml200198x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+Crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0lgC7CTQRmnXjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3389</span><span class="NLM_x">–</span> <span class="NLM_lpage">3395</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+alterations+of+anaplastic+lymphoma+kinase+may+sensitize+tumors+to+anaplastic+lymphoma+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-07-6186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0lgC7CTQRmnXjQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520alterations%2520of%2520anaplastic%2520lymphoma%2520kinase%2520may%2520sensitize%2520tumors%2520to%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395%26doi%3D10.1158%2F0008-5472.CAN-07-6186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lgvj50WK7QC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1006448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1006448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0lgvj50WK7QC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1006448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crinó, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crin%C3%B3author=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%E2%80%99Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+J%C3%A4nne&title=Crizotinib+versus+chemotherapy+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0lgvj50WK7QC5g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrin%25C3%25B3%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520chemotherapy%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group">Sahu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabhash, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span> </span><span class="NLM_article-title">Crizotinib: A comprehensive review</span> <span class="citation_source-journal">South Asian J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.4103/2278-330X.110506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.4103%2F2278-330X.110506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24455567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsFOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=91-97&author=A.+Sahuauthor=K.+Prabhashauthor=V.+Noronhaauthor=A.+Joshiauthor=S.+Desai&title=Crizotinib%3A+A+comprehensive+review&doi=10.4103%2F2278-330X.110506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib: A comprehensive review</span></div><div class="casAuthors">Sahu Arvind; Prabhash Kumar; Noronha Vanita; Joshi Amit; Desai Saral</div><div class="citationInfo"><span class="NLM_cas:title">South Asian journal of cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-7</span>
        ISSN:<span class="NLM_cas:issn">2278-330X</span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers.  ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib.  The integration of crizotinib into standard treatment practice in NSCLC will rest on the widespread implementation of an effective screening system for newly diagnosed patients with NSCLC which is flexible enough to incorporate new targets as treatments are developed for them.  Phase I and II studies of crizotinib in ALK-positive lung cancer have demonstrated significant activity and impressive clinical benefit, which led to its early approval by USFDA in 2011.  Although crizotinib induces remissions and extends the lives of patients, there have been reports of emerging resistance to Crizotinib therapy.  In this review, we discuss the history, mechanism of action, uses, adverse effects, dose modifications and future challenges and opportunities for patients with ALK-positive lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0KN9U3mPo0Nj_Vg2vObihfW6udTcc2ebgd8SmkCO1Yrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsFOhuw%253D%253D&md5=672452a3d9d60dc8cc439f8d79e4f3b4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.4103%2F2278-330X.110506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2278-330X.110506%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DA.%26aulast%3DPrabhash%26aufirst%3DK.%26aulast%3DNoronha%26aufirst%3DV.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DS.%26atitle%3DCrizotinib%253A%2520A%2520comprehensive%2520review%26jtitle%3DSouth%2520Asian%2520J.%2520Cancer%26date%3D2013%26volume%3D2%26spage%3D91%26epage%3D97%26doi%3D10.4103%2F2278-330X.110506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crinò, L.</span><span> </span><span class="NLM_article-title">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2014.59.0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25624436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1881&author=D.+B.+Costaauthor=A.+T.+Shawauthor=S.+H.+Ouauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=M.+J.+Ahnauthor=C.+Zhouauthor=S.+M.+Shreeveauthor=P.+Selaruauthor=A.+Polliauthor=P.+Schnellauthor=K.+D.+Wilnerauthor=R.+Wiltshireauthor=D.+R.+Camidgeauthor=L.+Crin%C3%B2&title=Clinical+experience+with+crizotinib+in+patients+with+advanced+ALK-rearranged+non-small-cell+lung+cancer+and+brain+metastases&doi=10.1200%2FJCO.2014.59.0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span></div><div class="casAuthors">Costa, Daniel B.; Shaw, Alice T.; Ou, Sai-Hong I.; Solomon, Benjamin J.; Riely, Gregory J.; Ahn, Myung-Ju; Zhou, Caicun; Shreeve, S. Martin; Selaru, Paulina; Polli, Anna; Schnell, Patrick; Wilner, Keith D.; Wiltshire, Robin; Camidge, D. Ross; Crino, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1881-1888</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  The clin. benefits of crizotinib in patients with brain metastases have not been previously studied.  Patients and Methods Patients with advanced ALK-rearranged NSCLC enrolled onto clin. trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included in this retrospective anal.  Patients with asymptomatic brain metastases (nontarget or target lesions) were allowed to enroll.  Tumor assessments were evaluated every 6 wk using RECIST (version 1.1).  Results At baseline, 31% of patients (275 of 888) had asymptomatic brain metastases; 109 had received no prior and 166 had received prior brain radiotherapy as treatment.  Among patients with previously untreated asymptomatic brain metastases, the systemic disease control rate (DCR) at 12 wk was 63% (95% CI, 54% to 72%), the intracranial DCR was 56% (95% CI, 46% to 66%), and the median intracranial time to progression (TTP) was 7 mo (95% CI, 6.7 to 16.4).  Among patients with previously treated brain metastases, the systemic DCR was 65% (95% CI, 57% to 72%), the intracranial DCR was 62% (95% CI, 54% to 70%), and the median intracranial TTP was 13.2 mo (95% CI, 9.9 to not reached).  Patients with systemic disease control were also likely to experience intracranial disease control at 12 wk (correlation coeff., 0.7652; P <.001).  Among patients without baseline brain metastases who developed progressive disease (n = 253) after initiation of crizotinib, 20% were diagnosed with brain metastases.  Conclusion Crizotinib was assocd. with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases.  However, progression of preexisting or development of new intracranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokOoSZRSEa-bVg90H21EOLACvtfcHk0lgQynWNDcPHIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM&md5=a398b73ebd0163c33c7805ffb17aabab</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0539%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DWiltshire%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DCrin%25C3%25B2%26aufirst%3DL.%26atitle%3DClinical%2520experience%2520with%2520crizotinib%2520in%2520patients%2520with%2520advanced%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520and%2520brain%2520metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1881%26doi%3D10.1200%2FJCO.2014.59.0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swart, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Croce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakalya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garewal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span> </span><span class="NLM_article-title">A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3909</span><span class="NLM_x">–</span> <span class="NLM_lpage">3919</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1210173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3909-3919&author=D.+Mahadevanauthor=L.+Cookeauthor=C.+Rileyauthor=R.+Swartauthor=B.+Simonsauthor=K.+Della+Croceauthor=L.+Wisnerauthor=M.+Iorioauthor=K.+Shakalyaauthor=H.+Garewalauthor=R.+Nagleauthor=D.+Bearss&title=A+novel+tyrosine+kinase+switch+is+a+mechanism+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1038%2Fsj.onc.1210173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210173%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DCooke%26aufirst%3DL.%26aulast%3DRiley%26aufirst%3DC.%26aulast%3DSwart%26aufirst%3DR.%26aulast%3DSimons%26aufirst%3DB.%26aulast%3DDella%2BCroce%26aufirst%3DK.%26aulast%3DWisner%26aufirst%3DL.%26aulast%3DIorio%26aufirst%3DM.%26aulast%3DShakalya%26aufirst%3DK.%26aulast%3DGarewal%26aufirst%3DH.%26aulast%3DNagle%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26atitle%3DA%2520novel%2520tyrosine%2520kinase%2520switch%2520is%2520a%2520mechanism%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3909%26epage%3D3919%26doi%3D10.1038%2Fsj.onc.1210173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group">Asiedu, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp-Perez, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radisky, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, K. L.</span><span> </span><span class="NLM_article-title">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.1038/onc.2013.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2013.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23474758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1316-1324&author=M.+K.+Asieduauthor=F.+D.+Beauchamp-Perezauthor=J.+N.+Ingleauthor=M.+D.+Behrensauthor=D.+C.+Radiskyauthor=K.+L.+Knutson&title=AXL+induces+epithelial-to-mesenchymal+transition+and+regulates+the+function+of+breast+cancer+stem+cells&doi=10.1038%2Fonc.2013.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span></div><div class="casAuthors">Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease.  It is becoming increasingly clear that a rare subpopulation of cells known as cancer stem cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases.  This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs.  Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent pos. feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance.  Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs.  AXL expression was also found to be assocd. with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration.  Inactivation of AXL also led to the downregulation of nuclear factor-κB pathway and reduced tumor formation in vivo.  Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3FaG5OgnVrVg90H21EOLACvtfcHk0lgQynWNDcPHIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D&md5=a30463cda3288fbc2c92d712f7ef43a8</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.57%26sid%3Dliteratum%253Aachs%26aulast%3DAsiedu%26aufirst%3DM.%2BK.%26aulast%3DBeauchamp-Perez%26aufirst%3DF.%2BD.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DBehrens%26aufirst%3DM.%2BD.%26aulast%3DRadisky%26aufirst%3DD.%2BC.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26atitle%3DAXL%2520induces%2520epithelial-to-mesenchymal%2520transition%2520and%2520regulates%2520the%2520function%2520of%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1316%26epage%3D1324%26doi%3D10.1038%2Fonc.2013.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group">Choy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi-Hangal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oganesian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1007/s00280-012-1821-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs00280-012-1821-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22349808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFajtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=183-190&author=G.+Choyauthor=R.+Joshi-Hangalauthor=A.+Oganesianauthor=G.+Fineauthor=S.+Rasmussenauthor=J.+Collierauthor=J.+Kisslingauthor=A.+Sahaiauthor=M.+Azabauthor=S.+Redkar&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+amuvatinib+from+three+phase+1+clinical+studies+in+healthy+volunteers&doi=10.1007%2Fs00280-012-1821-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers</span></div><div class="casAuthors">Choy, Gavin; Joshi-Hangal, Rajashree; Oganesian, Aram; Fine, Gil; Rasmussen, Scott; Collier, Joanne; Kissling, James; Sahai, Amarpal; Azab, Mohammad; Redkar, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Amuvatinib is a multi-targeted tyrosine kinase inhibitor with activity that also disrupts DNA damage repair through suppression of homologous recombination protein Rad51.  Amuvatinib dry-powder capsules (DPC) showed evidence of activity in early Phase 1 cancer studies but low systemic exposure.  The purposes of the studies were to investigate the cause of low exposure, develop, and test an alternative formulation with improved exposure, and establish the dose to be tested in future studies in cancer patients.  Methods: Three studies were conducted in a total of 58 healthy subjects: a food-effect study using amuvatinib DPC, a single-dose pharmacokinetic study comparing amuvatinib DPC to a new lipid-suspension capsules (LSC), and a multiple-dose pharmacokinetic study using amuvatinib LSC.  Results: A high-fat meal administered with amuvatinib DPC increased the rate and extent of absorption compared to the Fasted state, a 183 and 118% increase in the mean C max and AUC0-∞ of amuvatinib, resp.  The single-dose pharmacokinetics of amuvatinib LSC resulted in an approx. two-third-fold increased exposure (AUC) compared with amuvatinib DPC.  The multiple-dose pharmacokinetics of the amuvatinib LSC 300 mg administered every 8 h exhibited improved accumulation compared with the 12-h regimens and achieved presumed therapeutic level safely with no serious or severe adverse events reported.  No subject discontinued treatment due to an adverse event.  Conclusion: Amuvatinib LSC, 300 mg every 8 h, is being studied in cancer patients based on the improved exposure and similar safety profile to amuvatinib DPC.  A lipid-based formulation approach may be a useful tool for other low aq. sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrfzwPS5trbVg90H21EOLACvtfcHk0lijHOE54a0X8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFajtrs%253D&md5=4f53982982b318b548759783cfbb7a75</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1821-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1821-2%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DG.%26aulast%3DJoshi-Hangal%26aufirst%3DR.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DFine%26aufirst%3DG.%26aulast%3DRasmussen%26aufirst%3DS.%26aulast%3DCollier%26aufirst%3DJ.%26aulast%3DKissling%26aufirst%3DJ.%26aulast%3DSahai%26aufirst%3DA.%26aulast%3DAzab%26aufirst%3DM.%26aulast%3DRedkar%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520amuvatinib%2520from%2520three%2520phase%25201%2520clinical%2520studies%2520in%2520healthy%2520volunteers%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26spage%3D183%26epage%3D190%26doi%3D10.1007%2Fs00280-012-1821-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaros, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7031</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span><span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0lijHOE54a0X8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deryckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayakody, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0lijHOE54a0X8g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group">Schlegel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambade, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winges, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tentler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolaishvili-Feinberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midkiff, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">MERTK receptor tyrosine kinase is a therapeutic target in melanoma</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2257</span><span class="NLM_x">–</span> <span class="NLM_lpage">2267</span><span class="refDoi"> DOI: 10.1172/JCI67816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1172%2FJCI67816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2257-2267&author=J.+Schlegelauthor=M.+J.+Sambadeauthor=S.+Satherauthor=S.+J.+Moschosauthor=A.+C.+Tanauthor=A.+Wingesauthor=D.+DeRyckereauthor=C.+C.+Carsonauthor=D.+G.+Trembathauthor=J.+J.+Tentlerauthor=S.+G.+Eckhardtauthor=P.+F.+Kuanauthor=R.+L.+Hamiltonauthor=L.+M.+Duncanauthor=C.+R.+Millerauthor=N.+Nikolaishvili-Feinbergauthor=B.+R.+Midkiffauthor=J.+Liuauthor=W.+Zhangauthor=C.+Yangauthor=X.+Wangauthor=S.+V.+Fryeauthor=H.+S.+Earpauthor=J.+M.+Shieldsauthor=D.+K.+Graham&title=MERTK+receptor+tyrosine+kinase+is+a+therapeutic+target+in+melanoma&doi=10.1172%2FJCI67816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1172%2FJCI67816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI67816%26sid%3Dliteratum%253Aachs%26aulast%3DSchlegel%26aufirst%3DJ.%26aulast%3DSambade%26aufirst%3DM.%2BJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DWinges%26aufirst%3DA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DCarson%26aufirst%3DC.%2BC.%26aulast%3DTrembath%26aufirst%3DD.%2BG.%26aulast%3DTentler%26aufirst%3DJ.%2BJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DKuan%26aufirst%3DP.%2BF.%26aulast%3DHamilton%26aufirst%3DR.%2BL.%26aulast%3DDuncan%26aufirst%3DL.%2BM.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DNikolaishvili-Feinberg%26aufirst%3DN.%26aulast%3DMidkiff%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DShields%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DMERTK%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2257%26epage%3D2267%26doi%3D10.1172%2FJCI67816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group">Burbridge, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léonce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Violante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzom, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacquet-Bescond, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierré, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span> </span><span class="NLM_article-title">S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1762</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-13-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1749-1762&author=M.+F.+Burbridgeauthor=C.+J.+Bossardauthor=C.+Saunierauthor=I.+Fejesauthor=A.+Brunoauthor=S.+L%C3%A9onceauthor=G.+Ferryauthor=G.+Da+Violanteauthor=F.+Bouzomauthor=V.+Cattanauthor=A.+Jacquet-Bescondauthor=P.+M.+Comoglioauthor=B.+P.+Lockhartauthor=J.+A.+Boutinauthor=A.+Cordiauthor=J.+C.+Ortunoauthor=A.+Pierr%C3%A9author=J.+A.+Hickmanauthor=F.+H.+Cruzaleguiauthor=S.+Depil&title=S49076+is+a+novel+kinase+inhibitor+of+MET%2C+AXL%2C+and+FGFR+with+strong+preclinical+activity+alone+and+in+association+with+bevacizumab&doi=10.1158%2F1535-7163.MCT-13-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab</span></div><div class="casAuthors">Burbridge, Mike F.; Bossard, Celine J.; Saunier, Carine; Fejes, Imre; Bruno, Alain; Leonce, Stephane; Ferry, Gilles; Da Violante, Georges; Bouzom, Francois; Cattan, Valerie; Jacquet-Bescond, Anne; Comoglio, Paolo M.; Lockhart, Brian P.; Boutin, Jean A.; Cordi, Alex; Ortuno, Jean-Claude; Pierre, Alain; Hickman, John A.; Cruzalegui, Francisco H.; Depil, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1749-1762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been assocd. with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies.  This study describes the preclin. characterization of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3.  S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo.  In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL.  In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth.  MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab.  Accordingly, combination of S49076 with bevacizumab in colon carcinoma xenograft models led to near total inhibition of tumor growth.  Moreover, S49076 alone caused tumor growth arrest in bevacizumab-resistant tumors.  On the basis of these preclin. studies showing a favorable and novel pharmacol. profile of S49076, a phase I study is currently underway in patients with advanced solid tumors.  Mol Cancer Ther; 12(9); 1749-62. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodE4VwyiV-HrVg90H21EOLACvtfcHk0ljZkPPf-2pDCQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O&md5=a53009f7a7b0601cf45598ca5b8775c2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0075%26sid%3Dliteratum%253Aachs%26aulast%3DBurbridge%26aufirst%3DM.%2BF.%26aulast%3DBossard%26aufirst%3DC.%2BJ.%26aulast%3DSaunier%26aufirst%3DC.%26aulast%3DFejes%26aufirst%3DI.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DL%25C3%25A9once%26aufirst%3DS.%26aulast%3DFerry%26aufirst%3DG.%26aulast%3DDa%2BViolante%26aufirst%3DG.%26aulast%3DBouzom%26aufirst%3DF.%26aulast%3DCattan%26aufirst%3DV.%26aulast%3DJacquet-Bescond%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DOrtuno%26aufirst%3DJ.%2BC.%26aulast%3DPierr%25C3%25A9%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DCruzalegui%26aufirst%3DF.%2BH.%26aulast%3DDepil%26aufirst%3DS.%26atitle%3DS49076%2520is%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520MET%252C%2520AXL%252C%2520and%2520FGFR%2520with%2520strong%2520preclinical%2520activity%2520alone%2520and%2520in%2520association%2520with%2520bevacizumab%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1749%26epage%3D1762%26doi%3D10.1158%2F1535-7163.MCT-13-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1634%2Ftheoncologist.2012-0044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1108-1113&author=G.+M.+Blumenthalauthor=P.+Cortazarauthor=J.+Zhangauthor=S.+Tangauthor=R.+Sridharaauthor=A.+Murgoauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+sunitinib+for+the+treatment+of+progressive+well-differentiated+locally+advanced+or+metastatic+pancreatic+neuroendocrine+tumors&doi=10.1634%2Ftheoncologist.2012-0044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0044%26sid%3Dliteratum%253Aachs%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCortazar%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520progressive%2520well-differentiated%2520locally%2520advanced%2520or%2520metastatic%2520pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26spage%3D1108%26epage%3D1113%26doi%3D10.1634%2Ftheoncologist.2012-0044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0liCmxXuk5ndJw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-X+36. 5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span><span class="refDoi"> DOI: 10.1021/jm051106d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-X%2B36.+5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-+2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor&doi=10.1021%2Fjm051106d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-X%252B36.%25205-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-%25202-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146%26doi%3D10.1021%2Fjm051106d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1945</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bmcl.2008.01.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1945-1951&author=G.+M.+Schroederauthor=X.+T.+Chenauthor=D.+K.+Williamsauthor=D.+S.+Nirschlauthor=Z.+W.+Caiauthor=D.+Weiauthor=J.+S.+Tokarskiauthor=Y.+Anauthor=J.+Sackauthor=Z.+Chenauthor=T.+Huynhauthor=W.+Vaccaroauthor=M.+Possauthor=B.+Wautletauthor=J.+Gullo-Brownauthor=K.+Kellarauthor=V.+Manneauthor=J.+T.+Huntauthor=T.+W.+Wongauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Identification+of+pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazine-based+inhibitors+of+Met+kinase&doi=10.1016%2Fj.bmcl.2008.01.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.121%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DKellar%26aufirst%3DK.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazine-based%2520inhibitors%2520of%2520Met%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1945%26epage%3D1951%26doi%3D10.1016%2Fj.bmcl.2008.01.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3224</span><span class="NLM_x">–</span> <span class="NLM_lpage">3229</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bmcl.2008.04.047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3224-3229&author=Z.+W.+Caiauthor=D.+Weiauthor=G.+M.+Schroederauthor=L.+A.+Corneliusauthor=K.+Kimauthor=X.+T.+Chenauthor=R.+J.+Schmidtauthor=D.+K.+Williamsauthor=J.+S.+Tokarskiauthor=Y.+Anauthor=J.+S.+Sackauthor=V.+Manneauthor=A.+Kamathauthor=Y.+Zhangauthor=P.+Maratheauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+orally+active+pyrrolopyridine-+and+aminopyridine-based+Met+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.04.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520orally%2520active%2520pyrrolopyridine-%2520and%2520aminopyridine-based%2520Met%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3224%26epage%3D3229%26doi%3D10.1016%2Fj.bmcl.2008.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5330</span><span class="NLM_x">–</span> <span class="NLM_lpage">5341</span><span class="refDoi"> DOI: 10.1021/jm800476q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800476q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5330-5341&author=K.+S.+Kimauthor=L.+Zhangauthor=R.+Schmidtauthor=Z.+W.+Caiauthor=D.+Weiauthor=D.+K.+Williamsauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=D.+Xieauthor=Y.+Zhangauthor=Y.+Anauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Darienzoauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=J.+Lippyauthor=R.+Jeyaseelanauthor=B.+Wautletauthor=B.+Henleyauthor=J.+Gullo-Brownauthor=V.+Manneauthor=J.+T.+Huntauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+pyrrolopyridine-pyridone+based+inhibitors+of+Met+kinase%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities&doi=10.1021%2Fjm800476q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrolopyridine-Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities</span></div><div class="casAuthors">Kim, Kyoung Soon; Zhang, Liping; Schmidt, Robert; Cai, Zhen-Wei; Wei, Donna; Williams, David K.; Lombardo, Louis J.; Trainor, George L.; Xie, Dianlin; Zhang, Yaquan; An, Yongmi; Sack, John S.; Tokarski, John S.; Darienzo, Celia; Kamath, Amrita; Marathe, Punit; Zhang, Yueping; Lippy, Jonathan; Jeyaseelan, Robert; Wautlet, Barri; Henley, Benjamin; Gullo-Brown, Johnni; Manne, Veeraswamy; Hunt, John T.; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5330-5341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conformationally constrained 2-pyridone analog 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM.  Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4.  The X-ray crystallog. data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogs was rationalized.  Many of these analogs showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line.  Compd. 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, resp.  It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVhpyiMXT07Vg90H21EOLACvtfcHk0liHI1sw9sE6pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1KnsL8%253D&md5=ec5db4cd0ae460e569c5f728d221acf4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm800476q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800476q%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520pyrrolopyridine-pyridone%2520based%2520inhibitors%2520of%2520Met%2520kinase%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5330%26epage%3D5341%26doi%3D10.1021%2Fjm800476q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzberg, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtzberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anwar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span> </span><span class="NLM_article-title">Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2662</span><span class="NLM_x">–</span> <span class="NLM_lpage">2669</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-05-2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=16675557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2662-2669&author=D.+K.+Grahamauthor=D.+B.+Salzbergauthor=J.+Kurtzbergauthor=S.+Satherauthor=G.+K.+Matsushimaauthor=A.+K.+Keatingauthor=X.+Liangauthor=M.+A.+Lovellauthor=S.+A.+Williamsauthor=T.+L.+Dawsonauthor=M.+J.+Schellauthor=A.+A.+Anwarauthor=H.+R.+Snodgrassauthor=H.+S.+Earp&title=Ectopic+expression+of+the+proto-oncogene+Mer+in+pediatric+T-cell+acute+lymphoblastic+leukemia&doi=10.1158%2F1078-0432.CCR-05-2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Graham, Douglas K.; Salzberg, Dana B.; Kurtzberg, Joanne; Sather, Susan; Matsushima, Glenn K.; Keating, Amy K.; Liang, Xiayuan; Lovell, Mark A.; Williams, Sara A.; Dawson, Thomas L.; Schell, Michael J.; Anwar, Adil A.; Snodgrass, H. Ralph; Earp, H. Shelton</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2662-2669</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The Mer receptor tyrosine kinase, cloned from a B-lymphoblastoid library, is the mammalian orthologue of the chicken retroviral oncogene v-eyk and sends antiapoptotic and transforming signals when activated.  To det. if Mer expression is ectopic in T-cell acute lymphoblastic leukemia (ALL) and potentially important in leukemogenesis, we analyzed Mer expression in normal human thymocytes and lymphocytes and in pediatric ALL patient samples.  Exptl. Design: Reverse transcription-PCR, flow cytometry, and immunohistochem. were used to det. expression of Mer in sorted human thymocyte populations, lymphocytes, and lymphocytes activated by phytohemagglutinin or phorbol 12-myristate 13-acetate/ionophore.  Mer expression in 34 T-cell ALL (T-ALL) patient samples was evaluated by reverse transcription-PCR, and Mer protein expression in a sep. cohort of 16 patient samples was assayed by flow cytometry and Western blot.  Results: Mer expression was absent in normal thymocytes or lymphocytes, and in T cells activated with phytohemagglutinin or phorbol 12-myristate 13-acetate/ionophore.  In contrast, Jurkat cells and T-ALL patient samples expressed unique 180 to 185 kDa Mer protein glycoforms.  Substantial Mer RNA levels were principally obsd. in a subset of T-ALL patient samples that expressed B220 (P = 0.004) but lacked surface expression of CD3 (P = 0.02) and CD4 (P = 0.006), a phenotypic profile consistent with immature lymphoblasts.  In addn., 8 of 16 T-ALL patient samples had Mer protein detected by flow cytometry and Western blot.  Conclusions: Transforming Mer signals may contribute to T-cell leukemogenesis, and abnormal Mer expression may be a novel therapeutic target in pediatric ALL therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MShoRa9blLVg90H21EOLACvtfcHk0liHI1sw9sE6pQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamsrw%253D&md5=68f8310415b1984596118b40976cdd36</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2208%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DSalzberg%26aufirst%3DD.%2BB.%26aulast%3DKurtzberg%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DG.%2BK.%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLovell%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DDawson%26aufirst%3DT.%2BL.%26aulast%3DSchell%26aufirst%3DM.%2BJ.%26aulast%3DAnwar%26aufirst%3DA.%2BA.%26aulast%3DSnodgrass%26aufirst%3DH.%2BR.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26atitle%3DEctopic%2520expression%2520of%2520the%2520proto-oncogene%2520Mer%2520in%2520pediatric%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2662%26epage%3D2669%26doi%3D10.1158%2F1078-0432.CCR-05-2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeClerc, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span> </span><span class="NLM_article-title">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1126/science.281.5376.533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscience.281.5376.533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=9677190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=533-538&author=N.+S.+Grayauthor=L.+Wodickaauthor=A.+M.+Thunnissenauthor=T.+C.+Normanauthor=S.+Kwonauthor=F.+H.+Espinozaauthor=D.+O.+Morganauthor=G.+Barnesauthor=S.+LeClercauthor=L.+Meijerauthor=S.+H.+Kimauthor=D.+J.+Lockhartauthor=P.+G.+Schultz&title=Exploiting+chemical+libraries%2C+structure%2C+and+genomics+in+the+search+for+kinase+inhibitors&doi=10.1126%2Fscience.281.5376.533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span></div><div class="casAuthors">Gray, Nathanael S.; Wodicka, Lisa; Thunnissen, Andy-Mark W. H.; Norman, Thea C.; Kwon, Soojin; Espinoza, F. Hernan; Morgan, David O.; Barnes, Georjana; LeClerc, Sophie; Meijer, Laurent; Kim, Sung-Hou; Lockhart, David J.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5376</span>),
    <span class="NLM_cas:pages">533-538</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP-binding site of the human cyclin-dependent kinase 2 (CDK2).  By iterating chem. library synthesis and biol. screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified.  The structural basis for the binding affinity and selectivity was detd. by anal. of a three-dimensional crystal structure of a CDK2-inhibitor complex.  The cellular effects of these compds. were characterized in mammalian cells and yeast.  In the latter case the effects were characterized on a genome-wide scale by monitoring changes in mRNA levels in treated cells with high-d. oligonucleotide probe arrays.  Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may led to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTOOPjk16tbVg90H21EOLACvtfcHk0lj2leXcL0sh8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D&md5=08b8debe4d05c1169c152ccd6676def8</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5376.533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5376.533%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWodicka%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.%2BM.%26aulast%3DNorman%26aufirst%3DT.%2BC.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DEspinoza%26aufirst%3DF.%2BH.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DLeClerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DExploiting%2520chemical%2520libraries%252C%2520structure%252C%2520and%2520genomics%2520in%2520the%2520search%2520for%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D533%26epage%3D538%26doi%3D10.1126%2Fscience.281.5376.533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finerty, P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler-Cole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span> </span><span class="NLM_article-title">Structural insights into the inhibited states of the Mer receptor tyrosine kinase</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.jsb.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.jsb.2008.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2009&pages=88-96&author=X.+Huangauthor=P.+Finertyauthor=J.+R.+Walkerauthor=C.+Butler-Coleauthor=M.+Vedadiauthor=M.+Schapiraauthor=S.+A.+Parkerauthor=B.+E.+Turkauthor=D.+A.+Thompsonauthor=S.+Dhe-Paganon&title=Structural+insights+into+the+inhibited+states+of+the+Mer+receptor+tyrosine+kinase&doi=10.1016%2Fj.jsb.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFinerty%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DButler-Cole%26aufirst%3DC.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DS.%2BA.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520inhibited%2520states%2520of%2520the%2520Mer%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D165%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.jsb.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deryckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Deusen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korboukh, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1021/ml200239k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200239k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=129-134&author=J.+Liuauthor=C.+Yangauthor=C.+Simpsonauthor=D.+Deryckereauthor=A.+Van+Deusenauthor=M.+J.+Mileyauthor=D.+Kireevauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Hunterauthor=V.+K.+Korboukhauthor=H.+S.+Patelauthor=W.+P.+Janzenauthor=M.+Machiusauthor=G.+L.+Johnsonauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+novel+small+molecule+Mer+kinase+inhibitors+for+the+treatment+of+pediatric+acute+lymphoblastic+leukemia&doi=10.1021%2Fml200239k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Liu, Jing; Yang, Chao; Simpson, Catherine; DeRyckere, Deborah; Van Deusen, Amy; Miley, Michael J.; Kireev, Dmitri; Norris-Drouin, Jacqueline; Sather, Susan; Hunter, Debra; Korboukh, Victoria K.; Patel, Hari S.; Janzen, William P.; Machius, Mischa; Johnson, Gary L.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ectopic Mer expression promotes pro-survival signaling and contributes to leukemogenesis and chemoresistance in childhood acute lymphoblastic leukemia (ALL).  Consequently, Mer kinase inhibitors may promote leukemic cell death and further act as chemosensitizers increasing efficacy and reducing toxicities of current ALL regimens.  We have applied a structure-based design approach to discover novel small mol. Mer kinase inhibitors.  Several pyrazolopyrimidine derivs. effectively inhibit Mer kinase activity at subnanomolar concns.  Furthermore, the lead compd. shows a promising selectivity profile against a panel of 72 kinases and has excellent pharmacokinetic properties.  We also describe the crystal structure of the complex between the lead compd. and Mer, opening new opportunities for further optimization and new template design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgYt56zaMpS7Vg90H21EOLACvtfcHk0lj2leXcL0sh8A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlOktw%253D%253D&md5=200b89e7e1ebb6e1008fa8324adc05d1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fml200239k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200239k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DVan%2BDeusen%26aufirst%3DA.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKorboukh%26aufirst%3DV.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520small%2520molecule%2520Mer%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520pediatric%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D129%26epage%3D134%26doi%3D10.1021%2Fml200239k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9683</span><span class="NLM_x">–</span> <span class="NLM_lpage">9692</span><span class="refDoi"> DOI: 10.1021/jm401387j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401387j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCgtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9683-9692&author=W.+Zhangauthor=D.+Zhangauthor=M.+A.+Stashkoauthor=D.+DeRyckereauthor=D.+Hunterauthor=D.+Kireevauthor=M.+J.+Mileyauthor=C.+Cummingsauthor=M.+Leeauthor=J.+Norris-Drouinauthor=W.+M.+Stewartauthor=S.+Satherauthor=Y.+Zhouauthor=G.+Kirkpatrickauthor=M.+Machiusauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Pseudo-cyclization+through+intramolecular+hydrogen+bond+enables+discovery+of+pyridine+substituted+pyrimidines+as+new+Mer+kinase+inhibitors&doi=10.1021%2Fjm401387j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors</span></div><div class="casAuthors">Zhang, Weihe; Zhang, Dehui; Stashko, Michael A.; DeRyckere, Deborah; Hunter, Debra; Kireev, Dmitri; Miley, Michael J.; Cummings, Christopher; Lee, Minjung; Norris-Drouin, Jacqueline; Stewart, Wendy M.; Sather, Susan; Zhou, Yingqiu; Kirkpatrick, Gregory; Machius, Mischa; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9683-9692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abnormal activation or overexpression of Mer receptor tyrosine kinase has been implicated in survival signaling and chemoresistance in many human cancers.  Consequently, Mer is a promising novel cancer therapeutic target.  A structure-based drug design approach using a pseudo-ring replacement strategy was developed and validated to discover a new family of pyridinepyrimidine analogs as potent Mer inhibitors.  Through SAR studies, compd. I (UNC2250) was identified as the lead compd. for further investigation based on high selectivity against other kinases and good pharmacokinetic properties.  When applied to live cells, I inhibited steady-state phosphorylation of endogenous Mer with an IC50 of 9.8 nM and blocked ligand-stimulated activation of a chimeric EGFR-Mer protein.  Treatment with I also resulted in decreased colony-forming potential in rhabdoid and NSCLC tumor cells, thereby demonstrating functional antitumor activity.  The results provide a rationale for further investigation of this compd. for therapeutic application in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jRMr-85lKbVg90H21EOLACvtfcHk0ljJjRE4XGIpbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCgtbzF&md5=0a228cd34d0d23f8ade7443ca7fad8b8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm401387j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401387j%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DCummings%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DW.%2BM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKirkpatrick%26aufirst%3DG.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPseudo-cyclization%2520through%2520intramolecular%2520hydrogen%2520bond%2520enables%2520discovery%2520of%2520pyridine%2520substituted%2520pyrimidines%2520as%2520new%2520Mer%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9683%26epage%3D9692%26doi%3D10.1021%2Fjm401387j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIver, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchford, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paola, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9693</span><span class="NLM_x">–</span> <span class="NLM_lpage">9700</span><span class="refDoi"> DOI: 10.1021/jm4013888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4013888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9693-9700&author=W.+Zhangauthor=A.+L.+McIverauthor=M.+A.+Stashkoauthor=D.+DeRyckereauthor=B.+R.+Branchfordauthor=D.+Hunterauthor=D.+Kireevauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=W.+M.+Stewartauthor=M.+Leeauthor=S.+Satherauthor=Y.+Zhouauthor=J.+A.+Di+Paolaauthor=M.+Machiusauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+Mer+specific+tyrosine+kinase+inhibitors+for+the+treatment+and+prevention+of+thrombosis&doi=10.1021%2Fjm4013888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis</span></div><div class="casAuthors">Zhang, Weihe; McIver, Andrew L.; Stashko, Michael A.; DeRyckere, Deborah; Branchford, Brian R.; Hunter, Debra; Kireev, Dmitri; Miley, Michael J.; Norris-Drouin, Jacqueline; Stewart, Wendy M.; Lee, Minjung; Sather, Susan; Zhou, Yingqiu; Di Paola, Jorge A.; Machius, Mischa; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9693-9700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies.  Toward this end, we have discovered a novel, Mer kinase specific substituted-pyrimidine scaffold using a structure-based drug design and a pseudo ring replacement strategy.  The cocrystal structure of Mer with two compds. possessing distinct activity have been detd.  Subsequent SAR studies identified compd. I (UNC2881) as a lead compd. for in vivo evaluation.  When applied to live cells, I inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.  Treatment with I is also sufficient to block EGF-mediated stimulation of a chimeric receptor contg. the intracellular domain of Mer fused to the extracellular domain of EGFR.  In addn., I potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathol. thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv1DOYha0vlLVg90H21EOLACvtfcHk0ljJjRE4XGIpbw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOms7rK&md5=07f0b637d009061599c05caaf503372e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm4013888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4013888%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DBranchford%26aufirst%3DB.%2BR.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DW.%2BM.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDi%2BPaola%26aufirst%3DJ.%2BA.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Mer%2520specific%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520and%2520prevention%2520of%2520thrombosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9693%26epage%3D9700%26doi%3D10.1021%2Fjm4013888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group">Singh, R.; Heckrodt, T. J.; Holland, S.</span><span> </span><span class="NLM_article-title">Polycyclic heteroaryl substituted triazoles useful as axl inhibitors</span>. Int. Patent WO 2010/005876 A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Singh&author=T.+J.+Heckrodt&author=S.+Holland&title=Polycyclic+heteroaryl+substituted+triazoles+useful+as+axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DPolycyclic%2520heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520axl%2520inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group">Wnuk-Lipinska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gausdal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellesøy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blø, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J.</span><span> </span><span class="NLM_article-title">Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1747</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2014-1747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1538-7445.AM2014-1747" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1747&author=K.+Wnuk-Lipinskaauthor=C.+Tironauthor=G.+Gausdalauthor=T.+Sandalauthor=R.+Frinkauthor=S.+Hinzauthor=M.+Helles%C3%B8yauthor=L.+Ahmedauthor=H.+Haugenauthor=X.+Liangauthor=M.+Bl%C3%B8author=D.+Micklemauthor=M.+Yuleauthor=J.+Minnaauthor=L.+Zhouauthor=R.+Brekkenauthor=J.+Lorens&title=Abstract+1747%3A+BGB324%2C+a+selective+small+molecule+Axl+kinase+inhibitor+to+overcome+EMT-associated+drug+resistance+in+carcinomas%3A+Therapeutic+rationale+and+early+clinical+studies&doi=10.1158%2F1538-7445.AM2014-1747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-1747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-1747%26sid%3Dliteratum%253Aachs%26aulast%3DWnuk-Lipinska%26aufirst%3DK.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DFrink%26aufirst%3DR.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DHelles%25C3%25B8y%26aufirst%3DM.%26aulast%3DAhmed%26aufirst%3DL.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DBl%25C3%25B8%26aufirst%3DM.%26aulast%3DMicklem%26aufirst%3DD.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DMinna%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBrekken%26aufirst%3DR.%26aulast%3DLorens%26aufirst%3DJ.%26atitle%3DAbstract%25201747%253A%2520BGB324%252C%2520a%2520selective%2520small%2520molecule%2520Axl%2520kinase%2520inhibitor%2520to%2520overcome%2520EMT-associated%2520drug%2520resistance%2520in%2520carcinomas%253A%2520Therapeutic%2520rationale%2520and%2520early%2520clinical%2520studies%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D1747%26doi%3D10.1158%2F1538-7445.AM2014-1747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group">Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Ding, P.; Litvak, J.</span><span> </span><span class="NLM_article-title">Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors</span>. Int. Patent US 8,741,898 B2,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+Goff&author=J.+Zhang&author=R.+Singh&author=S.+Holland&author=J.+Yu&author=T.+J.+Heckrodt&author=P.+Ding&author=J.+Litvak&title=Polycyclic+heteroaryl+substituted+triazoles+useful+as+Axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DD.%26atitle%3DPolycyclic%2520heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520Axl%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref101"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref101'); return false;" data-citation="" class="refNumLink">101</a></strong><div class="NLM_citation" id="cit101"><span><span class="NLM_contrib-group">Ding, P.; Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Litvak, J.</span><span> </span><span class="NLM_article-title"><i>N</i>3-Heteroaryl substituted triazoles and <i>N</i>5-heteroaryl substituted triazoles useful as axl inhibitors</span>. Int. Patent US 8,796,259 B2,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+Ding&author=D.+Goff&author=J.+Zhang&author=R.+Singh&author=S.+Holland&author=J.+Yu&author=T.+J.+Heckrodt&author=J.+Litvak&title=N3-Heteroaryl+substituted+triazoles+and+N5-heteroaryl+substituted+triazoles+useful+as+axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DP.%26atitle%3DN3-Heteroaryl%2520substituted%2520triazoles%2520and%2520N5-heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520axl%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref102"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref102'); return false;" data-citation="" class="refNumLink">102</a></strong><div class="NLM_citation" id="cit102"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. F.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase family of the human genome</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5548</span><span class="NLM_x">–</span> <span class="NLM_lpage">5557</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1203957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11114734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5548-5557&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=S.+F.+Lin&title=The+protein+tyrosine+kinase+family+of+the+human+genome&doi=10.1038%2Fsj.onc.1203957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine kinase family of the human genome</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Lin, Su-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5548-5557</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the sequencing of the human genome is completed by the Human Genome Project, the anal. of this rich source of information will illuminate many areas in medicine and biol.  The protein tyrosine kinases are a large multigene family with particular relevance to many human diseases, including cancer.  A search of the human genome for tyrosine kinase coding elements identified several novel genes and enabled the creation of a nonredundant catalog of tyrosine kinase genes.  Ninety unique kinase genes can be identified in the human genome, along with five pseudogenes.  Of the 90 tyrosine kinases, 58 are receptor type, distributed into 20 subfamilies.  The 32 nonreceptor tyrosine kinases can be placed in 10 subfamilies.  Addnl., mouse orthologs can be identified for nearly all the human tyrosine kinases.  The completion of the human tyrosine kinase family tree provides a framework for further advances in biomedical science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KhPd82OXhLVg90H21EOLACvtfcHk0ljD1T67c1RWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D&md5=007f1f4a2d4ada11c5c9ea77d586816d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203957%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DS.%2BF.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520family%2520of%2520the%2520human%2520genome%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5548%26epage%3D5557%26doi%3D10.1038%2Fsj.onc.1203957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref103"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref103'); return false;" data-citation="" class="refNumLink">103</a></strong><div class="NLM_citation" id="cit103"><span><span class="NLM_contrib-group">Suárez, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavagnino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saettel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radvanyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piguel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard-Pierrot, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoven, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legraverend, M.</span><span> </span><span class="NLM_article-title">Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ejmech.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22749189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=2-25&author=R.+M.+Su%C3%A1rezauthor=F.+Chevotauthor=A.+Cavagninoauthor=N.+Saettelauthor=F.+Radvanyiauthor=S.+Piguelauthor=I.+Bernard-Pierrotauthor=V.+Stovenauthor=M.+Legraverend&title=Inhibitors+of+the+TAM+subfamily+of+tyrosine+kinases%3A+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation</span></div><div class="casAuthors">Suarez, Rosa M.; Chevot, Franciane; Cavagnino, Andrea; Saettel, Nicolas; Radvanyi, Francois; Piguel, Sandrine; Bernard-Pierrot, Isabelle; Stoven, Veronique; Legraverend, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-25</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The TAM subfamily of Receptor Tyrosine Kinases (RTKs) contains three human proteins of therapeutical interest, Axl, Mer, and Tyro3.  The authors' goal was to design a type II inhibitor specific for this family, i.e. able to interact with the allosteric pocket and with the hinge region of the kinase.  They report here the synthesis of several series of purine analogs of BMS-777607 (I).  The structural diversity of the designed inhibitors was expected to modify the interactions formed in the binding site and consequently to modulate their selectivity profiles.  The most potent inhibitor II exhibits Kds of 39, 42, 65 and 200 nM against Axl, Mer, Met and Tyro3 resp.  Anal. of the affinity of II for active and inactive forms of Abl1, an RTK protein that does not belong to the TAM subfamily, together with the binding modes of II predicted by docking studies, indicates that II displays some selectivity for the TAM family and may act as a type II inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvpVHBQMUl7Vg90H21EOLACvtfcHk0ljD1T67c1RWXA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFyit7k%253D&md5=1a0c1d34a4b95d425d7292befb502391</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DSu%25C3%25A1rez%26aufirst%3DR.%2BM.%26aulast%3DChevot%26aufirst%3DF.%26aulast%3DCavagnino%26aufirst%3DA.%26aulast%3DSaettel%26aufirst%3DN.%26aulast%3DRadvanyi%26aufirst%3DF.%26aulast%3DPiguel%26aufirst%3DS.%26aulast%3DBernard-Pierrot%26aufirst%3DI.%26aulast%3DStoven%26aufirst%3DV.%26aulast%3DLegraverend%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520the%2520TAM%2520subfamily%2520of%2520tyrosine%2520kinases%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D2%26epage%3D25%26doi%3D10.1016%2Fj.ejmech.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref104"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref104'); return false;" data-citation="" class="refNumLink">104</a></strong><div class="NLM_citation" id="cit104"><span><span class="NLM_contrib-group">Cui, J. J.</span><span> </span><span class="NLM_article-title">Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4427</span><span class="NLM_x">–</span> <span class="NLM_lpage">4453</span><span class="refDoi"> DOI: 10.1021/jm401427c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401427c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4427-4453&author=J.+J.+Cui&title=Targeting+receptor+tyrosine+kinase+MET+in+cancer%3A+small+molecule+inhibitors+and+clinical+progress&doi=10.1021%2Fjm401427c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress</span></div><div class="casAuthors">Cui, J. Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4427-4453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The HGF/MET signaling pathway is crit. in mediating a wide range of normal physiol. functions including embryol. development, wound healing, and tissue regeneration.  Aberrant activation of the pathway has frequently been found in human cancers via protein overexpression, mutation, gene amplification, and also paracrine or autocrine up-regulation.  In addn., the activation of HGF/MET signaling confers resistance to the effects of cancer treatments.  Therefore, inhibition of the HGF/MET signaling pathway has great potential for therapeutic intervention in cancer.  Currently, there are three approaches toward modulating HGF/MET signaling in human clin. studies of cancer: anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small mol. MET inhibitors.  Preliminary clin. benefit from inhibition of HGF or MET has been reported.  This Perspective will provide an overview of the HGF/MET signaling pathway in cancer and then will review the development of small mol. MET inhibitors and their progress in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoARAsEnH4X5rVg90H21EOLACvtfcHk0liY15vrwRcSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltbvE&md5=534fd1c6fd8b83be41251d0d556903d1</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401427c%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520receptor%2520tyrosine%2520kinase%2520MET%2520in%2520cancer%253A%2520small%2520molecule%2520inhibitors%2520and%2520clinical%2520progress%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4427%26epage%3D4453%26doi%3D10.1021%2Fjm401427c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref105"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref105'); return false;" data-citation="" class="refNumLink">105</a></strong><div class="NLM_citation" id="cit105"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0liY15vrwRcSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref106"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref106'); return false;" data-citation="" class="refNumLink">106</a></strong><div class="NLM_citation" id="cit106"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0liY15vrwRcSLg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref107"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref107'); return false;" data-citation="" class="refNumLink">107</a></strong><div class="NLM_citation" id="cit107"><span><span class="NLM_contrib-group">De Smet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Allosteric targeting of receptor tyrosine kinases</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1120</span><span class="refDoi"> DOI: 10.1038/nbt.3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt.3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25380447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Shu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1113-1120&author=F.+De+Smetauthor=A.+Christopoulosauthor=P.+Carmeliet&title=Allosteric+targeting+of+receptor+tyrosine+kinases&doi=10.1038%2Fnbt.3028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric targeting of receptor tyrosine kinases</span></div><div class="casAuthors">De Smet, Frederik; Christopoulos, Arthur; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1113-1120</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug discovery landscape has been transformed over the past decade by the discovery of allosteric modulators of all major mammalian receptor superfamilies.  Allosteric ligands are a rich potential source of drugs and drug targets with clear therapeutic advantages.  G protein-coupled receptors, ligand-gated ion channels and intracellular nuclear hormone receptors have all been targeted by allosteric modulators.  More recently, a receptor tyrosine kinase (RTK) has been targeted by an extracellular small-mol. allosteric modulator.  Allosteric mechanisms of structurally distinct mols. that target the various receptor families are more alike than originally anticipated and include selectivity, orthosteric probe dependence and pathway-biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUEiFrNdlxrVg90H21EOLACvtfcHk0liPpbXi8SYIhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Shu7c%253D&md5=5dd8e5bf1d6578a418dce00686cd2334</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3028%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSmet%26aufirst%3DF.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAllosteric%2520targeting%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D1113%26epage%3D1120%26doi%3D10.1038%2Fnbt.3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref108"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref108'); return false;" data-citation="" class="refNumLink">108</a></strong><div class="NLM_citation" id="cit108"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span> </span><span class="NLM_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1388</span><span class="NLM_x">–</span> <span class="NLM_lpage">1399</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bcp.2012.07.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1388-1399&author=C.+Carmiauthor=M.+Morauthor=P.+G.+Petroniniauthor=R.+R.+Alfieri&title=Clinical+perspectives+for+irreversible+tyrosine+kinase+inhibitors+in+cancer&doi=10.1016%2Fj.bcp.2012.07.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26atitle%3DClinical%2520perspectives%2520for%2520irreversible%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D1388%26epage%3D1399%26doi%3D10.1016%2Fj.bcp.2012.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref109"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref109'); return false;" data-citation="" class="refNumLink">109</a></strong><div class="NLM_citation" id="cit109"><span><span class="NLM_contrib-group">Lu, Q. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1126/science.1061663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscience.1061663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11452127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=306-311&author=Q.+X.+Luauthor=G.+Lemke&title=Homeostatic+regulation+of+the+immune+system+by+receptor+tyrosine+kinases+of+the+Tyro+3+family&doi=10.1126%2Fscience.1061663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span></div><div class="casAuthors">Lu, Qingxian; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5528</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases and their ligands mediate cell-cell communication and interaction in many organ systems, but have not been known to act in this capacity in the mature immune system.  The authors now provide genetic evidence that three closely related receptor tyrosine kinases, Tyro 3, Axl, and Mer, play an essential immunoregulatory role.  Mutant mice that lack these receptors develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmunity.  These phenotypes are cell non-autonomous with respect to lymphocytes and result from the hyperactivation of antigen-presenting cells in which the three receptors are normally expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8p8YELw6TLVg90H21EOLACvtfcHk0liPpbXi8SYIhw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D&md5=7b6a3d91485e82fdb47f715331b1f310</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1126%2Fscience.1061663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1061663%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%2BX.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DHomeostatic%2520regulation%2520of%2520the%2520immune%2520system%2520by%2520receptor%2520tyrosine%2520kinases%2520of%2520the%2520Tyro%25203%2520family%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D306%26epage%3D311%26doi%3D10.1126%2Fscience.1061663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref110"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref110'); return false;" data-citation="" class="refNumLink">110</a></strong><div class="NLM_citation" id="cit110"><span><span class="NLM_contrib-group">Bosurgi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado Cuevas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagliani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joannas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">13091</span><span class="NLM_x">–</span> <span class="NLM_lpage">13096</span><span class="refDoi"> DOI: 10.1073/pnas.1302507110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.1302507110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=13091-13096&author=L.+Bosurgiauthor=J.+H.+Berninkauthor=V.+Delgado+Cuevasauthor=N.+Gaglianiauthor=L.+Joannasauthor=E.+T.+Schmidauthor=C.+J.+Boothauthor=S.+Ghoshauthor=C.+V.+Rothlin&title=Paradoxical+role+of+the+proto-oncogene+Axl+and+Mer+receptor+tyrosine+kinases+in+colon+cancer&doi=10.1073%2Fpnas.1302507110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1302507110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1302507110%26sid%3Dliteratum%253Aachs%26aulast%3DBosurgi%26aufirst%3DL.%26aulast%3DBernink%26aufirst%3DJ.%2BH.%26aulast%3DDelgado%2BCuevas%26aufirst%3DV.%26aulast%3DGagliani%26aufirst%3DN.%26aulast%3DJoannas%26aufirst%3DL.%26aulast%3DSchmid%26aufirst%3DE.%2BT.%26aulast%3DBooth%26aufirst%3DC.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DParadoxical%2520role%2520of%2520the%2520proto-oncogene%2520Axl%2520and%2520Mer%2520receptor%2520tyrosine%2520kinases%2520in%2520colon%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D13091%26epage%3D13096%26doi%3D10.1073%2Fpnas.1302507110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref111"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref111'); return false;" data-citation="" class="refNumLink">111</a></strong><div class="NLM_citation" id="cit111"><span><span class="NLM_contrib-group">Schmidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1391</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1007/s00018-011-0863-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs00018-011-0863-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22076650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1391-1414&author=T.+Schmidtauthor=I.+Ben-Batallaauthor=A.+Schultzeauthor=S.+Loges&title=Macrophage-tumor+crosstalk%3A+role+of+TAMR+tyrosine+kinase+receptors+and+of+their+ligands&doi=10.1007%2Fs00018-011-0863-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands</span></div><div class="casAuthors">Schmidt, Thomas; Ben-Batalla, Isabel; Schultze, Alexander; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1391-1414</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Ample clin. and preclin. evidence indicates that macrophages interact with tumor cells as well as with virtually all populations of host cells present in the tumor microenvironment.  This crosstalk can strongly promote malignancy, but also has in principle the potential to inhibit tumor growth.  Thus, it is of the utmost importance to improve our understanding of the mechanisms driving the pro- and antimalignant behavior of tumor-assocd. macrophages (TAMs) in order to develop better anticancer therapies.  In this review, we discuss the biol. consequences of reciprocal interactions between TAMs, cancer cells, endothelial cells, fibroblasts and other leukocyte subfractions within tumors.  It was recently elucidated that tumors specifically educate macrophages to secrete growth arrest-specific gene 6 (Gas6), the common ligand of the Tyro3, Axl, Mer receptor (TAMR) family.  In turn, Gas6 fosters tumor growth by promoting cancer cell proliferation.  Therefore, the Gas6-TAMR axis might represent a novel target for disrupting tumor-macrophage crosstalk.  We summarize here what is known about TAMR and their ligands in (human) cancer biol.  In order to shed more light on the role of macrophages in human cancer, we addnl. provide an overview of what is currently known about the prognostic impact of TAMs in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp7eaxnYn_LVg90H21EOLACvtfcHk0lh0adz7yksFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFSntLc%253D&md5=d6bcdd32f1c134285bdd70b07d4384b7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0863-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0863-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DMacrophage-tumor%2520crosstalk%253A%2520role%2520of%2520TAMR%2520tyrosine%2520kinase%2520receptors%2520and%2520of%2520their%2520ligands%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D1391%26epage%3D1414%26doi%3D10.1007%2Fs00018-011-0863-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref112"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref112'); return false;" data-citation="" class="refNumLink">112</a></strong><div class="NLM_citation" id="cit112"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5659</span><span class="refDoi"> DOI: 10.1200/JCO.2009.22.9054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2009.22.9054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5650-5659&author=U.+McDermottauthor=J.+Settleman&title=Personalized+cancer+therapy+with+selective+kinase+inhibitors%3A+an+emerging+paradigm+in+medical+oncology&doi=10.1200%2FJCO.2009.22.9054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology</span></div><div class="casAuthors">McDermott, Ultan; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5650-5659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Selective kinase inhibitors have emerged as an important class of anticancer agents, with demonstrated clin. efficacy and generally favorable toxicity profiles in several common disease settings where conventional treatments have previously provided only modest benefit.  Consequently, a substantial effort is now underway to identify addnl. therapeutically relevant kinase targets and to develop and test inhibitors of those proteins in a variety of human malignancies.  However, it has also become clear that the clin. benefit assocd. with these agents is typically limited to a subset of treated patients, who in many cases are defined by a specific genomic lesion within their tumor cells-frequently, an activating mutation within the gene encoding the target kinase.  This discovery has prompted efforts to stratify patients before treatment with kinase inhibitors based on specific genomic biomarkers, with the goal of optimizing clin. outcomes through the effective personalization of treatment (ie, matching the right patients with the right therapies).  With recent advances in our understanding of the relationship between tumor genotypes and cancer cell sensitivity to kinase inhibition, together with improved technologies for rapidly genotyping tumor biopsies for relevant lesions, the implementation of personalized cancer care with this exciting new class of inhibitors is now becoming a reality.  In this review, we summarize recent developments in this area, and we highlight some of the logistical challenges posed by this emerging paradigm in medical oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq6rJzyK-uQbVg90H21EOLACvtfcHk0lh0adz7yksFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWit7c%253D&md5=d39ebdc45f21d3183dc26f5a2cf09be1</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.9054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.9054%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DPersonalized%2520cancer%2520therapy%2520with%2520selective%2520kinase%2520inhibitors%253A%2520an%2520emerging%2520paradigm%2520in%2520medical%2520oncology%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5650%26epage%3D5659%26doi%3D10.1200%2FJCO.2009.22.9054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref113"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref113'); return false;" data-citation="" class="refNumLink">113</a></strong><div class="NLM_citation" id="cit113"><span><span class="NLM_contrib-group">Carragher, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unciti-Broceta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. A.</span><span> </span><span class="NLM_article-title">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.4155/fmc.11.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.4155%2Ffmc.11.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22168166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=N.+O.+Carragherauthor=A.+Unciti-Brocetaauthor=D.+A.+Cameron&title=Advancing+cancer+drug+discovery+towards+more+agile+development+of+targeted+combination+therapies&doi=10.4155%2Ffmc.11.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span></div><div class="casAuthors">Carragher, Neil O.; Unciti-Broceta, Asier; Cameron, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-105</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Current drug-discovery strategies are typically target-centric'' and are based upon high-throughput screening of large chem. libraries against nominated targets and a selection of lead compds. with optimized on-target'' potency and selectivity profiles.  However, high attrition of targeted agents in clin. development suggest that combinations of targeted agents will be most effective in treating solid tumors if the biol. networks that permit cancer cells to subvert monotherapies are identified and retargeted.  Conventional drug-discovery and development strategies are suboptimal for the rational design and development of novel drug combinations.  In this article, we highlight a series of emerging technologies supporting a less reductionist, more agile, drug-discovery and development approach for the rational design, validation, prioritization and clin. development of novel drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKkliYmA82GLVg90H21EOLACvtfcHk0lh0adz7yksFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL&md5=d66f8996ad13dd84ce3667d527bc5516</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.169%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%2BA.%26atitle%3DAdvancing%2520cancer%2520drug%2520discovery%2520towards%2520more%2520agile%2520development%2520of%2520targeted%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105%26doi%3D10.4155%2Ffmc.11.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref114"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref114'); return false;" data-citation="" class="refNumLink">114</a></strong><div class="NLM_citation" id="cit114"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lh0adz7yksFzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref115"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref115'); return false;" data-citation="" class="refNumLink">115</a></strong><div class="NLM_citation" id="cit115"><span><span class="NLM_contrib-group">Elkabets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazarentzos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelossof, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brook, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaken, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teixidó, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghossein, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ccell.2015.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25873175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=533-546&author=M.+Elkabetsauthor=E.+Pazarentzosauthor=D.+Juricauthor=Q.+Shengauthor=R.+A.+Pelossofauthor=S.+Brookauthor=A.+O.+Benzakenauthor=J.+Rodonauthor=N.+Morseauthor=J.+J.+Yanauthor=M.+Liuauthor=R.+Dasauthor=Y.+Chenauthor=A.+Tamauthor=H.+Wangauthor=J.+Liangauthor=J.+M.+Gurskiauthor=D.+A.+Kerrauthor=R.+Rosellauthor=C.+Teixid%C3%B3author=A.+Huangauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=T.+G.+Bivonaauthor=M.+Scaltritiauthor=J.+Baselga&title=AXL+mediates+resistance+to+PI3K%CE%B1+inhibition+by+activating+the+EGFR%2FPKC%2FmTOR+axis+in+head+and+neck+and+esophageal+squamous+cell+carcinomas&doi=10.1016%2Fj.ccell.2015.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span></div><div class="casAuthors">Elkabets, Moshe; Pazarentzos, Evangelos; Juric, Dejan; Sheng, Qing; Pelossof, Raphael A.; Brook, Samuel; Benzaken, Ana Oaknin; Rodon, Jordi; Morse, Natasha; Yan, Jenny Jiacheng; Liu, Manway; Das, Rita; Chen, Yan; Tam, Angela; Wang, Huiqin; Liang, Jinsheng; Gurski, Joseph M.; Kerr, Darcy A.; Rosell, Rafael; Teixido, Cristina; Huang, Alan; Ghossein, Ronald A.; Rosen, Neal; Bivona, Trever G.; Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-546</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clin. activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification.  Studying models of therapeutic resistance, we have obsd. that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR).  This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL.  AXL is overexpressed in resistant tumors from both lab. models and patients treated with the PI3Kα inhibitor BYL719.  AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR.  Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkH5_tNi2YrVg90H21EOLACvtfcHk0lgKPnW7q2MKlg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D&md5=55b0362b0e32f0c305c5257aa66ecdc5</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DPelossof%26aufirst%3DR.%2BA.%26aulast%3DBrook%26aufirst%3DS.%26aulast%3DBenzaken%26aufirst%3DA.%2BO.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DGurski%26aufirst%3DJ.%2BM.%26aulast%3DKerr%26aufirst%3DD.%2BA.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520PI3K%25CE%25B1%2520inhibition%2520by%2520activating%2520the%2520EGFR%252FPKC%252FmTOR%2520axis%2520in%2520head%2520and%2520neck%2520and%2520esophageal%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D533%26epage%3D546%26doi%3D10.1016%2Fj.ccell.2015.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100'],'ref101':['cit101'],'ref102':['cit102'],'ref103':['cit103'],'ref104':['cit104'],'ref105':['cit105'],'ref106':['cit106'],'ref107':['cit107'],'ref108':['cit108'],'ref109':['cit109'],'ref110':['cit110'],'ref111':['cit111'],'ref112':['cit112'],'ref113':['cit113'],'ref114':['cit114'],'ref115':['cit115']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 115 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Hefeng Zhang, Xia Peng, Yang Dai, Jingwei Shao, Yinchun Ji, Yiming Sun, Bo Liu, Xu Cheng, Jing Ai, <span class="NLM_string-name hlFld-ContribAuthor">Wenhu Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Pyrimidinedione Derivative as a Potent and Orally Bioavailable Axl Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3956-3975. <a href="https://doi.org/10.1021/acs.jmedchem.0c02093" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c02093</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c02093&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c02093%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPyrimidinedione%252BDerivative%252Bas%252Ba%252BPotent%252Band%252BOrally%252BBioavailable%252BAxl%252BInhibitor%26aulast%3DZhang%26aufirst%3DHefeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D03122020%26date%3D18032021%26volume%3D64%26issue%3D7%26spage%3D3956%26epage%3D3975" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Ming-Shu Wang, Hong-Chuang Xu, Yi Gong, Ren-Yu Qu, Lin-Sheng Zhuo, <span class="NLM_string-name hlFld-ContribAuthor">Wei Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient Arylation of 2,7-Naphthyridin-1(2H)-one with Diaryliodonium Salts and Discovery of a New Selective MET/AXL Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">ACS Combinatorial Science</span><span> <strong>2020,</strong> <em>22 </em>
                                    (9)
                                     , 457-467. <a href="https://doi.org/10.1021/acscombsci.0c00074" title="DOI URL">https://doi.org/10.1021/acscombsci.0c00074</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acscombsci.0c00074&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facscombsci.0c00074%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Combinatorial%2520Science%26atitle%3DEfficient%252BArylation%252Bof%252B2%25252C7-Naphthyridin-1%2525282H%252529-one%252Bwith%252BDiaryliodonium%252BSalts%252Band%252BDiscovery%252Bof%252Ba%252BNew%252BSelective%252BMET%25252FAXL%252BKinase%252BInhibitor%26aulast%3DWang%26aufirst%3DMing-Shu%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03052020%26date%3D22062020%26date%3D10072020%26date%3D26062020%26volume%3D22%26issue%3D9%26spage%3D457%26epage%3D467" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Olga Cruz-López, Carolin Temps, Beatrice Longo, Samuel H. Myers, Francisco Franco-Montalban, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Synthesis and Characterization of a Click-Assembled 18-Atom Macrocycle That Displays Selective AXL Kinase Inhibitory Activity. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2019,</strong> <em>4 </em>
                                    (25)
                                     , 21620-21626. <a href="https://doi.org/10.1021/acsomega.9b03525" title="DOI URL">https://doi.org/10.1021/acsomega.9b03525</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.9b03525&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.9b03525%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DSynthesis%252Band%252BCharacterization%252Bof%252Ba%252BClick-Assembled%252B18-Atom%252BMacrocycle%252BThat%252BDisplays%252BSelective%252BAXL%252BKinase%252BInhibitory%252BActivity%26aulast%3DCruz-L%25C3%25B3pez%26aufirst%3DOlga%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D2019%26date%3D22102019%26date%3D14112019%26date%3D03122019%26volume%3D4%26issue%3D25%26spage%3D21620%26epage%3D21626" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhongfeng Luo, Tingting Liu, Weijie Guo, Zijia Wang, Jingjun Huang, Yulin Zhu, <span class="NLM_string-name hlFld-ContribAuthor">Zhuo Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">N-Acyl-5,5-dimethylhydantoin, a New Mild Acyl-Transfer Reagent in Pd Catalysis: Highly Efficient Synthesis of Functionalized Ketones. </span><span class="cited-content_cbyCitation_journal-name">Organic Process Research & Development</span><span> <strong>2018,</strong> <em>22 </em>
                                    (9)
                                     , 1188-1199. <a href="https://doi.org/10.1021/acs.oprd.8b00182" title="DOI URL">https://doi.org/10.1021/acs.oprd.8b00182</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.oprd.8b00182&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.oprd.8b00182%26sid%3Dliteratum%253Aachs%26jtitle%3DOrganic%2520Process%2520Research%2520%2526%2520Development%26atitle%3DN-Acyl-5%25252C5-dimethylhydantoin%25252C%252Ba%252BNew%252BMild%252BAcyl-Transfer%252BReagent%252Bin%252BPd%252BCatalysis%25253A%252BHighly%252BEfficient%252BSynthesis%252Bof%252BFunctionalized%252BKetones%26aulast%3DLuo%26aufirst%3DZhongfeng%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D01062018%26date%3D13082018%26date%3D30072018%26volume%3D22%26issue%3D9%26spage%3D1188%26epage%3D1199" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Zhen-Hua Li, Zhi-Jiang Jiang, Qiao-Ling Shao, Jin-Jing Qin, Qiang-Feng Shu, Wen-Hao Lu, <span class="NLM_string-name hlFld-ContribAuthor">Wei-Ke Su</span>. </span><span class="cited-content_cbyCitation_article-title">One-Pot Cascade Heterocyclization of γ- and β-Ketomalononitriles to 2,4-Dichloro-Substituted Pyrano[2,3-d]pyrimidines and Furo[2,3-d]pyrimidines Mediated by Triphosgene and Triphenylphosphine Oxide. </span><span class="cited-content_cbyCitation_journal-name">The Journal of Organic Chemistry</span><span> <strong>2018,</strong> <em>83 </em>
                                    (12)
                                     , 6423-6431. <a href="https://doi.org/10.1021/acs.joc.8b00669" title="DOI URL">https://doi.org/10.1021/acs.joc.8b00669</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.joc.8b00669&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.joc.8b00669%26sid%3Dliteratum%253Aachs%26jtitle%3DThe%2520Journal%2520of%2520Organic%2520Chemistry%26atitle%3DOne-Pot%252BCascade%252BHeterocyclization%252Bof%252B%2525CE%2525B3-%252Band%252B%2525CE%2525B2-Ketomalononitriles%252Bto%252B2%25252C4-Dichloro-Substituted%252BPyrano%25255B2%25252C3-d%25255Dpyrimidines%252Band%252BFuro%25255B2%25252C3-d%25255Dpyrimidines%252BMediated%252Bby%252BTriphosgene%252Band%252BTriphenylphosphine%252BOxide%26aulast%3DLi%26aufirst%3DZhen-Hua%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D15032018%26date%3D24052018%26date%3D21052018%26volume%3D83%26issue%3D12%26spage%3D6423%26epage%3D6431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Edita Sarukhanyan, Sergey Shityakov, <span class="NLM_string-name hlFld-ContribAuthor">Thomas Dandekar</span>. </span><span class="cited-content_cbyCitation_article-title">In Silico Designed Axl Receptor Blocking Drug Candidates Against Zika Virus Infection. </span><span class="cited-content_cbyCitation_journal-name">ACS Omega</span><span> <strong>2018,</strong> <em>3 </em>
                                    (5)
                                     , 5281-5290. <a href="https://doi.org/10.1021/acsomega.8b00223" title="DOI URL">https://doi.org/10.1021/acsomega.8b00223</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acsomega.8b00223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facsomega.8b00223%26sid%3Dliteratum%253Aachs%26jtitle%3DACS%2520Omega%26atitle%3DIn%252BSilico%252BDesigned%252BAxl%252BReceptor%252BBlocking%252BDrug%252BCandidates%252BAgainst%252BZika%252BVirus%252BInfection%26aulast%3DSarukhanyan%26aufirst%3DEdita%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D2018%26date%3D05022018%26date%3D13042018%26volume%3D3%26issue%3D5%26spage%3D5281%26epage%3D5290" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Samuel
H. Myers, Carolin Temps, Douglas R. Houston, Valerie G. Brunton, <span class="NLM_string-name hlFld-ContribAuthor">Asier Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Development of Potent Inhibitors of Receptor Tyrosine Kinases by Ligand-Based Drug Design and Target-Biased Phenotypic Screening. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2018,</strong> <em>61 </em>
                                    (5)
                                     , 2104-2110. <a href="https://doi.org/10.1021/acs.jmedchem.7b01605" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.7b01605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.7b01605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.7b01605%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDevelopment%252Bof%252BPotent%252BInhibitors%252Bof%252BReceptor%252BTyrosine%252BKinases%252Bby%252BLigand-Based%252BDrug%252BDesign%252Band%252BTarget-Biased%252BPhenotypic%252BScreening%26aulast%3DMyers%26aufirst%3DSamuel%2BH.%26date%3D2018%26date%3D2018%26date%3D2017%26date%3D30102017%26date%3D21022018%26volume%3D61%26issue%3D5%26spage%3D2104%26epage%3D2110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>, <span class="hlFld-ContribAuthor ">Lijie  Peng</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, and <span class="hlFld-ContribAuthor ">Ke  Ding</span>  . </span><span class="cited-content_cbyCitation_article-title">4-Oxo-1,4-dihydroquinoline-3-carboxamide Derivatives as New Axl Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (14)
                                     , 6807-6825. <a href="https://doi.org/10.1021/acs.jmedchem.6b00608" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00608</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00608&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00608%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3D4-Oxo-1%25252C4-dihydroquinoline-3-carboxamide%252BDerivatives%252Bas%252BNew%252BAxl%252BKinase%252BInhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D20042016%26date%3D19072016%26date%3D28072016%26date%3D05072016%26volume%3D59%26issue%3D14%26spage%3D6807%26epage%3D6825" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Craig  Fraser</span>, <span class="hlFld-ContribAuthor ">John C.  Dawson</span>, <span class="hlFld-ContribAuthor ">Reece  Dowling</span>, <span class="hlFld-ContribAuthor ">Douglas R.  Houston</span>, <span class="hlFld-ContribAuthor ">Jason T.  Weiss</span>, <span class="hlFld-ContribAuthor ">Alison F.  Munro</span>, <span class="hlFld-ContribAuthor ">Morwenna  Muir</span>, <span class="hlFld-ContribAuthor ">Lea  Harrington</span>, <span class="hlFld-ContribAuthor ">Scott P.  Webster</span>, <span class="hlFld-ContribAuthor ">Margaret C.  Frame</span>, <span class="hlFld-ContribAuthor ">Valerie G.  Brunton</span>, <span class="hlFld-ContribAuthor ">E. Elizabeth  Patton</span>, <span class="hlFld-ContribAuthor ">Neil O.  Carragher</span>, and <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>  . </span><span class="cited-content_cbyCitation_article-title">Rapid Discovery and Structure–Activity Relationships of Pyrazolopyrimidines That Potently Suppress Breast Cancer Cell Growth via SRC Kinase Inhibition with Exceptional Selectivity over ABL Kinase. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2016,</strong> <em>59 </em>
                                    (10)
                                     , 4697-4710. <a href="https://doi.org/10.1021/acs.jmedchem.6b00065" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.6b00065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.6b00065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.6b00065%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DRapid%252BDiscovery%252Band%252BStructure%2525E2%252580%252593Activity%252BRelationships%252Bof%252BPyrazolopyrimidines%252BThat%252BPotently%252BSuppress%252BBreast%252BCancer%252BCell%252BGrowth%252Bvia%252BSRC%252BKinase%252BInhibition%252Bwith%252BExceptional%252BSelectivity%252Bover%252BABL%252BKinase%26aulast%3DFraser%26aufirst%3DCraig%26date%3D2016%26date%3D2016%26date%3D2016%26date%3D14012016%26date%3D04052016%26date%3D26052016%26date%3D26042016%26volume%3D59%26issue%3D10%26spage%3D4697%26epage%3D4710" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mariam  Fatima</span>, <span class="hlFld-ContribAuthor ">Salik Javed  Kakar</span>, <span class="hlFld-ContribAuthor ">Fazal  Adnan</span>, <span class="hlFld-ContribAuthor ">Khalid  Khan</span>, <span class="hlFld-ContribAuthor ">Afsar Ali  Mian</span>, <span class="hlFld-ContribAuthor ">Dilawar  Khan</span>. </span><span class="cited-content_cbyCitation_article-title">AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia. </span><span class="cited-content_cbyCitation_journal-name">BMC Cancer</span><span> <strong>2021,</strong> <em>21 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12885-021-08450-y" title="DOI URL">https://doi.org/10.1186/s12885-021-08450-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12885-021-08450-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12885-021-08450-y%26sid%3Dliteratum%253Aachs%26jtitle%3DBMC%2520Cancer%26atitle%3DAXL%252Breceptor%252Btyrosine%252Bkinase%25253A%252Ba%252Bpossible%252Btherapeutic%252Btarget%252Bin%252Bacute%252Bpromyelocytic%252Bleukemia%26aulast%3DFatima%26aufirst%3DMariam%26date%3D2021%26date%3D2021%26volume%3D21%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dandan  Xu</span>, <span class="hlFld-ContribAuthor ">Deqiao  Sun</span>, <span class="hlFld-ContribAuthor ">Wei  Wang</span>, <span class="hlFld-ContribAuthor ">Xia  Peng</span>, <span class="hlFld-ContribAuthor ">Zhengsheng  Zhan</span>, <span class="hlFld-ContribAuthor ">Yinchun  Ji</span>, <span class="hlFld-ContribAuthor ">Yanyan  Shen</span>, <span class="hlFld-ContribAuthor ">Meiyu  Geng</span>, <span class="hlFld-ContribAuthor ">Jing  Ai</span>, <span class="hlFld-ContribAuthor ">Wenhu  Duan</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of pyrrolo[2,3-d]pyrimidine derivatives as potent Axl inhibitors: Design, synthesis and biological evaluation. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>220 </em>, 113497. <a href="https://doi.org/10.1016/j.ejmech.2021.113497" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113497</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113497&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113497%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bpyrrolo%25255B2%25252C3-d%25255Dpyrimidine%252Bderivatives%252Bas%252Bpotent%252BAxl%252Binhibitors%25253A%252BDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%26aulast%3DXu%26aufirst%3DDandan%26date%3D2021%26volume%3D220%26spage%3D113497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min  Tian</span>, <span class="hlFld-ContribAuthor ">Xi-sha  Chen</span>, <span class="hlFld-ContribAuthor ">Lan-ya  Li</span>, <span class="hlFld-ContribAuthor ">Hai-zhou  Wu</span>, <span class="hlFld-ContribAuthor ">Da  Zeng</span>, <span class="hlFld-ContribAuthor ">Xin-luan  Wang</span>, <span class="hlFld-ContribAuthor ">Yi  Zhang</span>, <span class="hlFld-ContribAuthor ">Song-shu  Xiao</span>, <span class="hlFld-ContribAuthor ">Yan  Cheng</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of AXL enhances chemosensitivity of human ovarian cancer cells to cisplatin via decreasing glycolysis. </span><span class="cited-content_cbyCitation_journal-name">Acta Pharmacologica Sinica</span><span> <strong>2021,</strong> <em>42 </em>
                                    (7)
                                     , 1180-1189. <a href="https://doi.org/10.1038/s41401-020-00546-8" title="DOI URL">https://doi.org/10.1038/s41401-020-00546-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41401-020-00546-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41401-020-00546-8%26sid%3Dliteratum%253Aachs%26jtitle%3DActa%2520Pharmacologica%2520Sinica%26atitle%3DInhibition%252Bof%252BAXL%252Benhances%252Bchemosensitivity%252Bof%252Bhuman%252Bovarian%252Bcancer%252Bcells%252Bto%252Bcisplatin%252Bvia%252Bdecreasing%252Bglycolysis%26aulast%3DTian%26aufirst%3DMin%26date%3D2021%26date%3D2020%26volume%3D42%26issue%3D7%26spage%3D1180%26epage%3D1189" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chih‐Ming  Su</span>, <span class="hlFld-ContribAuthor ">Tung‐Wei  Hsu</span>, <span class="hlFld-ContribAuthor ">Shian‐Ying  Sung</span>, <span class="hlFld-ContribAuthor ">Ming‐Te  Huang</span>, <span class="hlFld-ContribAuthor ">Kuan‐Chou  Chen</span>, <span class="hlFld-ContribAuthor ">Chih‐Yang  Huang</span>, <span class="hlFld-ContribAuthor ">Chien Yi  Chiang</span>, <span class="hlFld-ContribAuthor ">Yen‐Hao  Su</span>, <span class="hlFld-ContribAuthor ">Hsin‐An  Chen</span>, <span class="hlFld-ContribAuthor ">Po‐Hsiang  Liao</span>. </span><span class="cited-content_cbyCitation_article-title">AXL
              is crucial for
              E1A
              ‐enhanced therapeutic efficiency of
              EGFR
              tyrosine kinase inhibitors through
              NFI
              in breast cancer. </span><span class="cited-content_cbyCitation_journal-name">Environmental Toxicology</span><span> <strong>2021,</strong> <em>36 </em>
                                    (7)
                                     , 1278-1287. <a href="https://doi.org/10.1002/tox.23125" title="DOI URL">https://doi.org/10.1002/tox.23125</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/tox.23125&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Ftox.23125%26sid%3Dliteratum%253Aachs%26jtitle%3DEnvironmental%2520Toxicology%26atitle%3DAXL%252Bis%252Bcrucial%252Bfor%252BE1A%252B%2525E2%252580%252590enhanced%252Btherapeutic%252Befficiency%252Bof%252BEGFR%252Btyrosine%252Bkinase%252Binhibitors%252Bthrough%252BNFI%252Bin%252Bbreast%252Bcancer%26aulast%3DSu%26aufirst%3DChih%25E2%2580%2590Ming%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D7%26spage%3D1278%26epage%3D1287" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojia  Niu</span>, <span class="hlFld-ContribAuthor ">Katharina  Rothe</span>, <span class="hlFld-ContribAuthor ">Min  Chen</span>, <span class="hlFld-ContribAuthor ">Sarah  Grasedieck</span>, <span class="hlFld-ContribAuthor ">Rick  Li</span>, <span class="hlFld-ContribAuthor ">Sung-Eun  Nam</span>, <span class="hlFld-ContribAuthor ">Xiuyan  Zhang</span>, <span class="hlFld-ContribAuthor ">German E.  Novakovskiy</span>, <span class="hlFld-ContribAuthor ">Ye-Hyeon  Ahn</span>, <span class="hlFld-ContribAuthor ">Irina  Maksakova</span>, <span class="hlFld-ContribAuthor ">Shenshen  Lai</span>, <span class="hlFld-ContribAuthor ">Hong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jun  Yan</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Yun  Zhao</span>, <span class="hlFld-ContribAuthor ">Depei  Wu</span>, <span class="hlFld-ContribAuthor ">Yubin  Ge</span>, <span class="hlFld-ContribAuthor ">Wyeth W.  Wasserman</span>, <span class="hlFld-ContribAuthor ">Arefeh  Rouhi</span>, <span class="hlFld-ContribAuthor ">Florian  Kuchenbauer</span>, <span class="hlFld-ContribAuthor ">Calvin K.  Yip</span>, <span class="hlFld-ContribAuthor ">Zaihui  Zhang</span>, <span class="hlFld-ContribAuthor ">Xiaoyan  Jiang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting AXL kinase sensitizes leukemic stem and progenitor cells to venetoclax treatment in acute myeloid leukemia. </span><span class="cited-content_cbyCitation_journal-name">Blood</span><span> <strong>2021,</strong> <em>137 </em>
                                    (26)
                                     , 3641-3655. <a href="https://doi.org/10.1182/blood.2020007651" title="DOI URL">https://doi.org/10.1182/blood.2020007651</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1182/blood.2020007651&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1182%2Fblood.2020007651%26sid%3Dliteratum%253Aachs%26jtitle%3DBlood%26atitle%3DTargeting%252BAXL%252Bkinase%252Bsensitizes%252Bleukemic%252Bstem%252Band%252Bprogenitor%252Bcells%252Bto%252Bvenetoclax%252Btreatment%252Bin%252Bacute%252Bmyeloid%252Bleukemia%26aulast%3DNiu%26aufirst%3DXiaojia%26date%3D2021%26date%3D2021%26volume%3D137%26issue%3D26%26spage%3D3641%26epage%3D3655" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">David C.  Yang</span>, <span class="hlFld-ContribAuthor ">Shenwen  Gu</span>, <span class="hlFld-ContribAuthor ">Ji-Min  Li</span>, <span class="hlFld-ContribAuthor ">Ssu-Wei  Hsu</span>, <span class="hlFld-ContribAuthor ">Szu-Jung  Chen</span>, <span class="hlFld-ContribAuthor ">Wen-Hsin  Chang</span>, <span class="hlFld-ContribAuthor ">Ching-Hsien  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting the AXL Receptor in Combating Smoking-related Pulmonary Fibrosis. </span><span class="cited-content_cbyCitation_journal-name">American Journal of Respiratory Cell and Molecular Biology</span><span> <strong>2021,</strong> <em>64 </em>
                                    (6)
                                     , 734-746. <a href="https://doi.org/10.1165/rcmb.2020-0303OC" title="DOI URL">https://doi.org/10.1165/rcmb.2020-0303OC</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1165/rcmb.2020-0303OC&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1165%2Frcmb.2020-0303OC%26sid%3Dliteratum%253Aachs%26jtitle%3DAmerican%2520Journal%2520of%2520Respiratory%2520Cell%2520and%2520Molecular%2520Biology%26atitle%3DTargeting%252Bthe%252BAXL%252BReceptor%252Bin%252BCombating%252BSmoking-related%252BPulmonary%252BFibrosis%26aulast%3DYang%26aufirst%3DDavid%2BC.%26date%3D2021%26volume%3D64%26issue%3D6%26spage%3D734%26epage%3D746" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai  Tanaka</span>, <span class="hlFld-ContribAuthor ">Samantha S.  Dykes</span>, <span class="hlFld-ContribAuthor ">Dietmar W.  Siemann</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibition of the Axl pathway impairs breast and prostate cancer metastasis to the bones and bone remodeling. </span><span class="cited-content_cbyCitation_journal-name">Clinical & Experimental Metastasis</span><span> <strong>2021,</strong> <em>38 </em>
                                    (3)
                                     , 321-335. <a href="https://doi.org/10.1007/s10585-021-10093-z" title="DOI URL">https://doi.org/10.1007/s10585-021-10093-z</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10585-021-10093-z&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10585-021-10093-z%26sid%3Dliteratum%253Aachs%26jtitle%3DClinical%2520%2526%2520Experimental%2520Metastasis%26atitle%3DInhibition%252Bof%252Bthe%252BAxl%252Bpathway%252Bimpairs%252Bbreast%252Band%252Bprostate%252Bcancer%252Bmetastasis%252Bto%252Bthe%252Bbones%252Band%252Bbone%252Bremodeling%26aulast%3DTanaka%26aufirst%3DMai%26date%3D2021%26date%3D2021%26volume%3D38%26issue%3D3%26spage%3D321%26epage%3D335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katja  Möller-Hackbarth</span>, <span class="hlFld-ContribAuthor ">Dina  Dabaghie</span>, <span class="hlFld-ContribAuthor ">Emmanuelle  Charrin</span>, <span class="hlFld-ContribAuthor ">Sonia  Zambrano</span>, <span class="hlFld-ContribAuthor ">Guillem  Genové</span>, <span class="hlFld-ContribAuthor ">Xidan  Li</span>, <span class="hlFld-ContribAuthor ">Annika  Wernerson</span>, <span class="hlFld-ContribAuthor ">Mark  Lal</span>, <span class="hlFld-ContribAuthor ">Jaakko  Patrakka</span>. </span><span class="cited-content_cbyCitation_article-title">Retinoic acid receptor responder1 promotes development of glomerular diseases via the Nuclear Factor-κB signaling pathway. </span><span class="cited-content_cbyCitation_journal-name">Kidney International</span><span> <strong>2021,</strong> <em>124 </em><a href="https://doi.org/10.1016/j.kint.2021.05.036" title="DOI URL">https://doi.org/10.1016/j.kint.2021.05.036</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.kint.2021.05.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.kint.2021.05.036%26sid%3Dliteratum%253Aachs%26jtitle%3DKidney%2520International%26atitle%3DRetinoic%252Bacid%252Breceptor%252Bresponder1%252Bpromotes%252Bdevelopment%252Bof%252Bglomerular%252Bdiseases%252Bvia%252Bthe%252BNuclear%252BFactor-%2525CE%2525BAB%252Bsignaling%252Bpathway%26aulast%3DM%25C3%25B6ller-Hackbarth%26aufirst%3DKatja%26date%3D2021%26volume%3D124" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Haoyuan  Lv</span>, <span class="hlFld-ContribAuthor ">Shuai  Ma</span>, <span class="hlFld-ContribAuthor ">Zhenbo  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaoting  Ji</span>, <span class="hlFld-ContribAuthor ">Shaoping  Lv</span>, <span class="hlFld-ContribAuthor ">Caifeng  Ding</span>. </span><span class="cited-content_cbyCitation_article-title">Glutathione-triggered non-template synthesized porous carbon nanospheres serve as low toxicity targeted delivery system for cancer multi-therapy. </span><span class="cited-content_cbyCitation_journal-name">Chinese Chemical Letters</span><span> <strong>2021,</strong> <em>32 </em>
                                    (5)
                                     , 1765-1769. <a href="https://doi.org/10.1016/j.cclet.2020.11.058" title="DOI URL">https://doi.org/10.1016/j.cclet.2020.11.058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.cclet.2020.11.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.cclet.2020.11.058%26sid%3Dliteratum%253Aachs%26jtitle%3DChinese%2520Chemical%2520Letters%26atitle%3DGlutathione-triggered%252Bnon-template%252Bsynthesized%252Bporous%252Bcarbon%252Bnanospheres%252Bserve%252Bas%252Blow%252Btoxicity%252Btargeted%252Bdelivery%252Bsystem%252Bfor%252Bcancer%252Bmulti-therapy%26aulast%3DLv%26aufirst%3DHaoyuan%26date%3D2021%26volume%3D32%26issue%3D5%26spage%3D1765%26epage%3D1769" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shengda  Xie</span>, <span class="hlFld-ContribAuthor ">Huiru  Zhang</span>, <span class="hlFld-ContribAuthor ">Zhenjie  Liang</span>, <span class="hlFld-ContribAuthor ">Xingmiao  Yang</span>, <span class="hlFld-ContribAuthor ">Ruibing  Cao</span>. </span><span class="cited-content_cbyCitation_article-title">AXL, an Important Host Factor for DENV and ZIKV Replication. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Cellular and Infection Microbiology</span><span> <strong>2021,</strong> <em>11 </em><a href="https://doi.org/10.3389/fcimb.2021.575346" title="DOI URL">https://doi.org/10.3389/fcimb.2021.575346</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fcimb.2021.575346&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffcimb.2021.575346%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Cellular%2520and%2520Infection%2520Microbiology%26atitle%3DAXL%25252C%252Ban%252BImportant%252BHost%252BFactor%252Bfor%252BDENV%252Band%252BZIKV%252BReplication%26aulast%3DXie%26aufirst%3DShengda%26date%3D2021%26date%3D2021%26volume%3D11" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2021 update. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2021,</strong> <em>165 </em>, 105463. <a href="https://doi.org/10.1016/j.phrs.2021.105463" title="DOI URL">https://doi.org/10.1016/j.phrs.2021.105463</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2021.105463&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2021.105463%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%25253A%252BA%252B2021%252Bupdate%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2021%26volume%3D165%26spage%3D105463" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Kavya  Ramkumar</span>, <span class="hlFld-ContribAuthor ">C. Allison  Stewart</span>, <span class="hlFld-ContribAuthor ">Kasey R.  Cargill</span>, <span class="hlFld-ContribAuthor ">Carminia M.  Della Corte</span>, <span class="hlFld-ContribAuthor ">Qi  Wang</span>, <span class="hlFld-ContribAuthor ">Li  Shen</span>, <span class="hlFld-ContribAuthor ">Lixia  Diao</span>, <span class="hlFld-ContribAuthor ">Robert J.  Cardnell</span>, <span class="hlFld-ContribAuthor ">David H.  Peng</span>, <span class="hlFld-ContribAuthor ">B. Leticia  Rodriguez</span>, <span class="hlFld-ContribAuthor ">You-Hong  Fan</span>, <span class="hlFld-ContribAuthor ">John V.  Heymach</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Carl M.  Gay</span>, <span class="hlFld-ContribAuthor ">Don L.  Gibbons</span>, <span class="hlFld-ContribAuthor ">Lauren A.  Byers</span>. </span><span class="cited-content_cbyCitation_article-title">AXL Inhibition Induces DNA Damage and Replication Stress in Non–Small Cell Lung Cancer Cells and Promotes Sensitivity to ATR Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2021,</strong> <em>19 </em>
                                    (3)
                                     , 485-497. <a href="https://doi.org/10.1158/1541-7786.MCR-20-0414" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-20-0414</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-20-0414&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-20-0414%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DAXL%252BInhibition%252BInduces%252BDNA%252BDamage%252Band%252BReplication%252BStress%252Bin%252BNon%2525E2%252580%252593Small%252BCell%252BLung%252BCancer%252BCells%252Band%252BPromotes%252BSensitivity%252Bto%252BATR%252BInhibitors%26aulast%3DRamkumar%26aufirst%3DKavya%26date%3D2021%26date%3D2020%26volume%3D19%26issue%3D3%26spage%3D485%26epage%3D497" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Ting  Guo</span>, <span class="hlFld-ContribAuthor ">Shutao  Ma</span>. </span><span class="cited-content_cbyCitation_article-title">Recent Advances in the Discovery of Multitargeted Tyrosine Kinase Inhibitors as Anticancer Agents. </span><span class="cited-content_cbyCitation_journal-name">ChemMedChem</span><span> <strong>2021,</strong> <em>16 </em>
                                    (4)
                                     , 600-620. <a href="https://doi.org/10.1002/cmdc.202000658" title="DOI URL">https://doi.org/10.1002/cmdc.202000658</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cmdc.202000658&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcmdc.202000658%26sid%3Dliteratum%253Aachs%26jtitle%3DChemMedChem%26atitle%3DRecent%252BAdvances%252Bin%252Bthe%252BDiscovery%252Bof%252BMultitargeted%252BTyrosine%252BKinase%252BInhibitors%252Bas%252BAnticancer%252BAgents%26aulast%3DGuo%26aufirst%3DTing%26date%3D2021%26date%3D2020%26volume%3D16%26issue%3D4%26spage%3D600%26epage%3D620" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yeonji  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung Won  Lee</span>, <span class="hlFld-ContribAuthor ">Hyesu  Yeom</span>, <span class="hlFld-ContribAuthor ">Miok  Kim</span>, <span class="hlFld-ContribAuthor ">Yeon Kyung  Lee</span>, <span class="hlFld-ContribAuthor ">Joo‐Youn  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Yeon  Hwang</span>, <span class="hlFld-ContribAuthor ">Youngki  Min</span>, <span class="hlFld-ContribAuthor ">Do Hyun  Ryu</span>, <span class="hlFld-ContribAuthor ">Chang Hoon  Lee</span>, <span class="hlFld-ContribAuthor ">Sung Yun  Cho</span>. </span><span class="cited-content_cbyCitation_article-title">Design and Synthesis of
              5‐Aryl
              ‐substituted Phenylpyrimidine‐2,4‐diamine Derivatives as Novel Mer and Tyro3 Kinase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bulletin of the Korean Chemical Society</span><span> <strong>2021,</strong> <em>42 </em>
                                    (2)
                                     , 206-211. <a href="https://doi.org/10.1002/bkcs.12167" title="DOI URL">https://doi.org/10.1002/bkcs.12167</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/bkcs.12167&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fbkcs.12167%26sid%3Dliteratum%253Aachs%26jtitle%3DBulletin%2520of%2520the%2520Korean%2520Chemical%2520Society%26atitle%3DDesign%252Band%252BSynthesis%252Bof%252B5%2525E2%252580%252590Aryl%252B%2525E2%252580%252590substituted%252BPhenylpyrimidine%2525E2%252580%2525902%25252C4%2525E2%252580%252590diamine%252BDerivatives%252Bas%252BNovel%252BMer%252Band%252BTyro3%252BKinase%252BInhibitors%26aulast%3DKim%26aufirst%3DYeonji%26date%3D2021%26date%3D2020%26volume%3D42%26issue%3D2%26spage%3D206%26epage%3D211" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Biagio  Ricciuti</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Lamberti</span>, <span class="hlFld-ContribAuthor ">Elisa  Andrini</span>, <span class="hlFld-ContribAuthor ">Carlo  Genova</span>, <span class="hlFld-ContribAuthor ">Andrea  De Giglio</span>, <span class="hlFld-ContribAuthor ">Vanessa  Bianconi</span>, <span class="hlFld-ContribAuthor ">Amirhossein  Sahebkar</span>, <span class="hlFld-ContribAuthor ">Rita  Chiari</span>, <span class="hlFld-ContribAuthor ">Matteo  Pirro</span>. </span><span class="cited-content_cbyCitation_article-title">Antibody–drug conjugates for lung cancer in the era of personalized oncology. </span><span class="cited-content_cbyCitation_journal-name">Seminars in Cancer Biology</span><span> <strong>2021,</strong> <em>69 </em>, 268-278. <a href="https://doi.org/10.1016/j.semcancer.2019.12.024" title="DOI URL">https://doi.org/10.1016/j.semcancer.2019.12.024</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.semcancer.2019.12.024&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.semcancer.2019.12.024%26sid%3Dliteratum%253Aachs%26jtitle%3DSeminars%2520in%2520Cancer%2520Biology%26atitle%3DAntibody%2525E2%252580%252593drug%252Bconjugates%252Bfor%252Blung%252Bcancer%252Bin%252Bthe%252Bera%252Bof%252Bpersonalized%252Boncology%26aulast%3DRicciuti%26aufirst%3DBiagio%26date%3D2021%26volume%3D69%26spage%3D268%26epage%3D278" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mohamed  Mokhtar</span>, <span class="hlFld-ContribAuthor ">Khadijah S.  Alghamdi</span>, <span class="hlFld-ContribAuthor ">Nesreen S.  Ahmed</span>, <span class="hlFld-ContribAuthor ">Dina  Bakhotmah</span>, <span class="hlFld-ContribAuthor ">Tamer S.  Saleh</span>. </span><span class="cited-content_cbyCitation_article-title">Design and green synthesis of novel quinolinone derivatives of potential anti-breast cancer activity against MCF-7 cell line targeting multi-receptor tyrosine kinases. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2021,</strong> <em>36 </em>
                                    (1)
                                     , 1454-1471. <a href="https://doi.org/10.1080/14756366.2021.1944126" title="DOI URL">https://doi.org/10.1080/14756366.2021.1944126</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2021.1944126&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2021.1944126%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DDesign%252Band%252Bgreen%252Bsynthesis%252Bof%252Bnovel%252Bquinolinone%252Bderivatives%252Bof%252Bpotential%252Banti-breast%252Bcancer%252Bactivity%252Bagainst%252BMCF-7%252Bcell%252Bline%252Btargeting%252Bmulti-receptor%252Btyrosine%252Bkinases%26aulast%3DMokhtar%26aufirst%3DMohamed%26date%3D2021%26date%3D2021%26volume%3D36%26issue%3D1%26spage%3D1454%26epage%3D1471" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Siyuan  Qin</span>, <span class="hlFld-ContribAuthor ">Jingwen  Jiang</span>, <span class="hlFld-ContribAuthor ">Yi  Lu</span>, <span class="hlFld-ContribAuthor ">Edouard C.  Nice</span>, <span class="hlFld-ContribAuthor ">Canhua  Huang</span>, <span class="hlFld-ContribAuthor ">Jian  Zhang</span>, <span class="hlFld-ContribAuthor ">Weifeng  He</span>. </span><span class="cited-content_cbyCitation_article-title">Emerging role of tumor cell plasticity in modifying therapeutic response. </span><span class="cited-content_cbyCitation_journal-name">Signal Transduction and Targeted Therapy</span><span> <strong>2020,</strong> <em>5 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41392-020-00313-5" title="DOI URL">https://doi.org/10.1038/s41392-020-00313-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41392-020-00313-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41392-020-00313-5%26sid%3Dliteratum%253Aachs%26jtitle%3DSignal%2520Transduction%2520and%2520Targeted%2520Therapy%26atitle%3DEmerging%252Brole%252Bof%252Btumor%252Bcell%252Bplasticity%252Bin%252Bmodifying%252Btherapeutic%252Bresponse%26aulast%3DQin%26aufirst%3DSiyuan%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yaoyu  Chen</span>, <span class="hlFld-ContribAuthor ">Margaret  Favata</span>, <span class="hlFld-ContribAuthor ">Michelle  Pusey</span>, <span class="hlFld-ContribAuthor ">Jun  Li</span>, <span class="hlFld-ContribAuthor ">Yvonne  Lo</span>, <span class="hlFld-ContribAuthor ">Min  Ye</span>, <span class="hlFld-ContribAuthor ">Richard  Wynn</span>, <span class="hlFld-ContribAuthor ">Xiaozhao  Wang</span>, <span class="hlFld-ContribAuthor ">Wenqing  Yao</span>, <span class="hlFld-ContribAuthor ">Yingnan  Chen</span>. </span><span class="cited-content_cbyCitation_article-title">Identification of pAKT as a pharmacodynamic marker for MER kinase in human melanoma G361 cells. </span><span class="cited-content_cbyCitation_journal-name">Biomarker Research</span><span> <strong>2020,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s40364-020-0184-9" title="DOI URL">https://doi.org/10.1186/s40364-020-0184-9</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s40364-020-0184-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs40364-020-0184-9%26sid%3Dliteratum%253Aachs%26jtitle%3DBiomarker%2520Research%26atitle%3DIdentification%252Bof%252BpAKT%252Bas%252Ba%252Bpharmacodynamic%252Bmarker%252Bfor%252BMER%252Bkinase%252Bin%252Bhuman%252Bmelanoma%252BG361%252Bcells%26aulast%3DChen%26aufirst%3DYaoyu%26date%3D2020%26date%3D2020%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Daniel J.  Baillache</span>, <span class="hlFld-ContribAuthor ">Asier  Unciti-Broceta</span>. </span><span class="cited-content_cbyCitation_article-title">Recent developments in anticancer kinase inhibitors based on the pyrazolo[3,4-
              d
              ]pyrimidine scaffold. </span><span class="cited-content_cbyCitation_journal-name">RSC Medicinal Chemistry</span><span> <strong>2020,</strong> <em>11 </em>
                                    (10)
                                     , 1112-1135. <a href="https://doi.org/10.1039/D0MD00227E" title="DOI URL">https://doi.org/10.1039/D0MD00227E</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D0MD00227E&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD0MD00227E%26sid%3Dliteratum%253Aachs%26jtitle%3DRSC%2520Medicinal%2520Chemistry%26atitle%3DRecent%252Bdevelopments%252Bin%252Banticancer%252Bkinase%252Binhibitors%252Bbased%252Bon%252Bthe%252Bpyrazolo%25255B3%25252C4-%252Bd%252B%25255Dpyrimidine%252Bscaffold%26aulast%3DBaillache%26aufirst%3DDaniel%2BJ.%26date%3D2020%26date%3D2020%26volume%3D11%26issue%3D10%26spage%3D1112%26epage%3D1135" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Cheong A.  Bae</span>, <span class="hlFld-ContribAuthor ">In-Hye  Ham</span>, <span class="hlFld-ContribAuthor ">Hye Jeong  Oh</span>, <span class="hlFld-ContribAuthor ">Dagyeong  Lee</span>, <span class="hlFld-ContribAuthor ">Jongsu  Woo</span>, <span class="hlFld-ContribAuthor ">Sang-Yong  Son</span>, <span class="hlFld-ContribAuthor ">Jung Hwan  Yoon</span>, <span class="hlFld-ContribAuthor ">James B.  Lorens</span>, <span class="hlFld-ContribAuthor ">Rolf A.  Brekken</span>, <span class="hlFld-ContribAuthor ">Tae-Min  Kim</span>, <span class="hlFld-ContribAuthor ">Sang-Uk  Han</span>, <span class="hlFld-ContribAuthor ">Won Sang  Park</span>, <span class="hlFld-ContribAuthor ">Hoon  Hur</span>. </span><span class="cited-content_cbyCitation_article-title">Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma. </span><span class="cited-content_cbyCitation_journal-name">Gastric Cancer</span><span> <strong>2020,</strong> <em>23 </em>
                                    (5)
                                     , 824-836. <a href="https://doi.org/10.1007/s10120-020-01066-4" title="DOI URL">https://doi.org/10.1007/s10120-020-01066-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s10120-020-01066-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs10120-020-01066-4%26sid%3Dliteratum%253Aachs%26jtitle%3DGastric%2520Cancer%26atitle%3DInhibiting%252Bthe%252BGAS6%25252FAXL%252Baxis%252Bsuppresses%252Btumor%252Bprogression%252Bby%252Bblocking%252Bthe%252Binteraction%252Bbetween%252Bcancer-associated%252Bfibroblasts%252Band%252Bcancer%252Bcells%252Bin%252Bgastric%252Bcarcinoma%26aulast%3DBae%26aufirst%3DCheong%2BA.%26date%3D2020%26date%3D2020%26volume%3D23%26issue%3D5%26spage%3D824%26epage%3D836" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Fedeli</span>, <span class="hlFld-ContribAuthor ">Hector  Moreno</span>, <span class="hlFld-ContribAuthor ">Stefan  Kunz</span>. </span><span class="cited-content_cbyCitation_article-title">The Role of Receptor Tyrosine Kinases in Lassa Virus Cell Entry. </span><span class="cited-content_cbyCitation_journal-name">Viruses</span><span> <strong>2020,</strong> <em>12 </em>
                                    (8)
                                     , 857. <a href="https://doi.org/10.3390/v12080857" title="DOI URL">https://doi.org/10.3390/v12080857</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/v12080857&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fv12080857%26sid%3Dliteratum%253Aachs%26jtitle%3DViruses%26atitle%3DThe%252BRole%252Bof%252BReceptor%252BTyrosine%252BKinases%252Bin%252BLassa%252BVirus%252BCell%252BEntry%26aulast%3DFedeli%26aufirst%3DChiara%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D8%26spage%3D857" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Karin Juliane Pelizzaro  Rocha-Brito</span>, <span class="hlFld-ContribAuthor ">Emanuella Maria Barreto  Fonseca</span>, <span class="hlFld-ContribAuthor ">Breno Germano de Freitas  Oliveira</span>, <span class="hlFld-ContribAuthor ">Ângelo de  Fátima</span>, <span class="hlFld-ContribAuthor ">Carmen Veríssima  Ferreira-Halder</span>. </span><span class="cited-content_cbyCitation_article-title">Calix[6]arene diminishes receptor tyrosine kinase lifespan in pancreatic cancer cells and inhibits their migration and invasion efficiency. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic Chemistry</span><span> <strong>2020,</strong> <em>100 </em>, 103881. <a href="https://doi.org/10.1016/j.bioorg.2020.103881" title="DOI URL">https://doi.org/10.1016/j.bioorg.2020.103881</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bioorg.2020.103881&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bioorg.2020.103881%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520Chemistry%26atitle%3DCalix%25255B6%25255Darene%252Bdiminishes%252Breceptor%252Btyrosine%252Bkinase%252Blifespan%252Bin%252Bpancreatic%252Bcancer%252Bcells%252Band%252Binhibits%252Btheir%252Bmigration%252Band%252Binvasion%252Befficiency%26aulast%3DRocha-Brito%26aufirst%3DKarin%2BJuliane%2BPelizzaro%26date%3D2020%26volume%3D100%26spage%3D103881" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai  Tanaka</span>, <span class="hlFld-ContribAuthor ">Dietmar W.  Siemann</span>. </span><span class="cited-content_cbyCitation_article-title">Gas6/Axl Signaling Pathway in the Tumor Immune Microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Cancers</span><span> <strong>2020,</strong> <em>12 </em>
                                    (7)
                                     , 1850. <a href="https://doi.org/10.3390/cancers12071850" title="DOI URL">https://doi.org/10.3390/cancers12071850</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cancers12071850&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcancers12071850%26sid%3Dliteratum%253Aachs%26jtitle%3DCancers%26atitle%3DGas6%25252FAxl%252BSignaling%252BPathway%252Bin%252Bthe%252BTumor%252BImmune%252BMicroenvironment%26aulast%3DTanaka%26aufirst%3DMai%26date%3D2020%26date%3D2020%26volume%3D12%26issue%3D7%26spage%3D1850" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenjing  Zhu</span>, <span class="hlFld-ContribAuthor ">Huashan  Shi</span>, <span class="hlFld-ContribAuthor ">Min  Wu</span>, <span class="hlFld-ContribAuthor ">Xiawei  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">A dual MET/AXL small‐molecule inhibitor exerts efficacy against gastric carcinoma through killing cancer cells as well as modulating tumor microenvironment. </span><span class="cited-content_cbyCitation_journal-name">MedComm</span><span> <strong>2020,</strong> <em>1 </em>
                                    (1)
                                     , 103-118. <a href="https://doi.org/10.1002/mco2.11" title="DOI URL">https://doi.org/10.1002/mco2.11</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/mco2.11&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmco2.11%26sid%3Dliteratum%253Aachs%26jtitle%3DMedComm%26atitle%3DA%252Bdual%252BMET%25252FAXL%252Bsmall%2525E2%252580%252590molecule%252Binhibitor%252Bexerts%252Befficacy%252Bagainst%252Bgastric%252Bcarcinoma%252Bthrough%252Bkilling%252Bcancer%252Bcells%252Bas%252Bwell%252Bas%252Bmodulating%252Btumor%252Bmicroenvironment%26aulast%3DZhu%26aufirst%3DChenjing%26date%3D2020%26date%3D2020%26volume%3D1%26issue%3D1%26spage%3D103%26epage%3D118" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongchuang  Xu</span>, <span class="hlFld-ContribAuthor ">Minshu  Wang</span>, <span class="hlFld-ContribAuthor ">Fengxu  Wu</span>, <span class="hlFld-ContribAuthor ">Linsheng  Zhuo</span>, <span class="hlFld-ContribAuthor ">Wei  Huang</span>, <span class="hlFld-ContribAuthor ">Nengfang  She</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of N-substituted-3-phenyl-1,6-naphthyridinone derivatives bearing quinoline moiety as selective type II c-Met kinase inhibitors against VEGFR-2. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2020,</strong> <em>28 </em>
                                    (12)
                                     , 115555. <a href="https://doi.org/10.1016/j.bmc.2020.115555" title="DOI URL">https://doi.org/10.1016/j.bmc.2020.115555</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2020.115555&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2020.115555%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252BN-substituted-3-phenyl-1%25252C6-naphthyridinone%252Bderivatives%252Bbearing%252Bquinoline%252Bmoiety%252Bas%252Bselective%252Btype%252BII%252Bc-Met%252Bkinase%252Binhibitors%252Bagainst%252BVEGFR-2%26aulast%3DXu%26aufirst%3DHongchuang%26date%3D2020%26volume%3D28%26issue%3D12%26spage%3D115555" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">The role of small molecule Flt3 receptor protein-tyrosine kinase inhibitors in the treatment of Flt3-positive acute myelogenous leukemias. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>155 </em>, 104725. <a href="https://doi.org/10.1016/j.phrs.2020.104725" title="DOI URL">https://doi.org/10.1016/j.phrs.2020.104725</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2020.104725&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2020.104725%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DThe%252Brole%252Bof%252Bsmall%252Bmolecule%252BFlt3%252Breceptor%252Bprotein-tyrosine%252Bkinase%252Binhibitors%252Bin%252Bthe%252Btreatment%252Bof%252BFlt3-positive%252Bacute%252Bmyelogenous%252Bleukemias%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D155%26spage%3D104725" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stephanie J.  Wang</span>, <span class="hlFld-ContribAuthor ">Ran  Li</span>, <span class="hlFld-ContribAuthor ">Thomas S. C.  Ng</span>, <span class="hlFld-ContribAuthor ">Gaurav  Luthria</span>, <span class="hlFld-ContribAuthor ">Madeleine J.  Oudin</span>, <span class="hlFld-ContribAuthor ">Mark  Prytyskach</span>, <span class="hlFld-ContribAuthor ">Rainer H.  Kohler</span>, <span class="hlFld-ContribAuthor ">Ralph  Weissleder</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Lauffenburger</span>, <span class="hlFld-ContribAuthor ">Miles A.  Miller</span>. </span><span class="cited-content_cbyCitation_article-title">Efficient blockade of locally reciprocated tumor-macrophage signaling using a TAM-avid nanotherapy. </span><span class="cited-content_cbyCitation_journal-name">Science Advances</span><span> <strong>2020,</strong> <em>6 </em>
                                    (21)
                                     , eaaz8521. <a href="https://doi.org/10.1126/sciadv.aaz8521" title="DOI URL">https://doi.org/10.1126/sciadv.aaz8521</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1126/sciadv.aaz8521&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1126%2Fsciadv.aaz8521%26sid%3Dliteratum%253Aachs%26jtitle%3DScience%2520Advances%26atitle%3DEfficient%252Bblockade%252Bof%252Blocally%252Breciprocated%252Btumor-macrophage%252Bsignaling%252Busing%252Ba%252BTAM-avid%252Bnanotherapy%26aulast%3DWang%26aufirst%3DStephanie%2BJ.%26date%3D2020%26date%3D2020%26volume%3D6%26issue%3D21%26spage%3Deaaz8521" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Atsuo  Kurata</span>, <span class="hlFld-ContribAuthor ">Yukako  Tachibana</span>, <span class="hlFld-ContribAuthor ">Tadakatsu  Takahashi</span>, <span class="hlFld-ContribAuthor ">Naoshi  Horiba</span>, . </span><span class="cited-content_cbyCitation_article-title">Novel AXL-specific inhibitor ameliorates kidney dysfunction through the inhibition of epithelial-to-mesenchymal transition of renal tubular cells. </span><span class="cited-content_cbyCitation_journal-name">PLOS ONE</span><span> <strong>2020,</strong> <em>15 </em>
                                    (4)
                                     , e0232055. <a href="https://doi.org/10.1371/journal.pone.0232055" title="DOI URL">https://doi.org/10.1371/journal.pone.0232055</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1371/journal.pone.0232055&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1371%2Fjournal.pone.0232055%26sid%3Dliteratum%253Aachs%26jtitle%3DPLOS%2520ONE%26atitle%3DNovel%252BAXL-specific%252Binhibitor%252Bameliorates%252Bkidney%252Bdysfunction%252Bthrough%252Bthe%252Binhibition%252Bof%252Bepithelial-to-mesenchymal%252Btransition%252Bof%252Brenal%252Btubular%252Bcells%26aulast%3DKurata%26aufirst%3DAtsuo%26date%3D2020%26date%3D2020%26volume%3D15%26issue%3D4%26spage%3De0232055" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Pavel G.  Sergeev</span>, <span class="hlFld-ContribAuthor ">Valentin G.  Nenajdenko</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in the chemistry of pyridazine — an important representative of six-membered nitrogen heterocycles. </span><span class="cited-content_cbyCitation_journal-name">Russian Chemical Reviews</span><span> <strong>2020,</strong> <em>89 </em>
                                    (4)
                                     , 393-429. <a href="https://doi.org/10.1070/RCR4922" title="DOI URL">https://doi.org/10.1070/RCR4922</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1070/RCR4922&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1070%2FRCR4922%26sid%3Dliteratum%253Aachs%26jtitle%3DRussian%2520Chemical%2520Reviews%26atitle%3DRecent%252Badvances%252Bin%252Bthe%252Bchemistry%252Bof%252Bpyridazine%252B%2525E2%252580%252594%252Ban%252Bimportant%252Brepresentative%252Bof%252Bsix-membered%252Bnitrogen%252Bheterocycles%26aulast%3DSergeev%26aufirst%3DPavel%2BG.%26date%3D2020%26date%3D2020%26volume%3D89%26issue%3D4%26spage%3D393%26epage%3D429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jennifer  Mayor</span>, <span class="hlFld-ContribAuthor ">Giulia  Torriani</span>, <span class="hlFld-ContribAuthor ">Sylvia  Rothenberger</span>, <span class="hlFld-ContribAuthor ">Olivier  Engler</span>. </span><span class="cited-content_cbyCitation_article-title">T-cell immunoglobulin and mucin (TIM) contributes to the infection of human airway epithelial cells by pseudotype viruses containing Hantaan virus glycoproteins. </span><span class="cited-content_cbyCitation_journal-name">Virology</span><span> <strong>2020,</strong> <em>543 </em>, 54-62. <a href="https://doi.org/10.1016/j.virol.2020.02.002" title="DOI URL">https://doi.org/10.1016/j.virol.2020.02.002</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.virol.2020.02.002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.virol.2020.02.002%26sid%3Dliteratum%253Aachs%26jtitle%3DVirology%26atitle%3DT-cell%252Bimmunoglobulin%252Band%252Bmucin%252B%252528TIM%252529%252Bcontributes%252Bto%252Bthe%252Binfection%252Bof%252Bhuman%252Bairway%252Bepithelial%252Bcells%252Bby%252Bpseudotype%252Bviruses%252Bcontaining%252BHantaan%252Bvirus%252Bglycoproteins%26aulast%3DMayor%26aufirst%3DJennifer%26date%3D2020%26volume%3D543%26spage%3D54%26epage%3D62" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Edita  Sarukhanyan</span>, <span class="hlFld-ContribAuthor ">Sergey  Shityakov</span>, <span class="hlFld-ContribAuthor ">Thomas  Dandekar</span>. </span><span class="cited-content_cbyCitation_article-title">Rational Drug Design of Axl Tyrosine Kinase Type I Inhibitors as Promising Candidates Against Cancer. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Chemistry</span><span> <strong>2020,</strong> <em>7 </em><a href="https://doi.org/10.3389/fchem.2019.00920" title="DOI URL">https://doi.org/10.3389/fchem.2019.00920</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fchem.2019.00920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffchem.2019.00920%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Chemistry%26atitle%3DRational%252BDrug%252BDesign%252Bof%252BAxl%252BTyrosine%252BKinase%252BType%252BI%252BInhibitors%252Bas%252BPromising%252BCandidates%252BAgainst%252BCancer%26aulast%3DSarukhanyan%26aufirst%3DEdita%26date%3D2020%26date%3D2020%26volume%3D7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marlies J. W.  Peeters</span>, <span class="hlFld-ContribAuthor ">Anne  Rahbech</span>, <span class="hlFld-ContribAuthor ">Per  thor Straten</span>. </span><span class="cited-content_cbyCitation_article-title">TAM-ing T cells in the tumor microenvironment: implications for TAM receptor targeting. </span><span class="cited-content_cbyCitation_journal-name">Cancer Immunology, Immunotherapy</span><span> <strong>2020,</strong> <em>69 </em>
                                    (2)
                                     , 237-244. <a href="https://doi.org/10.1007/s00262-019-02421-w" title="DOI URL">https://doi.org/10.1007/s00262-019-02421-w</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00262-019-02421-w&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00262-019-02421-w%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Immunology%252C%2520Immunotherapy%26atitle%3DTAM-ing%252BT%252Bcells%252Bin%252Bthe%252Btumor%252Bmicroenvironment%25253A%252Bimplications%252Bfor%252BTAM%252Breceptor%252Btargeting%26aulast%3DPeeters%26aufirst%3DMarlies%2BJ.%2BW.%26date%3D2020%26date%3D2019%26volume%3D69%26issue%3D2%26spage%3D237%26epage%3D244" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2020,</strong> <em>152 </em>, 104609. <a href="https://doi.org/10.1016/j.phrs.2019.104609" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.104609</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.104609&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.104609%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%25253A%252BA%252B2020%252Bupdate%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2020%26volume%3D152%26spage%3D104609" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Congjun  Xu</span>, <span class="hlFld-ContribAuthor ">Yufei  Han</span>, <span class="hlFld-ContribAuthor ">Sicong  Xu</span>, <span class="hlFld-ContribAuthor ">Ruxin  Wang</span>, <span class="hlFld-ContribAuthor ">Ming  Yue</span>, <span class="hlFld-ContribAuthor ">Yu  Tian</span>, <span class="hlFld-ContribAuthor ">Xiaofan  Li</span>, <span class="hlFld-ContribAuthor ">Yanfang  Zhao</span>, <span class="hlFld-ContribAuthor ">Ping  Gong</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis and biological evaluation of new Axl kinase inhibitors containing 1,3,4-oxadiazole acetamide moiety as novel linker. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>186 </em>, 111867. <a href="https://doi.org/10.1016/j.ejmech.2019.111867" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.111867</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.111867&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.111867%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%252Band%252Bbiological%252Bevaluation%252Bof%252Bnew%252BAxl%252Bkinase%252Binhibitors%252Bcontaining%252B1%25252C3%25252C4-oxadiazole%252Bacetamide%252Bmoiety%252Bas%252Bnovel%252Blinker%26aulast%3DXu%26aufirst%3DCongjun%26date%3D2020%26volume%3D186%26spage%3D111867" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Lingli  Liang</span>, <span class="hlFld-ContribAuthor ">Jun  Zhang</span>, <span class="hlFld-ContribAuthor ">Lixia  Tian</span>, <span class="hlFld-ContribAuthor ">Shuo  Wang</span>, <span class="hlFld-ContribAuthor ">Linping  Xu</span>, <span class="hlFld-ContribAuthor ">Yingxuan  Wang</span>, <span class="hlFld-ContribAuthor ">Qingying  Guo-Shuai</span>, <span class="hlFld-ContribAuthor ">Yue  Dong</span>, <span class="hlFld-ContribAuthor ">Yu  Chen</span>, <span class="hlFld-ContribAuthor ">Hong  Jia</span>, <span class="hlFld-ContribAuthor ">Xuewei  Yang</span>, <span class="hlFld-ContribAuthor ">Chunmei  Yuan</span>. </span><span class="cited-content_cbyCitation_article-title">AXL signaling in primary sensory neurons contributes to chronic compression of dorsal root ganglion-induced neuropathic pain in rats. </span><span class="cited-content_cbyCitation_journal-name">Molecular Pain</span><span> <strong>2020,</strong> <em>16 </em>, 174480691990081. <a href="https://doi.org/10.1177/1744806919900814" title="DOI URL">https://doi.org/10.1177/1744806919900814</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1177/1744806919900814&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1177%2F1744806919900814%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Pain%26atitle%3DAXL%252Bsignaling%252Bin%252Bprimary%252Bsensory%252Bneurons%252Bcontributes%252Bto%252Bchronic%252Bcompression%252Bof%252Bdorsal%252Broot%252Bganglion-induced%252Bneuropathic%252Bpain%252Bin%252Brats%26aulast%3DLiang%26aufirst%3DLingli%26date%3D2020%26date%3D2020%26volume%3D16%26spage%3D174480691990081" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jordi  Bertran-Alamillo</span>, <span class="hlFld-ContribAuthor ">Valérie  Cattan</span>, <span class="hlFld-ContribAuthor ">Marie  Schoumacher</span>, <span class="hlFld-ContribAuthor ">Jordi  Codony-Servat</span>, <span class="hlFld-ContribAuthor ">Ana  Giménez-Capitán</span>, <span class="hlFld-ContribAuthor ">Frédérique  Cantero</span>, <span class="hlFld-ContribAuthor ">Mike  Burbridge</span>, <span class="hlFld-ContribAuthor ">Sonia  Rodríguez</span>, <span class="hlFld-ContribAuthor ">Cristina  Teixidó</span>, <span class="hlFld-ContribAuthor ">Ruth  Roman</span>, <span class="hlFld-ContribAuthor ">Josep  Castellví</span>, <span class="hlFld-ContribAuthor ">Silvia  García-Román</span>, <span class="hlFld-ContribAuthor ">Carles  Codony-Servat</span>, <span class="hlFld-ContribAuthor ">Santiago  Viteri</span>, <span class="hlFld-ContribAuthor ">Andrés-Felipe  Cardona</span>, <span class="hlFld-ContribAuthor ">Niki  Karachaliou</span>, <span class="hlFld-ContribAuthor ">Rafael  Rosell</span>, <span class="hlFld-ContribAuthor ">Miguel-Angel  Molina-Vila</span>. </span><span class="cited-content_cbyCitation_article-title">AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy. </span><span class="cited-content_cbyCitation_journal-name">Nature Communications</span><span> <strong>2019,</strong> <em>10 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41467-019-09734-5" title="DOI URL">https://doi.org/10.1038/s41467-019-09734-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41467-019-09734-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41467-019-09734-5%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Communications%26atitle%3DAURKB%252Bas%252Ba%252Btarget%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252Bwith%252Bacquired%252Bresistance%252Bto%252Banti-EGFR%252Btherapy%26aulast%3DBertran-Alamillo%26aufirst%3DJordi%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chenjing  Zhu</span>, <span class="hlFld-ContribAuthor ">Yuquan  Wei</span>, <span class="hlFld-ContribAuthor ">Xiawei  Wei</span>. </span><span class="cited-content_cbyCitation_article-title">AXL receptor tyrosine kinase as a promising anti-cancer approach: functions, molecular mechanisms and clinical applications. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2019,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-019-1090-3" title="DOI URL">https://doi.org/10.1186/s12943-019-1090-3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-019-1090-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-019-1090-3%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DAXL%252Breceptor%252Btyrosine%252Bkinase%252Bas%252Ba%252Bpromising%252Banti-cancer%252Bapproach%25253A%252Bfunctions%25252C%252Bmolecular%252Bmechanisms%252Band%252Bclinical%252Bapplications%26aulast%3DZhu%26aufirst%3DChenjing%26date%3D2019%26date%3D2019%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Markus  Lauter</span>, <span class="hlFld-ContribAuthor ">Anja  Weber</span>, <span class="hlFld-ContribAuthor ">Robert  Torka</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting of the AXL receptor tyrosine kinase by small molecule inhibitor leads to AXL cell surface accumulation by impairing the ubiquitin-dependent receptor degradation. </span><span class="cited-content_cbyCitation_journal-name">Cell Communication and Signaling</span><span> <strong>2019,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12964-019-0377-8" title="DOI URL">https://doi.org/10.1186/s12964-019-0377-8</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12964-019-0377-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12964-019-0377-8%26sid%3Dliteratum%253Aachs%26jtitle%3DCell%2520Communication%2520and%2520Signaling%26atitle%3DTargeting%252Bof%252Bthe%252BAXL%252Breceptor%252Btyrosine%252Bkinase%252Bby%252Bsmall%252Bmolecule%252Binhibitor%252Bleads%252Bto%252BAXL%252Bcell%252Bsurface%252Baccumulation%252Bby%252Bimpairing%252Bthe%252Bubiquitin-dependent%252Breceptor%252Bdegradation%26aulast%3DLauter%26aufirst%3DMarkus%26date%3D2019%26date%3D2019%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiangyi  Jiang</span>, <span class="hlFld-ContribAuthor ">Ji  Yu</span>, <span class="hlFld-ContribAuthor ">Zhongxia  Zhou</span>, <span class="hlFld-ContribAuthor ">Jacob  Kongsted</span>, <span class="hlFld-ContribAuthor ">Yuning  Song</span>, <span class="hlFld-ContribAuthor ">Christophe  Pannecouque</span>, <span class="hlFld-ContribAuthor ">Erik  De Clercq</span>, <span class="hlFld-ContribAuthor ">Dongwei  Kang</span>, <span class="hlFld-ContribAuthor ">Vasanthanathan  Poongavanam</span>, <span class="hlFld-ContribAuthor ">Xinyong  Liu</span>, <span class="hlFld-ContribAuthor ">Peng  Zhan</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular design opportunities presented by solvent‐exposed regions of target proteins. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2019,</strong> <em>39 </em>
                                    (6)
                                     , 2194-2238. <a href="https://doi.org/10.1002/med.21581" title="DOI URL">https://doi.org/10.1002/med.21581</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21581&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21581%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DMolecular%252Bdesign%252Bopportunities%252Bpresented%252Bby%252Bsolvent%2525E2%252580%252590exposed%252Bregions%252Bof%252Btarget%252Bproteins%26aulast%3DJiang%26aufirst%3DXiangyi%26date%3D2019%26date%3D2019%26volume%3D39%26issue%3D6%26spage%3D2194%26epage%3D2238" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Katherine Emilie  Rhoades Smith</span>, <span class="hlFld-ContribAuthor ">Mehmet Asim  Bilen</span>. </span><span class="cited-content_cbyCitation_article-title">A Review of Papillary Renal Cell Carcinoma and MET Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Kidney Cancer</span><span> <strong>2019,</strong> <em>3 </em>
                                    (3)
                                     , 151-161. <a href="https://doi.org/10.3233/KCA-190058" title="DOI URL">https://doi.org/10.3233/KCA-190058</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3233/KCA-190058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3233%2FKCA-190058%26sid%3Dliteratum%253Aachs%26jtitle%3DKidney%2520Cancer%26atitle%3DA%252BReview%252Bof%252BPapillary%252BRenal%252BCell%252BCarcinoma%252Band%252BMET%252BInhibitors%26aulast%3DRhoades%2BSmith%26aufirst%3DKatherine%2BEmilie%26date%3D2019%26volume%3D3%26issue%3D3%26spage%3D151%26epage%3D161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Emily N.  Arner</span>, <span class="hlFld-ContribAuthor ">Wenting  Du</span>, <span class="hlFld-ContribAuthor ">Rolf A.  Brekken</span>. </span><span class="cited-content_cbyCitation_article-title">Behind the Wheel of Epithelial Plasticity in KRAS-Driven Cancers. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Oncology</span><span> <strong>2019,</strong> <em>9 </em><a href="https://doi.org/10.3389/fonc.2019.01049" title="DOI URL">https://doi.org/10.3389/fonc.2019.01049</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fonc.2019.01049&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffonc.2019.01049%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Oncology%26atitle%3DBehind%252Bthe%252BWheel%252Bof%252BEpithelial%252BPlasticity%252Bin%252BKRAS-Driven%252BCancers%26aulast%3DArner%26aufirst%3DEmily%2BN.%26date%3D2019%26date%3D2019%26volume%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Neeraj  Kumar</span>, <span class="hlFld-ContribAuthor ">Anita  Singh</span>, <span class="hlFld-ContribAuthor ">Dinesh Kumar  Sharma</span>, <span class="hlFld-ContribAuthor ">Kamal  Kishore</span>. </span><span class="cited-content_cbyCitation_article-title">Novel Target Sites for Drug Screening: A Special Reference to Cancer, Rheumatoid Arthritis and Parkinson’s Disease. </span><span class="cited-content_cbyCitation_journal-name">Current Signal Transduction Therapy</span><span> <strong>2019,</strong> <em>14 </em>
                                    (2)
                                     , 107-121. <a href="https://doi.org/10.2174/1574362413666180320112810" title="DOI URL">https://doi.org/10.2174/1574362413666180320112810</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2174/1574362413666180320112810&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2174%2F1574362413666180320112810%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Signal%2520Transduction%2520Therapy%26atitle%3DNovel%252BTarget%252BSites%252Bfor%252BDrug%252BScreening%25253A%252BA%252BSpecial%252BReference%252Bto%252BCancer%25252C%252BRheumatoid%252BArthritis%252Band%252BParkinson%2525E2%252580%252599s%252BDisease%26aulast%3DKumar%26aufirst%3DNeeraj%26date%3D2019%26volume%3D14%26issue%3D2%26spage%3D107%26epage%3D121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhongfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Hongxiang  Wu</span>, <span class="hlFld-ContribAuthor ">Yue  Li</span>, <span class="hlFld-ContribAuthor ">Yuwen  Chen</span>, <span class="hlFld-ContribAuthor ">Jingyi  Nie</span>, <span class="hlFld-ContribAuthor ">Siqi  Lu</span>, <span class="hlFld-ContribAuthor ">Yulin  Zhu</span>, <span class="hlFld-ContribAuthor ">Zhuo  Zeng</span>. </span><span class="cited-content_cbyCitation_article-title">Cesium Fluoride and Copper‐Catalyzed One‐Pot Synthesis of Benzoxazoles
              via
              a Site‐Selective Amide C−N Bond Cleavage. </span><span class="cited-content_cbyCitation_journal-name">Advanced Synthesis & Catalysis</span><span> <strong>2019,</strong> <em>361 </em>
                                    (17)
                                     , 4117-4125. <a href="https://doi.org/10.1002/adsc.201900485" title="DOI URL">https://doi.org/10.1002/adsc.201900485</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/adsc.201900485&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fadsc.201900485%26sid%3Dliteratum%253Aachs%26jtitle%3DAdvanced%2520Synthesis%2520%2526%2520Catalysis%26atitle%3DCesium%252BFluoride%252Band%252BCopper%2525E2%252580%252590Catalyzed%252BOne%2525E2%252580%252590Pot%252BSynthesis%252Bof%252BBenzoxazoles%252Bvia%252Ba%252BSite%2525E2%252580%252590Selective%252BAmide%252BC%2525E2%252588%252592N%252BBond%252BCleavage%26aulast%3DLuo%26aufirst%3DZhongfeng%26date%3D2019%26date%3D2019%26volume%3D361%26issue%3D17%26spage%3D4117%26epage%3D4125" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanting  Duan</span>, <span class="hlFld-ContribAuthor ">Longlong  Luo</span>, <span class="hlFld-ContribAuthor ">Chunxia  Qiao</span>, <span class="hlFld-ContribAuthor ">Xinying  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhou</span>, <span class="hlFld-ContribAuthor ">Beifen  Shen</span>, <span class="hlFld-ContribAuthor ">Ming  Lv</span>, <span class="hlFld-ContribAuthor ">Jiannan  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">A novel human anti‐AXL monoclonal antibody attenuates tumour cell migration. </span><span class="cited-content_cbyCitation_journal-name">Scandinavian Journal of Immunology</span><span> <strong>2019,</strong> <em>90 </em>
                                    (2)
                                     <a href="https://doi.org/10.1111/sji.12777" title="DOI URL">https://doi.org/10.1111/sji.12777</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/sji.12777&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fsji.12777%26sid%3Dliteratum%253Aachs%26jtitle%3DScandinavian%2520Journal%2520of%2520Immunology%26atitle%3DA%252Bnovel%252Bhuman%252Banti%2525E2%252580%252590AXL%252Bmonoclonal%252Bantibody%252Battenuates%252Btumour%252Bcell%252Bmigration%26aulast%3DDuan%26aufirst%3DYanting%26date%3D2019%26date%3D2019%26volume%3D90%26issue%3D2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Omkara Lakshmi  Veeranki</span>, <span class="hlFld-ContribAuthor ">Zhimin  Tong</span>, <span class="hlFld-ContribAuthor ">Rashmi  Dokey</span>, <span class="hlFld-ContribAuthor ">Alicia  Mejia</span>, <span class="hlFld-ContribAuthor ">Jianhu  Zhang</span>, <span class="hlFld-ContribAuthor ">Yawei  Qiao</span>, <span class="hlFld-ContribAuthor ">Pankaj Kumar  Singh</span>, <span class="hlFld-ContribAuthor ">Riham  Katkhuda</span>, <span class="hlFld-ContribAuthor ">Barbara  Mino</span>, <span class="hlFld-ContribAuthor ">Ramesh  Tailor</span>, <span class="hlFld-ContribAuthor ">Jaime Rodriguez  Canales</span>, <span class="hlFld-ContribAuthor ">Roland  Bassett</span>, <span class="hlFld-ContribAuthor ">Jaffer  Ajani</span>, <span class="hlFld-ContribAuthor ">Ji Yuan  Wu</span>, <span class="hlFld-ContribAuthor ">Scott  Kopetz</span>, <span class="hlFld-ContribAuthor ">Mariela  Blum</span>, <span class="hlFld-ContribAuthor ">Wayne  Hofstetter</span>, <span class="hlFld-ContribAuthor ">Michael  Tetzlaff</span>, <span class="hlFld-ContribAuthor ">Sunil  Krishnan</span>, <span class="hlFld-ContribAuthor ">Steven H.  Lin</span>, <span class="hlFld-ContribAuthor ">Dipen  Maru</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting cyclin-dependent kinase 9 by a novel inhibitor enhances radiosensitization and identifies Axl as a novel downstream target in esophageal adenocarcinoma. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (45)
                                     , 4703-4718. <a href="https://doi.org/10.18632/oncotarget.27095" title="DOI URL">https://doi.org/10.18632/oncotarget.27095</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.27095&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.27095%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DTargeting%252Bcyclin-dependent%252Bkinase%252B9%252Bby%252Ba%252Bnovel%252Binhibitor%252Benhances%252Bradiosensitization%252Band%252Bidentifies%252BAxl%252Bas%252Ba%252Bnovel%252Bdownstream%252Btarget%252Bin%252Besophageal%252Badenocarcinoma%26aulast%3DVeeranki%26aufirst%3DOmkara%2BLakshmi%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D45%26spage%3D4703%26epage%3D4718" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Philip L.  Cohen</span>, <span class="hlFld-ContribAuthor ">Wen-Hai  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Gas6/TAM Receptors in Systemic Lupus Erythematosus. </span><span class="cited-content_cbyCitation_journal-name">Disease Markers</span><span> <strong>2019,</strong> <em>2019 </em>, 1-9. <a href="https://doi.org/10.1155/2019/7838195" title="DOI URL">https://doi.org/10.1155/2019/7838195</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1155/2019/7838195&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1155%2F2019%2F7838195%26sid%3Dliteratum%253Aachs%26jtitle%3DDisease%2520Markers%26atitle%3DGas6%25252FTAM%252BReceptors%252Bin%252BSystemic%252BLupus%252BErythematosus%26aulast%3DCohen%26aufirst%3DPhilip%2BL.%26date%3D2019%26volume%3D2019%26spage%3D1%26epage%3D9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Miso  Park</span>, <span class="hlFld-ContribAuthor ">Keon Wook  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Phosphatidylserine receptor-targeting therapies for the treatment of cancer. </span><span class="cited-content_cbyCitation_journal-name">Archives of Pharmacal Research</span><span> <strong>2019,</strong> <em>42 </em>
                                    (7)
                                     , 617-628. <a href="https://doi.org/10.1007/s12272-019-01167-4" title="DOI URL">https://doi.org/10.1007/s12272-019-01167-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s12272-019-01167-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs12272-019-01167-4%26sid%3Dliteratum%253Aachs%26jtitle%3DArchives%2520of%2520Pharmacal%2520Research%26atitle%3DPhosphatidylserine%252Breceptor-targeting%252Btherapies%252Bfor%252Bthe%252Btreatment%252Bof%252Bcancer%26aulast%3DPark%26aufirst%3DMiso%26date%3D2019%26date%3D2019%26volume%3D42%26issue%3D7%26spage%3D617%26epage%3D628" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Solène  Fernandez</span>, <span class="hlFld-ContribAuthor ">Vanessa  Desplat</span>, <span class="hlFld-ContribAuthor ">Arnaud  Villacreces</span>, <span class="hlFld-ContribAuthor ">Amélie V.  Guitart</span>, <span class="hlFld-ContribAuthor ">Noël  Milpied</span>, <span class="hlFld-ContribAuthor ">Arnaud  Pigneux</span>, <span class="hlFld-ContribAuthor ">Isabelle  Vigon</span>, <span class="hlFld-ContribAuthor ">Jean-Max  Pasquet</span>, <span class="hlFld-ContribAuthor ">Pierre-Yves  Dumas</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Tyrosine Kinases in Acute Myeloid Leukemia: Why, Who and How?. </span><span class="cited-content_cbyCitation_journal-name">International Journal of Molecular Sciences</span><span> <strong>2019,</strong> <em>20 </em>
                                    (14)
                                     , 3429. <a href="https://doi.org/10.3390/ijms20143429" title="DOI URL">https://doi.org/10.3390/ijms20143429</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/ijms20143429&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fijms20143429%26sid%3Dliteratum%253Aachs%26jtitle%3DInternational%2520Journal%2520of%2520Molecular%2520Sciences%26atitle%3DTargeting%252BTyrosine%252BKinases%252Bin%252BAcute%252BMyeloid%252BLeukemia%25253A%252BWhy%25252C%252BWho%252Band%252BHow%25253F%26aulast%3DFernandez%26aufirst%3DSol%25C3%25A8ne%26date%3D2019%26date%3D2019%26volume%3D20%26issue%3D14%26spage%3D3429" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Suraj S.  Kapale</span>, <span class="hlFld-ContribAuthor ">Suraj N.  Mali</span>, <span class="hlFld-ContribAuthor ">Hemchandra K.  Chaudhari</span>. </span><span class="cited-content_cbyCitation_article-title">Molecular modelling studies for 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as anticancer agents. </span><span class="cited-content_cbyCitation_journal-name">Medicine in Drug Discovery</span><span> <strong>2019,</strong> <em>2 </em>, 100008. <a href="https://doi.org/10.1016/j.medidd.2019.100008" title="DOI URL">https://doi.org/10.1016/j.medidd.2019.100008</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.medidd.2019.100008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.medidd.2019.100008%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicine%2520in%2520Drug%2520Discovery%26atitle%3DMolecular%252Bmodelling%252Bstudies%252Bfor%252B4-oxo-1%25252C4-dihydroquinoline-3-carboxamide%252Bderivatives%252Bas%252Banticancer%252Bagents%26aulast%3DKapale%26aufirst%3DSuraj%2BS.%26date%3D2019%26volume%3D2%26spage%3D100008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Properties of FDA-approved small molecule protein kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>144 </em>, 19-50. <a href="https://doi.org/10.1016/j.phrs.2019.03.006" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.03.006</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.03.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.03.006%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DProperties%252Bof%252BFDA-approved%252Bsmall%252Bmolecule%252Bprotein%252Bkinase%252Binhibitors%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2019%26volume%3D144%26spage%3D19%26epage%3D50" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Mai  Tanaka</span>, <span class="hlFld-ContribAuthor ">Dietmar W.  Siemann</span>. </span><span class="cited-content_cbyCitation_article-title">Axl signaling is an important mediator of tumor angiogenesis. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2019,</strong> <em>10 </em>
                                    (30)
                                     , 2887-2898. <a href="https://doi.org/10.18632/oncotarget.26882" title="DOI URL">https://doi.org/10.18632/oncotarget.26882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.26882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.26882%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DAxl%252Bsignaling%252Bis%252Ban%252Bimportant%252Bmediator%252Bof%252Btumor%252Bangiogenesis%26aulast%3DTanaka%26aufirst%3DMai%26date%3D2019%26date%3D2019%26volume%3D10%26issue%3D30%26spage%3D2887%26epage%3D2898" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yanting  Duan</span>, <span class="hlFld-ContribAuthor ">Bo  Hu</span>, <span class="hlFld-ContribAuthor ">Chunxia  Qiao</span>, <span class="hlFld-ContribAuthor ">Longlong  Luo</span>, <span class="hlFld-ContribAuthor ">Xinying  Li</span>, <span class="hlFld-ContribAuthor ">Jing  Wang</span>, <span class="hlFld-ContribAuthor ">Hao  Liu</span>, <span class="hlFld-ContribAuthor ">Tingting  Zhou</span>, <span class="hlFld-ContribAuthor ">Beifen  Shen</span>, <span class="hlFld-ContribAuthor ">Ming  Lv</span>, <span class="hlFld-ContribAuthor ">Jiannan  Feng</span>. </span><span class="cited-content_cbyCitation_article-title">Engineered AXL‑ECD‑Fc variants that abolish the AXL/Gas6 interaction suppress tumor cell migration. </span><span class="cited-content_cbyCitation_journal-name">Oncology Letters</span><span> <strong>2019,</strong> <em> </em><a href="https://doi.org/10.3892/ol.2019.10255" title="DOI URL">https://doi.org/10.3892/ol.2019.10255</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ol.2019.10255&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fol.2019.10255%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Letters%26atitle%3DEngineered%252BAXL%2525E2%252580%252591ECD%2525E2%252580%252591Fc%252Bvariants%252Bthat%252Babolish%252Bthe%252BAXL%25252FGas6%252Binteraction%252Bsuppress%252Btumor%252Bcell%252Bmigration%26aulast%3DDuan%26aufirst%3DYanting%26date%3D2019%26date%3D2019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Robert  Roskoski</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting ERK1/2 protein-serine/threonine kinases in human cancers. </span><span class="cited-content_cbyCitation_journal-name">Pharmacological Research</span><span> <strong>2019,</strong> <em>142 </em>, 151-168. <a href="https://doi.org/10.1016/j.phrs.2019.01.039" title="DOI URL">https://doi.org/10.1016/j.phrs.2019.01.039</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.phrs.2019.01.039&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.phrs.2019.01.039%26sid%3Dliteratum%253Aachs%26jtitle%3DPharmacological%2520Research%26atitle%3DTargeting%252BERK1%25252F2%252Bprotein-serine%25252Fthreonine%252Bkinases%252Bin%252Bhuman%252Bcancers%26aulast%3DRoskoski%26aufirst%3DRobert%26date%3D2019%26volume%3D142%26spage%3D151%26epage%3D168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Li  Tan</span>, <span class="hlFld-ContribAuthor ">Zhang  Zhang</span>, <span class="hlFld-ContribAuthor ">Donglin  Gao</span>, <span class="hlFld-ContribAuthor ">Shingpan  Chan</span>, <span class="hlFld-ContribAuthor ">Jinfeng  Luo</span>, <span class="hlFld-ContribAuthor ">Zheng-Chao  Tu</span>, <span class="hlFld-ContribAuthor ">Zhi-Min  Zhang</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Xiaomei  Ren</span>, <span class="hlFld-ContribAuthor ">Xiaoyun  Lu</span>. </span><span class="cited-content_cbyCitation_article-title">Quinolone antibiotic derivatives as new selective Axl kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2019,</strong> <em>166 </em>, 318-327. <a href="https://doi.org/10.1016/j.ejmech.2019.01.065" title="DOI URL">https://doi.org/10.1016/j.ejmech.2019.01.065</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2019.01.065&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2019.01.065%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DQuinolone%252Bantibiotic%252Bderivatives%252Bas%252Bnew%252Bselective%252BAxl%252Bkinase%252Binhibitors%26aulast%3DTan%26aufirst%3DLi%26date%3D2019%26volume%3D166%26spage%3D318%26epage%3D327" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Juliano D.  Paccez</span>, <span class="hlFld-ContribAuthor ">Kristal  Duncan</span>, <span class="hlFld-ContribAuthor ">Durairaj  Sekar</span>, <span class="hlFld-ContribAuthor ">Ricardo G.  Correa</span>, <span class="hlFld-ContribAuthor ">Yihong  Wang</span>, <span class="hlFld-ContribAuthor ">Xuesong  Gu</span>, <span class="hlFld-ContribAuthor ">Manoj  Bashin</span>, <span class="hlFld-ContribAuthor ">Kelly  Chibale</span>, <span class="hlFld-ContribAuthor ">Towia A.  Libermann</span>, <span class="hlFld-ContribAuthor ">Luiz F.  Zerbini</span>. </span><span class="cited-content_cbyCitation_article-title">Dihydroartemisinin inhibits prostate cancer via JARID2/miR-7/miR-34a-dependent downregulation of Axl. </span><span class="cited-content_cbyCitation_journal-name">Oncogenesis</span><span> <strong>2019,</strong> <em>8 </em>
                                    (3)
                                     <a href="https://doi.org/10.1038/s41389-019-0122-6" title="DOI URL">https://doi.org/10.1038/s41389-019-0122-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41389-019-0122-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41389-019-0122-6%26sid%3Dliteratum%253Aachs%26jtitle%3DOncogenesis%26atitle%3DDihydroartemisinin%252Binhibits%252Bprostate%252Bcancer%252Bvia%252BJARID2%25252FmiR-7%25252FmiR-34a-dependent%252Bdownregulation%252Bof%252BAxl%26aulast%3DPaccez%26aufirst%3DJuliano%2BD.%26date%3D2019%26date%3D2019%26volume%3D8%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yawei  Tian</span>, <span class="hlFld-ContribAuthor ">Mingzhu  Zhao</span>, <span class="hlFld-ContribAuthor ">Xiaoming  Zhao</span>, <span class="hlFld-ContribAuthor ">Gang  Zhou</span>. </span><span class="cited-content_cbyCitation_article-title">Ag-Catalyzed selective fluorination of 6-substituted 2-amionpyrazines. </span><span class="cited-content_cbyCitation_journal-name">Journal of Fluorine Chemistry</span><span> <strong>2019,</strong> <em>218 </em>, 111-115. <a href="https://doi.org/10.1016/j.jfluchem.2018.12.003" title="DOI URL">https://doi.org/10.1016/j.jfluchem.2018.12.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jfluchem.2018.12.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jfluchem.2018.12.003%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Fluorine%2520Chemistry%26atitle%3DAg-Catalyzed%252Bselective%252Bfluorination%252Bof%252B6-substituted%252B2-amionpyrazines%26aulast%3DTian%26aufirst%3DYawei%26date%3D2019%26volume%3D218%26spage%3D111%26epage%3D115" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Zhao-Shan  Niu</span>, <span class="hlFld-ContribAuthor ">Xiao-Jun  Niu</span>, <span class="hlFld-ContribAuthor ">Wen-Hong  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Role of the receptor tyrosine kinase Axl in hepatocellular carcinoma and its clinical relevance. </span><span class="cited-content_cbyCitation_journal-name">Future Oncology</span><span> <strong>2019,</strong> <em>15 </em>
                                    (6)
                                     , 653-662. <a href="https://doi.org/10.2217/fon-2018-0528" title="DOI URL">https://doi.org/10.2217/fon-2018-0528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.2217/fon-2018-0528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.2217%2Ffon-2018-0528%26sid%3Dliteratum%253Aachs%26jtitle%3DFuture%2520Oncology%26atitle%3DRole%252Bof%252Bthe%252Breceptor%252Btyrosine%252Bkinase%252BAxl%252Bin%252Bhepatocellular%252Bcarcinoma%252Band%252Bits%252Bclinical%252Brelevance%26aulast%3DNiu%26aufirst%3DZhao-Shan%26date%3D2019%26volume%3D15%26issue%3D6%26spage%3D653%26epage%3D662" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eugene  Tulchinsky</span>, <span class="hlFld-ContribAuthor ">Oleg  Demidov</span>, <span class="hlFld-ContribAuthor ">Marina  Kriajevska</span>, <span class="hlFld-ContribAuthor ">Nickolai A.  Barlev</span>, <span class="hlFld-ContribAuthor ">Evgeny  Imyanitov</span>. </span><span class="cited-content_cbyCitation_article-title">EMT: A mechanism for escape from EGFR-targeted therapy in lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Reviews on Cancer</span><span> <strong>2019,</strong> <em>1871 </em>
                                    (1)
                                     , 29-39. <a href="https://doi.org/10.1016/j.bbcan.2018.10.003" title="DOI URL">https://doi.org/10.1016/j.bbcan.2018.10.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbcan.2018.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbcan.2018.10.003%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Reviews%2520on%2520Cancer%26atitle%3DEMT%25253A%252BA%252Bmechanism%252Bfor%252Bescape%252Bfrom%252BEGFR-targeted%252Btherapy%252Bin%252Blung%252Bcancer%26aulast%3DTulchinsky%26aufirst%3DEugene%26date%3D2019%26volume%3D1871%26issue%3D1%26spage%3D29%26epage%3D39" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Min Jung  Choi</span>, <span class="hlFld-ContribAuthor ">Eun Joo  Roh</span>, <span class="hlFld-ContribAuthor ">Wooyoung  Hur</span>, <span class="hlFld-ContribAuthor ">So Ha  Lee</span>, <span class="hlFld-ContribAuthor ">Taebo  Sim</span>, <span class="hlFld-ContribAuthor ">Chang-Hyun  Oh</span>, <span class="hlFld-ContribAuthor ">Sun-Hwa  Lee</span>, <span class="hlFld-ContribAuthor ">Jong Seung  Kim</span>, <span class="hlFld-ContribAuthor ">Kyung Ho  Yoo</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, and biological evaluation of novel aminopyrimidinylisoindolines as AXL kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2018,</strong> <em>28 </em>
                                    (23-24)
                                     , 3761-3765. <a href="https://doi.org/10.1016/j.bmcl.2018.10.013" title="DOI URL">https://doi.org/10.1016/j.bmcl.2018.10.013</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2018.10.013&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2018.10.013%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Band%252Bbiological%252Bevaluation%252Bof%252Bnovel%252Baminopyrimidinylisoindolines%252Bas%252BAXL%252Bkinase%252Binhibitors%26aulast%3DChoi%26aufirst%3DMin%2BJung%26date%3D2018%26volume%3D28%26issue%3D23-24%26spage%3D3761%26epage%3D3765" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jang Hwan  Cho</span>, <span class="hlFld-ContribAuthor ">Atsushi  Okuma</span>, <span class="hlFld-ContribAuthor ">Dalal  Al-Rubaye</span>, <span class="hlFld-ContribAuthor ">Ejaj  Intisar</span>, <span class="hlFld-ContribAuthor ">Richard P.  Junghans</span>, <span class="hlFld-ContribAuthor ">Wilson W.  Wong</span>. </span><span class="cited-content_cbyCitation_article-title">Engineering Axl specific CAR and SynNotch receptor for cancer therapy. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2018,</strong> <em>8 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-018-22252-6" title="DOI URL">https://doi.org/10.1038/s41598-018-22252-6</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-018-22252-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-018-22252-6%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DEngineering%252BAxl%252Bspecific%252BCAR%252Band%252BSynNotch%252Breceptor%252Bfor%252Bcancer%252Btherapy%26aulast%3DCho%26aufirst%3DJang%2BHwan%26date%3D2018%26date%3D2018%26volume%3D8%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanja  Aveic</span>, <span class="hlFld-ContribAuthor ">Marcella  Pantile</span>, <span class="hlFld-ContribAuthor ">Pierfrancesco  Polo</span>, <span class="hlFld-ContribAuthor ">Viktoryia  Sidarovich</span>, <span class="hlFld-ContribAuthor ">Marilena  De Mariano</span>, <span class="hlFld-ContribAuthor ">Alessandro  Quattrone</span>, <span class="hlFld-ContribAuthor ">Luca  Longo</span>, <span class="hlFld-ContribAuthor ">Gian Paolo  Tonini</span>. </span><span class="cited-content_cbyCitation_article-title">Autophagy inhibition improves the cytotoxic effects of receptor tyrosine kinase inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Cancer Cell International</span><span> <strong>2018,</strong> <em>18 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12935-018-0557-4" title="DOI URL">https://doi.org/10.1186/s12935-018-0557-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12935-018-0557-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12935-018-0557-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Cell%2520International%26atitle%3DAutophagy%252Binhibition%252Bimproves%252Bthe%252Bcytotoxic%252Beffects%252Bof%252Breceptor%252Btyrosine%252Bkinase%252Binhibitors%26aulast%3DAveic%26aufirst%3DSanja%26date%3D2018%26date%3D2018%26volume%3D18%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guiling  Wu</span>, <span class="hlFld-ContribAuthor ">Zhiqiang  Ma</span>, <span class="hlFld-ContribAuthor ">Yicheng  Cheng</span>, <span class="hlFld-ContribAuthor ">Wei  Hu</span>, <span class="hlFld-ContribAuthor ">Chao  Deng</span>, <span class="hlFld-ContribAuthor ">Shuai  Jiang</span>, <span class="hlFld-ContribAuthor ">Tian  Li</span>, <span class="hlFld-ContribAuthor ">Fulin  Chen</span>, <span class="hlFld-ContribAuthor ">Yang  Yang</span>. </span><span class="cited-content_cbyCitation_article-title">Targeting Gas6/TAM in cancer cells and tumor microenvironment. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer</span><span> <strong>2018,</strong> <em>17 </em>
                                    (1)
                                     <a href="https://doi.org/10.1186/s12943-018-0769-1" title="DOI URL">https://doi.org/10.1186/s12943-018-0769-1</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1186/s12943-018-0769-1&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1186%2Fs12943-018-0769-1%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%26atitle%3DTargeting%252BGas6%25252FTAM%252Bin%252Bcancer%252Bcells%252Band%252Btumor%252Bmicroenvironment%26aulast%3DWu%26aufirst%3DGuiling%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Wenting  Du</span>, <span class="hlFld-ContribAuthor ">Rolf A.  Brekken</span>. </span><span class="cited-content_cbyCitation_article-title">Does Axl have potential as a therapeutic target in pancreatic cancer?. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Therapeutic Targets</span><span> <strong>2018,</strong> <em>22 </em>
                                    (11)
                                     , 955-966. <a href="https://doi.org/10.1080/14728222.2018.1527315" title="DOI URL">https://doi.org/10.1080/14728222.2018.1527315</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14728222.2018.1527315&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14728222.2018.1527315%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Therapeutic%2520Targets%26atitle%3DDoes%252BAxl%252Bhave%252Bpotential%252Bas%252Ba%252Btherapeutic%252Btarget%252Bin%252Bpancreatic%252Bcancer%25253F%26aulast%3DDu%26aufirst%3DWenting%26date%3D2018%26date%3D2018%26volume%3D22%26issue%3D11%26spage%3D955%26epage%3D966" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tom  Baladi</span>, <span class="hlFld-ContribAuthor ">Jessy  Aziz</span>, <span class="hlFld-ContribAuthor ">Florent  Dufour</span>, <span class="hlFld-ContribAuthor ">Valentina  Abet</span>, <span class="hlFld-ContribAuthor ">Véronique  Stoven</span>, <span class="hlFld-ContribAuthor ">François  Radvanyi</span>, <span class="hlFld-ContribAuthor ">Florent  Poyer</span>, <span class="hlFld-ContribAuthor ">Ting-Di  Wu</span>, <span class="hlFld-ContribAuthor ">Jean-Luc  Guerquin-Kern</span>, <span class="hlFld-ContribAuthor ">Isabelle  Bernard-Pierrot</span>, <span class="hlFld-ContribAuthor ">Sergio Marco  Garrido</span>, <span class="hlFld-ContribAuthor ">Sandrine  Piguel</span>. </span><span class="cited-content_cbyCitation_article-title">Design, synthesis, biological evaluation and cellular imaging of imidazo[4,5-b]pyridine derivatives as potent and selective TAM inhibitors. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry</span><span> <strong>2018,</strong> <em>26 </em>
                                    (20)
                                     , 5510-5530. <a href="https://doi.org/10.1016/j.bmc.2018.09.031" title="DOI URL">https://doi.org/10.1016/j.bmc.2018.09.031</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmc.2018.09.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmc.2018.09.031%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%26atitle%3DDesign%25252C%252Bsynthesis%25252C%252Bbiological%252Bevaluation%252Band%252Bcellular%252Bimaging%252Bof%252Bimidazo%25255B4%25252C5-b%25255Dpyridine%252Bderivatives%252Bas%252Bpotent%252Band%252Bselective%252BTAM%252Binhibitors%26aulast%3DBaladi%26aufirst%3DTom%26date%3D2018%26volume%3D26%26issue%3D20%26spage%3D5510%26epage%3D5530" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chao  Shen</span>, <span class="hlFld-ContribAuthor ">Zhe  Wang</span>, <span class="hlFld-ContribAuthor ">Xiaojun  Yao</span>, <span class="hlFld-ContribAuthor ">Youyong  Li</span>, <span class="hlFld-ContribAuthor ">Tailong  Lei</span>, <span class="hlFld-ContribAuthor ">Ercheng  Wang</span>, <span class="hlFld-ContribAuthor ">Lei  Xu</span>, <span class="hlFld-ContribAuthor ">Feng  Zhu</span>, <span class="hlFld-ContribAuthor ">Dan  Li</span>, <span class="hlFld-ContribAuthor ">Tingjun  Hou</span>. </span><span class="cited-content_cbyCitation_article-title">Comprehensive assessment of nine docking programs on type II kinase inhibitors: prediction accuracy of sampling power, scoring power and screening power. </span><span class="cited-content_cbyCitation_journal-name">Briefings in Bioinformatics</span><span> <strong>2018,</strong> <em>17 </em><a href="https://doi.org/10.1093/bib/bby103" title="DOI URL">https://doi.org/10.1093/bib/bby103</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1093/bib/bby103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1093%2Fbib%2Fbby103%26sid%3Dliteratum%253Aachs%26jtitle%3DBriefings%2520in%2520Bioinformatics%26atitle%3DComprehensive%252Bassessment%252Bof%252Bnine%252Bdocking%252Bprograms%252Bon%252Btype%252BII%252Bkinase%252Binhibitors%25253A%252Bprediction%252Baccuracy%252Bof%252Bsampling%252Bpower%25252C%252Bscoring%252Bpower%252Band%252Bscreening%252Bpower%26aulast%3DShen%26aufirst%3DChao%26date%3D2018%26date%3D2018%26volume%3D17" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuka  Kato</span>, <span class="hlFld-ContribAuthor ">Kiichiro  Ninomiya</span>, <span class="hlFld-ContribAuthor ">Kadoaki  Ohashi</span>, <span class="hlFld-ContribAuthor ">Shuta  Tomida</span>, <span class="hlFld-ContribAuthor ">Go  Makimoto</span>, <span class="hlFld-ContribAuthor ">Hiromi  Watanabe</span>, <span class="hlFld-ContribAuthor ">Kenichiro  Kudo</span>, <span class="hlFld-ContribAuthor ">Shingo  Matsumoto</span>, <span class="hlFld-ContribAuthor ">Shigeki  Umemura</span>, <span class="hlFld-ContribAuthor ">Koichi  Goto</span>, <span class="hlFld-ContribAuthor ">Eiki  Ichihara</span>, <span class="hlFld-ContribAuthor ">Takashi  Ninomiya</span>, <span class="hlFld-ContribAuthor ">Toshio  Kubo</span>, <span class="hlFld-ContribAuthor ">Akiko  Sato</span>, <span class="hlFld-ContribAuthor ">Katsuyuki  Hotta</span>, <span class="hlFld-ContribAuthor ">Masahiro  Tabata</span>, <span class="hlFld-ContribAuthor ">Shinichi  Toyooka</span>, <span class="hlFld-ContribAuthor ">Yoshinobu  Maeda</span>, <span class="hlFld-ContribAuthor ">Katsuyuki  Kiura</span>. </span><span class="cited-content_cbyCitation_article-title">Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring
              ROS1
              fusions. </span><span class="cited-content_cbyCitation_journal-name">Cancer Science</span><span> <strong>2018,</strong> <em>109 </em>
                                    (10)
                                     , 3149-3158. <a href="https://doi.org/10.1111/cas.13752" title="DOI URL">https://doi.org/10.1111/cas.13752</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1111/cas.13752&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1111%2Fcas.13752%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Science%26atitle%3DCombined%252Beffect%252Bof%252Bcabozantinib%252Band%252Bgefitinib%252Bin%252Bcrizotinib-resistant%252Blung%252Btumors%252Bharboring%252BROS1%252Bfusions%26aulast%3DKato%26aufirst%3DYuka%26date%3D2018%26date%3D2018%26volume%3D109%26issue%3D10%26spage%3D3149%26epage%3D3158" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Martha  Wium</span>, <span class="hlFld-ContribAuthor ">Juliano  Paccez</span>, <span class="hlFld-ContribAuthor ">Luiz  Zerbini</span>. </span><span class="cited-content_cbyCitation_article-title">The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview. </span><span class="cited-content_cbyCitation_journal-name">Cells</span><span> <strong>2018,</strong> <em>7 </em>
                                    (10)
                                     , 166. <a href="https://doi.org/10.3390/cells7100166" title="DOI URL">https://doi.org/10.3390/cells7100166</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/cells7100166&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fcells7100166%26sid%3Dliteratum%253Aachs%26jtitle%3DCells%26atitle%3DThe%252BDual%252BRole%252Bof%252BTAM%252BReceptors%252Bin%252BAutoimmune%252BDiseases%252Band%252BCancer%25253A%252BAn%252BOverview%26aulast%3DWium%26aufirst%3DMartha%26date%3D2018%26date%3D2018%26volume%3D7%26issue%3D10%26spage%3D166" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Binbin  Zheng</span>, <span class="hlFld-ContribAuthor ">Haijun  Guo</span>, <span class="hlFld-ContribAuthor ">Nan  Ma</span>, <span class="hlFld-ContribAuthor ">Yun  Ni</span>, <span class="hlFld-ContribAuthor ">Jiaqian  Xu</span>, <span class="hlFld-ContribAuthor ">Lin  Li</span>, <span class="hlFld-ContribAuthor ">Piliang  Hao</span>, <span class="hlFld-ContribAuthor ">Ke  Ding</span>, <span class="hlFld-ContribAuthor ">Zhengqiu  Li</span>. </span><span class="cited-content_cbyCitation_article-title">Cell- and Tissue-Based Proteome Profiling and Bioimaging with Probes Derived from a Potent AXL Kinase Inhibitor. </span><span class="cited-content_cbyCitation_journal-name">Chemistry - An Asian Journal</span><span> <strong>2018,</strong> <em>13 </em>
                                    (18)
                                     , 2601-2605. <a href="https://doi.org/10.1002/asia.201800605" title="DOI URL">https://doi.org/10.1002/asia.201800605</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/asia.201800605&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fasia.201800605%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520-%2520An%2520Asian%2520Journal%26atitle%3DCell-%252Band%252BTissue-Based%252BProteome%252BProfiling%252Band%252BBioimaging%252Bwith%252BProbes%252BDerived%252Bfrom%252Ba%252BPotent%252BAXL%252BKinase%252BInhibitor%26aulast%3DZheng%26aufirst%3DBinbin%26date%3D2018%26date%3D2018%26volume%3D13%26issue%3D18%26spage%3D2601%26epage%3D2605" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yuxuan  Zhen</span>, <span class="hlFld-ContribAuthor ">Iris J.  Lee</span>, <span class="hlFld-ContribAuthor ">Fred D.  Finkelman</span>, <span class="hlFld-ContribAuthor ">Wen-Hai  Shao</span>. </span><span class="cited-content_cbyCitation_article-title">Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis. </span><span class="cited-content_cbyCitation_journal-name">Journal of Autoimmunity</span><span> <strong>2018,</strong> <em>93 </em>, 37-44. <a href="https://doi.org/10.1016/j.jaut.2018.06.001" title="DOI URL">https://doi.org/10.1016/j.jaut.2018.06.001</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.jaut.2018.06.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.jaut.2018.06.001%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Autoimmunity%26atitle%3DTargeted%252Binhibition%252Bof%252BAxl%252Breceptor%252Btyrosine%252Bkinase%252Bameliorates%252Banti-GBM-induced%252Blupus-like%252Bnephritis%26aulast%3DZhen%26aufirst%3DYuxuan%26date%3D2018%26volume%3D93%26spage%3D37%26epage%3D44" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shinji  Nakamichi</span>, <span class="hlFld-ContribAuthor ">Masahiro  Seike</span>, <span class="hlFld-ContribAuthor ">Akihiko  Miyanaga</span>, <span class="hlFld-ContribAuthor ">Mika  Chiba</span>, <span class="hlFld-ContribAuthor ">Fenfei  Zou</span>, <span class="hlFld-ContribAuthor ">Akiko  Takahashi</span>, <span class="hlFld-ContribAuthor ">Arimi  Ishikawa</span>, <span class="hlFld-ContribAuthor ">Shinobu  Kunugi</span>, <span class="hlFld-ContribAuthor ">Rintaro  Noro</span>, <span class="hlFld-ContribAuthor ">Kaoru  Kubota</span>, <span class="hlFld-ContribAuthor ">Akihiko  Gemma</span>. </span><span class="cited-content_cbyCitation_article-title">Overcoming drug-tolerant cancer cell subpopulations showing AXL activation and epithelial-mesenchymal transition is critical in conquering ALK-positive lung cancer. </span><span class="cited-content_cbyCitation_journal-name">Oncotarget</span><span> <strong>2018,</strong> <em>9 </em>
                                    (43)
                                     , 27242-27255. <a href="https://doi.org/10.18632/oncotarget.25531" title="DOI URL">https://doi.org/10.18632/oncotarget.25531</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.18632/oncotarget.25531&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.18632%2Foncotarget.25531%26sid%3Dliteratum%253Aachs%26jtitle%3DOncotarget%26atitle%3DOvercoming%252Bdrug-tolerant%252Bcancer%252Bcell%252Bsubpopulations%252Bshowing%252BAXL%252Bactivation%252Band%252Bepithelial-mesenchymal%252Btransition%252Bis%252Bcritical%252Bin%252Bconquering%252BALK-positive%252Blung%252Bcancer%26aulast%3DNakamichi%26aufirst%3DShinji%26date%3D2018%26date%3D2018%26volume%3D9%26issue%3D43%26spage%3D27242%26epage%3D27255" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Xiaojin  Li</span>, <span class="hlFld-ContribAuthor ">Anjian  Xu</span>, <span class="hlFld-ContribAuthor ">Huihui  Li</span>, <span class="hlFld-ContribAuthor ">Bei  Zhang</span>, <span class="hlFld-ContribAuthor ">Bangwei  Cao</span>, <span class="hlFld-ContribAuthor ">Jian  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">Novel role of apatinib as a multi-target RTK inhibitor in the direct suppression of hepatocellular carcinoma cells. </span><span class="cited-content_cbyCitation_journal-name">Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease</span><span> <strong>2018,</strong> <em>1864 </em>
                                    (5)
                                     , 1693-1701. <a href="https://doi.org/10.1016/j.bbadis.2018.02.014" title="DOI URL">https://doi.org/10.1016/j.bbadis.2018.02.014</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bbadis.2018.02.014&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bbadis.2018.02.014%26sid%3Dliteratum%253Aachs%26jtitle%3DBiochimica%2520et%2520Biophysica%2520Acta%2520%2528BBA%2529%2520-%2520Molecular%2520Basis%2520of%2520Disease%26atitle%3DNovel%252Brole%252Bof%252Bapatinib%252Bas%252Ba%252Bmulti-target%252BRTK%252Binhibitor%252Bin%252Bthe%252Bdirect%252Bsuppression%252Bof%252Bhepatocellular%252Bcarcinoma%252Bcells%26aulast%3DLi%26aufirst%3DXiaojin%26date%3D2018%26volume%3D1864%26issue%3D5%26spage%3D1693%26epage%3D1701" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jingjing  Wang</span>, <span class="hlFld-ContribAuthor ">Feng  Li</span>, <span class="hlFld-ContribAuthor ">Wenlong  Pei</span>, <span class="hlFld-ContribAuthor ">Mixue  Yang</span>, <span class="hlFld-ContribAuthor ">Yidan  Wu</span>, <span class="hlFld-ContribAuthor ">Danyang  Ma</span>, <span class="hlFld-ContribAuthor ">Furong  Zhang</span>, <span class="hlFld-ContribAuthor ">Jianhui  Wang</span>. </span><span class="cited-content_cbyCitation_article-title">Selective cleavage of the N-propargyl group from sulfonamides and amides under ruthenium catalysis. </span><span class="cited-content_cbyCitation_journal-name">Tetrahedron Letters</span><span> <strong>2018,</strong> <em>59 </em>
                                    (20)
                                     , 1902-1905. <a href="https://doi.org/10.1016/j.tetlet.2018.03.046" title="DOI URL">https://doi.org/10.1016/j.tetlet.2018.03.046</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.tetlet.2018.03.046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.tetlet.2018.03.046%26sid%3Dliteratum%253Aachs%26jtitle%3DTetrahedron%2520Letters%26atitle%3DSelective%252Bcleavage%252Bof%252Bthe%252BN-propargyl%252Bgroup%252Bfrom%252Bsulfonamides%252Band%252Bamides%252Bunder%252Bruthenium%252Bcatalysis%26aulast%3DWang%26aufirst%3DJingjing%26date%3D2018%26volume%3D59%26issue%3D20%26spage%3D1902%26epage%3D1905" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Fleur M.  Ferguson</span>, <span class="hlFld-ContribAuthor ">Nathanael S.  Gray</span>. </span><span class="cited-content_cbyCitation_article-title">Kinase inhibitors: the road ahead. </span><span class="cited-content_cbyCitation_journal-name">Nature Reviews Drug Discovery</span><span> <strong>2018,</strong> <em>17 </em>
                                    (5)
                                     , 353-377. <a href="https://doi.org/10.1038/nrd.2018.21" title="DOI URL">https://doi.org/10.1038/nrd.2018.21</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/nrd.2018.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fnrd.2018.21%26sid%3Dliteratum%253Aachs%26jtitle%3DNature%2520Reviews%2520Drug%2520Discovery%26atitle%3DKinase%252Binhibitors%25253A%252Bthe%252Broad%252Bahead%26aulast%3DFerguson%26aufirst%3DFleur%2BM.%26date%3D2018%26date%3D2018%26volume%3D17%26issue%3D5%26spage%3D353%26epage%3D377" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Yingying  Shen</span>, <span class="hlFld-ContribAuthor ">Xiguang  Chen</span>, <span class="hlFld-ContribAuthor ">Jun  He</span>, <span class="hlFld-ContribAuthor ">Duanfang  Liao</span>, <span class="hlFld-ContribAuthor ">Xuyu  Zu</span>. </span><span class="cited-content_cbyCitation_article-title">Axl inhibitors as novel cancer therapeutic agents. </span><span class="cited-content_cbyCitation_journal-name">Life Sciences</span><span> <strong>2018,</strong> <em>198 </em>, 99-111. <a href="https://doi.org/10.1016/j.lfs.2018.02.033" title="DOI URL">https://doi.org/10.1016/j.lfs.2018.02.033</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.lfs.2018.02.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.lfs.2018.02.033%26sid%3Dliteratum%253Aachs%26jtitle%3DLife%2520Sciences%26atitle%3DAxl%252Binhibitors%252Bas%252Bnovel%252Bcancer%252Btherapeutic%252Bagents%26aulast%3DShen%26aufirst%3DYingying%26date%3D2018%26volume%3D198%26spage%3D99%26epage%3D111" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Chiara  Fedeli</span>, <span class="hlFld-ContribAuthor ">Giulia  Torriani</span>, <span class="hlFld-ContribAuthor ">Clara  Galan-Navarro</span>, <span class="hlFld-ContribAuthor ">Marie-Laurence  Moraz</span>, <span class="hlFld-ContribAuthor ">Hector  Moreno</span>, <span class="hlFld-ContribAuthor ">Gisa  Gerold</span>, <span class="hlFld-ContribAuthor ">Stefan  Kunz</span>, . </span><span class="cited-content_cbyCitation_article-title">Axl Can Serve as Entry Factor for Lassa Virus Depending on the Functional Glycosylation of Dystroglycan. </span><span class="cited-content_cbyCitation_journal-name">Journal of Virology</span><span> <strong>2018,</strong> <em>92 </em>
                                    (5)
                                     <a href="https://doi.org/10.1128/JVI.01613-17" title="DOI URL">https://doi.org/10.1128/JVI.01613-17</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1128/JVI.01613-17&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1128%2FJVI.01613-17%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Virology%26atitle%3DAxl%252BCan%252BServe%252Bas%252BEntry%252BFactor%252Bfor%252BLassa%252BVirus%252BDepending%252Bon%252Bthe%252BFunctional%252BGlycosylation%252Bof%252BDystroglycan%26aulast%3DFedeli%26aufirst%3DChiara%26date%3D2018%26volume%3D92%26issue%3D5" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Derek B.  Oien</span>, <span class="hlFld-ContribAuthor ">Tamás  Garay</span>, <span class="hlFld-ContribAuthor ">Sarah  Eckstein</span>, <span class="hlFld-ContribAuthor ">Jeremy  Chien</span>. </span><span class="cited-content_cbyCitation_article-title">Cisplatin and Pemetrexed Activate AXL and AXL Inhibitor BGB324 Enhances Mesothelioma Cell Death from Chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Frontiers in Pharmacology</span><span> <strong>2018,</strong> <em>8 </em><a href="https://doi.org/10.3389/fphar.2017.00970" title="DOI URL">https://doi.org/10.3389/fphar.2017.00970</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3389/fphar.2017.00970&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3389%2Ffphar.2017.00970%26sid%3Dliteratum%253Aachs%26jtitle%3DFrontiers%2520in%2520Pharmacology%26atitle%3DCisplatin%252Band%252BPemetrexed%252BActivate%252BAXL%252Band%252BAXL%252BInhibitor%252BBGB324%252BEnhances%252BMesothelioma%252BCell%252BDeath%252Bfrom%252BChemotherapy%26aulast%3DOien%26aufirst%3DDerek%2BB.%26date%3D2018%26date%3D2018%26volume%3D8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Leonid I.  Belen’kii</span>, <span class="hlFld-ContribAuthor ">Yulia B.  Evdokimenkova</span>. </span><span class="cited-content_cbyCitation_article-title">The Literature of Heterocyclic Chemistry, Part XVI, 2016. </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2018,</strong>,, 173-254. <a href="https://doi.org/10.1016/bs.aihch.2018.02.003" title="DOI URL">https://doi.org/10.1016/bs.aihch.2018.02.003</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/bs.aihch.2018.02.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fbs.aihch.2018.02.003%26sid%3Dliteratum%253Aachs%26atitle%3DThe%252BLiterature%252Bof%252BHeterocyclic%252BChemistry%25252C%252BPart%252BXVI%25252C%252B2016%26aulast%3DBelen%25E2%2580%2599kii%26aufirst%3DLeonid%2BI.%26date%3D2018%26spage%3D173%26epage%3D254%26pub%3DElsevier%26date%3D2018%26volume%3D126" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Sanja  Aveic</span>, <span class="hlFld-ContribAuthor ">Diana  Corallo</span>, <span class="hlFld-ContribAuthor ">Elena  Porcù</span>, <span class="hlFld-ContribAuthor ">Marcella  Pantile</span>, <span class="hlFld-ContribAuthor ">Daniele  Boso</span>, <span class="hlFld-ContribAuthor ">Carlo  Zanon</span>, <span class="hlFld-ContribAuthor ">Giampietro  Viola</span>, <span class="hlFld-ContribAuthor ">Viktoryia  Sidarovich</span>, <span class="hlFld-ContribAuthor ">Elena  Mariotto</span>, <span class="hlFld-ContribAuthor ">Alessandro  Quattrone</span>, <span class="hlFld-ContribAuthor ">Giuseppe  Basso</span>, <span class="hlFld-ContribAuthor ">Gian Paolo  Tonini</span>. </span><span class="cited-content_cbyCitation_article-title">TP-0903 inhibits neuroblastoma cell growth and enhances the sensitivity to conventional chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Pharmacology</span><span> <strong>2018,</strong> <em>818 </em>, 435-448. <a href="https://doi.org/10.1016/j.ejphar.2017.11.016" title="DOI URL">https://doi.org/10.1016/j.ejphar.2017.11.016</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejphar.2017.11.016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejphar.2017.11.016%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Pharmacology%26atitle%3DTP-0903%252Binhibits%252Bneuroblastoma%252Bcell%252Bgrowth%252Band%252Benhances%252Bthe%252Bsensitivity%252Bto%252Bconventional%252Bchemotherapy%26aulast%3DAveic%26aufirst%3DSanja%26date%3D2018%26volume%3D818%26spage%3D435%26epage%3D448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Guoan  Zhang</span>, <span class="hlFld-ContribAuthor ">Meng  Wang</span>, <span class="hlFld-ContribAuthor ">Hongli  Zhao</span>, <span class="hlFld-ContribAuthor ">Wen  Cui</span>. </span><span class="cited-content_cbyCitation_article-title">Function of Axl receptor tyrosine kinase in non-small cell lung cancer (Review). </span><span class="cited-content_cbyCitation_journal-name">Oncology Letters</span><span> <strong>2017,</strong> <em> </em><a href="https://doi.org/10.3892/ol.2017.7694" title="DOI URL">https://doi.org/10.3892/ol.2017.7694</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3892/ol.2017.7694&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3892%2Fol.2017.7694%26sid%3Dliteratum%253Aachs%26jtitle%3DOncology%2520Letters%26atitle%3DFunction%252Bof%252BAxl%252Breceptor%252Btyrosine%252Bkinase%252Bin%252Bnon-small%252Bcell%252Blung%252Bcancer%252B%252528Review%252529%26aulast%3DZhang%26aufirst%3DGuoan%26date%3D2017%26date%3D2017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Tyler  Shelby</span>, <span class="hlFld-ContribAuthor ">Tuhina  Banerjee</span>, <span class="hlFld-ContribAuthor ">Irene  Zegar</span>, <span class="hlFld-ContribAuthor ">Santimukul  Santra</span>. </span><span class="cited-content_cbyCitation_article-title">Highly Sensitive, Engineered Magnetic Nanosensors to Investigate the Ambiguous Activity of Zika Virus and Binding Receptors. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-07620-y" title="DOI URL">https://doi.org/10.1038/s41598-017-07620-y</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-07620-y&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-07620-y%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DHighly%252BSensitive%25252C%252BEngineered%252BMagnetic%252BNanosensors%252Bto%252BInvestigate%252Bthe%252BAmbiguous%252BActivity%252Bof%252BZika%252BVirus%252Band%252BBinding%252BReceptors%26aulast%3DShelby%26aufirst%3DTyler%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Keisuke  Iida</span>, <span class="hlFld-ContribAuthor ">Ryo  Sakai</span>, <span class="hlFld-ContribAuthor ">Shota  Yokoyama</span>, <span class="hlFld-ContribAuthor ">Naritaka  Kobayashi</span>, <span class="hlFld-ContribAuthor ">Shodai  Togo</span>, <span class="hlFld-ContribAuthor ">Hiroshi Y.  Yoshikawa</span>, <span class="hlFld-ContribAuthor ">Anchalee  Rawangkan</span>, <span class="hlFld-ContribAuthor ">Kozue  Namiki</span>, <span class="hlFld-ContribAuthor ">Masami  Suganuma</span>. </span><span class="cited-content_cbyCitation_article-title">Cell softening in malignant progression of human lung cancer cells by activation of receptor tyrosine kinase AXL. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/s41598-017-18120-4" title="DOI URL">https://doi.org/10.1038/s41598-017-18120-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/s41598-017-18120-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fs41598-017-18120-4%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DCell%252Bsoftening%252Bin%252Bmalignant%252Bprogression%252Bof%252Bhuman%252Blung%252Bcancer%252Bcells%252Bby%252Bactivation%252Bof%252Breceptor%252Btyrosine%252Bkinase%252BAXL%26aulast%3DIida%26aufirst%3DKeisuke%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Annelien J.M.  Zweemer</span>, <span class="hlFld-ContribAuthor ">Cory B.  French</span>, <span class="hlFld-ContribAuthor ">Joshua  Mesfin</span>, <span class="hlFld-ContribAuthor ">Simon  Gordonov</span>, <span class="hlFld-ContribAuthor ">Aaron S.  Meyer</span>, <span class="hlFld-ContribAuthor ">Douglas A.  Lauffenburger</span>. </span><span class="cited-content_cbyCitation_article-title">Apoptotic Bodies Elicit Gas6-Mediated Migration of AXL-Expressing Tumor Cells. </span><span class="cited-content_cbyCitation_journal-name">Molecular Cancer Research</span><span> <strong>2017,</strong> <em>15 </em>
                                    (12)
                                     , 1656-1666. <a href="https://doi.org/10.1158/1541-7786.MCR-17-0012" title="DOI URL">https://doi.org/10.1158/1541-7786.MCR-17-0012</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/1541-7786.MCR-17-0012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F1541-7786.MCR-17-0012%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Cancer%2520Research%26atitle%3DApoptotic%252BBodies%252BElicit%252BGas6-Mediated%252BMigration%252Bof%252BAXL-Expressing%252BTumor%252BCells%26aulast%3DZweemer%26aufirst%3DAnnelien%2BJ.M.%26date%3D2017%26date%3D2017%26volume%3D15%26issue%3D12%26spage%3D1656%26epage%3D1666" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Christine  Baumann</span>, <span class="hlFld-ContribAuthor ">Axel  Ullrich</span>, <span class="hlFld-ContribAuthor ">Robert  Torka</span>. </span><span class="cited-content_cbyCitation_article-title">GAS6-expressing and self-sustaining cancer cells in 3D spheroids activate the PDK-RSK-mTOR pathway for survival and drug resistance. </span><span class="cited-content_cbyCitation_journal-name">Molecular Oncology</span><span> <strong>2017,</strong> <em>11 </em>
                                    (10)
                                     , 1430-1447. <a href="https://doi.org/10.1002/1878-0261.12109" title="DOI URL">https://doi.org/10.1002/1878-0261.12109</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/1878-0261.12109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F1878-0261.12109%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecular%2520Oncology%26atitle%3DGAS6-expressing%252Band%252Bself-sustaining%252Bcancer%252Bcells%252Bin%252B3D%252Bspheroids%252Bactivate%252Bthe%252BPDK-RSK-mTOR%252Bpathway%252Bfor%252Bsurvival%252Band%252Bdrug%252Bresistance%26aulast%3DBaumann%26aufirst%3DChristine%26date%3D2017%26date%3D2017%26volume%3D11%26issue%3D10%26spage%3D1430%26epage%3D1447" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Dane  Goff</span>, <span class="hlFld-ContribAuthor ">Jing  Zhang</span>, <span class="hlFld-ContribAuthor ">Thilo  Heckrodt</span>, <span class="hlFld-ContribAuthor ">Jiaxin  Yu</span>, <span class="hlFld-ContribAuthor ">Pingyu  Ding</span>, <span class="hlFld-ContribAuthor ">Raj  Singh</span>, <span class="hlFld-ContribAuthor ">Sacha  Holland</span>, <span class="hlFld-ContribAuthor ">Weiqun  Li</span>, <span class="hlFld-ContribAuthor ">Mark  Irving</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of dual Axl/VEGF-R2 inhibitors as potential anti-angiogenic and anti-metastatic drugs for cancer chemotherapy. </span><span class="cited-content_cbyCitation_journal-name">Bioorganic & Medicinal Chemistry Letters</span><span> <strong>2017,</strong> <em>27 </em>
                                    (16)
                                     , 3766-3771. <a href="https://doi.org/10.1016/j.bmcl.2017.06.071" title="DOI URL">https://doi.org/10.1016/j.bmcl.2017.06.071</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.bmcl.2017.06.071&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.bmcl.2017.06.071%26sid%3Dliteratum%253Aachs%26jtitle%3DBioorganic%2520%2526%2520Medicinal%2520Chemistry%2520Letters%26atitle%3DDiscovery%252Bof%252Bdual%252BAxl%25252FVEGF-R2%252Binhibitors%252Bas%252Bpotential%252Banti-angiogenic%252Band%252Banti-metastatic%252Bdrugs%252Bfor%252Bcancer%252Bchemotherapy%26aulast%3DGoff%26aufirst%3DDane%26date%3D2017%26volume%3D27%26issue%3D16%26spage%3D3766%26epage%3D3771" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jane  Antony</span>, <span class="hlFld-ContribAuthor ">Ruby Yun-Ju  Huang</span>. </span><span class="cited-content_cbyCitation_article-title">AXL-Driven EMT State as a Targetable Conduit in Cancer. </span><span class="cited-content_cbyCitation_journal-name">Cancer Research</span><span> <strong>2017,</strong> <em>77 </em>
                                    (14)
                                     , 3725-3732. <a href="https://doi.org/10.1158/0008-5472.CAN-17-0392" title="DOI URL">https://doi.org/10.1158/0008-5472.CAN-17-0392</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1158/0008-5472.CAN-17-0392&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1158%2F0008-5472.CAN-17-0392%26sid%3Dliteratum%253Aachs%26jtitle%3DCancer%2520Research%26atitle%3DAXL-Driven%252BEMT%252BState%252Bas%252Ba%252BTargetable%252BConduit%252Bin%252BCancer%26aulast%3DAntony%26aufirst%3DJane%26date%3D2017%26date%3D2017%26volume%3D77%26issue%3D14%26spage%3D3725%26epage%3D3732" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Axel  Kleemann</span>. </span><span class="cited-content_cbyCitation_article-title">Antineoplastic and Immunomodulating Agents (L). </span><span class="cited-content_cbyCitation_journal-name"></span><span> <strong>2017,</strong>,, 1-56. <a href="https://doi.org/10.1002/14356007.a05_001.pub3" title="DOI URL">https://doi.org/10.1002/14356007.a05_001.pub3</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/14356007.a05_001.pub3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2F14356007.a05_001.pub3%26sid%3Dliteratum%253Aachs%26atitle%3DAntineoplastic%252Band%252BImmunomodulating%252BAgents%252B%252528L%252529%26aulast%3DKleemann%26aufirst%3DAxel%26date%3D2017%26date%3D2017%26spage%3D1%26epage%3D56%26pub%3DWiley-VCH%2520Verlag%2520GmbH%2520%2526%2520Co.%2520KGaA%26atitle%3DUllmann%252527s%252BEncyclopedia%252Bof%252BIndustrial%252BChemistry%26date%3D2000%26date%3D2000%26volume%3D13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Stanley G.  Kimani</span>, <span class="hlFld-ContribAuthor ">Sushil  Kumar</span>, <span class="hlFld-ContribAuthor ">Nitu  Bansal</span>, <span class="hlFld-ContribAuthor ">Kamalendra  Singh</span>, <span class="hlFld-ContribAuthor ">Vladyslav  Kholodovych</span>, <span class="hlFld-ContribAuthor ">Thomas  Comollo</span>, <span class="hlFld-ContribAuthor ">Youyi  Peng</span>, <span class="hlFld-ContribAuthor ">Sergei V.  Kotenko</span>, <span class="hlFld-ContribAuthor ">Stefan G.  Sarafianos</span>, <span class="hlFld-ContribAuthor ">Joseph R.  Bertino</span>, <span class="hlFld-ContribAuthor ">William J.  Welsh</span>, <span class="hlFld-ContribAuthor ">Raymond B.  Birge</span>. </span><span class="cited-content_cbyCitation_article-title">Small molecule inhibitors block Gas6-inducible TAM activation and tumorigenicity. </span><span class="cited-content_cbyCitation_journal-name">Scientific Reports</span><span> <strong>2017,</strong> <em>7 </em>
                                    (1)
                                     <a href="https://doi.org/10.1038/srep43908" title="DOI URL">https://doi.org/10.1038/srep43908</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1038/srep43908&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1038%2Fsrep43908%26sid%3Dliteratum%253Aachs%26jtitle%3DScientific%2520Reports%26atitle%3DSmall%252Bmolecule%252Binhibitors%252Bblock%252BGas6-inducible%252BTAM%252Bactivation%252Band%252Btumorigenicity%26aulast%3DKimani%26aufirst%3DStanley%2BG.%26date%3D2017%26date%3D2017%26volume%3D7%26issue%3D1" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Peter M.  Fischer</span>. </span><span class="cited-content_cbyCitation_article-title">Approved and Experimental Small-Molecule Oncology Kinase Inhibitor Drugs: A Mid-2016 Overview. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2017,</strong> <em>37 </em>
                                    (2)
                                     , 314-367. <a href="https://doi.org/10.1002/med.21409" title="DOI URL">https://doi.org/10.1002/med.21409</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21409&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21409%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DApproved%252Band%252BExperimental%252BSmall-Molecule%252BOncology%252BKinase%252BInhibitor%252BDrugs%25253A%252BA%252BMid-2016%252BOverview%26aulast%3DFischer%26aufirst%3DPeter%2BM.%26date%3D2017%26date%3D2016%26volume%3D37%26issue%3D2%26spage%3D314%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Eun-Mi  Kim</span>, <span class="hlFld-ContribAuthor ">Eun-Hee  Lee</span>, <span class="hlFld-ContribAuthor ">Hwa-Yeon  Lee</span>, <span class="hlFld-ContribAuthor ">Ha-Rim  Choi</span>, <span class="hlFld-ContribAuthor ">Kon-Young  Ji</span>, <span class="hlFld-ContribAuthor ">Su-Man  Kim</span>, <span class="hlFld-ContribAuthor ">Kwang Dong  Kim</span>, <span class="hlFld-ContribAuthor ">Hyung-Sik  Kang</span>. </span><span class="cited-content_cbyCitation_article-title">Axl signaling induces development of natural killer cells in vitro and in vivo. </span><span class="cited-content_cbyCitation_journal-name">Protoplasma</span><span> <strong>2017,</strong> <em>254 </em>
                                    (2)
                                     , 1091-1101. <a href="https://doi.org/10.1007/s00709-016-1016-5" title="DOI URL">https://doi.org/10.1007/s00709-016-1016-5</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s00709-016-1016-5&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs00709-016-1016-5%26sid%3Dliteratum%253Aachs%26jtitle%3DProtoplasma%26atitle%3DAxl%252Bsignaling%252Binduces%252Bdevelopment%252Bof%252Bnatural%252Bkiller%252Bcells%252Bin%252Bvitro%252Band%252Bin%252Bvivo%26aulast%3DKim%26aufirst%3DEun-Mi%26date%3D2017%26date%3D2016%26volume%3D254%26issue%3D2%26spage%3D1091%26epage%3D1101" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Marie  Schoumacher</span>, <span class="hlFld-ContribAuthor ">Mike  Burbridge</span>. </span><span class="cited-content_cbyCitation_article-title">Key Roles of AXL and MER Receptor Tyrosine Kinases in Resistance to Multiple Anticancer Therapies. </span><span class="cited-content_cbyCitation_journal-name">Current Oncology Reports</span><span> <strong>2017,</strong> <em>19 </em>
                                    (3)
                                     <a href="https://doi.org/10.1007/s11912-017-0579-4" title="DOI URL">https://doi.org/10.1007/s11912-017-0579-4</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1007/s11912-017-0579-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1007%2Fs11912-017-0579-4%26sid%3Dliteratum%253Aachs%26jtitle%3DCurrent%2520Oncology%2520Reports%26atitle%3DKey%252BRoles%252Bof%252BAXL%252Band%252BMER%252BReceptor%252BTyrosine%252BKinases%252Bin%252BResistance%252Bto%252BMultiple%252BAnticancer%252BTherapies%26aulast%3DSchoumacher%26aufirst%3DMarie%26date%3D2017%26date%3D2017%26volume%3D19%26issue%3D3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Niki  Karachaliou</span>, <span class="hlFld-ContribAuthor ">Aaron E.  Sosa</span>, <span class="hlFld-ContribAuthor ">Feliciano Barron  Barron</span>, <span class="hlFld-ContribAuthor ">Maria  Gonzalez Cao</span>, <span class="hlFld-ContribAuthor ">Mariacarmela  Santarpia</span>, <span class="hlFld-ContribAuthor ">Rafael  Rosell</span>. </span><span class="cited-content_cbyCitation_article-title">Pharmacological management of relapsed/refractory NSCLC with chemical drugs. </span><span class="cited-content_cbyCitation_journal-name">Expert Opinion on Pharmacotherapy</span><span> <strong>2017,</strong> <em>18 </em>
                                    (3)
                                     , 295-304. <a href="https://doi.org/10.1080/14656566.2017.1285284" title="DOI URL">https://doi.org/10.1080/14656566.2017.1285284</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14656566.2017.1285284&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14656566.2017.1285284%26sid%3Dliteratum%253Aachs%26jtitle%3DExpert%2520Opinion%2520on%2520Pharmacotherapy%26atitle%3DPharmacological%252Bmanagement%252Bof%252Brelapsed%25252Frefractory%252BNSCLC%252Bwith%252Bchemical%252Bdrugs%26aulast%3DKarachaliou%26aufirst%3DNiki%26date%3D2017%26date%3D2017%26volume%3D18%26issue%3D3%26spage%3D295%26epage%3D304" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div><a href="#" data-source="/pb/widgets/cited-by?doi=10.1021%2Facs.jmedchem.5b01273&amp;widgetId=9cf770f4-a9a2-46e0-bd29-3da15bcf4ae0&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01273%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-8%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text&amp;citedByCount=115&amp;pagesCount=2&amp;pageNumber=-1" title="Load all citations" class="button_primary float-right cited-by__see-more mb-5"><i aria-hidden="”true”" class="icon-angle-double-down"></i><span>Load all citations</span></a></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="f_tgr1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0011.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=f_tgr1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0002.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. (a) AXL kinase and its extracellular ligand GAS6. (b) Types of AXL activation: (1) GAS6 ligand-dependent activation of AXL; (2) ligand independent activation of AXL; (3) heterophilic activation of AXL with a non-TAM family protein; (4) heterophilic activation of AXL with MER or TYRO3; (5) transcellular ligand independent activation of AXL. (c) Downstream AXL signaling pathways upon classical GAS6-mediated activation.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0003.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Structures of type II kinase inhibitors in clinical and preclinical development that target the AXL RTK.<a onclick="showRef(event, 'ref49 ref51 ref52 ref59 ref60 ref61 ref62'); return false;" href="javascript:void(0);" class="ref ref49 ref51 ref52 ref59 ref60 ref61 ref62">(49, 51, 52, 59-62)</a> The hinge-binding heterocycles are displayed at the left side of the structures. The chemically related structural motifs that connect the “head” heterocycle with the terminal phenyl ring (in red) are highlighted in blue. Note that all compounds but <b>4</b> present a fluoro atom at the para position of the terminal phenyl ring.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0004.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Cocrystal structure of <b>5</b> bound to the inactive conformation of MET kinase domain (left panel)<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and main binding interactions of the inhibitor (right panel).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig4" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0005.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Chemical structures of multikinase type I inhibitors <b>8</b>–<b>11</b> and cocrystal structure of <b>8</b> bound to the active conformation of ABL kinase (reproduced from  <cite>Trends in Pharmacological Sciences</cite>, Vol. <em>36</em>, <contrib-group>Wu, P.; Nielsen, T. E.; Clausen, M. H.</contrib-group>FDA-approved small-molecule kinase inhibitors, pp 422–439, Copyright <span class="NLM_year">2015</span>, with permission from Elsevier<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a>). Shared chemical motifs are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0006.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Structures of type I AXL inhibitors <b>12</b>–<b>17</b>. Shared chemical motifs between compounds <b>15</b> and <b>16</b> are highlighted in blue.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0007.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. Development of the ATP-competitive (type II), orally available, dual MET/AXL inhibitor <b>5</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0008.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Medicinal chemistry campaigns for the discovery of TAM inhibitor <b>14</b> and related compounds by Wang and co-workers.<a onclick="showRef(event, 'ref82 ref83 ref95 ref96 ref97'); return false;" href="javascript:void(0);" class="ref ref82 ref83 ref95 ref96 ref97">(82, 83, 95-97)</a> MER-compound <b>52</b> cocrystal structure was adapted from Huang et al.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> from <i>Journal of Structural Biology</i>, Elsevier, under the Creative Commons License Deed.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0009.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Synthesis of the specific AXL inhibitor <b>17</b> from commercial starting materials <b>36</b> and <b>39</b>.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/medium/jm-2015-01273g_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0010.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Chemical scaffolds investigated by Holland et al. in the search for specific AXL inhibitors.<a onclick="showRef(event, 'ref98'); return false;" href="javascript:void(0);" class="ref ref98">(98)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2016/jmcmar.2016.59.issue-8/acs.jmedchem.5b01273/20160422/images/large/jm-2015-01273g_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.5b01273&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i22">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13023" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13023" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 115 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. F.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase family of the human genome</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5548</span><span class="NLM_x">–</span> <span class="NLM_lpage">5557</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1203957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11114734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref1/cit1&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5548-5557&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=S.+F.+Lin&title=The+protein+tyrosine+kinase+family+of+the+human+genome&doi=10.1038%2Fsj.onc.1203957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit1R"><div class="casContent"><span class="casTitleNuber">1</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine kinase family of the human genome</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Lin, Su-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5548-5557</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the sequencing of the human genome is completed by the Human Genome Project, the anal. of this rich source of information will illuminate many areas in medicine and biol.  The protein tyrosine kinases are a large multigene family with particular relevance to many human diseases, including cancer.  A search of the human genome for tyrosine kinase coding elements identified several novel genes and enabled the creation of a nonredundant catalog of tyrosine kinase genes.  Ninety unique kinase genes can be identified in the human genome, along with five pseudogenes.  Of the 90 tyrosine kinases, 58 are receptor type, distributed into 20 subfamilies.  The 32 nonreceptor tyrosine kinases can be placed in 10 subfamilies.  Addnl., mouse orthologs can be identified for nearly all the human tyrosine kinases.  The completion of the human tyrosine kinase family tree provides a framework for further advances in biomedical science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KhPd82OXhLVg90H21EOLACvtfcHk0lhXVGCGtzSjpA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D&md5=007f1f4a2d4ada11c5c9ea77d586816d</span></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203957%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DS.%2BF.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520family%2520of%2520the%2520human%2520genome%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5548%26epage%3D5557%26doi%3D10.1038%2Fsj.onc.1203957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group">Ségaliny, A. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tellez-Gabriel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymann, M.-F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymann, D.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span> <span class="citation_source-journal">J. Bone Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">12</span><span class="refDoi"> DOI: 10.1016/j.jbo.2015.01.001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.jbo.2015.01.001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=26579483" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2015&pages=1-12&author=A.+I.+S%C3%A9galinyauthor=M.+Tellez-Gabrielauthor=M.-F.+Heymannauthor=D.+Heymann&title=Receptor+tyrosine+kinases%3A+Characterisation%2C+mechanism+of+action+and+therapeutic+interests+for+bone+cancers&doi=10.1016%2Fj.jbo.2015.01.001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinases: Characterisation, mechanism of action and therapeutic interests for bone cancers</span></div><div class="casAuthors">Segaliny Aude I; Tellez-Gabriel Marta; Heymann Marie-Francoise; Heymann Dominique</div><div class="citationInfo"><span class="NLM_cas:title">Journal of bone oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">1-12</span>
        ISSN:<span class="NLM_cas:issn">2212-1366</span>.
    </div><div class="casAbstract">Bone cancers are characterised by the development of tumour cells in bone sites, associated with a dysregulation of their environment.  In the last two decades, numerous therapeutic strategies have been developed to target the cancer cells or tumour niche.  As the crosstalk between these two entities is tightly controlled by the release of polypeptide mediators activating signalling pathways through several receptor tyrosine kinases (RTKs), RTK inhibitors have been designed.  These inhibitors have shown exciting clinical impacts, such as imatinib mesylate, which has become a reference treatment for chronic myeloid leukaemia and gastrointestinal tumours.  The present review gives an overview of the main molecular and functional characteristics of RTKs, and focuses on the clinical applications that are envisaged and already assessed for the treatment of bone sarcomas and bone metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQ-qtzzXrDFl42y4bB4mnvYfW6udTcc2eZz_D_6cqJ207ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC28rgtlyjtg%253D%253D&md5=57563bfe33ca5752242d56cc24546c1c</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1016%2Fj.jbo.2015.01.001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jbo.2015.01.001%26sid%3Dliteratum%253Aachs%26aulast%3DS%25C3%25A9galiny%26aufirst%3DA.%2BI.%26aulast%3DTellez-Gabriel%26aufirst%3DM.%26aulast%3DHeymann%26aufirst%3DM.-F.%26aulast%3DHeymann%26aufirst%3DD.%26atitle%3DReceptor%2520tyrosine%2520kinases%253A%2520Characterisation%252C%2520mechanism%2520of%2520action%2520and%2520therapeutic%2520interests%2520for%2520bone%2520cancers%26jtitle%3DJ.%2520Bone%2520Oncol.%26date%3D2015%26volume%3D4%26spage%3D1%26epage%3D12%26doi%3D10.1016%2Fj.jbo.2015.01.001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group">O’Bryan, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cogswell, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Neubauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kitch, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prokop, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinosa, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Le Beau, M. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, E. T.</span><span> </span><span class="NLM_article-title">Axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1991</span><span class="NLM_x">, </span> <span class="NLM_volume">11</span><span class="NLM_x">, </span> <span class="NLM_fpage">5016</span><span class="NLM_x">–</span> <span class="NLM_lpage">5031</span><span class="refDoi"> DOI: 10.1128/MCB.11.10.5016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1128%2FMCB.11.10.5016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1656220" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=1991&pages=5016-5031&author=J.+P.+O%E2%80%99Bryanauthor=R.+A.+Fryeauthor=P.+C.+Cogswellauthor=A.+Neubauerauthor=B.+Kitchauthor=C.+Prokopauthor=R.+Espinosaauthor=M.+M.+Le+Beauauthor=H.+S.+Earpauthor=E.+T.+Liu&title=Axl%2C+a+transforming+gene+isolated+from+primary+human+myeloid+leukemia+cells%2C+encodes+a+novel+receptor+tyrosine+kinase&doi=10.1128%2FMCB.11.10.5016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">axl, A transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase</span></div><div class="casAuthors">O'Bryan, John P.; Frye, Roy A.; Cogswell, Patricia C.; Neubauer, Andreas; Kitch, Barry; Prokop, Carol; Espinosa, Rafael, III; Le Beau, Michelle M.; Earp, H. Shelton; Liu, Edison T.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">5016-31</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    </div><div class="casAbstract">A sensitive transfection-tumorigenicity assay was used to isolate a novel transforming gene from the DNA of 2 patients with chronic myelogenous leukemia.  Sequence anal. indicates that the product of this gene, axl, is a receptor tyrosine kinase.  Overexpression of axl cDNA in NIH 3T3 cells induces neoplastic transformation with the concomitant appearance of a 140-kDa axl tyrosine-phosphorylated protein.  Expression of axl cDNA in the baculovirus system results in the expression of the appropriate recombinant protein that is tyrosine kinase.  The juxtaposition of fibronectin type III and immunoglobulinlike repeats in the extracellular domain, as well as distinct amino acid sequences in the kinase domain, indicate that the axl protein represents a novel subclass of receptor tyrosine kinases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrCIaouGK3RfrVg90H21EOLACvtfcHk0ljEj2dPg_BDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK38XlvVGrsLs%253D&md5=f244ff83822fdb98c22a35f918723d3a</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1128%2FMCB.11.10.5016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.11.10.5016%26sid%3Dliteratum%253Aachs%26aulast%3DO%25E2%2580%2599Bryan%26aufirst%3DJ.%2BP.%26aulast%3DFrye%26aufirst%3DR.%2BA.%26aulast%3DCogswell%26aufirst%3DP.%2BC.%26aulast%3DNeubauer%26aufirst%3DA.%26aulast%3DKitch%26aufirst%3DB.%26aulast%3DProkop%26aufirst%3DC.%26aulast%3DEspinosa%26aufirst%3DR.%26aulast%3DLe%2BBeau%26aufirst%3DM.%2BM.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DLiu%26aufirst%3DE.%2BT.%26atitle%3DAxl%252C%2520a%2520transforming%2520gene%2520isolated%2520from%2520primary%2520human%2520myeloid%2520leukemia%2520cells%252C%2520encodes%2520a%2520novel%2520receptor%2520tyrosine%2520kinase%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1991%26volume%3D11%26spage%3D5016%26epage%3D5031%26doi%3D10.1128%2FMCB.11.10.5016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group">Hutterer, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abate, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reschke, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maier, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanova, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazeva, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbieri, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reindl, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muigg, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kostron, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stockhammer, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Axl and growth arrest-specific gene 6 are frequently overexpressed in human gliomas and predict poor prognosis in patients with glioblastoma multiforme</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">130</span><span class="NLM_x">–</span> <span class="NLM_lpage">138</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-07-0862</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-07-0862" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18172262" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXoslCn" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2008&pages=130-138&author=M.+Huttererauthor=P.+Knyazevauthor=A.+Abateauthor=M.+Reschkeauthor=H.+Maierauthor=N.+Stefanovaauthor=T.+Knyazevaauthor=V.+Barbieriauthor=M.+Reindlauthor=A.+Muiggauthor=H.+Kostronauthor=G.+Stockhammerauthor=A.+Ullrich&title=Axl+and+growth+arrest-specific+gene+6+are+frequently+overexpressed+in+human+gliomas+and+predict+poor+prognosis+in+patients+with+glioblastoma+multiforme&doi=10.1158%2F1078-0432.CCR-07-0862"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Axl and Growth Arrest-Specific Gene 6 Are Frequently Overexpressed in Human Gliomas and Predict Poor Prognosis in Patients with Glioblastoma Multiforme</span></div><div class="casAuthors">Hutterer, Markus; Knyazev, Pjotr; Abate, Ariane; Reschke, Markus; Maier, Hans; Stefanova, Nadia; Knyazeva, Tatjana; Barbieri, Verena; Reindl, Markus; Muigg, Armin; Kostron, Herwig; Stockhammer, Guenther; Ullrich, Axel</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">130-138</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: The receptor tyrosine kinase Axl has recently been identified as a crit. element in the invasive properties of glioma cell lines.  However, the effect of Axl and its ligand growth arrest-specific gene 6 (Gas6) in human gliomas is still unknown.  Exptl. Design: Axl and Gas6 expression was studied in 42 fresh-frozen and 79 paraffin-embedded glioma specimens by means of reverse transcription-PCR and immunohistochem.  The prognostic value of Axl and Gas6 expression was evaluated using a population-based tissue microarray derived from a cohort of 55 glioblastoma multiforme (GBM) patients.  RESULTS: Axl and Gas6 were detectable in gliomas of malignancy grades WHO 2 to 4.  Moderate to high Axl mRNA expression was found in 61%, Axl protein in 55%, Gas6 mRNA in 81%, and Gas6 protein in 74% of GBM samples, resp.  GBM patients with high Axl expression and Axl/Gas6 coexpression showed a significantly shorter time to tumor progression and an assocn. with poorer overall survival.  Comparative immunohistochem. studies showed that Axl staining was most pronounced in glioma cells of pseudopalisades and reactive astrocytes.  Addnl., Axl/Gas6 coexpression was obsd. in glioma cells and tumor vessels.  In contrast, Axl staining was not detectable in nonneoplastic brain tissue and Gas6 was strongly expressed in neurons.  CONCLUSIONS: In human gliomas, Axl and Gas6 are frequently overexpressed in both glioma and vascular cells and predict poor prognosis in GBM patients.  Our results indicate that specific targeting of the Axl/Gas6 signaling pathway may represent a potential new approach for glioma treatment.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr-54ka16GPkrVg90H21EOLACvtfcHk0ljEj2dPg_BDeA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXoslCn&md5=45d8887803613422b9e704b803ee757c</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-07-0862&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-07-0862%26sid%3Dliteratum%253Aachs%26aulast%3DHutterer%26aufirst%3DM.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DAbate%26aufirst%3DA.%26aulast%3DReschke%26aufirst%3DM.%26aulast%3DMaier%26aufirst%3DH.%26aulast%3DStefanova%26aufirst%3DN.%26aulast%3DKnyazeva%26aufirst%3DT.%26aulast%3DBarbieri%26aufirst%3DV.%26aulast%3DReindl%26aufirst%3DM.%26aulast%3DMuigg%26aufirst%3DA.%26aulast%3DKostron%26aufirst%3DH.%26aulast%3DStockhammer%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAxl%2520and%2520growth%2520arrest-specific%2520gene%25206%2520are%2520frequently%2520overexpressed%2520in%2520human%2520gliomas%2520and%2520predict%2520poor%2520prognosis%2520in%2520patients%2520with%2520glioblastoma%2520multiforme%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2008%26volume%3D14%26spage%3D130%26epage%3D138%26doi%3D10.1158%2F1078-0432.CCR-07-0862" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saso, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, N. T.</span><span> </span><span class="NLM_article-title">TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6525</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-0967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-0967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6516-6525&author=X.+Wangauthor=H.+Sasoauthor=T.+Iwamotoauthor=W.+Xiaauthor=Y.+Gongauthor=L.+Pusztaiauthor=W.+A.+Woodwardauthor=J.+M.+Reubenauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=G.+N.+Hortobagyiauthor=M.+C.+Hungauthor=N.+T.+Ueno&title=TIG1+promotes+the+development+and+progression+of+inflammatory+breast+cancer+through+activation+of+Axl+kinase&doi=10.1158%2F0008-5472.CAN-13-0967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-0967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-0967%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSaso%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DTIG1%2520promotes%2520the%2520development%2520and%2520progression%2520of%2520inflammatory%2520breast%2520cancer%2520through%2520activation%2520of%2520Axl%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6516%26epage%3D6525%26doi%3D10.1158%2F0008-5472.CAN-13-0967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group">Niederst, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span> </span><span class="NLM_article-title">Bypass mechanisms of resistance to receptor tyrosine kinase inhibition in lung cancer</span> <span class="citation_source-journal">Sci. Signaling</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">re6</span><span class="refDoi"> DOI: 10.1126/scisignal.2004652</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscisignal.2004652" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24065147" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=re6&author=M.+J.+Niederstauthor=J.+A.+Engelman&title=Bypass+mechanisms+of+resistance+to+receptor+tyrosine+kinase+inhibition+in+lung+cancer&doi=10.1126%2Fscisignal.2004652"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1126%2Fscisignal.2004652&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscisignal.2004652%26sid%3Dliteratum%253Aachs%26aulast%3DNiederst%26aufirst%3DM.%2BJ.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26atitle%3DBypass%2520mechanisms%2520of%2520resistance%2520to%2520receptor%2520tyrosine%2520kinase%2520inhibition%2520in%2520lung%2520cancer%26jtitle%3DSci.%2520Signaling%26date%3D2013%26volume%3D6%26spage%3Dre6%26doi%3D10.1126%2Fscisignal.2004652" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group">Han, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tian, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, T.</span><span> </span><span class="NLM_article-title">Gas6/Axl mediates tumor cell apoptosis, migration and invasion and predicts the clinical outcome of osteosarcoma patients</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">435</span><span class="NLM_x">, </span> <span class="NLM_fpage">493</span><span class="NLM_x">–</span> <span class="NLM_lpage">500</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2013.05.019</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bbrc.2013.05.019" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=435&publication_year=2013&pages=493-500&author=J.+Hanauthor=R.+Tianauthor=B.+Yongauthor=C.+Luoauthor=P.+Tanauthor=J.+Shenauthor=T.+Peng&title=Gas6%2FAxl+mediates+tumor+cell+apoptosis%2C+migration+and+invasion+and+predicts+the+clinical+outcome+of+osteosarcoma+patients&doi=10.1016%2Fj.bbrc.2013.05.019"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2013.05.019&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2013.05.019%26sid%3Dliteratum%253Aachs%26aulast%3DHan%26aufirst%3DJ.%26aulast%3DTian%26aufirst%3DR.%26aulast%3DYong%26aufirst%3DB.%26aulast%3DLuo%26aufirst%3DC.%26aulast%3DTan%26aufirst%3DP.%26aulast%3DShen%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DT.%26atitle%3DGas6%252FAxl%2520mediates%2520tumor%2520cell%2520apoptosis%252C%2520migration%2520and%2520invasion%2520and%2520predicts%2520the%2520clinical%2520outcome%2520of%2520osteosarcoma%2520patients%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2013%26volume%3D435%26spage%3D493%26epage%3D500%26doi%3D10.1016%2Fj.bbrc.2013.05.019" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0liw1Yq28ubR5Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group">Byers, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Diao, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saintigny, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Girard, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyton, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fan, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Giri, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tumula, P. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nilsson, M. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gudikote, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cardnell, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foulks, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kanner, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krett, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, S. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herbst, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blumenschein, G. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippman, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ang, K. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mills, G. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hong, W. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Weinstein, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wistuba, I. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Coombes, K. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heymach, J. V.</span><span> </span><span class="NLM_article-title">An epithelial-mesenchymal transition gene signature predicts resistance to EGFR and PI3K inhibitors and identifies Axl as a therapeutic target for overcoming EGFR inhibitor resistance</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">279</span><span class="NLM_x">–</span> <span class="NLM_lpage">290</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-12-1558</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-12-1558" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23091115" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=279-290&author=L.+A.+Byersauthor=L.+Diaoauthor=J.+Wangauthor=P.+Saintignyauthor=L.+Girardauthor=M.+Peytonauthor=L.+Shenauthor=Y.+Fanauthor=U.+Giriauthor=P.+K.+Tumulaauthor=M.+B.+Nilssonauthor=J.+Gudikoteauthor=H.+Tranauthor=R.+J.+Cardnellauthor=D.+J.+Bearssauthor=S.+L.+Warnerauthor=J.+M.+Foulksauthor=S.+B.+Kannerauthor=V.+Gandhiauthor=N.+Krettauthor=S.+T.+Rosenauthor=E.+S.+Kimauthor=R.+S.+Herbstauthor=G.+R.+Blumenscheinauthor=J.+J.+Leeauthor=S.+M.+Lippmanauthor=K.+K.+Angauthor=G.+B.+Millsauthor=W.+K.+Hongauthor=J.+N.+Weinsteinauthor=I.+I.+Wistubaauthor=K.+R.+Coombesauthor=J.+D.+Minnaauthor=J.+V.+Heymach&title=An+epithelial-mesenchymal+transition+gene+signature+predicts+resistance+to+EGFR+and+PI3K+inhibitors+and+identifies+Axl+as+a+therapeutic+target+for+overcoming+EGFR+inhibitor+resistance&doi=10.1158%2F1078-0432.CCR-12-1558"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">An Epithelial-Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance</span></div><div class="casAuthors">Byers, Lauren Averett; Diao, Lixia; Wang, Jing; Saintigny, Pierre; Girard, Luc; Peyton, Michael; Shen, Li; Fan, Youhong; Giri, Uma; Tumula, Praveen K.; Nilsson, Monique B.; Gudikote, Jayanthi; Tran, Hai; Cardnell, Robert J. G.; Bearss, David J.; Warner, Steven L.; Foulks, Jason M.; Kanner, Steven B.; Gandhi, Varsha; Krett, Nancy; Rosen, Steven T.; Kim, Edward S.; Herbst, Roy S.; Blumenschein, George R.; Lee, J. Jack; Lippman, Scott M.; Ang, K. Kian; Mills, Gordon B.; Hong, Waun K.; Weinstein, John N.; Wistuba, Ignacio I.; Coombes, Kevin R.; Minna, John D.; Heymach, John V.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">279-290</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: Epithelial-mesenchymal transition (EMT) has been assocd. with metastatic spread and EGF receptor (EGFR) inhibitor resistance.  We developed and validated a robust 76-gene EMT signature using gene expression profiles from four platforms using non-small cell lung carcinoma (NSCLC) cell lines and patients treated in the Biomarker-Integrated Approaches of Targeted Therapy for Lung Cancer Elimination (BATTLE) study.  Exptl. Design: We conducted an integrated gene expression, proteomic, and drug response anal. using cell lines and tumors from patients with NSCLC.  A 76-gene EMT signature was developed and validated using gene expression profiles from four microarray platforms of NSCLC cell lines and patients treated in the BATTLE study, and potential therapeutic targets assocd. with EMT were identified.  Results: Compared with epithelial cells, mesenchymal cells showed significantly greater resistance to EGFR and PI3K/Akt pathway inhibitors, independent of EGFR mutation status, but more sensitivity to certain chemotherapies.  Mesenchymal cells also expressed increased levels of the receptor tyrosine kinase Axl and showed a trend toward greater sensitivity to the Axl inhibitor SGI-7079, whereas the combination of SGI-7079 with erlotinib reversed erlotinib resistance in mesenchymal lines expressing Axl and in a xenograft model of mesenchymal NSCLC.  In patients with NSCLC, the EMT signature predicted 8-wk disease control in patients receiving erlotinib but not other therapies.  Conclusion: We have developed a robust EMT signature that predicts resistance to EGFR and PI3K/Akt inhibitors, highlights different patterns of drug responsiveness for epithelial and mesenchymal cells, and identifies Axl as a potential therapeutic target for overcoming EGFR inhibitor resistance assocd. with the mesenchymal phenotype.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwav-PXLuwi7Vg90H21EOLACvtfcHk0limL7hw5_yEJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFGlsg%253D%253D&md5=d02e08e505b8487a48874abdb8a553a9</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-12-1558&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-12-1558%26sid%3Dliteratum%253Aachs%26aulast%3DByers%26aufirst%3DL.%2BA.%26aulast%3DDiao%26aufirst%3DL.%26aulast%3DWang%26aufirst%3DJ.%26aulast%3DSaintigny%26aufirst%3DP.%26aulast%3DGirard%26aufirst%3DL.%26aulast%3DPeyton%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DL.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGiri%26aufirst%3DU.%26aulast%3DTumula%26aufirst%3DP.%2BK.%26aulast%3DNilsson%26aufirst%3DM.%2BB.%26aulast%3DGudikote%26aufirst%3DJ.%26aulast%3DTran%26aufirst%3DH.%26aulast%3DCardnell%26aufirst%3DR.%2BJ.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DFoulks%26aufirst%3DJ.%2BM.%26aulast%3DKanner%26aufirst%3DS.%2BB.%26aulast%3DGandhi%26aufirst%3DV.%26aulast%3DKrett%26aufirst%3DN.%26aulast%3DRosen%26aufirst%3DS.%2BT.%26aulast%3DKim%26aufirst%3DE.%2BS.%26aulast%3DHerbst%26aufirst%3DR.%2BS.%26aulast%3DBlumenschein%26aufirst%3DG.%2BR.%26aulast%3DLee%26aufirst%3DJ.%2BJ.%26aulast%3DLippman%26aufirst%3DS.%2BM.%26aulast%3DAng%26aufirst%3DK.%2BK.%26aulast%3DMills%26aufirst%3DG.%2BB.%26aulast%3DHong%26aufirst%3DW.%2BK.%26aulast%3DWeinstein%26aufirst%3DJ.%2BN.%26aulast%3DWistuba%26aufirst%3DI.%2BI.%26aulast%3DCoombes%26aufirst%3DK.%2BR.%26aulast%3DMinna%26aufirst%3DJ.%2BD.%26aulast%3DHeymach%26aufirst%3DJ.%2BV.%26atitle%3DAn%2520epithelial-mesenchymal%2520transition%2520gene%2520signature%2520predicts%2520resistance%2520to%2520EGFR%2520and%2520PI3K%2520inhibitors%2520and%2520identifies%2520Axl%2520as%2520a%2520therapeutic%2520target%2520for%2520overcoming%2520EGFR%2520inhibitor%2520resistance%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2013%26volume%3D19%26spage%3D279%26epage%3D290%26doi%3D10.1158%2F1078-0432.CCR-12-1558" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group">Cichoń, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szentpetery, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Caley, M. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papadakis, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mackenzie, I. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brennan, C. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Toole, E. A.</span><span> </span><span class="NLM_article-title">The receptor tyrosine kinase Axl regulates cell-cell adhesion and stemness in cutaneous squamous cell carcinoma</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">4185</span><span class="NLM_x">–</span> <span class="NLM_lpage">4192</span><span class="refDoi"> DOI: 10.1038/onc.2013.388</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2013.388" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=4185-4192&author=M.+A.+Cicho%C5%84author=Z.+Szentpeteryauthor=M.+P.+Caleyauthor=E.+S.+Papadakisauthor=I.+C.+Mackenzieauthor=C.+H.+Brennanauthor=E.+A.+O%E2%80%99Toole&title=The+receptor+tyrosine+kinase+Axl+regulates+cell-cell+adhesion+and+stemness+in+cutaneous+squamous+cell+carcinoma&doi=10.1038%2Fonc.2013.388"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.388&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.388%26sid%3Dliteratum%253Aachs%26aulast%3DCicho%25C5%2584%26aufirst%3DM.%2BA.%26aulast%3DSzentpetery%26aufirst%3DZ.%26aulast%3DCaley%26aufirst%3DM.%2BP.%26aulast%3DPapadakis%26aufirst%3DE.%2BS.%26aulast%3DMackenzie%26aufirst%3DI.%2BC.%26aulast%3DBrennan%26aufirst%3DC.%2BH.%26aulast%3DO%25E2%2580%2599Toole%26aufirst%3DE.%2BA.%26atitle%3DThe%2520receptor%2520tyrosine%2520kinase%2520Axl%2520regulates%2520cell-cell%2520adhesion%2520and%2520stemness%2520in%2520cutaneous%2520squamous%2520cell%2520carcinoma%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D4185%26epage%3D4192%26doi%3D10.1038%2Fonc.2013.388" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+Zhangauthor=J.+C.+Leeauthor=L.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0limL7hw5_yEJQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group">Brand, T. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iida, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stein, A. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corrigan, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Braverman, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Luthar, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Toulany, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gill, P. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kimple, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wheeler, D. L.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to cetuximab therapy</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">5152</span><span class="NLM_x">–</span> <span class="NLM_lpage">5164</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-14-0294</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-14-0294" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=5152-5164&author=T.+M.+Brandauthor=M.+Iidaauthor=A.+P.+Steinauthor=K.+L.+Corriganauthor=C.+M.+Bravermanauthor=N.+Lutharauthor=M.+Toulanyauthor=P.+S.+Gillauthor=R.+Salgiaauthor=R.+J.+Kimpleauthor=D.+L.+Wheeler&title=AXL+mediates+resistance+to+cetuximab+therapy&doi=10.1158%2F0008-5472.CAN-14-0294"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-14-0294&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-14-0294%26sid%3Dliteratum%253Aachs%26aulast%3DBrand%26aufirst%3DT.%2BM.%26aulast%3DIida%26aufirst%3DM.%26aulast%3DStein%26aufirst%3DA.%2BP.%26aulast%3DCorrigan%26aufirst%3DK.%2BL.%26aulast%3DBraverman%26aufirst%3DC.%2BM.%26aulast%3DLuthar%26aufirst%3DN.%26aulast%3DToulany%26aufirst%3DM.%26aulast%3DGill%26aufirst%3DP.%2BS.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DKimple%26aufirst%3DR.%2BJ.%26aulast%3DWheeler%26aufirst%3DD.%2BL.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520cetuximab%2520therapy%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D5152%26epage%3D5164%26doi%3D10.1158%2F0008-5472.CAN-14-0294" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group">Hong, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peng, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sehdev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Belkhiri, A.</span><span> </span><span class="NLM_article-title">ABL regulation by AXL promotes cisplatin resistance in oesophageal cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">331</span><span class="NLM_x">–</span> <span class="NLM_lpage">340</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-12-3151</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-12-3151" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=331-340&author=J.+Hongauthor=D.+Pengauthor=Z.+Chenauthor=V.+Sehdevauthor=A.+Belkhiri&title=ABL+regulation+by+AXL+promotes+cisplatin+resistance+in+oesophageal+cancer&doi=10.1158%2F0008-5472.CAN-12-3151"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-12-3151&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-12-3151%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DJ.%26aulast%3DPeng%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DSehdev%26aufirst%3DV.%26aulast%3DBelkhiri%26aufirst%3DA.%26atitle%3DABL%2520regulation%2520by%2520AXL%2520promotes%2520cisplatin%2520resistance%2520in%2520oesophageal%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D331%26epage%3D340%26doi%3D10.1158%2F0008-5472.CAN-12-3151" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group">Hong, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lay, J. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chuang, S. E.</span><span> </span><span class="NLM_article-title">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</span> <span class="citation_source-journal">Cancer Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">268</span><span class="NLM_x">, </span> <span class="NLM_fpage">314</span><span class="NLM_x">–</span> <span class="NLM_lpage">324</span><span class="refDoi"> DOI: 10.1016/j.canlet.2008.04.017</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.canlet.2008.04.017" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18502572" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=268&publication_year=2008&pages=314-324&author=C.+C.+Hongauthor=J.+D.+Layauthor=J.+S.+Huangauthor=A.+L.+Chengauthor=J.+L.+Tangauthor=M.+T.+Linauthor=G.+M.+Laiauthor=S.+E.+Chuang&title=Receptor+tyrosine+kinase+AXL+is+induced+by+chemotherapy+drugs+and+overexpression+of+AXL+confers+drug+resistance+in+acute+myeloid+leukemia&doi=10.1016%2Fj.canlet.2008.04.017"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia</span></div><div class="casAuthors">Hong, Chih-Chen; Lay, Jong-Ding; Huang, Jhy-Shrian; Cheng, Ann-Lii; Tang, Jih-Luh; Lin, Ming-Tseh; Lai, Gi-Ming; Chuang, Shuang-En</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Letters (Shannon, Ireland)</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">268</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">314-324</span>CODEN:
                <span class="NLM_cas:coden">CALEDQ</span>;
        ISSN:<span class="NLM_cas:issn">0304-3835</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">By using a novel profiling anal. of protein tyrosine kinases differentially expressed in the sensitive and refractory leukemia from the same patients we found that AXL was up-regulated in drug-resistant leukemia.  Furthermore, AXL could be induced by chemotherapy drugs in the acute myeloid leukemia U937 cells and this induction was dependent on the CCWGG methylation status of the AXL promoter.  In U937 cells ectopically over-expressing AXL, addn. of exogenous Gas6 induced AXL phosphorylation and activation of the Akt and ERK1/2 survival pathways.  The Gas6-AXL activation pathway of drug resistance was assocd. with increased expression of Bcl-2 and Twist.  These results show that up-regulation of AXL by chemotherapy might induce drug resistance in acute myeloid leukemia in the presence of Gas6 stimulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZUB9br3lBSrVg90H21EOLACvtfcHk0lgRMCJ6c4_zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1Gkt70%253D&md5=03facdf77393a8a82c8554664234a6d5</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1016%2Fj.canlet.2008.04.017&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.canlet.2008.04.017%26sid%3Dliteratum%253Aachs%26aulast%3DHong%26aufirst%3DC.%2BC.%26aulast%3DLay%26aufirst%3DJ.%2BD.%26aulast%3DHuang%26aufirst%3DJ.%2BS.%26aulast%3DCheng%26aufirst%3DA.%2BL.%26aulast%3DTang%26aufirst%3DJ.%2BL.%26aulast%3DLin%26aufirst%3DM.%2BT.%26aulast%3DLai%26aufirst%3DG.%2BM.%26aulast%3DChuang%26aufirst%3DS.%2BE.%26atitle%3DReceptor%2520tyrosine%2520kinase%2520AXL%2520is%2520induced%2520by%2520chemotherapy%2520drugs%2520and%2520overexpression%2520of%2520AXL%2520confers%2520drug%2520resistance%2520in%2520acute%2520myeloid%2520leukemia%26jtitle%3DCancer%2520Lett.%26date%3D2008%26volume%3D268%26spage%3D314%26epage%3D324%26doi%3D10.1016%2Fj.canlet.2008.04.017" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group">Sheridan, C.</span><span> </span><span class="NLM_article-title">First Axl inhibitor enters clinical trials</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">775</span><span class="NLM_x">–</span> <span class="NLM_lpage">776</span><span class="refDoi"> DOI: 10.1038/nbt0913-775a</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt0913-775a" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=775-776&author=C.+Sheridan&title=First+Axl+inhibitor+enters+clinical+trials&doi=10.1038%2Fnbt0913-775a"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1038%2Fnbt0913-775a&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt0913-775a%26sid%3Dliteratum%253Aachs%26aulast%3DSheridan%26aufirst%3DC.%26atitle%3DFirst%2520Axl%2520inhibitor%2520enters%2520clinical%2520trials%26jtitle%3DNat.%2520Biotechnol.%26date%3D2013%26volume%3D31%26spage%3D775%26epage%3D776%26doi%3D10.1038%2Fnbt0913-775a" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span> </span><span class="NLM_article-title">Targeting Axl and Mer kinases in cancer</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">1763</span><span class="NLM_x">–</span> <span class="NLM_lpage">1773</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0116</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-11-0116" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21933973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrfJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=1763-1773&author=A.+Vermaauthor=S.+L.+Warnerauthor=H.+Vankayalapatiauthor=D.+J.+Bearssauthor=S.+Sharma&title=Targeting+Axl+and+Mer+kinases+in+cancer&doi=10.1158%2F1535-7163.MCT-11-0116"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Axl and Mer Kinases in Cancer</span></div><div class="casAuthors">Verma, Anupam; Warner, Steven L.; Vankayalapati, Hariprasad; Bearss, David J.; Sharma, Sunil</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1763-1773</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are cell-surface transmembrane receptors that contain regulated kinase activity within their cytoplasmic domain and play an important role in signal transduction in both normal and malignant cells.  The mammalian TAM RTK family includes 3 closely related members: Tyro-3, Axl, and Mer.  Overexpression or ectopic expression of the TAM receptors has been detected in a wide array of human cancers.  Growth arrest-specific gene 6 has been identified as the major ligand for these TAM RTKs, and its binding to the receptors has been shown to promote proliferation and survival of cancer cells in vitro.  Abnormal expression and activation of Axl or Mer can provide a survival advantage for certain cancer cells.  Inhibition of Axl and Mer may enhance the sensitivity of cancer cells to cytotoxic agents and would potentially be a therapeutic strategy to target cancer cells.  This review elucidates the role of Axl and Mer in normal cellular function and their role in oncogenesis.  In addn., we review the potential to inhibit these RTKs for the development of therapeutic targets in treatment of cancer.  Mol Cancer Ther; 10(10); 1763-73.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGogR8epfrv2ArVg90H21EOLACvtfcHk0lgRMCJ6c4_zMQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1ylsrfJ&md5=5048fdf6f6874a61bfbc6576db18d61c</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0116&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0116%26sid%3Dliteratum%253Aachs%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DSharma%26aufirst%3DS.%26atitle%3DTargeting%2520Axl%2520and%2520Mer%2520kinases%2520in%2520cancer%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D1763%26epage%3D1773%26doi%3D10.1158%2F1535-7163.MCT-11-0116" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group">Wu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koul, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span> </span><span class="NLM_article-title">AXL kinase as a novel target for cancer therapy</span> <span class="citation_source-journal">Oncotarget</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">5</span><span class="NLM_x">, </span> <span class="NLM_fpage">9546</span><span class="NLM_x">–</span> <span class="NLM_lpage">9563</span><span class="refDoi"> DOI: 10.18632/oncotarget.2542</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.18632%2Foncotarget.2542" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=5&publication_year=2014&pages=9546-9563&author=X.+Wuauthor=X.+Liuauthor=S.+Koulauthor=C.+Y.+Leeauthor=Z.+Zhangauthor=B.+Halmos&title=AXL+kinase+as+a+novel+target+for+cancer+therapy&doi=10.18632%2Foncotarget.2542"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.18632%2Foncotarget.2542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.18632%252Foncotarget.2542%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DX.%26aulast%3DLiu%26aufirst%3DX.%26aulast%3DKoul%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DC.%2BY.%26aulast%3DZhang%26aufirst%3DZ.%26aulast%3DHalmos%26aufirst%3DB.%26atitle%3DAXL%2520kinase%2520as%2520a%2520novel%2520target%2520for%2520cancer%2520therapy%26jtitle%3DOncotarget%26date%3D2014%26volume%3D5%26spage%3D9546%26epage%3D9563%26doi%3D10.18632%2Foncotarget.2542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Spenlinhauer, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guiet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fauvel, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daydé-Cazals, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warnault, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevé, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Axl kinase as a key target for oncology: focus on small molecule inhibitors</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">2141</span><span class="NLM_x">–</span> <span class="NLM_lpage">2148</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-1083</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-13-1083" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25139999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=2141-2148&author=C.+Feneyrollesauthor=A.+Spenlinhauerauthor=L.+Guietauthor=B.+Fauvelauthor=B.+Dayd%C3%A9-Cazalsauthor=P.+Warnaultauthor=G.+Chev%C3%A9author=A.+Yasri&title=Axl+kinase+as+a+key+target+for+oncology%3A+focus+on+small+molecule+inhibitors&doi=10.1158%2F1535-7163.MCT-13-1083"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">Axl Kinase as a Key Target for Oncology: Focus on Small Molecule Inhibitors</span></div><div class="casAuthors">Feneyrolles, Clemence; Spenlinhauer, Aurelia; Guiet, Lea; Fauvel, Benedicte; Dayde-Cazals, Benedicte; Warnault, Pierre; Cheve, Gwenael; Yasri, Aziz</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2141-2148</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">A review.  Receptor tyrosine kinases (RTK) are transmembrane receptors that regulate signal transduction in cells.  As a member of the TAM (Tyro-3, Axl, Mer) RTK subfamily, Axl regulates key processes such as cell growth, migration, aggregation, and apoptosis through several pathways.  Its overexpression/overactivation has been underlined in several conditions, esp. cancers, and in both chemotherapy and targeted therapy sensitivity loss.  In this review, we propose to highlight the therapeutic implication of Axl, starting with the pathways it regulates, validating its interest as a therapeutic target, and defining the tools available to develop strategies for its inhibition.  We esp. focus on small mol. inhibitors, their structure, inhibition profile, and development stages.  Mol Cancer Ther; 13(9); 2141-8. ©2014 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRn5-b7gNJkLVg90H21EOLACvtfcHk0li9BMHTUTe4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhsVOitLrO&md5=6c569ae44113e6cae2f59e8ba462a787</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-1083&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-1083%26sid%3Dliteratum%253Aachs%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DSpenlinhauer%26aufirst%3DA.%26aulast%3DGuiet%26aufirst%3DL.%26aulast%3DFauvel%26aufirst%3DB.%26aulast%3DDayd%25C3%25A9-Cazals%26aufirst%3DB.%26aulast%3DWarnault%26aufirst%3DP.%26aulast%3DChev%25C3%25A9%26aufirst%3DG.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DAxl%2520kinase%2520as%2520a%2520key%2520target%2520for%2520oncology%253A%2520focus%2520on%2520small%2520molecule%2520inhibitors%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2014%26volume%3D13%26spage%3D2141%26epage%3D2148%26doi%3D10.1158%2F1535-7163.MCT-13-1083" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davies, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span> </span><span class="NLM_article-title">The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">14</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">785</span><span class="refDoi"> DOI: 10.1038/nrc3847</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnrc3847" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25568918" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7jK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=14&publication_year=2014&pages=769-785&author=D.+K.+Grahamauthor=D.+DeRyckereauthor=K.+D.+Daviesauthor=H.+S.+Earp&title=The+TAM+family%3A+phosphatidylserine+sensing+receptor+tyrosine+kinases+gone+awry+in+cancer&doi=10.1038%2Fnrc3847"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">phosphatidylserine-sensing receptor tyrosine kinases gone awry in cancer</span></div><div class="casAuthors">Graham, Douglas K.; DeRyckere, Deborah; Davies, Kurtis D.; Earp, H. Shelton</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">14</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">769-785</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine kinases (RTKs) are aberrantly expressed in multiple haematol. and epithelial malignancies.  Rather than functioning as oncogenic drivers, their induction in tumor cells predominately promotes survival, chemoresistance and motility.  The unique mode of maximal activation of this RTK family requires an extracellular lipid-protein complex.  For example, the protein ligand, growth arrest-specific protein 6 (GAS6), binds to phosphatidylserine (PtdSer) that is externalized on apoptotic cell membranes, which activates MERTK on macrophages.  This triggers engulfment of apoptotic material and subsequent anti-inflammatory macrophage polarization.  In tumors, autocrine and paracrine ligands and apoptotic cells are abundant, which provide a survival signal to the tumor cell and favor an anti-inflammatory, immunosuppressive microenvironment.  Thus, TAM kinase inhibition could stimulate antitumor immunity, reduce tumor cell survival, enhance chemosensitivity and diminish metastatic potential.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoj8tV8-04ed7Vg90H21EOLACvtfcHk0li9BMHTUTe4qQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhvFKmu7jK&md5=b92c6d091b711b586ed1bfe02a3d6345</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrc3847&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3847%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DDavies%26aufirst%3DK.%2BD.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26atitle%3DThe%2520TAM%2520family%253A%2520phosphatidylserine%2520sensing%2520receptor%2520tyrosine%2520kinases%2520gone%2520awry%2520in%2520cancer%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2014%26volume%3D14%26spage%3D769%26epage%3D785%26doi%3D10.1038%2Fnrc3847" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group">Caberoy, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span> </span><span class="NLM_article-title">Tubby and tubby-like protein 1 are new MerTK ligands for phagocytosis</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">3898</span><span class="NLM_x">–</span> <span class="NLM_lpage">3910</span><span class="refDoi"> DOI: 10.1038/emboj.2010.265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Femboj.2010.265" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2010&pages=3898-3910&author=N.+B.+Caberoyauthor=Y.+Zhouauthor=W.+Li&title=Tubby+and+tubby-like+protein+1+are+new+MerTK+ligands+for+phagocytosis&doi=10.1038%2Femboj.2010.265"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1038%2Femboj.2010.265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2010.265%26sid%3Dliteratum%253Aachs%26aulast%3DCaberoy%26aufirst%3DN.%2BB.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DTubby%2520and%2520tubby-like%2520protein%25201%2520are%2520new%2520MerTK%2520ligands%2520for%2520phagocytosis%26jtitle%3DEMBO%2520J.%26date%3D2010%26volume%3D29%26spage%3D3898%26epage%3D3910%26doi%3D10.1038%2Femboj.2010.265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group">Caberoy, N. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alvarado, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bigcas, J.-L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span> </span><span class="NLM_article-title">Galectin-3 is a new MerTK-specific eat-me signal</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">227</span><span class="NLM_x">, </span> <span class="NLM_fpage">401</span><span class="NLM_x">–</span> <span class="NLM_lpage">407</span><span class="refDoi"> DOI: 10.1002/jcp.22955</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1002%2Fjcp.22955" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21792939" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFartLnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=227&publication_year=2012&pages=401-407&author=N.+B.+Caberoyauthor=G.+Alvaradoauthor=J.-L.+Bigcasauthor=W.+Li&title=Galectin-3+is+a+new+MerTK-specific+eat-me+signal&doi=10.1002%2Fjcp.22955"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Galectin-3 is a new MerTK-specific eat-me signal</span></div><div class="casAuthors">Caberoy, Nora B.; Alvarado, Gabriela; Bigcas, Jo-Lawrence; Li, Wei</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">227</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">401-407</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Phagocytosis of apoptotic cells and cellular debris is a crit. process of maintaining tissue and immune homeostasis.  Defects in the phagocytosis process cause autoimmunity and degenerative diseases.  Phagocytosis ligands or "eat-me" signals control the initiation of the process by linking apoptotic cells to receptors on phagocyte surface and triggering signaling cascades for cargo engulfment.  Eat-me signals are traditionally identified on a case-by-case basis with challenges, and the identification of their cognate receptors is equally daunting.  Here, we identified galectin-3 (Gal-3) as a new MerTK ligand by an advanced dual functional cloning strategy, in which phagocytosis-based functional cloning is combined with receptor-based affinity cloning to directly identify receptor-specific eat-me signal.  Gal-3 interaction with MerTK was independently verified by co-immunopptn.  Functional analyses showed that Gal-3 stimulated the phagocytosis of apoptotic cells and cellular debris by macrophages and retinal pigment epithelial cells with MerTK activation and autophosphorylation.  The Gal-3-mediated phagocytosis was blocked by excessive sol. MerTK extracellular domain and lactose.  These results suggest that Gal-3 is a legitimate MerTK-specific eat-me signal.  The strategy of dual functional cloning with applicability to other phagocytic receptors will facilitate unbiased identification of their unknown ligands and improve our capacity for therapeutic modulation of phagocytic activity and innate immune response.  J. Cell. Physiol. 227: 401-407, 2012. © 2011 Wiley Periodicals, Inc.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoTvCbQdt3DRLVg90H21EOLACvtfcHk0lj_S3oWCtSAuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFartLnE&md5=3cf8e16295c5bedcfe4ad5fd11e814dd</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1002%2Fjcp.22955&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.22955%26sid%3Dliteratum%253Aachs%26aulast%3DCaberoy%26aufirst%3DN.%2BB.%26aulast%3DAlvarado%26aufirst%3DG.%26aulast%3DBigcas%26aufirst%3DJ.-L.%26aulast%3DLi%26aufirst%3DW.%26atitle%3DGalectin-3%2520is%2520a%2520new%2520MerTK-specific%2520eat-me%2520signal%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2012%26volume%3D227%26spage%3D401%26epage%3D407%26doi%3D10.1002%2Fjcp.22955" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group">Heiring, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Muller, Y. A.</span><span> </span><span class="NLM_article-title">Ligand recognition and homophilic interactions in Tyro3: structural insights into the Axl/Tyro3 receptor tyrosine kinase family</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">6952</span><span class="NLM_x">–</span> <span class="NLM_lpage">6958</span><span class="refDoi"> DOI: 10.1074/jbc.M311750200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1074%2Fjbc.M311750200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=6952-6958&author=C.+Heiringauthor=B.+Dahlbackauthor=Y.+A.+Muller&title=Ligand+recognition+and+homophilic+interactions+in+Tyro3%3A+structural+insights+into+the+Axl%2FTyro3+receptor+tyrosine+kinase+family&doi=10.1074%2Fjbc.M311750200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M311750200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M311750200%26sid%3Dliteratum%253Aachs%26aulast%3DHeiring%26aufirst%3DC.%26aulast%3DDahlback%26aufirst%3DB.%26aulast%3DMuller%26aufirst%3DY.%2BA.%26atitle%3DLigand%2520recognition%2520and%2520homophilic%2520interactions%2520in%2520Tyro3%253A%2520structural%2520insights%2520into%2520the%2520Axl%252FTyro3%2520receptor%2520tyrosine%2520kinase%2520family%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D6952%26epage%3D6958%26doi%3D10.1074%2Fjbc.M311750200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group">Konishi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Aizawa, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mohan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korshunov, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Berk, B. C.</span><span> </span><span class="NLM_article-title">Hydrogen peroxide activates the Gas6-Axl pathway in vascular smooth muscle cells</span> <span class="citation_source-journal">J. Biol. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">279</span><span class="NLM_x">, </span> <span class="NLM_fpage">28766</span><span class="NLM_x">–</span> <span class="NLM_lpage">28770</span><span class="refDoi"> DOI: 10.1074/jbc.M401977200</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1074%2Fjbc.M401977200" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=279&publication_year=2004&pages=28766-28770&author=A.+Konishiauthor=T.+Aizawaauthor=A.+Mohanauthor=V.+A.+Korshunovauthor=B.+C.+Berk&title=Hydrogen+peroxide+activates+the+Gas6-Axl+pathway+in+vascular+smooth+muscle+cells&doi=10.1074%2Fjbc.M401977200"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1074%2Fjbc.M401977200&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1074%252Fjbc.M401977200%26sid%3Dliteratum%253Aachs%26aulast%3DKonishi%26aufirst%3DA.%26aulast%3DAizawa%26aufirst%3DT.%26aulast%3DMohan%26aufirst%3DA.%26aulast%3DKorshunov%26aufirst%3DV.%2BA.%26aulast%3DBerk%26aufirst%3DB.%2BC.%26atitle%3DHydrogen%2520peroxide%2520activates%2520the%2520Gas6-Axl%2520pathway%2520in%2520vascular%2520smooth%2520muscle%2520cells%26jtitle%3DJ.%2520Biol.%2520Chem.%26date%3D2004%26volume%3D279%26spage%3D28766%26epage%3D28770%26doi%3D10.1074%2Fjbc.M401977200" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group">Lemke, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Immunobiology of the TAM receptors</span> <span class="citation_source-journal">Nat. Rev. Immunol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">327</span><span class="NLM_x">–</span> <span class="NLM_lpage">336</span><span class="refDoi"> DOI: 10.1038/nri2303</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnri2303" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18421305" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2008&pages=327-336&author=G.+Lemkeauthor=C.+V.+Rothlin&title=Immunobiology+of+the+TAM+receptors&doi=10.1038%2Fnri2303"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Immunobiology of the TAM receptors</span></div><div class="casAuthors">Lemke, Greg; Rothlin, Carla V.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Immunology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">327-336</span>CODEN:
                <span class="NLM_cas:coden">NRIABX</span>;
        ISSN:<span class="NLM_cas:issn">1474-1733</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Recent studies have revealed that the TAM receptor protein tyrosine kinases - TYRO3, AXL and MER - have pivotal roles in innate immunity.  They inhibit inflammation in dendritic cells and macrophages, promote the phagocytosis of apoptotic cells and membranous organelles, and stimulate the maturation of natural killer cells.  Each of these phenomena may depend on a cooperative interaction between TAM receptor and cytokine receptor signalling systems.  Although its importance was previously unrecognized, TAM signalling promises to have an increasingly prominent role in studies of innate immune regulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpW_CJak8Sc-LVg90H21EOLACvtfcHk0lj_S3oWCtSAuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltFejsbg%253D&md5=7726fd6ab58ce205941aa74f7bcdcf32</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.1038%2Fnri2303&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnri2303%26sid%3Dliteratum%253Aachs%26aulast%3DLemke%26aufirst%3DG.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DImmunobiology%2520of%2520the%2520TAM%2520receptors%26jtitle%3DNat.%2520Rev.%2520Immunol.%26date%3D2008%26volume%3D8%26spage%3D327%26epage%3D336%26doi%3D10.1038%2Fnri2303" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group">Sinha, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boysen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Secreto, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesnick, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shanafelt, T. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kay, N. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, A. K.</span><span> </span><span class="NLM_article-title">Targeted Axl inhibition primes Chronic Lymphocytic Leukemia B cells to apoptosis and shows synergistic/additive effects in combination with BTK inhibitors</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">21</span><span class="NLM_x">, </span> <span class="NLM_fpage">2115</span><span class="NLM_x">–</span> <span class="NLM_lpage">2126</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-14-1892</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-14-1892" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25673699" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2015&pages=2115-2126&author=S.+Sinhaauthor=J.+Boysenauthor=M.+Nelsonauthor=C.+Secretoauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=C.+Lesnickauthor=T.+D.+Shanafeltauthor=N.+E.+Kayauthor=A.+K.+Ghosh&title=Targeted+Axl+inhibition+primes+Chronic+Lymphocytic+Leukemia+B+cells+to+apoptosis+and+shows+synergistic%2Fadditive+effects+in+combination+with+BTK+inhibitors&doi=10.1158%2F1078-0432.CCR-14-1892"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Targeted Axl Inhibition Primes Chronic Lymphocytic Leukemia B Cells to Apoptosis and Shows Synergistic/Additive Effects in Combination with BTK Inhibitors</span></div><div class="casAuthors">Sinha, Sutapa; Boysen, Justin; Nelson, Michael; Secreto, Charla; Warner, Steven L.; Bearss, David J.; Lesnick, Connie; Shanafelt, Tait D.; Kay, Neil E.; Ghosh, Asish K.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2115-2126</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: B-cell chronic lymphocytic leukemia (CLL) is an incurable disease despite aggressive therapeutic approaches.  We previously found that Axl receptor tyrosine kinase (RTK) plays a crit. role in CLL B-cell survival.  Here, we explored the possibility of using a high-affinity Axl inhibitor as a single agent or in combination with Bruton's tyrosine kinase (BTK) inhibitors for future clin. trial to treat patients with CLL.  Exptl. Design: Expression/activation status of other members of the TAM (e.g., Tyro3, Axl, and MER) family of RTKs in CLL B cells was evaluated.  Cells were treated with a high-affinity orally bioavailable Axl inhibitor TP-0903 with or without the presence of CLL bone marrow stromal cells (BMSCs).  Inhibitory effects of TP-0903 on the Axl signaling pathway were also evaluated in CLL B cells.  Finally, cells were exposed to TP-0903 in combination with BTK inhibitors to det. any synergistic/additive effects of the combination.  Results: CLL B cells overexpress Tyro3, but not MER.  Of interest, Tyro3 remains as constitutively phosphorylated and forms a complex with Axl in CLL B cells.  TP-0903 induces massive apoptosis in CLL B cells with LD50 values of nanomolar ranges.  Importantly, CLL BMSCs could not protect the leukemic B cells from TP-0903-induced apoptosis.  A marked redn. of the antiapoptotic proteins Mcl-1, Bcl-2, and XIAP and upregulation of the proapoptotic protein BIM in CLL B cells was detected as a result of Axl inhibition.  Finally, combination of TP-0903 with BTK inhibitors augments CLL B-cell apoptosis.  Conclusions: Administration of TP-0903 either as a single agent or in combination with BTK inhibitors may be effective in treating patients with CLL.  Clin Cancer Res; 21(9); 2115-26. ©2015 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqmCcdSntQPu7Vg90H21EOLACvtfcHk0lj_S3oWCtSAuQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXnvFaqs7o%253D&md5=2d7554e400d1d5e4bee347f43dea2762</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-14-1892&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-14-1892%26sid%3Dliteratum%253Aachs%26aulast%3DSinha%26aufirst%3DS.%26aulast%3DBoysen%26aufirst%3DJ.%26aulast%3DNelson%26aufirst%3DM.%26aulast%3DSecreto%26aufirst%3DC.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DLesnick%26aufirst%3DC.%26aulast%3DShanafelt%26aufirst%3DT.%2BD.%26aulast%3DKay%26aufirst%3DN.%2BE.%26aulast%3DGhosh%26aufirst%3DA.%2BK.%26atitle%3DTargeted%2520Axl%2520inhibition%2520primes%2520Chronic%2520Lymphocytic%2520Leukemia%2520B%2520cells%2520to%2520apoptosis%2520and%2520shows%2520synergistic%252Fadditive%2520effects%2520in%2520combination%2520with%2520BTK%2520inhibitors%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2015%26volume%3D21%26spage%3D2115%26epage%3D2126%26doi%3D10.1158%2F1078-0432.CCR-14-1892" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group">Ruan, G. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kazlauskas, A.</span><span> </span><span class="NLM_article-title">Axl is essential for VEGF-A-dependent activation of PI3K/Akt</span> <span class="citation_source-journal">EMBO J.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">1692</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1038/emboj.2012.21</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Femboj.2012.21" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22327215" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XhvVGnt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2012&pages=1692-1703&author=G.+X.+Ruanauthor=A.+Kazlauskas&title=Axl+is+essential+for+VEGF-A-dependent+activation+of+PI3K%2FAkt&doi=10.1038%2Femboj.2012.21"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is essential for VEGF-A-dependent activation of PI3K/Akt</span></div><div class="casAuthors">Ruan, Guo-Xiang; Kazlauskas, Andrius</div><div class="citationInfo"><span class="NLM_cas:title">EMBO Journal</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">1692-1703</span>CODEN:
                <span class="NLM_cas:coden">EMJODG</span>;
        ISSN:<span class="NLM_cas:issn">0261-4189</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Here, the authors report that vascular endothelial growth factor A (VEGF-A) engages the phosphatidylinositol 3-kinase (PI3K)/Akt kinase pathway by a previously unknown mechanism that involves 3 protein tyrosine kinases.  Upon VEGF-A-dependent activation of VEGF receptor-2 (VEGFR-2), and subsequent TSAd-mediated activation of Src family kinases (SFKs), SFKs engaged receptor tyrosine kinase Axl via its juxtamembrane domain to trigger ligand-independent autophosphorylation at a pair of YXXM motifs that promoted assocn. with PI3K and activation of Akt.  Other VEGF-A-mediated signaling pathways were independent of Axl.  Interfering with Axl expression or function impaired VEGF-A- but not bFGF-dependent migration of endothelial cells.  Similarly, Axl-null mice respond poorly to VEGF-A-induced vascular permeability or angiogenesis, whereas other agonists induce a normal response.  Thus, these results elucidated the mechanism by which VEGF-A activates PI3K/Akt, and identified previously unappreciated potential therapeutic targets of VEGF-A-driven processes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrtunGB7l3o5rVg90H21EOLACvtfcHk0lg1obPkgyDfAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhvVGnt7s%253D&md5=f9db8bd5f1453b20e2fe1898cdf3a4d9</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1038%2Femboj.2012.21&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Femboj.2012.21%26sid%3Dliteratum%253Aachs%26aulast%3DRuan%26aufirst%3DG.%2BX.%26aulast%3DKazlauskas%26aufirst%3DA.%26atitle%3DAxl%2520is%2520essential%2520for%2520VEGF-A-dependent%2520activation%2520of%2520PI3K%252FAkt%26jtitle%3DEMBO%2520J.%26date%3D2012%26volume%3D31%26spage%3D1692%26epage%3D1703%26doi%3D10.1038%2Femboj.2012.21" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Basilico, C.</span><span> </span><span class="NLM_article-title">The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding</span> <span class="citation_source-journal">Mol. Cell. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1995</span><span class="NLM_x">, </span> <span class="NLM_volume">15</span><span class="NLM_x">, </span> <span class="NLM_fpage">614</span><span class="NLM_x">–</span> <span class="NLM_lpage">625</span><span class="refDoi"> DOI: 10.1128/MCB.15.2.614</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1128%2FMCB.15.2.614" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=7823930" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK2MXjtlansL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=1995&pages=614-625&author=P.+Bellostaauthor=M.+Costaauthor=D.+A.+Linauthor=C.+Basilico&title=The+receptor+tyrosine+kinase+ARK+mediates+cell+aggregation+by+homophilic+binding&doi=10.1128%2FMCB.15.2.614"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding</span></div><div class="casAuthors">Bellosta, Paola; Costa, Mario; Lin, Debby A.; Basilico, Claudio</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Biology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">15</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">614-25</span>CODEN:
                <span class="NLM_cas:coden">MCEBD4</span>;
        ISSN:<span class="NLM_cas:issn">0270-7306</span>.
    
            (<span class="NLM_cas:orgname">American Society for Microbiology</span>)
        </div><div class="casAbstract">The ARK (AXL, UFO) receptor is a member of a new family of receptor tyrosine kinases whose extracellular domain contains combination of fibronectin type III and Ig motifs similar to those found in many cell adhesion mols.  ARK mRNA is expressed at high levels in the mouse brain, prevalently in the hippocampus and cerebellum, and this pattern of expression resembles that of adhesion mols. that are capable of promoting cell aggregation through homophilic or heterophilic binding.  We report here the ability of the murine ARK receptor to mediate homophilic binding.  Expression of the ARK protein in Drosophila S2 cells induces formation of cell aggregates consists of ARK-expressing cells, and aggregation leads to receptor activation, with an increase in receptor phosphorylation.  Homophilic binding does not require ARK tyrosine kinase activity, since S2 cells expressing a receptor in which the intracellular domain was deleted were able to undergo aggregation as well as cells expressing the wild-type ARK receptor.  Similar results were obtained with NIH 3T3 and CHO cells expressing high levels of ARK, although in this case ARK expression appeared to be accompanied by constitutive activation.  The purified recombinant extracellular domain of ARK can induce homotypic aggregation of coated fluorescent beads (Covaspheres), and this protein can also function as a substrate for adhesion by S2 and NIH 3T3 cells expressing ARK.  The results suggest that ARK represents a new cell adhesion mol. that through its homophilic interaction may regulate cellular functions during cell recognition.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpD5IlXBp2I7bVg90H21EOLACvtfcHk0lg1obPkgyDfAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXjtlansL4%253D&md5=405989ab8dc7a9be50cd2bd1e82a722a</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1128%2FMCB.15.2.614&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1128%252FMCB.15.2.614%26sid%3Dliteratum%253Aachs%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DCosta%26aufirst%3DM.%26aulast%3DLin%26aufirst%3DD.%2BA.%26aulast%3DBasilico%26aufirst%3DC.%26atitle%3DThe%2520receptor%2520tyrosine%2520kinase%2520ARK%2520mediates%2520cell%2520aggregation%2520by%2520homophilic%2520binding%26jtitle%3DMol.%2520Cell.%2520Biol.%26date%3D1995%26volume%3D15%26spage%3D614%26epage%3D625%26doi%3D10.1128%2FMCB.15.2.614" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group">Hankins, H. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baldridge, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, T. R.</span><span> </span><span class="NLM_article-title">Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution</span> <span class="citation_source-journal">Traffic</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">35</span><span class="NLM_x">–</span> <span class="NLM_lpage">47</span><span class="refDoi"> DOI: 10.1111/tra.12233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1111%2Ftra.12233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25284293" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXitFansLzO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=35-47&author=H.+M.+Hankinsauthor=R.+D.+Baldridgeauthor=P.+Xuauthor=T.+R.+Graham&title=Role+of+flippases%2C+scramblases+and+transfer+proteins+in+phosphatidylserine+subcellular+distribution&doi=10.1111%2Ftra.12233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Role of flippases, scramblases and transfer proteins in phosphatidylserine subcellular distribution</span></div><div class="casAuthors">Hankins, Hannah M.; Baldridge, Ryan D.; Xu, Peng; Graham, Todd R.</div><div class="citationInfo"><span class="NLM_cas:title">Traffic (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">35-47</span>CODEN:
                <span class="NLM_cas:coden">TRAFFA</span>;
        ISSN:<span class="NLM_cas:issn">1398-9219</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Blackwell</span>)
        </div><div class="casAbstract">A review.  It is well known that lipids are heterogeneously distributed throughout the cell.  Most lipid species are synthesized in the endoplasmic reticulum (ER) and then distributed to different cellular locations in order to create the distinct membrane compns. obsd. in eukaryotes.  However, the mechanisms by which specific lipid species are trafficked to and maintained in specific areas of the cell are poorly understood and constitute an active area of research.  Of particular interest is the distribution of phosphatidylserine (PS), an anionic phospholipid that is enriched in the cytosolic leaflet of the plasma membrane.  PS transport occurs by both vesicular and non-vesicular routes, with members of the oxysterol-binding protein family (Osh6 and Osh7) recently implicated in the latter route.  In addn., the flippase activity of P4-ATPases helps build PS membrane asymmetry by preferentially translocating PS to the cytosolic leaflet.  This asym. PS distribution can be used as a signaling device by the regulated activation of scramblases, which rapidly expose PS on the extracellular leaflet and play important roles in blood clotting and apoptosis.  Here, the authors discuss recent advances made in the study of phospholipid flippases, scramblases, and PS-specific lipid transfer proteins, as well as how these proteins contribute to subcellular PS distribution.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpRw8_NcmXSSbVg90H21EOLACvtfcHk0lg1obPkgyDfAA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXitFansLzO&md5=830e3a821330aab6777080e4cedca6e5</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1111%2Ftra.12233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Ftra.12233%26sid%3Dliteratum%253Aachs%26aulast%3DHankins%26aufirst%3DH.%2BM.%26aulast%3DBaldridge%26aufirst%3DR.%2BD.%26aulast%3DXu%26aufirst%3DP.%26aulast%3DGraham%26aufirst%3DT.%2BR.%26atitle%3DRole%2520of%2520flippases%252C%2520scramblases%2520and%2520transfer%2520proteins%2520in%2520phosphatidylserine%2520subcellular%2520distribution%26jtitle%3DTraffic%26date%3D2015%26volume%3D16%26spage%3D35%26epage%3D47%26doi%3D10.1111%2Ftra.12233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group">Stenhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dahlback, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hafizi, S.</span><span> </span><span class="NLM_article-title">Vitamin K-dependent Gas6 activates ERK kinase and stimulates growth of cardiac fibroblasts</span> <span class="citation_source-journal">Biochem. Biophys. Res. Commun.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2004</span><span class="NLM_x">, </span> <span class="NLM_volume">319</span><span class="NLM_x">, </span> <span class="NLM_fpage">871</span><span class="NLM_x">–</span> <span class="NLM_lpage">878</span><span class="refDoi"> DOI: 10.1016/j.bbrc.2004.05.070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bbrc.2004.05.070" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=319&publication_year=2004&pages=871-878&author=J.+Stenhoffauthor=B.+Dahlbackauthor=S.+Hafizi&title=Vitamin+K-dependent+Gas6+activates+ERK+kinase+and+stimulates+growth+of+cardiac+fibroblasts&doi=10.1016%2Fj.bbrc.2004.05.070"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1016%2Fj.bbrc.2004.05.070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbrc.2004.05.070%26sid%3Dliteratum%253Aachs%26aulast%3DStenhoff%26aufirst%3DJ.%26aulast%3DDahlback%26aufirst%3DB.%26aulast%3DHafizi%26aufirst%3DS.%26atitle%3DVitamin%2520K-dependent%2520Gas6%2520activates%2520ERK%2520kinase%2520and%2520stimulates%2520growth%2520of%2520cardiac%2520fibroblasts%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D2004%26volume%3D319%26spage%3D871%26epage%3D878%26doi%3D10.1016%2Fj.bbrc.2004.05.070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group">Vazquez-Martin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cufí, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oliveras-Ferraros, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torres-Garcia, V. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Corominas-Faja, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cuyàs, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bonavia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Visa, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin-Castillo, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrajón-Catalán, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micol, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bosch-Barrera, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menendez, J. A.</span><span> </span><span class="NLM_article-title">IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations</span> <span class="citation_source-journal">Sci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">2560</span><span class="refDoi"> DOI: 10.1038/srep02560</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsrep02560" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23994953" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC3sbksFentw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2013&pages=2560&author=A.+Vazquez-Martinauthor=S.+Cuf%C3%ADauthor=C.+Oliveras-Ferrarosauthor=V.+Z.+Torres-Garciaauthor=B.+Corominas-Fajaauthor=E.+Cuy%C3%A0sauthor=R.+Bonaviaauthor=J.+Visaauthor=B.+Martin-Castilloauthor=E.+Barraj%C3%B3n-Catal%C3%A1nauthor=V.+Micolauthor=J.+Bosch-Barreraauthor=J.+A.+Menendez&title=IGF-1R%2Fepithelial-to-mesenchymal+transition+%28EMT%29+crosstalk+suppresses+the+erlotinib-sensitizing+effect+of+EGFR+exon+19+deletion+mutations&doi=10.1038%2Fsrep02560"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">IGF-1R/epithelial-to-mesenchymal transition (EMT) crosstalk suppresses the erlotinib-sensitizing effect of EGFR exon 19 deletion mutations</span></div><div class="casAuthors">Vazquez-Martin Alejandro; Cufi Silvia; Oliveras-Ferraros Cristina; Torres-Garcia Violeta Zenobia; Corominas-Faja Bruna; Cuyas Elisabet; Bonavia Rosa; Visa Joana; Martin-Castillo Begona; Barrajon-Catalan Enrique; Micol Vicente; Bosch-Barrera Joaquim; Menendez Javier A</div><div class="citationInfo"><span class="NLM_cas:title">Scientific reports</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2560</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Using non-small cell lung carcinoma (NSCLC) cells harboring the erlotinib-sensitizing Epidermal Growth Factor Receptor (EGFR) exon 19 mutation delE746-A750, we developed erlotinib-refractory derivatives in which hyperactive Insulin-like Growth Factor-1 Receptor (IGF-1R) signaling associated with enrichment in epithelial-to-mesenchymal transition (EMT)-related morphological and transcriptional features.  We then explored whether an IGF-1R/EMT crosstalk was sufficient to promote erlotinib refractoriness in the absence of second-site EGFR mutations, MET and AXL hyperactivation.  Transforming Growth Factor-beta1 (TGFβ1)-induced mesenchymal trans-differentiation was sufficient to impede erlotinib functioning in the presence of drug-sensitive delE746-A750 EGFR mutation.  Pharmacological blockade of IGF-1R fully prevented the TGFβ1's ability to activate an EMT protein signature [E-cadherin low/vimentin high].  The sole presence of erlotinib was capable of rapidly activate an IGF-1R-dependent, vimentin-enriched mesenchymal-like phenotype in delE746-A750-mutated epithelial cells.  Even if transient, NSCLC cells' intrinsic plasticity to undergo crosstalk between IGF-1R and EMT signaling pathways can sufficiently eliminate the erlotinib-sensitizing effect of highly prevalent EGFR mutations and suggests the urgent need for dual IGF-1R/EMT-targeting strategies to circumvent erlotinib resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQdsob6YTymuIIRAdBLKY41fW6udTcc2eZuW8R60LiDyLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC3sbksFentw%253D%253D&md5=cbf7bc50267fcc3cb753509fd7e80dab</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1038%2Fsrep02560&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsrep02560%26sid%3Dliteratum%253Aachs%26aulast%3DVazquez-Martin%26aufirst%3DA.%26aulast%3DCuf%25C3%25AD%26aufirst%3DS.%26aulast%3DOliveras-Ferraros%26aufirst%3DC.%26aulast%3DTorres-Garcia%26aufirst%3DV.%2BZ.%26aulast%3DCorominas-Faja%26aufirst%3DB.%26aulast%3DCuy%25C3%25A0s%26aufirst%3DE.%26aulast%3DBonavia%26aufirst%3DR.%26aulast%3DVisa%26aufirst%3DJ.%26aulast%3DMartin-Castillo%26aufirst%3DB.%26aulast%3DBarraj%25C3%25B3n-Catal%25C3%25A1n%26aufirst%3DE.%26aulast%3DMicol%26aufirst%3DV.%26aulast%3DBosch-Barrera%26aufirst%3DJ.%26aulast%3DMenendez%26aufirst%3DJ.%2BA.%26atitle%3DIGF-1R%252Fepithelial-to-mesenchymal%2520transition%2520%2528EMT%2529%2520crosstalk%2520suppresses%2520the%2520erlotinib-sensitizing%2520effect%2520of%2520EGFR%2520exon%252019%2520deletion%2520mutations%26jtitle%3DSci.%2520Rep.%26date%3D2013%26volume%3D3%26spage%3D2560%26doi%3D10.1038%2Fsrep02560" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group">Salian-Mehta, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wierman, M. E.</span><span> </span><span class="NLM_article-title">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span> <span class="citation_source-journal">Mol. Cell. Endocrinol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">374</span><span class="NLM_x">, </span> <span class="NLM_fpage">92</span><span class="NLM_x">–</span> <span class="NLM_lpage">100</span><span class="refDoi"> DOI: 10.1016/j.mce.2013.04.018</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.mce.2013.04.018" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23648337" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=2013&pages=92-100&author=S.+Salian-Mehtaauthor=M.+Xuauthor=M.+E.+Wierman&title=AXL+and+MET+crosstalk+to+promote+gonadotropin+releasing+hormone+%28GnRH%29+neuronal+cell+migration+and+survival&doi=10.1016%2Fj.mce.2013.04.018"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit31R"><div class="casContent"><span class="casTitleNuber">31</span><div class="casTitle"><span class="NLM_cas:atitle">AXL and MET crosstalk to promote gonadotropin releasing hormone (GnRH) neuronal cell migration and survival</span></div><div class="casAuthors">Salian-Mehta, Smita; Xu, Mei; Wierman, Margaret E.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular and Cellular Endocrinology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">92-100</span>CODEN:
                <span class="NLM_cas:coden">MCEND6</span>;
        ISSN:<span class="NLM_cas:issn">0303-7207</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ireland Ltd.</span>)
        </div><div class="casAbstract">The membrane tyrosine kinase receptors, AXL and MET, are implicated in GnRH neuron migration and/or survival.  We hypothesized that the receptors with their ligands, GAS6 and HGF, resp. may cross-talk in GnRH neuronal function.  In NLT GnRH neuronal cells, MET co-immunopptd. with AXL, although HGF or GAS6 did not transphosphorylate AXL or MET, resp.  Co-expression of a kinase dead AXL blocked HGF activation of MET and indirectly AKT and p38MAPK.  Silencing of AXL decreased HGF's ability to phosphorylate MET and activate AXL's downstream effectors, p38MAPK and AKT.  HGF/MET signaling modulated neuron migration dependent and independent of AXL co-expression and p38MAPK.  Conversely, AXL's control of GnRH neuronal survival was dependent on HGF/MET signaling.  Together, these data support that the importance of membrane tyrosine kinase receptor crosstalk to regulate neuronal cell-specific developmental functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpFg8H1UC0HerVg90H21EOLACvtfcHk0lgpjDmYN7xFng"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXptV2hu7Y%253D&md5=de528dce1d3a19fe4392b25017d3cbb0</span></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1016%2Fj.mce.2013.04.018&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.mce.2013.04.018%26sid%3Dliteratum%253Aachs%26aulast%3DSalian-Mehta%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DM.%26aulast%3DWierman%26aufirst%3DM.%2BE.%26atitle%3DAXL%2520and%2520MET%2520crosstalk%2520to%2520promote%2520gonadotropin%2520releasing%2520hormone%2520%2528GnRH%2529%2520neuronal%2520cell%2520migration%2520and%2520survival%26jtitle%3DMol.%2520Cell.%2520Endocrinol.%26date%3D2013%26volume%3D374%26spage%3D92%26epage%3D100%26doi%3D10.1016%2Fj.mce.2013.04.018" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group">Rothlin, C. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zuniga, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oldstone, M. B. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">TAM receptors are pleiotropic inhibitors of the innate immune response</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1136</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.10.034</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.cell.2007.10.034" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18083102" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1124-1136&author=C.+V.+Rothlinauthor=S.+Ghoshauthor=E.+I.+Zunigaauthor=M.+B.+A.+Oldstoneauthor=G.+Lemke&title=TAM+receptors+are+pleiotropic+inhibitors+of+the+innate+immune+response&doi=10.1016%2Fj.cell.2007.10.034"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit32R"><div class="casContent"><span class="casTitleNuber">32</span><div class="casTitle"><span class="NLM_cas:atitle">TAM receptors are pleiotropic inhibitors of the innate immune response</span></div><div class="casAuthors">Rothlin, Carla V.; Ghosh, Sourav; Zuniga, Elina I.; Oldstone, Michael B. A.; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Cell (Cambridge, MA, United States)</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">131</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1124-1136</span>CODEN:
                <span class="NLM_cas:coden">CELLB5</span>;
        ISSN:<span class="NLM_cas:issn">0092-8674</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">The activation of Toll-like receptors (TLRs) in dendritic cells (DCs) triggers a rapid inflammatory response to pathogens.  However, this response must be tightly regulated because unrestrained TLR signaling generates a chronic inflammatory milieu that often leads to autoimmunity.  We have found that the TAM receptor tyrosine kinases-Tyro3, Axl, and Mer-broadly inhibit both TLR and TLR-induced cytokine-receptor cascades.  Remarkably, TAM inhibition of inflammation is transduced through an essential stimulator of inflammation-the type I interferon receptor (IFNAR)-and its assocd. transcription factor STAT1.  TLR induction of IFNAR-STAT1 signaling upregulates the TAM system, which in turn usurps the IFNAR-STAT1 cassette to induce the cytokine and TLR suppressors SOCS1 and SOCS3.  These results illuminate a self-regulating cycle of inflammation, in which the obligatory, cytokine-dependent activation of TAM signaling hijacks a proinflammatory pathway to provide an intrinsic feedback inhibitor of both TLR- and cytokine-driven immune responses.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWCPRBPKbiNrVg90H21EOLACvtfcHk0lhR96d3ZKfEsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXksFGgug%253D%253D&md5=32511c20288ef6f92b60d9a6bc94637d</span></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.10.034&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.10.034%26sid%3Dliteratum%253Aachs%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DZuniga%26aufirst%3DE.%2BI.%26aulast%3DOldstone%26aufirst%3DM.%2BB.%2BA.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DTAM%2520receptors%2520are%2520pleiotropic%2520inhibitors%2520of%2520the%2520innate%2520immune%2520response%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1124%26epage%3D1136%26doi%3D10.1016%2Fj.cell.2007.10.034" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group">Mudduluru, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgayer, H.</span><span> </span><span class="NLM_article-title">The human receptor tyrosine kinase Axl gene-promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation</span> <span class="citation_source-journal">Biosci. Rep.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">161</span><span class="NLM_x">–</span> <span class="NLM_lpage">176</span><span class="refDoi"> DOI: 10.1042/BSR20080046</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1042%2FBSR20080046" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18522535" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXpsVaktL0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2008&pages=161-176&author=G.+Mudduluruauthor=H.+Allgayer&title=The+human+receptor+tyrosine+kinase+Axl+gene-promoter+characterization+and+regulation+of+constitutive+expression+by+Sp1%2C+Sp3+and+CpG+methylation&doi=10.1042%2FBSR20080046"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit33R"><div class="casContent"><span class="casTitleNuber">33</span><div class="casTitle"><span class="NLM_cas:atitle">The human receptor tyrosine kinase Axl gene - promoter characterization and regulation of constitutive expression by Sp1, Sp3 and CpG methylation</span></div><div class="casAuthors">Mudduluru, Giridhar; Allgayer, Heike</div><div class="citationInfo"><span class="NLM_cas:title">Bioscience Reports</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">28</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">161-176</span>CODEN:
                <span class="NLM_cas:coden">BRPTDT</span>;
        ISSN:<span class="NLM_cas:issn">0144-8463</span>.
    
            (<span class="NLM_cas:orgname">Portland Press Ltd.</span>)
        </div><div class="casAbstract">Axl is a receptor tyrosine kinase which promotes anti-apoptosis, mitogenesis, invasion, angiogenesis and metastasis, and is highly expressed in cancers.  However, the transcriptional regulation of this important gene has never been characterized.  The present study was initiated to characterize the promoter, cis-acting elements and promoter methylation driving expression of Axl.  The 2.4 kb sequence upstream of the translational start site, and sequential 5'-deletions were cloned and revealed a minimal GC-rich region (-556 to +7) to be sufficient for basal Axl promoter activity in Rko, HCT116 and HeLa cells.  Within this minimal region, five Sp (specificity protein)-binding sites were identified.  Two sites (Sp a and Sp b) proximal to the translation start site were indispensable for Axl promoter activity, whereas mutation of three addnl. upstream motifs (Sp c, Sp d and Sp e) was of addnl. relevance.  Gel-shift assays and chromatin immunopptn. identified that Sp1 and Sp3 bound to all five motifs, and mutation of all motifs abolished binding.  Mithramycin, which inhibits binding of Sp factors to GC-rich sites, dramatically reduced Axl promoter activity and Axl, Sp1 and Sp3 expression.  In Drosophila Schneider SL2-cells, exogenous expression of Sp1/Sp3 increased Axl promoter activity.  Use of Sp1/Sp3 siRNAs (small interfering RNAs) significantly reduced Axl promoter activity and protein levels in Rko and HeLa cells.  Methylation-bisulfite sequencing detected methylated CpG sites within three Sp motifs (Sp a, Sp b and Sp c) and GC-rich flanking sequences, and demethylation by 5-aza-2'-deoxycytidine up-regulated Axl and Sp3 expression in low-Axl-expressing Colo206f/WiDr cells, but not in high-Axl-expressing Rko cells.  The results of the present study suggest that Axl gene expression in cancer cells is (1) constitutively driven by Sp1/Sp3 bound to five core promoter motifs, and (2) restricted by methylation within/around Sp-binding sites.  This might enhance the understanding and treatment of essential mechanisms assocd. with cancer and other diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGolVG5cjhmrXrVg90H21EOLACvtfcHk0lhR96d3ZKfEsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXpsVaktL0%253D&md5=88baae37d4c3089ec66dcd4663fa47ce</span></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1042%2FBSR20080046&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1042%252FBSR20080046%26sid%3Dliteratum%253Aachs%26aulast%3DMudduluru%26aufirst%3DG.%26aulast%3DAllgayer%26aufirst%3DH.%26atitle%3DThe%2520human%2520receptor%2520tyrosine%2520kinase%2520Axl%2520gene-promoter%2520characterization%2520and%2520regulation%2520of%2520constitutive%2520expression%2520by%2520Sp1%252C%2520Sp3%2520and%2520CpG%2520methylation%26jtitle%3DBiosci.%2520Rep.%26date%3D2008%26volume%3D28%26spage%3D161%26epage%3D176%26doi%3D10.1042%2FBSR20080046" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group">Mudduluru, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ceppi, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kumarswamy, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scagliotti, G. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Papotti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Allgayer, H.</span><span> </span><span class="NLM_article-title">Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">30</span><span class="NLM_x">, </span> <span class="NLM_fpage">2888</span><span class="NLM_x">–</span> <span class="NLM_lpage">2899</span><span class="refDoi"> DOI: 10.1038/onc.2011.13</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2011.13" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=30&publication_year=2011&pages=2888-2899&author=G.+Mudduluruauthor=P.+Ceppiauthor=R.+Kumarswamyauthor=G.+V.+Scagliottiauthor=M.+Papottiauthor=H.+Allgayer&title=Regulation+of+Axl+receptor+tyrosine+kinase+expression+by+miR-34a+and+miR-199a%2Fb+in+solid+cancer&doi=10.1038%2Fonc.2011.13"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1038%2Fonc.2011.13&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2011.13%26sid%3Dliteratum%253Aachs%26aulast%3DMudduluru%26aufirst%3DG.%26aulast%3DCeppi%26aufirst%3DP.%26aulast%3DKumarswamy%26aufirst%3DR.%26aulast%3DScagliotti%26aufirst%3DG.%2BV.%26aulast%3DPapotti%26aufirst%3DM.%26aulast%3DAllgayer%26aufirst%3DH.%26atitle%3DRegulation%2520of%2520Axl%2520receptor%2520tyrosine%2520kinase%2520expression%2520by%2520miR-34a%2520and%2520miR-199a%252Fb%2520in%2520solid%2520cancer%26jtitle%3DOncogene%26date%3D2011%26volume%3D30%26spage%3D2888%26epage%3D2899%26doi%3D10.1038%2Fonc.2011.13" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group">Zhang, Z. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, L. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Olivas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Au, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LaFramboise, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Abdel-Rahman, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X. Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Levine, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jang, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, D. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, V. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arcila, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ladanyi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moonsamy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawyers, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boggon, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ma, P. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Taron, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halmos, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span> </span><span class="NLM_article-title">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span> <span class="citation_source-journal">Nat. Genet.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">44</span><span class="NLM_x">, </span> <span class="NLM_fpage">852</span><span class="NLM_x">–</span> <span class="NLM_lpage">860</span><span class="refDoi"> DOI: 10.1038/ng.2330</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fng.2330" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22751098" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=44&publication_year=2012&pages=852-860&author=Z.+F.+Zhangauthor=J.+C.+Leeauthor=L.+P.+Linauthor=V.+Olivasauthor=V.+Auauthor=T.+LaFramboiseauthor=M.+Abdel-Rahmanauthor=X.+Q.+Wangauthor=A.+D.+Levineauthor=J.+K.+Rhoauthor=Y.+J.+Choiauthor=C.+M.+Choiauthor=S.+W.+Kimauthor=S.+J.+Jangauthor=Y.+S.+Parkauthor=W.+S.+Kimauthor=D.+H.+Leeauthor=J.+S.+Leeauthor=V.+A.+Millerauthor=M.+Arcilaauthor=M.+Ladanyiauthor=P.+Moonsamyauthor=C.+Sawyersauthor=T.+J.+Boggonauthor=P.+C.+Maauthor=C.+Costaauthor=M.+Taronauthor=R.+Rosellauthor=B.+Halmosauthor=T.+G.+Bivona&title=Activation+of+the+AXL+kinase+causes+resistance+to+EGFR-targeted+therapy+in+lung+cancer&doi=10.1038%2Fng.2330"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer</span></div><div class="casAuthors">Zhang, Zhenfeng; Lee, Jae Cheol; Lin, Luping; Olivas, Victor; Au, Valerie; LaFramboise, Thomas; Abdel-Rahman, Mohamed; Wang, Xiaoqi; Levine, Alan D.; Rho, Jin Kyung; Choi, Yun Jung; Choi, Chang-Min; Kim, Sang-We; Jang, Se Jin; Park, Young Soo; Kim, Woo Sung; Lee, Dae Ho; Lee, Jung-Shin; Miller, Vincent A.; Arcila, Maria; Ladanyi, Marc; Moonsamy, Philicia; Sawyers, Charles; Boggon, Titus J.; Ma, Patrick C.; Costa, Carlota; Taron, Miquel; Rosell, Rafael; Halmos, Balazs; Bivona, Trever G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Genetics</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">44</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">852-860</span>CODEN:
                <span class="NLM_cas:coden">NGENEC</span>;
        ISSN:<span class="NLM_cas:issn">1061-4036</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Human non-small cell lung cancers (NSCLCs) with activating mutations in EGFR frequently respond to treatment with EGFR-targeted tyrosine kinase inhibitors (TKIs), such as erlotinib, but responses are not durable, as tumors acquire resistance.  Secondary mutations in EGFR (such as T790M) or upregulation of the MET kinase are found in over 50% of resistant tumors.  Here, we report increased activation of AXL and evidence for epithelial-to-mesenchymal transition (EMT) in multiple in vitro and in vivo EGFR-mutant lung cancer models with acquired resistance to erlotinib in the absence of the EGFR p.  Thr790Met alteration or MET activation.  Genetic or pharmacol. inhibition of AXL restored sensitivity to erlotinib in these tumor models.  Increased expression of AXL and, in some cases, of its ligand GAS6 was found in EGFR-mutant lung cancers obtained from individuals with acquired resistance to TKIs.  These data identify AXL as a promising therapeutic target whose inhibition could prevent or overcome acquired resistance to EGFR TKIs in individuals with EGFR-mutant lung cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGothnhyjpkwaLVg90H21EOLACvtfcHk0lhR96d3ZKfEsA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsVWit7s%253D&md5=f186a5b9ad4bfdbe12f68ef93d2da254</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1038%2Fng.2330&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fng.2330%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DZ.%2BF.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26aulast%3DLin%26aufirst%3DL.%2BP.%26aulast%3DOlivas%26aufirst%3DV.%26aulast%3DAu%26aufirst%3DV.%26aulast%3DLaFramboise%26aufirst%3DT.%26aulast%3DAbdel-Rahman%26aufirst%3DM.%26aulast%3DWang%26aufirst%3DX.%2BQ.%26aulast%3DLevine%26aufirst%3DA.%2BD.%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DKim%26aufirst%3DS.%2BW.%26aulast%3DJang%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DY.%2BS.%26aulast%3DKim%26aufirst%3DW.%2BS.%26aulast%3DLee%26aufirst%3DD.%2BH.%26aulast%3DLee%26aufirst%3DJ.%2BS.%26aulast%3DMiller%26aufirst%3DV.%2BA.%26aulast%3DArcila%26aufirst%3DM.%26aulast%3DLadanyi%26aufirst%3DM.%26aulast%3DMoonsamy%26aufirst%3DP.%26aulast%3DSawyers%26aufirst%3DC.%26aulast%3DBoggon%26aufirst%3DT.%2BJ.%26aulast%3DMa%26aufirst%3DP.%2BC.%26aulast%3DCosta%26aufirst%3DC.%26aulast%3DTaron%26aufirst%3DM.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DHalmos%26aufirst%3DB.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26atitle%3DActivation%2520of%2520the%2520AXL%2520kinase%2520causes%2520resistance%2520to%2520EGFR-targeted%2520therapy%2520in%2520lung%2520cancer%26jtitle%3DNat.%2520Genet.%26date%3D2012%26volume%3D44%26spage%3D852%26epage%3D860%26doi%3D10.1038%2Fng.2330" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group">Rikova, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Guo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zeng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Possemato, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haack, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nardone, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reeves, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stokes, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sullivan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mitchell, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wetzel, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Macneill, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ren, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bakalarski, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Villen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kornhauser, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gygi, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gu, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polakiewicz, R. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rush, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comb, M. J.</span><span> </span><span class="NLM_article-title">Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer</span> <span class="citation_source-journal">Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">131</span><span class="NLM_x">, </span> <span class="NLM_fpage">1190</span><span class="NLM_x">–</span> <span class="NLM_lpage">1203</span><span class="refDoi"> DOI: 10.1016/j.cell.2007.11.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.cell.2007.11.025" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=131&publication_year=2007&pages=1190-1203&author=K.+Rikovaauthor=A.+Guoauthor=Q.+Zengauthor=A.+Possematoauthor=J.+Yuauthor=H.+Haackauthor=J.+Nardoneauthor=K.+Leeauthor=C.+Reevesauthor=Y.+Liauthor=Y.+Huauthor=Z.+Tanauthor=M.+Stokesauthor=L.+Sullivanauthor=J.+Mitchellauthor=R.+Wetzelauthor=J.+Macneillauthor=J.+M.+Renauthor=J.+Yuanauthor=C.+E.+Bakalarskiauthor=J.+Villenauthor=J.+M.+Kornhauserauthor=B.+Smithauthor=D.+Liauthor=X.+Zhouauthor=S.+P.+Gygiauthor=T.+L.+Guauthor=R.+D.+Polakiewiczauthor=J.+Rushauthor=M.+J.+Comb&title=Global+survey+of+phosphotyrosine+signaling+identifies+oncogenic+kinases+in+lung+cancer&doi=10.1016%2Fj.cell.2007.11.025"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1016%2Fj.cell.2007.11.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.cell.2007.11.025%26sid%3Dliteratum%253Aachs%26aulast%3DRikova%26aufirst%3DK.%26aulast%3DGuo%26aufirst%3DA.%26aulast%3DZeng%26aufirst%3DQ.%26aulast%3DPossemato%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHaack%26aufirst%3DH.%26aulast%3DNardone%26aufirst%3DJ.%26aulast%3DLee%26aufirst%3DK.%26aulast%3DReeves%26aufirst%3DC.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DTan%26aufirst%3DZ.%26aulast%3DStokes%26aufirst%3DM.%26aulast%3DSullivan%26aufirst%3DL.%26aulast%3DMitchell%26aufirst%3DJ.%26aulast%3DWetzel%26aufirst%3DR.%26aulast%3DMacneill%26aufirst%3DJ.%26aulast%3DRen%26aufirst%3DJ.%2BM.%26aulast%3DYuan%26aufirst%3DJ.%26aulast%3DBakalarski%26aufirst%3DC.%2BE.%26aulast%3DVillen%26aufirst%3DJ.%26aulast%3DKornhauser%26aufirst%3DJ.%2BM.%26aulast%3DSmith%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DD.%26aulast%3DZhou%26aufirst%3DX.%26aulast%3DGygi%26aufirst%3DS.%2BP.%26aulast%3DGu%26aufirst%3DT.%2BL.%26aulast%3DPolakiewicz%26aufirst%3DR.%2BD.%26aulast%3DRush%26aufirst%3DJ.%26aulast%3DComb%26aufirst%3DM.%2BJ.%26atitle%3DGlobal%2520survey%2520of%2520phosphotyrosine%2520signaling%2520identifies%2520oncogenic%2520kinases%2520in%2520lung%2520cancer%26jtitle%3DCell%26date%3D2007%26volume%3D131%26spage%3D1190%26epage%3D1203%26doi%3D10.1016%2Fj.cell.2007.11.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group">Shieh, Y. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lai, C. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kao, Y. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shiah, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, Y. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, C. W.</span><span> </span><span class="NLM_article-title">Expression of axl in lung adenocarcinoma and correlation with tumor progression</span> <span class="citation_source-journal">Neoplasia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">7</span><span class="NLM_x">, </span> <span class="NLM_fpage">1058</span><span class="NLM_x">–</span> <span class="NLM_lpage">1064</span><span class="refDoi"> DOI: 10.1593/neo.05640</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1593%2Fneo.05640" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2005&pages=1058-1064&author=Y.+S.+Shiehauthor=C.+Y.+Laiauthor=Y.+R.+Kaoauthor=S.+G.+Shiahauthor=Y.+W.+Chuauthor=H.+S.+Leeauthor=C.+W.+Wu&title=Expression+of+axl+in+lung+adenocarcinoma+and+correlation+with+tumor+progression&doi=10.1593%2Fneo.05640"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1593%2Fneo.05640&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1593%252Fneo.05640%26sid%3Dliteratum%253Aachs%26aulast%3DShieh%26aufirst%3DY.%2BS.%26aulast%3DLai%26aufirst%3DC.%2BY.%26aulast%3DKao%26aufirst%3DY.%2BR.%26aulast%3DShiah%26aufirst%3DS.%2BG.%26aulast%3DChu%26aufirst%3DY.%2BW.%26aulast%3DLee%26aufirst%3DH.%2BS.%26aulast%3DWu%26aufirst%3DC.%2BW.%26atitle%3DExpression%2520of%2520axl%2520in%2520lung%2520adenocarcinoma%2520and%2520correlation%2520with%2520tumor%2520progression%26jtitle%3DNeoplasia%26date%3D2005%26volume%3D7%26spage%3D1058%26epage%3D1064%26doi%3D10.1593%2Fneo.05640" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group">Li, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ye, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hongo, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zha, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kallop, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ludlam, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pei, L.</span><span> </span><span class="NLM_article-title">Axl as a potential therapeutic target in cancer: role of Axl in tumor growth, metastasis and angiogenesis</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">28</span><span class="NLM_x">, </span> <span class="NLM_fpage">3442</span><span class="NLM_x">–</span> <span class="NLM_lpage">3455</span><span class="refDoi"> DOI: 10.1038/onc.2009.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2009.212" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=28&publication_year=2009&pages=3442-3455&author=Y.+Liauthor=X.+Yeauthor=C.+Tanauthor=J.+A.+Hongoauthor=J.+Zhaauthor=J.+Liuauthor=D.+Kallopauthor=M.+J.+Ludlamauthor=L.+Pei&title=Axl+as+a+potential+therapeutic+target+in+cancer%3A+role+of+Axl+in+tumor+growth%2C+metastasis+and+angiogenesis&doi=10.1038%2Fonc.2009.212"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fonc.2009.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2009.212%26sid%3Dliteratum%253Aachs%26aulast%3DLi%26aufirst%3DY.%26aulast%3DYe%26aufirst%3DX.%26aulast%3DTan%26aufirst%3DC.%26aulast%3DHongo%26aufirst%3DJ.%2BA.%26aulast%3DZha%26aufirst%3DJ.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DKallop%26aufirst%3DD.%26aulast%3DLudlam%26aufirst%3DM.%2BJ.%26aulast%3DPei%26aufirst%3DL.%26atitle%3DAxl%2520as%2520a%2520potential%2520therapeutic%2520target%2520in%2520cancer%253A%2520role%2520of%2520Axl%2520in%2520tumor%2520growth%252C%2520metastasis%2520and%2520angiogenesis%26jtitle%3DOncogene%26date%3D2009%26volume%3D28%26spage%3D3442%26epage%3D3455%26doi%3D10.1038%2Fonc.2009.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group">Berclaz, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Altermatt, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rohrbach, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kieffer, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dreher, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Andres, A. C.</span><span> </span><span class="NLM_article-title">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span> <span class="citation_source-journal">Ann. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">819</span><span class="NLM_x">–</span> <span class="NLM_lpage">824</span><span class="refDoi"> DOI: 10.1023/A:1011126330233</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1023%2FA%3A1011126330233" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11484958" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2001&pages=819-824&author=G.+Berclazauthor=H.+J.+Altermattauthor=V.+Rohrbachauthor=I.+Kiefferauthor=E.+Dreherauthor=A.+C.+Andres&title=Estrogen+dependent+expression+of+the+receptor+tyrosine+kinase+axl+in+normal+and+malignant+human+breast&doi=10.1023%2FA%3A1011126330233"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Estrogen dependent expression of the receptor tyrosine kinase axl in normal and malignant human breast</span></div><div class="casAuthors">Berclaz G; Altermatt H J; Rohrbach V; Kieffer I; Dreher E; Andres A C</div><div class="citationInfo"><span class="NLM_cas:title">Annals of oncology : official journal of the European Society for Medical Oncology / ESMO</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">819-24</span>
        ISSN:<span class="NLM_cas:issn">0923-7534</span>.
    </div><div class="casAbstract">BACKGROUND:  Axl, a member of a family of receptor tyrosine kinases characterized by an extracellular domain resembling cell adhesion molecules and an intracellular conserved tyrosine kinase domain has been reported to induce cell proliferation and transformation.  In mice, axl is expressed in the normal mammary gland and over-expressed in aggressive mammary tumors.  PATIENTS AND METHODS:  We have investigated the expression of axl immunohistochemically in 23 normal human breast samples and in 111 consecutive breast carcinomas.  Expression of axl was correlated with tumour characteristics (lymph node involvement, stage, grade) and immunohistochemical expression of ER, PR, Ki-67 and c-erbB-2.  RESULTS:  In normal tissue, axl localizes to the membrane of breast epithelial cells.  Axl protein shows membrane associated staining in high correlation (P = 0.004) with the expression of the estrogen receptor (ER).  Axl expression was found in a subset of breast carcinomas and was also correlated with high significance (P < 0.0001) with the presence of ER.  CONCLUSION:  Our results suggest that axl may serve as a mediator of estrogen stimulation preventing the completion of the breast epithelial life cycle and that estrogen induced axl expression may give a survival signal to cancerous cells, preventing them from dying through apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcS4jH3dLUflJ91QT_1O5WBYfW6udTcc2ebsGFlGzZbrG7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD38%252FislSrtw%253D%253D&md5=36a9041a5d19646e01b47ea4886e182e</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1023%2FA%3A1011126330233&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1023%252FA%253A1011126330233%26sid%3Dliteratum%253Aachs%26aulast%3DBerclaz%26aufirst%3DG.%26aulast%3DAltermatt%26aufirst%3DH.%2BJ.%26aulast%3DRohrbach%26aufirst%3DV.%26aulast%3DKieffer%26aufirst%3DI.%26aulast%3DDreher%26aufirst%3DE.%26aulast%3DAndres%26aufirst%3DA.%2BC.%26atitle%3DEstrogen%2520dependent%2520expression%2520of%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520normal%2520and%2520malignant%2520human%2520breast%26jtitle%3DAnn.%2520Oncol.%26date%3D2001%26volume%3D12%26spage%3D819%26epage%3D824%26doi%3D10.1023%2FA%3A1011126330233" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group">Meric, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahin, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span> </span><span class="NLM_article-title">Expression profile of tyrosine kinases in breast cancer</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2002</span><span class="NLM_x">, </span> <span class="NLM_volume">8</span><span class="NLM_x">, </span> <span class="NLM_fpage">361</span><span class="NLM_x">–</span> <span class="NLM_lpage">367</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11839650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFegurw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2002&pages=361-367&author=F.+Mericauthor=W.+P.+Leeauthor=A.+Sahinauthor=H.+Zhangauthor=H.+J.+Kungauthor=M.+C.+Hung&title=Expression+profile+of+tyrosine+kinases+in+breast+cancer"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit40R"><div class="casContent"><span class="casTitleNuber">40</span><div class="casTitle"><span class="NLM_cas:atitle">Expression profile of tyrosine kinases in breast cancer</span></div><div class="casAuthors">Meric, Funda; Lee, Wei-Ping; Sahin, Aysegul; Zhang, Haixia; Kung, Hsing-Jien; Hung, Mien-Chie</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">361-367</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The tyrosine kinase (TK) family includes many growth factor receptors, cell cycle regulators, and oncoproteins.  Moreover, the receptor TKs HER2/neu and epidermal growth factor receptor are overexpressed in a subgroup of breast tumors and correlate with more aggressive behavior.  Thus, TKs are being actively pursued as therapeutic targets.  The purpose of this study was to det. the expression pattern of TKs in breast cancer.  Reverse transcription-PCR was performed with degenerate primers based on conserved motifs of the catalytic domains of TKs, and the identities of the reverse transcription-PCR products were detd. by digestion with a panel of restriction enzymes.  Using a TK display assay, we studied the TK profiles of 13 breast cancer cell lines and two normal immortalized breast epithelial cell lines.  The TK display assay reproducibly demonstrated known differences in HER-2/neu expression between cell lines.  Several TKs, including receptor TKs Axl, Cak, fibroblast growth factor receptor 4, HEK8, HER2/neu, c-MET, RET, and nonreceptor TKs ARG, BRK, Janus kinase 1, Rak, and YES were detected in breast cancer cells.  Several kinases were differentially expressed among the cell lines.  Similar TK profiles were found using RNA from human breast tumors.  We conclude that there is significant variability in the TK expression pattern of breast cancers.  This variability should be considered when selecting TK inhibitors to treat patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPW5sVLEPxNrVg90H21EOLACvtfcHk0lii8xs1yDFG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFegurw%253D&md5=c110703426c511054849ea0d679b712e</span></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMeric%26aufirst%3DF.%26aulast%3DLee%26aufirst%3DW.%2BP.%26aulast%3DSahin%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DH.%26aulast%3DKung%26aufirst%3DH.%2BJ.%26aulast%3DHung%26aufirst%3DM.%2BC.%26atitle%3DExpression%2520profile%2520of%2520tyrosine%2520kinases%2520in%2520breast%2520cancer%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2002%26volume%3D8%26spage%3D361%26epage%3D367" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group">Bose, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Molina, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patterson, A. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bitok, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Periaswamy, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bader, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pandey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cole, P. A.</span><span> </span><span class="NLM_article-title">Phosphoproteomic analysis of Her2/neu signaling and inhibition</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">9773</span><span class="NLM_x">–</span> <span class="NLM_lpage">9778</span><span class="refDoi"> DOI: 10.1073/pnas.0603948103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0603948103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=16785428" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD28XmvVajtro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=9773-9778&author=R.+Boseauthor=H.+Molinaauthor=A.+S.+Pattersonauthor=J.+K.+Bitokauthor=B.+Periaswamyauthor=J.+S.+Baderauthor=A.+Pandeyauthor=P.+A.+Cole&title=Phosphoproteomic+analysis+of+Her2%2Fneu+signaling+and+inhibition&doi=10.1073%2Fpnas.0603948103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Phosphoproteomic analysis of Her2/neu signaling and inhibition</span></div><div class="casAuthors">Bose, Ron; Molina, Henrik; Patterson, A. Scott; Bitok, John K.; Periaswamy, Balamurugan; Bader, Joel S.; Pandey, Akhilesh; Cole, Philip A.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">103</span>
        (<span class="NLM_cas:issue">26</span>),
    <span class="NLM_cas:pages">9773-9778</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Her2/neu (Her2) is a tyrosine kinase belonging to the EGF receptor (EGFR)/ErbB family and is overexpressed in 20-30% of human breast cancers.  The authors sought to characterize Her2 signal transduction pathways further by using MS-based quant. proteomics.  Stably transfected cell lines overexpressing Her2 or empty vector were generated, and the effect of an EGFR and Her2 selective tyrosine kinase inhibitor, PD168393, on these cells was characterized.  Quant. measurements were obtained on 462 proteins by using the SILAC (stable isotope labeling with amino acids in cell culture) method to monitor three conditions simultaneously.  Of these proteins, 198 showed a significant increase in tyrosine phosphorylation in Her2-overexpressing cells, and 81 showed a significant decrease in phosphorylation.  Treatment of Her2-overexpressing cells with PD168393 showed rapid reversibility of the majority of the Her2-triggered phosphorylation events.  Phosphoproteins that were identified included many known Her2 signaling mols. as well as known EGFR signaling proteins that had not been previously linked to Her2, such as Stat1, Dok1, and δ-catenin.  Importantly, several previously uncharacterized Her2 signaling proteins were identified, including Axl tyrosine kinase, the adaptor protein Fyb, and the calcium-binding protein Pdcd-6/Alg-2.  The authors also identified a phosphorylation site in Her2, Y877, which is located in the activation loop of the kinase domain, is distinct from the known C-terminal tail autophosphorylation sites, and may have important implications for regulation of Her2 signaling.  Network modeling, which combined phosphoproteomic results with literature-curated protein-protein interaction data, was used to suggest roles for some of the previously unidentified Her2 signaling proteins.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnr6Plokluo7Vg90H21EOLACvtfcHk0lii8xs1yDFG9w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28XmvVajtro%253D&md5=0f091b606ed216f61981865c0b720f34</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0603948103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0603948103%26sid%3Dliteratum%253Aachs%26aulast%3DBose%26aufirst%3DR.%26aulast%3DMolina%26aufirst%3DH.%26aulast%3DPatterson%26aufirst%3DA.%2BS.%26aulast%3DBitok%26aufirst%3DJ.%2BK.%26aulast%3DPeriaswamy%26aufirst%3DB.%26aulast%3DBader%26aufirst%3DJ.%2BS.%26aulast%3DPandey%26aufirst%3DA.%26aulast%3DCole%26aufirst%3DP.%2BA.%26atitle%3DPhosphoproteomic%2520analysis%2520of%2520Her2%252Fneu%2520signaling%2520and%2520inhibition%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D9773%26epage%3D9778%26doi%3D10.1073%2Fpnas.0603948103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, E. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Friera, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atchison, R. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McLaughlin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swift, S. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pali, E. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yam, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lasaga, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, M. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bogenberger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nör, J. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Multiple roles for the receptor tyrosine kinase axl in tumor formation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">9294</span><span class="NLM_x">–</span> <span class="NLM_lpage">9303</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-05-0993</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-05-0993" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2005&pages=9294-9303&author=S.+J.+Hollandauthor=M.+J.+Powellauthor=C.+Franciauthor=E.+W.+Chanauthor=A.+M.+Frieraauthor=R.+E.+Atchisonauthor=J.+McLaughlinauthor=S.+E.+Swiftauthor=E.+S.+Paliauthor=G.+Yamauthor=S.+Wongauthor=J.+Lasagaauthor=M.+R.+Shenauthor=S.+Yuauthor=W.+Xuauthor=Y.+Hitoshiauthor=J.+Bogenbergerauthor=J.+E.+N%C3%B6rauthor=D.+G.+Payanauthor=J.+B.+Lorens&title=Multiple+roles+for+the+receptor+tyrosine+kinase+axl+in+tumor+formation&doi=10.1158%2F0008-5472.CAN-05-0993"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-05-0993&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-05-0993%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPowell%26aufirst%3DM.%2BJ.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DChan%26aufirst%3DE.%2BW.%26aulast%3DFriera%26aufirst%3DA.%2BM.%26aulast%3DAtchison%26aufirst%3DR.%2BE.%26aulast%3DMcLaughlin%26aufirst%3DJ.%26aulast%3DSwift%26aufirst%3DS.%2BE.%26aulast%3DPali%26aufirst%3DE.%2BS.%26aulast%3DYam%26aufirst%3DG.%26aulast%3DWong%26aufirst%3DS.%26aulast%3DLasaga%26aufirst%3DJ.%26aulast%3DShen%26aufirst%3DM.%2BR.%26aulast%3DYu%26aufirst%3DS.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DHitoshi%26aufirst%3DY.%26aulast%3DBogenberger%26aufirst%3DJ.%26aulast%3DN%25C3%25B6r%26aufirst%3DJ.%2BE.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DMultiple%2520roles%2520for%2520the%2520receptor%2520tyrosine%2520kinase%2520axl%2520in%2520tumor%2520formation%26jtitle%3DCancer%2520Res.%26date%3D2005%26volume%3D65%26spage%3D9294%26epage%3D9303%26doi%3D10.1158%2F0008-5472.CAN-05-0993" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group">Gjerdrum, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Høiby, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefansson, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collett, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCormack, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gjertsen, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Akslen, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glackin, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span> </span><span class="NLM_article-title">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">107</span><span class="NLM_x">, </span> <span class="NLM_fpage">1124</span><span class="NLM_x">–</span> <span class="NLM_lpage">1149</span><span class="refDoi"> DOI: 10.1073/pnas.0909333107</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0909333107" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20080645" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=107&publication_year=2010&pages=1124-1149&author=C.+Gjerdrumauthor=C.+Tironauthor=T.+H%C3%B8ibyauthor=I.+Stefanssonauthor=H.+Haugenauthor=T.+Sandalauthor=K.+Collettauthor=S.+Liauthor=E.+McCormackauthor=B.+T.+Gjertsenauthor=D.+R.+Micklemauthor=L.+A.+Akslenauthor=C.+Glackinauthor=J.+B.+Lorens&title=Axl+is+an+essential+epithelial-to-mesenchymal+transition-induced+regulator+of+breast+cancer+metastasis+and+patient+survival&doi=10.1073%2Fpnas.0909333107"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Axl is an essential epithelial-to-mesenchymal transition-induced regulator of breast cancer metastasis and patient survival</span></div><div class="casAuthors">Gjerdrum, Christine; Tiron, Crina; Hoeiby, Torill; Stefansson, Ingunn; Haugen, Hallvard; Sandal, Tone; Collett, Karin; Li, Shan; McCormack, Emmet; Gjertsen, Bjoern Tore; Micklem, David R.; Akslen, Lars A.; Glackin, Carlotta; Lorens, James B.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">107</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1124-1129, S1124/1-S1124/11</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Metastasis underlies the majority of cancer-related deaths.  Thus, furthering our understanding of the mol. mechanisms that enable tumor cell dissemination is a vital health issue.  Epithelial-to-mesenchymal transitions (EMTs) endow carcinoma cells with enhanced migratory and survival attributes that facilitate malignant progression.  Characterization of EMT effectors is likely to yield new insights into metastasis and novel avenues for treatment.  We show that the presence of the receptor tyrosine kinase Axl in primary breast cancers independently predicts strongly reduced overall patient survival, and that matched patient metastatic lesions show enhanced Axl expression.  We demonstrate that Axl is strongly induced by EMT in immortalized mammary epithelial cells that establishes an autocrine signaling loop with its ligand, Gas6.  Epiallelic RNA interference anal. in metastatic breast cancer cells delineated a distinct threshold of Axl expression for mesenchymal-like in vitro cell invasiveness and formation of tumors in foreign and tissue-engineered micro-environments in vivo.  Importantly, in two different optical imaging-based exptl. breast cancer models, Axl knockdown completely prevented the spread of highly metastatic breast carcinoma cells from the mammary gland to lymph nodes and several major organs and increased overall survival.  These findings suggest that Axl represents a downstream effector of the tumor cell EMT that is required for breast cancer metastasis.  Thus, the detection and targeted treatment of Axl-expressing tumors represents an important new therapeutic strategy for breast cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrPiST_cnXhqrVg90H21EOLACvtfcHk0ljIVuKCX99tZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtFyku7s%253D&md5=dbd7113028010a800e22ff1f206b9337</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0909333107&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0909333107%26sid%3Dliteratum%253Aachs%26aulast%3DGjerdrum%26aufirst%3DC.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DH%25C3%25B8iby%26aufirst%3DT.%26aulast%3DStefansson%26aufirst%3DI.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DCollett%26aufirst%3DK.%26aulast%3DLi%26aufirst%3DS.%26aulast%3DMcCormack%26aufirst%3DE.%26aulast%3DGjertsen%26aufirst%3DB.%2BT.%26aulast%3DMicklem%26aufirst%3DD.%2BR.%26aulast%3DAkslen%26aufirst%3DL.%2BA.%26aulast%3DGlackin%26aufirst%3DC.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26atitle%3DAxl%2520is%2520an%2520essential%2520epithelial-to-mesenchymal%2520transition-induced%2520regulator%2520of%2520breast%2520cancer%2520metastasis%2520and%2520patient%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2010%26volume%3D107%26spage%3D1124%26epage%3D1149%26doi%3D10.1073%2Fpnas.0909333107" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group">Liu, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greger, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Annan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Halsey, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sathe, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Martin, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gilmer, T. M.</span><span> </span><span class="NLM_article-title">Novel mechanism of lapatinib resistance in HER2-positive breast tumor cells: activation of AXL</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">6871</span><span class="NLM_x">–</span> <span class="NLM_lpage">6878</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4490</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-08-4490" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=6871-6878&author=L.+Liuauthor=J.+Gregerauthor=H.+Shiauthor=Y.+Liuauthor=J.+Greshockauthor=R.+Annanauthor=W.+Halseyauthor=G.+M.+Satheauthor=A.+M.+Martinauthor=T.+M.+Gilmer&title=Novel+mechanism+of+lapatinib+resistance+in+HER2-positive+breast+tumor+cells%3A+activation+of+AXL&doi=10.1158%2F0008-5472.CAN-08-4490"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4490&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4490%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DL.%26aulast%3DGreger%26aufirst%3DJ.%26aulast%3DShi%26aufirst%3DH.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DAnnan%26aufirst%3DR.%26aulast%3DHalsey%26aufirst%3DW.%26aulast%3DSathe%26aufirst%3DG.%2BM.%26aulast%3DMartin%26aufirst%3DA.%2BM.%26aulast%3DGilmer%26aufirst%3DT.%2BM.%26atitle%3DNovel%2520mechanism%2520of%2520lapatinib%2520resistance%2520in%2520HER2-positive%2520breast%2520tumor%2520cells%253A%2520activation%2520of%2520AXL%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D6871%26epage%3D6878%26doi%3D10.1158%2F0008-5472.CAN-08-4490" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group">Vajkoczy, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kunkel, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Capelle, H. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrndt, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">von Tengg-Kobligk, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kiessling, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eichelsbacher, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Essig, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Read, T. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erber, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">Dominant-negative inhibition of the Axl receptor tyrosine kinase suppresses brain tumor cell growth and invasion and prolongs survival</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">103</span><span class="NLM_x">, </span> <span class="NLM_fpage">5799</span><span class="NLM_x">–</span> <span class="NLM_lpage">5804</span><span class="refDoi"> DOI: 10.1073/pnas.0510923103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.0510923103" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=103&publication_year=2006&pages=5799-5804&author=P.+Vajkoczyauthor=P.+Knyazevauthor=A.+Kunkelauthor=H.+H.+Capelleauthor=S.+Behrndtauthor=H.+von+Tengg-Kobligkauthor=F.+Kiesslingauthor=U.+Eichelsbacherauthor=M.+Essigauthor=T.+A.+Readauthor=R.+Erberauthor=A.+Ullrich&title=Dominant-negative+inhibition+of+the+Axl+receptor+tyrosine+kinase+suppresses+brain+tumor+cell+growth+and+invasion+and+prolongs+survival&doi=10.1073%2Fpnas.0510923103"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0510923103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0510923103%26sid%3Dliteratum%253Aachs%26aulast%3DVajkoczy%26aufirst%3DP.%26aulast%3DKnyazev%26aufirst%3DP.%26aulast%3DKunkel%26aufirst%3DA.%26aulast%3DCapelle%26aufirst%3DH.%2BH.%26aulast%3DBehrndt%26aufirst%3DS.%26aulast%3Dvon%2BTengg-Kobligk%26aufirst%3DH.%26aulast%3DKiessling%26aufirst%3DF.%26aulast%3DEichelsbacher%26aufirst%3DU.%26aulast%3DEssig%26aufirst%3DM.%26aulast%3DRead%26aufirst%3DT.%2BA.%26aulast%3DErber%26aufirst%3DR.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DDominant-negative%2520inhibition%2520of%2520the%2520Axl%2520receptor%2520tyrosine%2520kinase%2520suppresses%2520brain%2520tumor%2520cell%2520growth%2520and%2520invasion%2520and%2520prolongs%2520survival%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2006%26volume%3D103%26spage%3D5799%26epage%3D5804%26doi%3D10.1073%2Fpnas.0510923103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group">Keating, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jones, A. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ware, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mulcahy, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzberg, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Foreman, N. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thorburn, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">Inhibition of Mer and Axl receptor tyrosine kinases in astrocytoma cells leads to increased apoptosis and improved chemosensitivity</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1298</span><span class="NLM_x">–</span> <span class="NLM_lpage">1307</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-09-0707</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-09-0707" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20423999" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXlslektrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2010&pages=1298-1307&author=A.+K.+Keatingauthor=G.+K.+Kimauthor=A.+E.+Jonesauthor=A.+M.+Donsonauthor=K.+Wareauthor=J.+M.+Mulcahyauthor=D.+B.+Salzbergauthor=N.+K.+Foremanauthor=X.+Liangauthor=A.+Thorburnauthor=D.+K.+Graham&title=Inhibition+of+Mer+and+Axl+receptor+tyrosine+kinases+in+astrocytoma+cells+leads+to+increased+apoptosis+and+improved+chemosensitivity&doi=10.1158%2F1535-7163.MCT-09-0707"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Mer and Axl Receptor Tyrosine Kinases in Astrocytoma Cells Leads to Increased Apoptosis and Improved Chemosensitivity</span></div><div class="casAuthors">Keating, Amy K.; Kim, Grace K.; Jones, Ashley E.; Donson, Andrew M.; Ware, Kathryn; Mulcahy, Jean M.; Salzberg, Dana B.; Foreman, Nicholas K.; Liang, Xiayuan; Thorburn, Andrew; Graham, Douglas K.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1298-1307</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Astrocytomas account for the majority of malignant brain tumors diagnosed in both adult and pediatric patients.  The therapies available to treat these neoplasms are limited, and the prognosis assocd. with high-grade lesions is extremely poor.  Mer (MerTK) and Axl receptor tyrosine kinases (RTK) are expressed at abnormally high levels in a variety of malignancies, and these receptors are known to activate strong antiapoptotic signaling pathways that promote oncogenesis.  In this study, the authors found that Mer and Axl mRNA transcript and protein expression were elevated in astrocytic patient samples and cell lines.  ShRNA-mediated knockdown of Mer and Axl RTK expression led to an increase in apoptosis in astrocytoma cells.  Apoptotic signaling pathways including Akt and extracellular signal-regulated kinase 1/2, which have been shown to be activated in resistant astrocytomas, were downregulated with Mer and Axl inhibition, whereas poly(ADP-ribose) polymerase cleavage was increased.  Furthermore, Mer and Axl shRNA knockdown led to a profound decrease of astrocytoma cell proliferation in soft agar and a significant increase in chemosensitivity in response to temozolomide, carboplatin, and vincristine treatment.  The authors' results suggest Mer and Axl RTK inhibition as a novel method to improve apoptotic response and chemosensitivity in astrocytoma and provide support for these oncogenes as attractive biol. targets for astrocytoma drug development.  Mol Cancer Ther; 9(5); 1298-307.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpPZlqtANWfZbVg90H21EOLACvtfcHk0ljIVuKCX99tZA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXlslektrY%253D&md5=04e8a0c70eba12c28f58a989131ab885</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-09-0707&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-09-0707%26sid%3Dliteratum%253Aachs%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DKim%26aufirst%3DG.%2BK.%26aulast%3DJones%26aufirst%3DA.%2BE.%26aulast%3DDonson%26aufirst%3DA.%2BM.%26aulast%3DWare%26aufirst%3DK.%26aulast%3DMulcahy%26aufirst%3DJ.%2BM.%26aulast%3DSalzberg%26aufirst%3DD.%2BB.%26aulast%3DForeman%26aufirst%3DN.%2BK.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DThorburn%26aufirst%3DA.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DInhibition%2520of%2520Mer%2520and%2520Axl%2520receptor%2520tyrosine%2520kinases%2520in%2520astrocytoma%2520cells%2520leads%2520to%2520increased%2520apoptosis%2520and%2520improved%2520chemosensitivity%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2010%26volume%3D9%26spage%3D1298%26epage%3D1307%26doi%3D10.1158%2F1535-7163.MCT-09-0707" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group">Sainaghi, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Castello, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bergamasco, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Galletti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bellosta, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Avanzi, G. C.</span><span> </span><span class="NLM_article-title">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span> <span class="citation_source-journal">J. Cell. Physiol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2005</span><span class="NLM_x">, </span> <span class="NLM_volume">204</span><span class="NLM_x">, </span> <span class="NLM_fpage">36</span><span class="NLM_x">–</span> <span class="NLM_lpage">44</span><span class="refDoi"> DOI: 10.1002/jcp.20265</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1002%2Fjcp.20265" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=15605394" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=204&publication_year=2005&pages=36-44&author=P.+P.+Sainaghiauthor=L.+Castelloauthor=L.+Bergamascoauthor=M.+Gallettiauthor=P.+Bellostaauthor=G.+C.+Avanzi&title=Gas6+induces+proliferation+in+prostate+carcinoma+cell+lines+expressing+the+Axl+receptor&doi=10.1002%2Fjcp.20265"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit47R"><div class="casContent"><span class="casTitleNuber">47</span><div class="casTitle"><span class="NLM_cas:atitle">Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor</span></div><div class="casAuthors">Sainaghi, Pier Paolo; Castello, Luigi; Bergamasco, Luca; Galletti, Margherita; Bellosta, Paola; Avanzi, Gian Carlo</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Cellular Physiology</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">204</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">36-44</span>CODEN:
                <span class="NLM_cas:coden">JCLLAX</span>;
        ISSN:<span class="NLM_cas:issn">0021-9541</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Axl is a Tyr kinase receptor and although it is expressed in malignancy such as leukemia, colon cancer, melanoma, endometrial, prostate and thyroid cancers, its role was not completely elucidated yet and appears to be complex.  The ligand of Axl, Gas6, is a 75 KDa multimodular protein with an N-terminal γ-carboxy-glutamic acid that is essential for binding.  Gas6 has a mitogenic effect on several normal cell lines.  The receptor Axl is expressed in primary prostate carcinoma and in prostate cancer cell lines as such as PC-3 and DU 145.  We demonstrated a mitogenic activity detd. by Gas6/Axl interaction in these undifferentiated metastatic human prostatic cancer cell lines.  This effect is proportional to Axl expression, not due to inhibition of apoptosis, and induces AKT and MAPK phosphorylation.  However, only MEK phosphorylation seems to be essential for growth signaling.  Our results suggest that Axl overexpression and activation by Gas6 could be involved in progression of prostate neoplastic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgNkOPWaojibVg90H21EOLACvtfcHk0liZBuJarTqizA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXkvF2qsr0%253D&md5=21e2ec8a6dab885ea9dcfed641c71f9c</span></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1002%2Fjcp.20265&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjcp.20265%26sid%3Dliteratum%253Aachs%26aulast%3DSainaghi%26aufirst%3DP.%2BP.%26aulast%3DCastello%26aufirst%3DL.%26aulast%3DBergamasco%26aufirst%3DL.%26aulast%3DGalletti%26aufirst%3DM.%26aulast%3DBellosta%26aufirst%3DP.%26aulast%3DAvanzi%26aufirst%3DG.%2BC.%26atitle%3DGas6%2520induces%2520proliferation%2520in%2520prostate%2520carcinoma%2520cell%2520lines%2520expressing%2520the%2520Axl%2520receptor%26jtitle%3DJ.%2520Cell.%2520Physiol.%26date%3D2005%26volume%3D204%26spage%3D36%26epage%3D44%26doi%3D10.1002%2Fjcp.20265" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wroblewski, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Erdmann, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heuser, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Waizenegger, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riecken, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Binder, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schewe, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sawall, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Witzke, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cubas-Cordova, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janning, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wellbrock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fehse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hagel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Krauter, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ganser, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fiedler, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pantel, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bokemeyer, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span> <span class="citation_source-journal">Blood</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">122</span><span class="NLM_x">, </span> <span class="NLM_fpage">2443</span><span class="NLM_x">–</span> <span class="NLM_lpage">2452</span><span class="refDoi"> DOI: 10.1182/blood-2013-03-491431</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1182%2Fblood-2013-03-491431" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23982172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=122&publication_year=2013&pages=2443-2452&author=I.+Ben-Batallaauthor=A.+Schultzeauthor=M.+Wroblewskiauthor=R.+Erdmannauthor=M.+Heuserauthor=J.+S.+Waizeneggerauthor=K.+Rieckenauthor=M.+Binderauthor=D.+Scheweauthor=S.+Sawallauthor=V.+Witzkeauthor=M.+Cubas-Cordovaauthor=M.+Janningauthor=J.+Wellbrockauthor=B.+Fehseauthor=C.+Hagelauthor=J.+Krauterauthor=A.+Ganserauthor=J.+B.+Lorensauthor=W.+Fiedlerauthor=P.+Carmelietauthor=K.+Pantelauthor=C.+Bokemeyerauthor=S.+Loges&title=Axl%2C+a+prognostic+and+therapeutic+target+in+acute+myeloid+leukemia+mediates+paracrine+crosstalk+of+leukemia+cells+with+bone+marrow+stroma&doi=10.1182%2Fblood-2013-03-491431"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Axl, a prognostic and therapeutic target in acute myeloid leukemia mediates paracrine crosstalk of leukemia cells with bone marrow stroma</span></div><div class="casAuthors">Ben-Batalla, Isabel; Schultze, Alexander; Wroblewski, Mark; Erdmann, Robert; Heuser, Michael; Waizenegger, Jonas S.; Riecken, Kristoffer; Binder, Mascha; Schewe, Denis; Sawall, Stefanie; Witzke, Victoria; Cubas-Cordova, Miguel; Janning, Melanie; Wellbrock, Jasmin; Fehse, Boris; Hagel, Christian; Krauter, Juergen; Ganser, Arnold; Lorens, James B.; Fiedler, Walter; Carmeliet, Peter; Pantel, Klaus; Bokemeyer, Carsten; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Blood</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">122</span>
        (<span class="NLM_cas:issue">14</span>),
    <span class="NLM_cas:pages">2443-2452</span>CODEN:
                <span class="NLM_cas:coden">BLOOAW</span>;
        ISSN:<span class="NLM_cas:issn">0006-4971</span>.
    
            (<span class="NLM_cas:orgname">American Society of Hematology</span>)
        </div><div class="casAbstract">Acute myeloid leukemia (AML) represents a clonal disease of hematopoietic progenitors characterized by acquired heterogeneous genetic changes that alter normal mechanisms of proliferation, self-renewal, and differentiation.  Although 40% to 45% of patients younger than 65 years of age can be cured with current therapies, only 10% of older patients reach long-term survival.  Because only very few novel AML drugs were approved in the past 2 decades, there is an urgent need to identify novel targets and therapeutic strategies to treat underserved AML patients.  We report here that Axl, a member of the Tyro3, Axl, Mer receptor tyrosine kinase family, represents an independent prognostic marker and therapeutic target in AML.  AML cells induce expression and secretion of the Axl ligand growth arrest-specific gene 6 (Gas6) by bone marrow-derived stromal cells (BMDSCs).  Gas6 in turn mediates proliferation, survival, and chemoresistance of Axl-expressing AML cells.  This Gas6-Axl paracrine axis between AML cells and BMDSCs establishes a chemoprotective tumor cell niche that can be abrogated by Axl-targeting approaches.  Axl inhibition is active in FLT3-mutated and FLT3 wild-type AML, improves clin. relevant end points, and its efficacy depends on presence of Gas6 and Axl.  Axl inhibition alone or in combination with chemotherapy might represent a novel therapeutic avenue for AML.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCdV7UN_cvNLVg90H21EOLACvtfcHk0liZBuJarTqizA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhs1Sqt7nO&md5=7b2b67ec3ba0c46218e88e4ea190026c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1182%2Fblood-2013-03-491431&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1182%252Fblood-2013-03-491431%26sid%3Dliteratum%253Aachs%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DWroblewski%26aufirst%3DM.%26aulast%3DErdmann%26aufirst%3DR.%26aulast%3DHeuser%26aufirst%3DM.%26aulast%3DWaizenegger%26aufirst%3DJ.%2BS.%26aulast%3DRiecken%26aufirst%3DK.%26aulast%3DBinder%26aufirst%3DM.%26aulast%3DSchewe%26aufirst%3DD.%26aulast%3DSawall%26aufirst%3DS.%26aulast%3DWitzke%26aufirst%3DV.%26aulast%3DCubas-Cordova%26aufirst%3DM.%26aulast%3DJanning%26aufirst%3DM.%26aulast%3DWellbrock%26aufirst%3DJ.%26aulast%3DFehse%26aufirst%3DB.%26aulast%3DHagel%26aufirst%3DC.%26aulast%3DKrauter%26aufirst%3DJ.%26aulast%3DGanser%26aufirst%3DA.%26aulast%3DLorens%26aufirst%3DJ.%2BB.%26aulast%3DFiedler%26aufirst%3DW.%26aulast%3DCarmeliet%26aufirst%3DP.%26aulast%3DPantel%26aufirst%3DK.%26aulast%3DBokemeyer%26aufirst%3DC.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DAxl%252C%2520a%2520prognostic%2520and%2520therapeutic%2520target%2520in%2520acute%2520myeloid%2520leukemia%2520mediates%2520paracrine%2520crosstalk%2520of%2520leukemia%2520cells%2520with%2520bone%2520marrow%2520stroma%26jtitle%3DBlood%26date%3D2013%26volume%3D122%26spage%3D2443%26epage%3D2452%26doi%3D10.1182%2Fblood-2013-03-491431" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group">Hart, C. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Boer, R. H.</span><span> </span><span class="NLM_article-title">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span> <span class="citation_source-journal">OncoTargets Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">6</span><span class="NLM_x">, </span> <span class="NLM_fpage">1</span><span class="NLM_x">–</span> <span class="NLM_lpage">7</span><span class="refDoi"> DOI: 10.2147/OTT.S27671</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.2147%2FOTT.S27671" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23319867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=6&publication_year=2013&pages=1-7&author=C.+D.+Hartauthor=R.+H.+De+Boer&title=Profile+of+cabozantinib+and+its+potential+in+the+treatment+of+advanced+medullary+thyroid+cancer&doi=10.2147%2FOTT.S27671"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Profile of cabozantinib and its potential in the treatment of advanced medullary thyroid cancer</span></div><div class="casAuthors">Hart, Christopher D.; De Boer, Richard H.</div><div class="citationInfo"><span class="NLM_cas:title">OncoTargets and Therapy</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">6</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">1-7</span>CODEN:
                <span class="NLM_cas:coden">OTNHAZ</span>;
        ISSN:<span class="NLM_cas:issn">1178-6930</span>.
    
            (<span class="NLM_cas:orgname">Dove Medical Press Ltd.</span>)
        </div><div class="casAbstract">A review.  Medullary thyroid cancer is an uncommon malignancy for which until recently little effective treatment existed.  It is often characterized by mutation and overexpression of the receptor tyrosine kinases RET (rearranged during transfection), VEGFR2 (vascular endothelial growth factor receptor 2) and MET (mesenchymal-epithelial transition factor), which make attractive targets for drug development.  Cabozantinib is an orally bioavailable tyrosine kinase inhibitor which blocks MET, VEGRF2 and RET, and has shown considerable activity in medullary thyroid cancer in a Phase III trial, including in heavily pretreated patients.  Its novel combination of vascular endothelial growth factor and MET inhibition is believed to address the MET escape pathway, which is thought to be the cause of nonsustained tumor responses resulting from inhibition of vascular endothelial growth factor alone.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcdeH_ML0s97Vg90H21EOLACvtfcHk0liP8akLHaPyIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvVOqtr4%253D&md5=048635660f5262d406ec13baef91bc78</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.2147%2FOTT.S27671&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2147%252FOTT.S27671%26sid%3Dliteratum%253Aachs%26aulast%3DHart%26aufirst%3DC.%2BD.%26aulast%3DDe%2BBoer%26aufirst%3DR.%2BH.%26atitle%3DProfile%2520of%2520cabozantinib%2520and%2520its%2520potential%2520in%2520the%2520treatment%2520of%2520advanced%2520medullary%2520thyroid%2520cancer%26jtitle%3DOncoTargets%2520Ther.%26date%3D2013%26volume%3D6%26spage%3D1%26epage%3D7%26doi%3D10.2147%2FOTT.S27671" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group">Lee, H. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeng, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chung, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yuan, R. H.</span><span> </span><span class="NLM_article-title">Gas6/Axl pathway promotes tumor invasion through the transcriptional activation of Slug in hepatocellular carcinoma</span> <span class="citation_source-journal">Carcinogenesis</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">35</span><span class="NLM_x">, </span> <span class="NLM_fpage">769</span><span class="NLM_x">–</span> <span class="NLM_lpage">775</span><span class="refDoi"> DOI: 10.1093/carcin/bgt372</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1093%2Fcarcin%2Fbgt372" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2014&pages=769-775&author=H.+J.+Leeauthor=Y.+M.+Jengauthor=Y.+L.+Chenauthor=L.+Chungauthor=R.+H.+Yuan&title=Gas6%2FAxl+pathway+promotes+tumor+invasion+through+the+transcriptional+activation+of+Slug+in+hepatocellular+carcinoma&doi=10.1093%2Fcarcin%2Fbgt372"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1093%2Fcarcin%2Fbgt372&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fcarcin%252Fbgt372%26sid%3Dliteratum%253Aachs%26aulast%3DLee%26aufirst%3DH.%2BJ.%26aulast%3DJeng%26aufirst%3DY.%2BM.%26aulast%3DChen%26aufirst%3DY.%2BL.%26aulast%3DChung%26aufirst%3DL.%26aulast%3DYuan%26aufirst%3DR.%2BH.%26atitle%3DGas6%252FAxl%2520pathway%2520promotes%2520tumor%2520invasion%2520through%2520the%2520transcriptional%2520activation%2520of%2520Slug%2520in%2520hepatocellular%2520carcinoma%26jtitle%3DCarcinogenesis%26date%3D2014%26volume%3D35%26spage%3D769%26epage%3D775%26doi%3D10.1093%2Fcarcin%2Fbgt372" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group">Eder, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Appleman, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhu, A. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miles, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keer, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitchcock-Bryan, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McCallum, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heath, E. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boerner, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LoRusso, P. M.</span><span> </span><span class="NLM_article-title">A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">16</span><span class="NLM_x">, </span> <span class="NLM_fpage">3507</span><span class="NLM_x">–</span> <span class="NLM_lpage">3516</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-10-0574</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-10-0574" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20472683" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2010&pages=3507-3516&author=J.+P.+Ederauthor=G.+I.+Shapiroauthor=L.+J.+Applemanauthor=A.+X.+Zhuauthor=D.+Milesauthor=H.+Keerauthor=B.+Cancillaauthor=F.+Chuauthor=S.+Hitchcock-Bryanauthor=L.+Shermanauthor=S.+McCallumauthor=E.+I.+Heathauthor=S.+A.+Boernerauthor=P.+M.+LoRusso&title=A+phase+I+study+of+foretinib%2C+a+multi-targeted+inhibitor+of+c-Met+and+vascular+endothelial+growth+factor+receptor+2&doi=10.1158%2F1078-0432.CCR-10-0574"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">A Phase I Study of Foretinib, a Multi-Targeted Inhibitor of c-Met and Vascular Endothelial Growth Factor Receptor 2</span></div><div class="casAuthors">Eder, Joseph Paul; Shapiro, Geoffrey I.; Appleman, Leonard J.; Zhu, Andrew X.; Miles, Dale; Keer, Harold; Cancilla, Belinda; Chu, Felix; Hitchcock-Bryan, Suzanne; Sherman, Laurie; McCallum, Stewart; Heath, Elisabeth I.; Boerner, Scott A.; Lo Russo, Patricia M.</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3507-3516</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">PURPOSE: Foretinib is an oral multikinase inhibitor targeting Met, RON, Axl, and vascular endothelial growth factor receptor.  We conducted a phase I, first-time-in-human, clin. trial using escalating doses of oral foretinib.  The primary objectives are to identify a max. tolerated dose and det. the safety profile of foretinib.  Secondary objectives included evaluation of plasma pharmacokinetics, long-term safety after repeated administration, preliminary antitumor activity, and pharmacodynamic activity.  Exptl. Design: Patients had histol. confirmed metastatic or unresectable solid tumors for which no std. measures exist.  All patients received foretinib orally for 5 consecutive days every 14 days.  Dose escalation followed a conventional "3+3" design.  RESULTS: Forty patients were treated in eight dose cohorts.  The max. tolerated dose was defined as 3.6 mg/kg, with a max. administered dose of 4.5 mg/kg.  Dose-limiting toxicities included grade 3 elevations in aspartate aminotransferase and lipase.  Addnl. non-dose-limiting adverse events included hypertension, fatigue, diarrhea, vomiting, proteinuria, and hematuria.  Responses were obsd. in two patients with papillary renal cell cancer and one patient with medullary thyroid cancer.  Stable disease was identified in 22 patients.  Foretinib pharmacokinetics increased linearly with dose.  Pharmacodynamic evaluation indicated inhibition of MET phosphorylation and decreased proliferation in select tumor biopsies at submaximal doses.  CONCLUSIONS: The recommended dose of foretinib was detd. to be 240 mg, given on the first 5 days of a 14-day cycle.  This dose and schedule were identified as having acceptable safety and pharmacokinetics, and will be the dose used in subsequent phase II trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo1LAL1xiRe-rVg90H21EOLACvtfcHk0liP8akLHaPyIQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXot1Wlt74%253D&md5=d37b24383a08fdde5f78ed40b077963b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-10-0574&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-10-0574%26sid%3Dliteratum%253Aachs%26aulast%3DEder%26aufirst%3DJ.%2BP.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DAppleman%26aufirst%3DL.%2BJ.%26aulast%3DZhu%26aufirst%3DA.%2BX.%26aulast%3DMiles%26aufirst%3DD.%26aulast%3DKeer%26aufirst%3DH.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DHitchcock-Bryan%26aufirst%3DS.%26aulast%3DSherman%26aufirst%3DL.%26aulast%3DMcCallum%26aufirst%3DS.%26aulast%3DHeath%26aufirst%3DE.%2BI.%26aulast%3DBoerner%26aufirst%3DS.%2BA.%26aulast%3DLoRusso%26aufirst%3DP.%2BM.%26atitle%3DA%2520phase%2520I%2520study%2520of%2520foretinib%252C%2520a%2520multi-targeted%2520inhibitor%2520of%2520c-Met%2520and%2520vascular%2520endothelial%2520growth%2520factor%2520receptor%25202%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2010%26volume%3D16%26spage%3D3507%26epage%3D3516%26doi%3D10.1158%2F1078-0432.CCR-10-0574" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dai, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gupta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oppenheimer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stefanski, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally efficacious inhibitor of the Met kinase superfamily</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">52</span><span class="NLM_x">, </span> <span class="NLM_fpage">1251</span><span class="NLM_x">–</span> <span class="NLM_lpage">1254</span><span class="refDoi"> DOI: 10.1021/jm801586s</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm801586s" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=52&publication_year=2009&pages=1251-1254&author=G.+M.+Schroederauthor=Y.+Anauthor=Z.+W.+Caiauthor=X.+T.+Chenauthor=C.+Clarkauthor=L.+A.+Corneliusauthor=J.+Daiauthor=J.+Gullo-Brownauthor=A.+Guptaauthor=B.+Henleyauthor=J.+T.+Huntauthor=R.+Jeyaseelanauthor=A.+Kamathauthor=K.+Kimauthor=J.+Lippyauthor=L.+J.+Lombardoauthor=V.+Manneauthor=S.+Oppenheimerauthor=J.+S.+Sackauthor=R.+J.+Schmidtauthor=G.+Shenauthor=K.+Stefanskiauthor=J.+S.+Tokarskiauthor=G.+L.+Trainorauthor=B.+S.+Wautletauthor=D.+Weiauthor=D.+K.+Williamsauthor=Y.+Zhangauthor=Y.+Zhangauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+N-%284-%282-amino-3-chloropyridin-4-yloxy%29-3-fluorophenyl%29-4-ethoxy-1-%284-fluorophenyl%29-2-oxo-1%2C2-dihydropyridine-3-carboxamide+%28BMS-777607%29%2C+a+selective+and+orally+efficacious+inhibitor+of+the+Met+kinase+superfamily&doi=10.1021%2Fjm801586s"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily</span></div><div class="casAuthors">Schroeder, Gretchen M.; An, Yongmi; Cai, Zhen-Wei; Chen, Xiao-Tao; Clark, Cheryl; Cornelius, Lyndon A. M.; Dai, Jun; Gullo-Brown, Johnni; Gupta, Ashok; Henley, Benjamin; Hunt, John T.; Jeyaseelan, Robert; Kamath, Amrita; Kim, Kyoung; Lippy, Jonathan; Lombardo, Louis J.; Manne, Veeraswamy; Oppenheimer, Simone; Sack, John S.; Schmidt, Robert J.; Shen, Guoxiang; Stefanski, Kevin; Tokarski, John S.; Trainor, George L.; Wautlet, Barri S.; Wei, Donna; Williams, David K.; Zhang, Yingru; Zhang, Yueping; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">52</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1251-1254</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Substituted N-(4-(2-aminopyridin-4-yloxy)-3-fluoro-phenyl)-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamides were identified as potent and selective Met kinase inhibitors.  Substitution of the pyridine 3-position gave improved enzyme potency, while substitution of the pyridone 4-position led to improved aq. soly. and kinase selectivity.  Analog 10 demonstrated complete tumor stasis in a Met-dependent GTL-16 human gastric carcinoma xenograft model following oral administration.  Because of its excellent in vivo efficacy and favorable pharmacokinetic and preclin. safety profiles, 10 has been advanced into phase I clin. trials.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAHEvJXf0Fq7Vg90H21EOLACvtfcHk0lgF7JH0kdf5Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXhvVCnsLc%253D&md5=784623be820fcc8b931200ced3a476df</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.1021%2Fjm801586s&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm801586s%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DClark%26aufirst%3DC.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DDai%26aufirst%3DJ.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DGupta%26aufirst%3DA.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DOppenheimer%26aufirst%3DS.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DShen%26aufirst%3DG.%26aulast%3DStefanski%26aufirst%3DK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DWautlet%26aufirst%3DB.%2BS.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520N-%25284-%25282-amino-3-chloropyridin-4-yloxy%2529-3-fluorophenyl%2529-4-ethoxy-1-%25284-fluorophenyl%2529-2-oxo-1%252C2-dihydropyridine-3-carboxamide%2520%2528BMS-777607%2529%252C%2520a%2520selective%2520and%2520orally%2520efficacious%2520inhibitor%2520of%2520the%2520Met%2520kinase%2520superfamily%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2009%26volume%3D52%26spage%3D1251%26epage%3D1254%26doi%3D10.1021%2Fjm801586s" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group">Holland, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pan, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Franci, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chang, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duan, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torneros, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heckrodt, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ding, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Apatira, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chua, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brandt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pine, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Goff, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Singh, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Payan, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hitoshi, Y.</span><span> </span><span class="NLM_article-title">R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">1544</span><span class="NLM_x">–</span> <span class="NLM_lpage">1554</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-09-2997</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-09-2997" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2010&pages=1544-1554&author=S.+J.+Hollandauthor=A.+Panauthor=C.+Franciauthor=Y.+Huauthor=B.+Changauthor=W.+Liauthor=M.+Duanauthor=A.+Tornerosauthor=J.+Yuauthor=T.+J.+Heckrodtauthor=J.+Zhangauthor=P.+Dingauthor=A.+Apatiraauthor=J.+Chuaauthor=R.+Brandtauthor=P.+Pineauthor=D.+Goffauthor=R.+Singhauthor=D.+G.+Payanauthor=Y.+Hitoshi&title=R428%2C+a+selective+small+molecule+inhibitor+of+Axl+kinase%2C+blocks+tumor+spread+and+prolongs+survival+in+models+of+metastatic+breast+cancer&doi=10.1158%2F0008-5472.CAN-09-2997"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-09-2997&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-09-2997%26sid%3Dliteratum%253Aachs%26aulast%3DHolland%26aufirst%3DS.%2BJ.%26aulast%3DPan%26aufirst%3DA.%26aulast%3DFranci%26aufirst%3DC.%26aulast%3DHu%26aufirst%3DY.%26aulast%3DChang%26aufirst%3DB.%26aulast%3DLi%26aufirst%3DW.%26aulast%3DDuan%26aufirst%3DM.%26aulast%3DTorneros%26aufirst%3DA.%26aulast%3DYu%26aufirst%3DJ.%26aulast%3DHeckrodt%26aufirst%3DT.%2BJ.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DDing%26aufirst%3DP.%26aulast%3DApatira%26aufirst%3DA.%26aulast%3DChua%26aufirst%3DJ.%26aulast%3DBrandt%26aufirst%3DR.%26aulast%3DPine%26aufirst%3DP.%26aulast%3DGoff%26aufirst%3DD.%26aulast%3DSingh%26aufirst%3DR.%26aulast%3DPayan%26aufirst%3DD.%2BG.%26aulast%3DHitoshi%26aufirst%3DY.%26atitle%3DR428%252C%2520a%2520selective%2520small%2520molecule%2520inhibitor%2520of%2520Axl%2520kinase%252C%2520blocks%2520tumor%2520spread%2520and%2520prolongs%2520survival%2520in%2520models%2520of%2520metastatic%2520breast%2520cancer%26jtitle%3DCancer%2520Res.%26date%3D2010%26volume%3D70%26spage%3D1544%26epage%3D1554%26doi%3D10.1158%2F0008-5472.CAN-09-2997" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group">Zhao, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knapp, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span> </span><span class="NLM_article-title">Exploration of type II binding mode: A privileged approach for kinase inhibitor focused drug discovery?</span> <span class="citation_source-journal">ACS Chem. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">9</span><span class="NLM_x">, </span> <span class="NLM_fpage">1230</span><span class="NLM_x">–</span> <span class="NLM_lpage">1241</span><span class="refDoi"> DOI: 10.1021/cb500129t</span> </span><div class="citationLinks">[<a href="/doi/10.1021/cb500129t" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2014&pages=1230-1241&author=Z.+Zhaoauthor=H.+Wuauthor=L.+Wangauthor=Y.+Liuauthor=S.+Knappauthor=Q.+Liuauthor=N.+S.+Gray&title=Exploration+of+type+II+binding+mode%3A+A+privileged+approach+for+kinase+inhibitor+focused+drug+discovery%3F&doi=10.1021%2Fcb500129t"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Exploration of Type II Binding Mode: A Privileged Approach for Kinase Inhibitor Focused Drug Discovery?</span></div><div class="casAuthors">Zhao, Zheng; Wu, Hong; Wang, Li; Liu, Yi; Knapp, Stefan; Liu, Qingsong; Gray, Nathanael S.</div><div class="citationInfo"><span class="NLM_cas:title">ACS Chemical Biology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1230-1241</span>CODEN:
                <span class="NLM_cas:coden">ACBCCT</span>;
        ISSN:<span class="NLM_cas:issn">1554-8929</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The ATP site of kinases displays remarkable conformational flexibility when accommodating chem. diverse small mol. inhibitors.  The so-called activation segment, whose conformation controls catalytic activity and access to the substrate binding pocket, can undergo a large conformational change with the active state assuming a 'DFG-in' and an inactive state assuming a 'DFG-out' conformation.  Compds. that preferentially bind to the DFG-out conformation are typically called 'type II' inhibitors in contrast to 'type I' inhibitors that bind to the DFG-in conformation.  This review surveys the large no. of type II inhibitors that have been developed and provides an anal. of their crystallog. detd. binding modes.  Using a small library of type II inhibitors, we demonstrate that more than 200 kinases can be targeted, suggesting that type II inhibitors may not be intrinsically more selective than type I inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq4jYt6Db3Ap7Vg90H21EOLACvtfcHk0lgF7JH0kdf5Ow"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXmtV2nt7s%253D&md5=95bf185ff7f973eda5a65f4096bfaa82</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fcb500129t&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fcb500129t%26sid%3Dliteratum%253Aachs%26aulast%3DZhao%26aufirst%3DZ.%26aulast%3DWu%26aufirst%3DH.%26aulast%3DWang%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DY.%26aulast%3DKnapp%26aufirst%3DS.%26aulast%3DLiu%26aufirst%3DQ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26atitle%3DExploration%2520of%2520type%2520II%2520binding%2520mode%253A%2520A%2520privileged%2520approach%2520for%2520kinase%2520inhibitor%2520focused%2520drug%2520discovery%253F%26jtitle%3DACS%2520Chem.%2520Biol.%26date%3D2014%26volume%3D9%26spage%3D1230%26epage%3D1241%26doi%3D10.1021%2Fcb500129t" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Won, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mock, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lou, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lougheed, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zaks, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wooster, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greshock, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">8009</span><span class="NLM_x">–</span> <span class="NLM_lpage">8016</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-08-4889</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-08-4889" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19808973" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2009&pages=8009-8016&author=F.+Qianauthor=S.+Engstauthor=K.+Yamaguchiauthor=P.+Yuauthor=K.+A.+Wonauthor=L.+Mockauthor=T.+Louauthor=J.+Tanauthor=C.+Liauthor=D.+Tamauthor=J.+Lougheedauthor=F.+M.+Yakesauthor=F.+Bentzienauthor=W.+Xuauthor=T.+Zaksauthor=R.+Woosterauthor=J.+Greshockauthor=A.+H.+Joly&title=Inhibition+of+tumor+cell+growth%2C+invasion%2C+and+metastasis+by+EXEL-2880+%28XL880%2C+GSK1363089%29%2C+a+novel+inhibitor+of+HGF+and+VEGF+receptor+tyrosine+kinases&doi=10.1158%2F0008-5472.CAN-08-4889"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of Tumor Cell Growth, Invasion, and Metastasis by EXEL-2880 (XL880, GSK1363089), a Novel Inhibitor of HGF and VEGF Receptor Tyrosine Kinases</span></div><div class="casAuthors">Qian, Fawn; Engst, Stefan; Yamaguchi, Kyoko; Yu, Peiwen; Won, Kwang-Ai; Mock, Lillian; Lou, Tracy; Tan, Jenny; Li, Connie; Tam, Danny; Lougheed, Julie; Yakes, F. Michael; Bentzien, Frauke; Xu, Wei; Zaks, Tal; Wooster, Richard; Greshock, Joel; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">8009-8016</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), are overexpressed and/or activated in a wide variety of human malignancies.  Vascular endothelial growth factor (VEGF) receptors are expressed on the surface of vascular endothelial cells and cooperate with Met to induce tumor invasion and vascularization.  EXEL-2880 (XL880, GSK1363089) is a small-mol. kinase inhibitor that targets members of the HGF and VEGF receptor tyrosine kinase families, with addnl. inhibitory activity toward KIT, Flt-3, platelet-derived growth factor receptor β, and Tie-2.  Binding of EXEL-2880 to Met and VEGF receptor 2 (KDR) is characterized by a very slow off-rate, consistent with X-ray crystallog. data showing that the inhibitor is deeply bound in the Met kinase active site cleft.  EXEL-2880 inhibits cellular HGF-induced Met phosphorylation and VEGF-induced extracellular signal-regulated kinase phosphorylation and prevents both HGF-induced responses of tumor cells and HGF/VEGF-induced responses of endothelial cells.  In addn., EXEL-2880 prevents anchorage-independent proliferation of tumor cells under both normoxic and hypoxic conditions.  In vivo, these effects produce significant dose-dependent inhibition of tumor burden in an exptl. model of lung metastasis.  Collectively, these data indicate that EXEL-2880 may prevent tumor growth through a direct effect on tumor cell proliferation and by inhibition of invasion and angiogenesis mediated by HGF and VEGF receptors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoviVE_HZ5p_bVg90H21EOLACvtfcHk0lhDS2FvL8Hygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXht1ynurbF&md5=f3bf5b432ee42b164d23b690828e3c78</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-08-4889&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-08-4889%26sid%3Dliteratum%253Aachs%26aulast%3DQian%26aufirst%3DF.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DWon%26aufirst%3DK.%2BA.%26aulast%3DMock%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DT.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DLi%26aufirst%3DC.%26aulast%3DTam%26aufirst%3DD.%26aulast%3DLougheed%26aufirst%3DJ.%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DXu%26aufirst%3DW.%26aulast%3DZaks%26aufirst%3DT.%26aulast%3DWooster%26aufirst%3DR.%26aulast%3DGreshock%26aufirst%3DJ.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DInhibition%2520of%2520tumor%2520cell%2520growth%252C%2520invasion%252C%2520and%2520metastasis%2520by%2520EXEL-2880%2520%2528XL880%252C%2520GSK1363089%2529%252C%2520a%2520novel%2520inhibitor%2520of%2520HGF%2520and%2520VEGF%2520receptor%2520tyrosine%2520kinases%26jtitle%3DCancer%2520Res.%26date%3D2009%26volume%3D69%26spage%3D8009%26epage%3D8016%26doi%3D10.1158%2F0008-5472.CAN-08-4889" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><a href="http://ClinicalTrials.gov" class="extLink">ClinicalTrials.gov</a> (accessed Sep 30,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">) </span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar?hl=en&q=ClinicalTrials.gov+%28accessed+Sep+30%2C+2015%29+."target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dweb%26sid%3Dliteratum%253Aachs%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group">Yakes, F. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamaguchi, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shi, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chu, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bentzien, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cancilla, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orf, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">You, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Laird, A. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engst, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lesch, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chou, Y. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joly, A. H.</span><span> </span><span class="NLM_article-title">Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">10</span><span class="NLM_x">, </span> <span class="NLM_fpage">2298</span><span class="NLM_x">–</span> <span class="NLM_lpage">2308</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-11-0264</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-11-0264" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=21926191" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2011&pages=2298-2308&author=F.+M.+Yakesauthor=J.+Chenauthor=J.+Tanauthor=K.+Yamaguchiauthor=Y.+Shiauthor=P.+Yuauthor=F.+Qianauthor=F.+Chuauthor=F.+Bentzienauthor=B.+Cancillaauthor=J.+Orfauthor=A.+Youauthor=A.+D.+Lairdauthor=S.+Engstauthor=L.+Leeauthor=J.+Leschauthor=Y.+C.+Chouauthor=A.+H.+Joly&title=Cabozantinib+%28XL184%29%2C+a+novel+MET+and+VEGFR2+inhibitor%2C+simultaneously+suppresses+metastasis%2C+angiogenesis%2C+and+tumor+growth&doi=10.1158%2F1535-7163.MCT-11-0264"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib (XL184), a Novel MET and VEGFR2 Inhibitor, Simultaneously Suppresses Metastasis, Angiogenesis, and Tumor Growth</span></div><div class="casAuthors">Yakes, F. Michael; Chen, Jason; Tan, Jenny; Yamaguchi, Kyoko; Shi, Yongchang; Yu, Peiwen; Qian, Fawn; Chu, Felix; Bentzien, Frauke; Cancilla, Belinda; Orf, Jessica; You, Andrew; Laird, A. Douglas; Engst, Stefan; Lee, Lillian; Lesch, Justin; Chou, Yu-Chien; Joly, Alison H.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">2298-2308</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The signaling pathway of the receptor tyrosine kinase MET and its ligand hepatocyte growth factor (HGF) is important for cell growth, survival, and motility and is functionally linked to the signaling pathway of VEGF, which is widely recognized as a key effector in angiogenesis and cancer progression.  Dysregulation of the MET/VEGF axis is found in a no. of human malignancies and has been assocd. with tumorigenesis.  Cabozantinib (XL184) is a small-mol. kinase inhibitor with potent activity toward MET and VEGF receptor 2 (VEGFR2), as well as a no. of other receptor tyrosine kinases that have also been implicated in tumor pathobiol., including RET, KIT, AXL, and FLT3.  Treatment with cabozantinib inhibited MET and VEGFR2 phosphorylation in vitro and in tumor models in vivo and led to significant redns. in cell invasion in vitro.  In mouse models, cabozantinib dramatically altered tumor pathol., resulting in decreased tumor and endothelial cell proliferation coupled with increased apoptosis and dose-dependent inhibition of tumor growth in breast, lung, and glioma tumor models.  Importantly, treatment with cabozantinib did not increase lung tumor burden in an exptl. model of metastasis, which has been obsd. with inhibitors of VEGF signaling that do not target MET.  Collectively, these data suggest that cabozantinib is a promising agent for inhibiting tumor angiogenesis and metastasis in cancers with dysregulated MET and VEGFR signaling.  Mol Cancer Ther; 10(12); 2298-308.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoGtQ_JaTP9IrVg90H21EOLACvtfcHk0lhDS2FvL8Hygw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhsFylurnF&md5=3f573795ecee42deeee25005f991868f</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-11-0264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-11-0264%26sid%3Dliteratum%253Aachs%26aulast%3DYakes%26aufirst%3DF.%2BM.%26aulast%3DChen%26aufirst%3DJ.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DYamaguchi%26aufirst%3DK.%26aulast%3DShi%26aufirst%3DY.%26aulast%3DYu%26aufirst%3DP.%26aulast%3DQian%26aufirst%3DF.%26aulast%3DChu%26aufirst%3DF.%26aulast%3DBentzien%26aufirst%3DF.%26aulast%3DCancilla%26aufirst%3DB.%26aulast%3DOrf%26aufirst%3DJ.%26aulast%3DYou%26aufirst%3DA.%26aulast%3DLaird%26aufirst%3DA.%2BD.%26aulast%3DEngst%26aufirst%3DS.%26aulast%3DLee%26aufirst%3DL.%26aulast%3DLesch%26aufirst%3DJ.%26aulast%3DChou%26aufirst%3DY.%2BC.%26aulast%3DJoly%26aufirst%3DA.%2BH.%26atitle%3DCabozantinib%2520%2528XL184%2529%252C%2520a%2520novel%2520MET%2520and%2520VEGFR2%2520inhibitor%252C%2520simultaneously%2520suppresses%2520metastasis%252C%2520angiogenesis%252C%2520and%2520tumor%2520growth%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2011%26volume%3D10%26spage%3D2298%26epage%3D2308%26doi%3D10.1158%2F1535-7163.MCT-11-0264" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group">Choueiri, T. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Escudier, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Powles, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mainwaring, P. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rini, B. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Donskov, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hammers, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hutson, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peltola, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Roth, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bjarnason, G. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Géczi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keam, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroto, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heng, D. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidinger, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kantoff, P. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borgman-Hagey, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scheffold, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schwab, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tannir, N. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Motzer, R. J.</span><span> </span><span class="NLM_article-title">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">373</span><span class="NLM_x">, </span> <span class="NLM_fpage">1814</span><span class="refDoi"> DOI: 10.1056/NEJMoa1510016</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1510016" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=26406150" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=373&publication_year=2015&pages=1814&author=T.+K.+Choueiriauthor=B.+Escudierauthor=T.+Powlesauthor=P.+N.+Mainwaringauthor=B.+I.+Riniauthor=F.+Donskovauthor=H.+Hammersauthor=T.+E.+Hutsonauthor=J.+L.+Leeauthor=K.+Peltolaauthor=B.+J.+Rothauthor=G.+A.+Bjarnasonauthor=L.+G%C3%A9cziauthor=B.+Keamauthor=P.+Marotoauthor=D.+Y.+Hengauthor=M.+Schmidingerauthor=P.+W.+Kantoffauthor=A.+Borgman-Hageyauthor=C.+Hesselauthor=C.+Scheffoldauthor=G.+M.+Schwabauthor=N.+M.+Tannirauthor=R.+J.+Motzer&title=Cabozantinib+versus+everolimus+in+advanced+renal-cell+carcinoma&doi=10.1056%2FNEJMoa1510016"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib versus everolimus in advanced renal-cell carcinoma</span></div><div class="casAuthors">Choueiri, T. K.; Escudier, B.; Powles, T.; Mainwaring, P. N.; Rini, B. I.; Donskov, F.; Hammers, H.; Hutson, T. E.; Lee, J.-L.; Peltola, K.; Roth, B. J.; Bjarnason, G. A.; Geczi, L.; Keam, B.; Maroto, P.; Heng, D. Y. C.; Schmidinger, M.; Kantoff, P. W.; Borgman-Hagey, A.; Hessel, C.; Scheffold, C.; Schwab, G. M.; Tannir, N. M.; Motzer, R. J.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">373</span>
        (<span class="NLM_cas:issue">19</span>),
    <span class="NLM_cas:pages">1814-1823</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">1533-4406</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">Cabozantinib is an oral, small-mol. tyrosine kinase inhibitor that targets vascular endothelial growth factor receptor (VEGFR) as well as MET and AXL, each of which has been implicated in the pathobiol. of metastatic renal-cell carcinoma or in the development of resistance to antiangiogenic drugs.  This randomized, open-label, phase 3 trial evaluated the efficacy of cabozantinib, as compared with everolimus, in patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.  We randomly assigned 658 patients to receive cabozantinib at a dose of 60 mg daily or everolimus at a dose of 10 mg daily.  The primary end point was progression- free survival.  Secondary efficacy end points were overall survival and objective response rate.  Median progression-free survival was 7.4 mo with cabozantinib and 3.8 mo with everolimus.  The rate of progression or death was 42% lower with cabozantinib than with everolimus (hazard ratio, 0.58; 95% confidence interval [CI] 0.45 to 0.75; P<0.001).  The objective response rate was 21% with cabozantinib and 5% with everolimus (P<0.001).  A planned interim anal. showed that overall survival was longer with cabozantinib than with everolimus (hazard ratio for death, 0.67; 95% CI, 0.51 to 0.89; P = 0.005) but did not cross the significance boundary for the interim anal.  Adverse events were managed with dose redns.; doses were reduced in 60% of the patients who received cabozantinib and in 25% of those who received everolimus.  Discontinuation of study treatment owing to adverse events occurred in 9% of the patients who received cabozantinib and in 10% of those who received everolimus.  Progression-free survival was longer with cabozantinib than with everolimus among patients with renal-cell carcinoma that had progressed after VEGFR-targeted therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGobvjc8n5w4zbVg90H21EOLACvtfcHk0lhAF0YC7oEcMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnvFCktLY%253D&md5=09927cde8f581f4ff2060679df1ff5b8</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1510016&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1510016%26sid%3Dliteratum%253Aachs%26aulast%3DChoueiri%26aufirst%3DT.%2BK.%26aulast%3DEscudier%26aufirst%3DB.%26aulast%3DPowles%26aufirst%3DT.%26aulast%3DMainwaring%26aufirst%3DP.%2BN.%26aulast%3DRini%26aufirst%3DB.%2BI.%26aulast%3DDonskov%26aufirst%3DF.%26aulast%3DHammers%26aufirst%3DH.%26aulast%3DHutson%26aufirst%3DT.%2BE.%26aulast%3DLee%26aufirst%3DJ.%2BL.%26aulast%3DPeltola%26aufirst%3DK.%26aulast%3DRoth%26aufirst%3DB.%2BJ.%26aulast%3DBjarnason%26aufirst%3DG.%2BA.%26aulast%3DG%25C3%25A9czi%26aufirst%3DL.%26aulast%3DKeam%26aufirst%3DB.%26aulast%3DMaroto%26aufirst%3DP.%26aulast%3DHeng%26aufirst%3DD.%2BY.%26aulast%3DSchmidinger%26aufirst%3DM.%26aulast%3DKantoff%26aufirst%3DP.%2BW.%26aulast%3DBorgman-Hagey%26aufirst%3DA.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DScheffold%26aufirst%3DC.%26aulast%3DSchwab%26aufirst%3DG.%2BM.%26aulast%3DTannir%26aufirst%3DN.%2BM.%26aulast%3DMotzer%26aufirst%3DR.%2BJ.%26atitle%3DCabozantinib%2520versus%2520everolimus%2520in%2520advanced%2520renal-cell%2520carcinoma%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2015%26volume%3D373%26spage%3D1814%26doi%3D10.1056%2FNEJMoa1510016" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group">Yan, S. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peek, V. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ajamie, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Buchanan, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graff, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Heidler, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hui, Y. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huss, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Konicek, B. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manro, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shih, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, T. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stout, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uhlik, M. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Um, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, W. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhong, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walgren, R. A.</span><span> </span><span class="NLM_article-title">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span> <span class="citation_source-journal">Invest. New Drugs</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">833</span><span class="NLM_x">–</span> <span class="NLM_lpage">844</span><span class="refDoi"> DOI: 10.1007/s10637-012-9912-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs10637-012-9912-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23275061" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=833-844&author=S.+B.+Yanauthor=V.+L.+Peekauthor=R.+Ajamieauthor=S.+G.+Buchananauthor=J.+R.+Graffauthor=S.+A.+Heidlerauthor=Y.+H.+Huiauthor=K.+L.+Hussauthor=B.+W.+Konicekauthor=J.+R.+Manroauthor=C.+Shihauthor=J.+A.+Stewartauthor=T.+R.+Stewartauthor=S.+L.+Stoutauthor=M.+T.+Uhlikauthor=S.+L.+Umauthor=Y.+Wangauthor=W.+Wuauthor=L.+Yanauthor=W.+J.+Yangauthor=B.+Zhongauthor=R.+A.+Walgren&title=LY2801653+is+an+orally+bioavailable+multi-kinase+inhibitor+with+potent+activity+against+MET%2C+MST1R%2C+and+other+oncoproteins%2C+and+displays+anti-tumor+activities+in+mouse+xenograft+models&doi=10.1007%2Fs10637-012-9912-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit59R"><div class="casContent"><span class="casTitleNuber">59</span><div class="casTitle"><span class="NLM_cas:atitle">LY2801653 is an orally bioavailable multi-kinase inhibitor with potent activity against MET, MST1R, and other oncoproteins, and displays anti-tumor activities in mouse xenograft models</span></div><div class="casAuthors">Yan, S. Betty; Peek, Victoria L.; Ajamie, Rose; Buchanan, Sean G.; Graff, Jeremy R.; Heidler, Steven A.; Hui, Yu-Hua; Huss, Karen L.; Konicek, Bruce W.; Manro, Jason R.; Shih, Chuan; Stewart, Julie A.; Stewart, Trent R.; Stout, Stephanie L.; Uhlik, Mark T.; Um, Suzane L.; Wang, Yong; Wu, Wenjuan; Yan, Lei; Yang, Wei J.; Zhong, Boyu; Walgren, Richard A.</div><div class="citationInfo"><span class="NLM_cas:title">Investigational New Drugs</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">833-844</span>CODEN:
                <span class="NLM_cas:coden">INNDDK</span>;
        ISSN:<span class="NLM_cas:issn">0167-6997</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">The HGF/MET signaling pathway regulates a wide variety of normal cellular functions that can be subverted to support neoplasia, including cell proliferation, survival, apoptosis, scattering and motility, invasion, and angiogenesis.  MET over-expression (with or without gene amplification), aberrant autocrine or paracrine ligand prodn., and missense MET mutations are mechanisms that lead to activation of the MET pathway in tumors and are assocd. with poor prognostic outcome.  We report here preclin. development of a potent, orally bioavailable, small-mol. inhibitor LY2801653 targeting MET kinase.  LY2801653 is a type-II ATP competitive, slow-off inhibitor of MET tyrosine kinase with a dissocn. const. (Ki) of 2 nM, a pharmacodynamic residence time (Koff) of 0.00132 min-1 and t1/2 of 525 min.  LY2801653 demonstrated in vitro effects on MET pathway-dependent cell scattering and cell proliferation; in vivo anti-tumor effects in MET amplified (MKN45), MET autocrine (U-87MG, and KP4) and MET over-expressed (H441) xenograft models; and in vivo vessel normalization effects.  LY2801653 also maintained potency against 13 MET variants, each bearing a single-point mutation.  In subsequent nonclin. characterization, LY2801653 was found to have potent activity against several other receptor tyrosine oncokinases including MST1R, FLT3, AXL, MERTK, TEK, ROS1, DDR1/2 and against the serine/threonine kinases MKNK1/2.  The potential value of MET and other inhibited targets within a no. of malignancies (such as colon, bile ducts, and lung) is discussed.  LY2801653 is currently in phase 1 clin. testing in patients with advanced cancer (trial I3O-MC-JSBA, NCT01285037).</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo04limPWxrHLVg90H21EOLACvtfcHk0lhAF0YC7oEcMA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFOksLzE&md5=9d80bcdb04ebec24e2516dcf26821ad3</span></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1007%2Fs10637-012-9912-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs10637-012-9912-9%26sid%3Dliteratum%253Aachs%26aulast%3DYan%26aufirst%3DS.%2BB.%26aulast%3DPeek%26aufirst%3DV.%2BL.%26aulast%3DAjamie%26aufirst%3DR.%26aulast%3DBuchanan%26aufirst%3DS.%2BG.%26aulast%3DGraff%26aufirst%3DJ.%2BR.%26aulast%3DHeidler%26aufirst%3DS.%2BA.%26aulast%3DHui%26aufirst%3DY.%2BH.%26aulast%3DHuss%26aufirst%3DK.%2BL.%26aulast%3DKonicek%26aufirst%3DB.%2BW.%26aulast%3DManro%26aufirst%3DJ.%2BR.%26aulast%3DShih%26aufirst%3DC.%26aulast%3DStewart%26aufirst%3DJ.%2BA.%26aulast%3DStewart%26aufirst%3DT.%2BR.%26aulast%3DStout%26aufirst%3DS.%2BL.%26aulast%3DUhlik%26aufirst%3DM.%2BT.%26aulast%3DUm%26aufirst%3DS.%2BL.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DWu%26aufirst%3DW.%26aulast%3DYan%26aufirst%3DL.%26aulast%3DYang%26aufirst%3DW.%2BJ.%26aulast%3DZhong%26aufirst%3DB.%26aulast%3DWalgren%26aufirst%3DR.%2BA.%26atitle%3DLY2801653%2520is%2520an%2520orally%2520bioavailable%2520multi-kinase%2520inhibitor%2520with%2520potent%2520activity%2520against%2520MET%252C%2520MST1R%252C%2520and%2520other%2520oncoproteins%252C%2520and%2520displays%2520anti-tumor%2520activities%2520in%2520mouse%2520xenograft%2520models%26jtitle%3DInvest.%2520New%2520Drugs%26date%3D2013%26volume%3D31%26spage%3D833%26epage%3D844%26doi%3D10.1007%2Fs10637-012-9912-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group">Bonfils, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beaulieu, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fournel, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ste-Croix, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besterman, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maroun, C. R.</span><span> </span><span class="NLM_article-title">The combination of MGCD265, a MET/VEGFR inhibitor in clinical development, and erlotinib potently inhibits tumor growth by altering multiple pathways including glycolysis</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">72</span><span class="NLM_x">, </span> <span class="NLM_fpage">1790</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2012-1790</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1538-7445.AM2012-1790" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=72&publication_year=2012&pages=1790&author=C.+Bonfilsauthor=N.+Beaulieuauthor=M.+Fournelauthor=H.+Ste-Croixauthor=J.+M.+Bestermanauthor=C.+R.+Maroun&title=The+combination+of+MGCD265%2C+a+MET%2FVEGFR+inhibitor+in+clinical+development%2C+and+erlotinib+potently+inhibits+tumor+growth+by+altering+multiple+pathways+including+glycolysis&doi=10.1158%2F1538-7445.AM2012-1790"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2012-1790&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2012-1790%26sid%3Dliteratum%253Aachs%26aulast%3DBonfils%26aufirst%3DC.%26aulast%3DBeaulieu%26aufirst%3DN.%26aulast%3DFournel%26aufirst%3DM.%26aulast%3DSte-Croix%26aufirst%3DH.%26aulast%3DBesterman%26aufirst%3DJ.%2BM.%26aulast%3DMaroun%26aufirst%3DC.%2BR.%26atitle%3DThe%2520combination%2520of%2520MGCD265%252C%2520a%2520MET%252FVEGFR%2520inhibitor%2520in%2520clinical%2520development%252C%2520and%2520erlotinib%2520potently%2520inhibits%2520tumor%2520growth%2520by%2520altering%2520multiple%2520pathways%2520including%2520glycolysis%26jtitle%3DCancer%2520Res.%26date%3D2012%26volume%3D72%26spage%3D1790%26doi%3D10.1158%2F1538-7445.AM2012-1790" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group">Rho, J. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, E. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yoon, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Park, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bae, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, C. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. C.</span><span> </span><span class="NLM_article-title">MET and AXL inhibitor NPS-1034 exerts efficacy against lung cancer cells resistant to EGFR kinase inhibitors because of MET or AXL activation</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">253</span><span class="NLM_x">–</span> <span class="NLM_lpage">262</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-1103</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-1103" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24165158" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=253-262&author=J.+K.+Rhoauthor=Y.+J.+Choiauthor=S.+Y.+Kimauthor=T.+W.+Kimauthor=E.+K.+Choiauthor=S.+J.+Yoonauthor=B.+M.+Parkauthor=E.+Parkauthor=J.+H.+Baeauthor=C.+M.+Choiauthor=J.+C.+Lee&title=MET+and+AXL+inhibitor+NPS-1034+exerts+efficacy+against+lung+cancer+cells+resistant+to+EGFR+kinase+inhibitors+because+of+MET+or+AXL+activation&doi=10.1158%2F0008-5472.CAN-13-1103"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">MET and AXL Inhibitor NPS-1034 Exerts Efficacy against Lung Cancer Cells Resistant to EGFR Kinase Inhibitors Because of MET or AXL Activation</span></div><div class="casAuthors">Rho, Jin Kyung; Choi, Yun Jung; Kim, Seon Ye; Kim, Tae Won; Choi, Eun Kyung; Yoon, Seon-Joo; Park, Bu Man; Park, Eunhye; Bae, Jong Hwan; Choi, Chang-Min; Lee, Jae Cheol</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">74</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">253-262</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">In non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, acquired resistance to EGFR-tyrosine kinase inhibitors (EGFR-TK1) can occur through a generation of bypass signals such as MET or AXL activation.  In this study, we investigated the antitumor activity of NPS-1034, a newly developed drug that targets both MET and AXL, in NSCLC cells with acquired resistance to gefitinib or erlotinib (HCC827/GR and HCC827/ER, resp.).  Characterization of H820 cells and evaluation of NPS-1034 efficacy in these cells were also performed.  The resistance of HCC827/GR was mediated by MET activation, whereas AXL activation led to resistance in HCC827/ER.  The combination of gefitinib or erlotinib with NPS-1034 synergistically inhibited cell proliferation and induced cell death in both resistant cell lines.  Accordingly, suppression of Akt was noted only in the presence of treatment with both drugs.  NPS-1034 was also effective in xenograft mouse models of HCC827/GR.  Although the H820 cell line was reported previously to have T790M and MET amplification, we discovered that AXL was also activated in this cell line.  There were no antitumor effects of siRNA or inhibitors specific for EGFR or MET, whereas combined treatment with AXL siRNA or NPS-1034 and EGFR-TKIs controlled H820 cells, suggesting that AXL is the main signal responsible for resistance.  In addn., NPS-1034 inhibited cell proliferation as well as ROS1 activity in HCC78 cells with ROS1 rearrangement.  Our results establish the efficacy of NPS-1034 in NSCLC cells rendered resistant to EGFR-TKIs because of MET or AXL activation or ROS1 rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqzVRl7xbUBLrVg90H21EOLACvtfcHk0liYXBlnuuhIZQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXislKjtA%253D%253D&md5=35929f2dcfd5d1502ba745f367dccd27</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-1103&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-1103%26sid%3Dliteratum%253Aachs%26aulast%3DRho%26aufirst%3DJ.%2BK.%26aulast%3DChoi%26aufirst%3DY.%2BJ.%26aulast%3DKim%26aufirst%3DS.%2BY.%26aulast%3DKim%26aufirst%3DT.%2BW.%26aulast%3DChoi%26aufirst%3DE.%2BK.%26aulast%3DYoon%26aufirst%3DS.%2BJ.%26aulast%3DPark%26aufirst%3DB.%2BM.%26aulast%3DPark%26aufirst%3DE.%26aulast%3DBae%26aufirst%3DJ.%2BH.%26aulast%3DChoi%26aufirst%3DC.%2BM.%26aulast%3DLee%26aufirst%3DJ.%2BC.%26atitle%3DMET%2520and%2520AXL%2520inhibitor%2520NPS-1034%2520exerts%2520efficacy%2520against%2520lung%2520cancer%2520cells%2520resistant%2520to%2520EGFR%2520kinase%2520inhibitors%2520because%2520of%2520MET%2520or%2520AXL%2520activation%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D253%26epage%3D262%26doi%3D10.1158%2F0008-5472.CAN-13-1103" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group">Paolino, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choidas, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wallner, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pranjic, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Uribesalgo, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loeser, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jamieson, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Langdon, W. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ikeda, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fededa, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cronin, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nitsch, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz-Fademrecht, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eickhoff, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Menninger, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unger, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Torka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gruber, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinterleitner, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baier, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wolf, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Klebl, B. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Penninger, J. M.</span><span> </span><span class="NLM_article-title">The E3 ligase Cbl-b and TAM receptors regulate cancer metastasis via natural killer cells</span> <span class="citation_source-journal">Nature</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">507</span><span class="NLM_x">, </span> <span class="NLM_fpage">508</span><span class="NLM_x">–</span> <span class="NLM_lpage">512</span><span class="refDoi"> DOI: 10.1038/nature12998</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnature12998" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=507&publication_year=2014&pages=508-512&author=M.+Paolinoauthor=A.+Choidasauthor=S.+Wallnerauthor=B.+Pranjicauthor=I.+Uribesalgoauthor=S.+Loeserauthor=A.+M.+Jamiesonauthor=W.+Y.+Langdonauthor=F.+Ikedaauthor=J.+P.+Fededaauthor=S.+J.+Croninauthor=R.+Nitschauthor=C.+Schultz-Fademrechtauthor=J.+Eickhoffauthor=S.+Menningerauthor=A.+Ungerauthor=R.+Torkaauthor=T.+Gruberauthor=R.+Hinterleitnerauthor=G.+Baierauthor=D.+Wolfauthor=A.+Ullrichauthor=B.+M.+Kleblauthor=J.+M.+Penninger&title=The+E3+ligase+Cbl-b+and+TAM+receptors+regulate+cancer+metastasis+via+natural+killer+cells&doi=10.1038%2Fnature12998"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1038%2Fnature12998&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnature12998%26sid%3Dliteratum%253Aachs%26aulast%3DPaolino%26aufirst%3DM.%26aulast%3DChoidas%26aufirst%3DA.%26aulast%3DWallner%26aufirst%3DS.%26aulast%3DPranjic%26aufirst%3DB.%26aulast%3DUribesalgo%26aufirst%3DI.%26aulast%3DLoeser%26aufirst%3DS.%26aulast%3DJamieson%26aufirst%3DA.%2BM.%26aulast%3DLangdon%26aufirst%3DW.%2BY.%26aulast%3DIkeda%26aufirst%3DF.%26aulast%3DFededa%26aufirst%3DJ.%2BP.%26aulast%3DCronin%26aufirst%3DS.%2BJ.%26aulast%3DNitsch%26aufirst%3DR.%26aulast%3DSchultz-Fademrecht%26aufirst%3DC.%26aulast%3DEickhoff%26aufirst%3DJ.%26aulast%3DMenninger%26aufirst%3DS.%26aulast%3DUnger%26aufirst%3DA.%26aulast%3DTorka%26aufirst%3DR.%26aulast%3DGruber%26aufirst%3DT.%26aulast%3DHinterleitner%26aufirst%3DR.%26aulast%3DBaier%26aufirst%3DG.%26aulast%3DWolf%26aufirst%3DD.%26aulast%3DUllrich%26aufirst%3DA.%26aulast%3DKlebl%26aufirst%3DB.%2BM.%26aulast%3DPenninger%26aufirst%3DJ.%2BM.%26atitle%3DThe%2520E3%2520ligase%2520Cbl-b%2520and%2520TAM%2520receptors%2520regulate%2520cancer%2520metastasis%2520via%2520natural%2520killer%2520cells%26jtitle%3DNature%26date%3D2014%26volume%3D507%26spage%3D508%26epage%3D512%26doi%3D10.1038%2Fnature12998" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group">Sholl, L.</span><span> </span><span class="NLM_article-title">Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring <i>AXL</i> Amplification</span>. Presented at the IASLC 16th World Conference on Lung Cancer, Denver, CO,<span class="NLM_x"> </span><span class="NLM_year">2015</span><span class="NLM_x">; </span>3611.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2015&author=L.+Sholl&title=Evaluation+of+the+MET%2FAxl+Receptor+Tyrosine+Kinase+%28RTK%29+Inhibitor+MGCD265+in+a+Patient+with+Metastatic+Non-Small+Cell+Lung+Cancer+%28NSCLC%29+Harboring+AXL+Amplification"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dsimple%26sid%3Dliteratum%253Aachs%26aulast%3DSholl%26aufirst%3DL.%26atitle%3DEvaluation%2520of%2520the%2520MET%252FAxl%2520Receptor%2520Tyrosine%2520Kinase%2520%2528RTK%2529%2520Inhibitor%2520MGCD265%2520in%2520a%2520Patient%2520with%2520Metastatic%2520Non-Small%2520Cell%2520Lung%2520Cancer%2520%2528NSCLC%2529%2520Harboring%2520AXL%2520Amplification%26date%3D2015" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group">Messoussi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Peyronnet, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Feneyrolles, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheve, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bougrin, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yasri, A.</span><span> </span><span class="NLM_article-title">Structural elucidation of the DFG-Asp in and DFG-Asp out states of TAM kinases and insight into the selectivity of their inhibitors</span> <span class="citation_source-journal">Molecules</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">16223</span><span class="NLM_x">–</span> <span class="NLM_lpage">16239</span><span class="refDoi"> DOI: 10.3390/molecules191016223</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.3390%2Fmolecules191016223" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2014&pages=16223-16239&author=A.+Messoussiauthor=L.+Peyronnetauthor=C.+Feneyrollesauthor=G.+Cheveauthor=K.+Bougrinauthor=A.+Yasri&title=Structural+elucidation+of+the+DFG-Asp+in+and+DFG-Asp+out+states+of+TAM+kinases+and+insight+into+the+selectivity+of+their+inhibitors&doi=10.3390%2Fmolecules191016223"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.3390%2Fmolecules191016223&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3390%252Fmolecules191016223%26sid%3Dliteratum%253Aachs%26aulast%3DMessoussi%26aufirst%3DA.%26aulast%3DPeyronnet%26aufirst%3DL.%26aulast%3DFeneyrolles%26aufirst%3DC.%26aulast%3DCheve%26aufirst%3DG.%26aulast%3DBougrin%26aufirst%3DK.%26aulast%3DYasri%26aufirst%3DA.%26atitle%3DStructural%2520elucidation%2520of%2520the%2520DFG-Asp%2520in%2520and%2520DFG-Asp%2520out%2520states%2520of%2520TAM%2520kinases%2520and%2520insight%2520into%2520the%2520selectivity%2520of%2520their%2520inhibitors%26jtitle%3DMolecules%26date%3D2014%26volume%3D19%26spage%3D16223%26epage%3D16239%26doi%3D10.3390%2Fmolecules191016223" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group">Remsing Rix, L. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rix, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Colinge, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hantschel, O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bennett, K. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stranzl, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baumgartner, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Valent, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Augustin, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Till, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Superti-Furga, G.</span><span> </span><span class="NLM_article-title">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span> <span class="citation_source-journal">Leukemia</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">23</span><span class="NLM_x">, </span> <span class="NLM_fpage">477</span><span class="NLM_x">–</span> <span class="NLM_lpage">485</span><span class="refDoi"> DOI: 10.1038/leu.2008.334</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fleu.2008.334" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19039322" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2009&pages=477-485&author=L.+L.+Remsing+Rixauthor=U.+Rixauthor=J.+Colingeauthor=O.+Hantschelauthor=K.+L.+Bennettauthor=T.+Stranzlauthor=A.+M%C3%BCllerauthor=C.+Baumgartnerauthor=P.+Valentauthor=M.+Augustinauthor=J.+H.+Tillauthor=G.+Superti-Furga&title=Global+target+profile+of+the+kinase+inhibitor+bosutinib+in+primary+chronic+myeloid+leukemia+cells&doi=10.1038%2Fleu.2008.334"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">Global target profile of the kinase inhibitor bosutinib in primary chronic myeloid leukemia cells</span></div><div class="casAuthors">Remsing Rix, L. L.; Rix, U.; Colinge, J.; Hantschel, O.; Bennett, K. L.; Stranzl, T.; Mueller, A.; Baumgartner, C.; Valent, P.; Augustin, M.; Till, J. H.; Superti-Furga, G.</div><div class="citationInfo"><span class="NLM_cas:title">Leukemia</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">477-485</span>CODEN:
                <span class="NLM_cas:coden">LEUKED</span>;
        ISSN:<span class="NLM_cas:issn">0887-6924</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The detailed mol. mechanism of action of second-generation BCR-ABL tyrosine kinase inhibitors, including perturbed targets and pathways, should contribute to rationalized therapy in chronic myeloid leukemia (CML) or in other affected diseases.  Here, we characterized the target profile of the dual SRC/ABL inhibitor bosutinib employing a two-tiered approach using chem. proteomics to identify natural binders in whole cell lysates of primary CML and K562 cells in parallel to in vitro kinase assays against a large recombinant kinase panel.  The combined strategy resulted in a global survey of bosutinib targets comprised of over 45 novel tyrosine and serine/threonine kinases.  We have found clear differences in the target patterns of bosutinib in primary CML cells vs. the K562 cell line.  A comparison of bosutinib with dasatinib across the whole kinase panel revealed overlapping, but distinct, inhibition profiles.  Common among those were the SRC, ABL and TEC family kinases.  Bosutinib did not inhibit KIT or platelet-derived growth factor receptor, but prominently targeted the apoptosis-linked STE20 kinases.  Although in vivo bosutinib is inactive against ABL T315I, we found this clin. important mutant to be enzymically inhibited in the mid-nanomolar range.  Finally, bosutinib is the first kinase inhibitor shown to target CAMK2G, recently implicated in myeloid leukemia cell proliferation.  Leukemia (2009) 23, 477-485; doi:10.1038/leu.2008.334; published online 27 Nov. 2008.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8u0ixFotIMLVg90H21EOLACvtfcHk0lh4KnwCvmRWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXivVKhu7w%253D&md5=b0d56d468ef66ddc2a6f012d08f8c1a4</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1038%2Fleu.2008.334&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fleu.2008.334%26sid%3Dliteratum%253Aachs%26aulast%3DRemsing%2BRix%26aufirst%3DL.%2BL.%26aulast%3DRix%26aufirst%3DU.%26aulast%3DColinge%26aufirst%3DJ.%26aulast%3DHantschel%26aufirst%3DO.%26aulast%3DBennett%26aufirst%3DK.%2BL.%26aulast%3DStranzl%26aufirst%3DT.%26aulast%3DM%25C3%25BCller%26aufirst%3DA.%26aulast%3DBaumgartner%26aufirst%3DC.%26aulast%3DValent%26aufirst%3DP.%26aulast%3DAugustin%26aufirst%3DM.%26aulast%3DTill%26aufirst%3DJ.%2BH.%26aulast%3DSuperti-Furga%26aufirst%3DG.%26atitle%3DGlobal%2520target%2520profile%2520of%2520the%2520kinase%2520inhibitor%2520bosutinib%2520in%2520primary%2520chronic%2520myeloid%2520leukemia%2520cells%26jtitle%3DLeukemia%26date%3D2009%26volume%3D23%26spage%3D477%26epage%3D485%26doi%3D10.1038%2Fleu.2008.334" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group">Zhang, Y. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheburkin, Y. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knyazev, Y. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Orfi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Szabadkai, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Daub, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kéri, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ullrich, A.</span><span> </span><span class="NLM_article-title">AXL is a potential target for therapeutic intervention in breast cancer progression</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">1905</span><span class="NLM_x">–</span> <span class="NLM_lpage">1915</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-2661</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-07-2661" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=1905-1915&author=Y.+X.+Zhangauthor=P.+G.+Knyazevauthor=Y.+V.+Cheburkinauthor=K.+Sharmaauthor=Y.+P.+Knyazevauthor=L.+Orfiauthor=I.+Szabadkaiauthor=H.+Daubauthor=G.+K%C3%A9riauthor=A.+Ullrich&title=AXL+is+a+potential+target+for+therapeutic+intervention+in+breast+cancer+progression&doi=10.1158%2F0008-5472.CAN-07-2661"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-2661&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-2661%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DY.%2BX.%26aulast%3DKnyazev%26aufirst%3DP.%2BG.%26aulast%3DCheburkin%26aufirst%3DY.%2BV.%26aulast%3DSharma%26aufirst%3DK.%26aulast%3DKnyazev%26aufirst%3DY.%2BP.%26aulast%3DOrfi%26aufirst%3DL.%26aulast%3DSzabadkai%26aufirst%3DI.%26aulast%3DDaub%26aufirst%3DH.%26aulast%3DK%25C3%25A9ri%26aufirst%3DG.%26aulast%3DUllrich%26aufirst%3DA.%26atitle%3DAXL%2520is%2520a%2520potential%2520target%2520for%2520therapeutic%2520intervention%2520in%2520breast%2520cancer%2520progression%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D1905%26epage%3D1915%26doi%3D10.1158%2F0008-5472.CAN-07-2661" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group">Wu, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nielsen, T. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clausen, M. H.</span><span> </span><span class="NLM_article-title">FDA-approved small-molecule kinase inhibitors</span> <span class="citation_source-journal">Trends Pharmacol. Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">36</span><span class="NLM_x">, </span> <span class="NLM_fpage">422</span><span class="NLM_x">–</span> <span class="NLM_lpage">439</span><span class="refDoi"> DOI: 10.1016/j.tips.2015.04.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.tips.2015.04.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25975227" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=2015&pages=422-439&author=P.+Wuauthor=T.+E.+Nielsenauthor=M.+H.+Clausen&title=FDA-approved+small-molecule+kinase+inhibitors&doi=10.1016%2Fj.tips.2015.04.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">FDA-approved small-molecule kinase inhibitors</span></div><div class="casAuthors">Wu, Peng; Nielsen, Thomas E.; Clausen, Mads H.</div><div class="citationInfo"><span class="NLM_cas:title">Trends in Pharmacological Sciences</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">7</span>),
    <span class="NLM_cas:pages">422-439</span>CODEN:
                <span class="NLM_cas:coden">TPHSDY</span>;
        ISSN:<span class="NLM_cas:issn">0165-6147</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">A review.  Kinases have emerged as one of the most intensively pursued targets in current pharmacol. research, esp. for cancer, due to their crit. roles in cellular signaling.  To date, the US FDA has approved 28 small-mol. kinase inhibitors, half of which were approved in the past 3 years.  While the clin. data of these approved mols. are widely presented and structure-activity relationship (SAR) has been reported for individual mols., an updated review that analyzes all approved mols. and summarizes current achievements and trends in the field has yet to be found.  Here we present all approved small-mol. kinase inhibitors with an emphasis on binding mechanism and structural features, summarize current challenges, and discuss future directions in this field.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrudyvM3eO09bVg90H21EOLACvtfcHk0lh4KnwCvmRWUA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXns1KisLg%253D&md5=a6aa3dbb11e6fe3001fa5fa03a4c950a</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1016%2Fj.tips.2015.04.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.tips.2015.04.005%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DP.%26aulast%3DNielsen%26aufirst%3DT.%2BE.%26aulast%3DClausen%26aufirst%3DM.%2BH.%26atitle%3DFDA-approved%2520small-molecule%2520kinase%2520inhibitors%26jtitle%3DTrends%2520Pharmacol.%2520Sci.%26date%3D2015%26volume%3D36%26spage%3D422%26epage%3D439%26doi%3D10.1016%2Fj.tips.2015.04.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group">Mori, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kaneko, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tanaka, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cho, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saito, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kondoh, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shimada, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuromitsu, S.</span><span> </span><span class="NLM_article-title">ASP2215, a novel FLT3/AXL inhibitor: preclinical evaluation in acute myeloid leukemia (AML)</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">7070</span></span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=7070&author=M.+Moriauthor=N.+Kanekoauthor=Y.+Uenoauthor=R.+Tanakaauthor=K.+Choauthor=R.+Saitoauthor=Y.+Kondohauthor=I.+Shimadaauthor=S.+Kuromitsu&title=ASP2215%2C+a+novel+FLT3%2FAXL+inhibitor%3A+preclinical+evaluation+in+acute+myeloid+leukemia+%28AML%29"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMori%26aufirst%3DM.%26aulast%3DKaneko%26aufirst%3DN.%26aulast%3DUeno%26aufirst%3DY.%26aulast%3DTanaka%26aufirst%3DR.%26aulast%3DCho%26aufirst%3DK.%26aulast%3DSaito%26aufirst%3DR.%26aulast%3DKondoh%26aufirst%3DY.%26aulast%3DShimada%26aufirst%3DI.%26aulast%3DKuromitsu%26aufirst%3DS.%26atitle%3DASP2215%252C%2520a%2520novel%2520FLT3%252FAXL%2520inhibitor%253A%2520preclinical%2520evaluation%2520in%2520acute%2520myeloid%2520leukemia%2520%2528AML%2529%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2014%26volume%3D32%26spage%3D7070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group">Annesley, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brown, P.</span><span> </span><span class="NLM_article-title">The biology and targeting of FLT3 in pediatric leukemia</span> <span class="citation_source-journal">Front. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">263</span><span class="refDoi"> DOI: 10.3389/fonc.2014.00263</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.3389%2Ffonc.2014.00263" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25295230" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC2M7os1eluw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2014&pages=263&author=C.+E.+Annesleyauthor=P.+Brown&title=The+biology+and+targeting+of+FLT3+in+pediatric+leukemia&doi=10.3389%2Ffonc.2014.00263"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">The Biology and Targeting of FLT3 in Pediatric Leukemia</span></div><div class="casAuthors">Annesley Colleen E; Brown Patrick</div><div class="citationInfo"><span class="NLM_cas:title">Frontiers in oncology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">263</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Despite remarkable improvement in treatment outcomes in pediatric leukemia over the past several decades, the prognosis for high-risk groups of acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL), as well as for relapsed leukemia, remains poor.  Intensification of chemotherapy regimens for those at highest risk has improved success rates, but at the cost of significantly increased morbidity and long-term adverse effects.  With the success of imatinib in Philadelphia-chromosome-positive leukemia and all-trans retinoic acid in acute promyelocytic leukemia, the quest to find additional molecularly targeted therapies has generated much excitement over recent years.  Another such possible target in pediatric acute leukemia is FMS-like tyrosine kinase 3 (FLT3).  FLT3 aberrations are among the most frequently identified transforming events in AML, and have significant clinical implications in both high-risk pediatric AML and in certain high-risk groups of pediatric ALL.  Therefore, the successful targeting of FLT3 has tremendous potential to improve outcomes in these subsets of patients.  This article will give an overview of the molecular function and signaling of the FLT3 receptor, as well as its pathogenic role in leukemia.  We review the discovery of targeting FLT3, discuss currently available FLT3 inhibitors in pediatric leukemia and results of clinical trials to date, and finally, consider the future promise and challenges of FLT3 inhibitor therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQuFK2u7sSOZJdYoSR9eyvsfW6udTcc2ebFmIE6UEULw7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2M7os1eluw%253D%253D&md5=b263d4c239232c8eb102fa9cada4be4c</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.3389%2Ffonc.2014.00263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3389%252Ffonc.2014.00263%26sid%3Dliteratum%253Aachs%26aulast%3DAnnesley%26aufirst%3DC.%2BE.%26aulast%3DBrown%26aufirst%3DP.%26atitle%3DThe%2520biology%2520and%2520targeting%2520of%2520FLT3%2520in%2520pediatric%2520leukemia%26jtitle%3DFront.%2520Oncol.%26date%3D2014%26volume%3D4%26spage%3D263%26doi%3D10.3389%2Ffonc.2014.00263" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saso, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iwamoto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xia, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gong, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pusztai, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Woodward, W. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Reuben, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hortobagyi, G. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hung, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ueno, N. T.</span><span> </span><span class="NLM_article-title">TIG1 promotes the development and progression of inflammatory breast cancer through activation of Axl kinase</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">73</span><span class="NLM_x">, </span> <span class="NLM_fpage">6516</span><span class="NLM_x">–</span> <span class="NLM_lpage">6525</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-13-0967</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-13-0967" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=73&publication_year=2013&pages=6516-6525&author=X.+Wangauthor=H.+Sasoauthor=T.+Iwamotoauthor=W.+Xiaauthor=Y.+Gongauthor=L.+Pusztaiauthor=W.+A.+Woodwardauthor=J.+M.+Reubenauthor=S.+L.+Warnerauthor=D.+J.+Bearssauthor=G.+N.+Hortobagyiauthor=M.+C.+Hungauthor=N.+T.+Ueno&title=TIG1+promotes+the+development+and+progression+of+inflammatory+breast+cancer+through+activation+of+Axl+kinase&doi=10.1158%2F0008-5472.CAN-13-0967"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-13-0967&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-13-0967%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DX.%26aulast%3DSaso%26aufirst%3DH.%26aulast%3DIwamoto%26aufirst%3DT.%26aulast%3DXia%26aufirst%3DW.%26aulast%3DGong%26aufirst%3DY.%26aulast%3DPusztai%26aufirst%3DL.%26aulast%3DWoodward%26aufirst%3DW.%2BA.%26aulast%3DReuben%26aufirst%3DJ.%2BM.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26aulast%3DHortobagyi%26aufirst%3DG.%2BN.%26aulast%3DHung%26aufirst%3DM.%2BC.%26aulast%3DUeno%26aufirst%3DN.%2BT.%26atitle%3DTIG1%2520promotes%2520the%2520development%2520and%2520progression%2520of%2520inflammatory%2520breast%2520cancer%2520through%2520activation%2520of%2520Axl%2520kinase%26jtitle%3DCancer%2520Res.%26date%3D2013%26volume%3D73%26spage%3D6516%26epage%3D6525%26doi%3D10.1158%2F0008-5472.CAN-13-0967" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group">Mollard, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Warner, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Call, L. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wade, M. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Verma, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sharma, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vankayalapati, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D. J.</span><span> </span><span class="NLM_article-title">Design, synthesis and biological evaluation of a series of novel AXL kinase inhibitors</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">907</span><span class="NLM_x">–</span> <span class="NLM_lpage">912</span><span class="refDoi"> DOI: 10.1021/ml200198x</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200198x" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2011&pages=907-912&author=A.+Mollardauthor=S.+L.+Warnerauthor=L.+T.+Callauthor=M.+L.+Wadeauthor=J.+J.+Bearssauthor=A.+Vermaauthor=S.+Sharmaauthor=H.+Vankayalapatiauthor=D.+J.+Bearss&title=Design%2C+synthesis+and+biological+evaluation+of+a+series+of+novel+AXL+kinase+inhibitors&doi=10.1021%2Fml200198x"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1021%2Fml200198x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200198x%26sid%3Dliteratum%253Aachs%26aulast%3DMollard%26aufirst%3DA.%26aulast%3DWarner%26aufirst%3DS.%2BL.%26aulast%3DCall%26aufirst%3DL.%2BT.%26aulast%3DWade%26aufirst%3DM.%2BL.%26aulast%3DBearss%26aufirst%3DJ.%2BJ.%26aulast%3DVerma%26aufirst%3DA.%26aulast%3DSharma%26aufirst%3DS.%26aulast%3DVankayalapati%26aufirst%3DH.%26aulast%3DBearss%26aufirst%3DD.%2BJ.%26atitle%3DDesign%252C%2520synthesis%2520and%2520biological%2520evaluation%2520of%2520a%2520series%2520of%2520novel%2520AXL%2520kinase%2520inhibitors%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2011%26volume%3D2%26spage%3D907%26epage%3D912%26doi%3D10.1021%2Fml200198x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tran-Dubé, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pairish, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jia, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meng, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Funk, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Botrous, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McTigue, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Grodsky, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ryan, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Padrique, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Timofeevski, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zou, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kania, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edwards, M. P.</span><span> </span><span class="NLM_article-title">Structure based drug design of Crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal–epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK)</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">54</span><span class="NLM_x">, </span> <span class="NLM_fpage">6342</span><span class="NLM_x">–</span> <span class="NLM_lpage">6363</span><span class="refDoi"> DOI: 10.1021/jm2007613</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm2007613" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2011&pages=6342-6363&author=J.+J.+Cuiauthor=M.+Tran-Dub%C3%A9author=H.+Shenauthor=M.+Nambuauthor=P.+P.+Kungauthor=M.+Pairishauthor=L.+Jiaauthor=J.+Mengauthor=L.+Funkauthor=I.+Botrousauthor=M.+McTigueauthor=N.+Grodskyauthor=K.+Ryanauthor=E.+Padriqueauthor=G.+Altonauthor=S.+Timofeevskiauthor=S.+Yamazakiauthor=Q.+Liauthor=H.+Zouauthor=J.+Christensenauthor=B.+Mroczkowskiauthor=S.+Benderauthor=R.+S.+Kaniaauthor=M.+P.+Edwards&title=Structure+based+drug+design+of+Crizotinib+%28PF-02341066%29%2C+a+potent+and+selective+dual+inhibitor+of+mesenchymal%E2%80%93epithelial+transition+factor+%28c-MET%29+kinase+and+anaplastic+lymphoma+kinase+%28ALK%29&doi=10.1021%2Fjm2007613"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">Structure Based Drug Design of Crizotinib (PF-02341066), a Potent and Selective Dual Inhibitor of Mesenchymal-Epithelial Transition Factor (c-MET) Kinase and Anaplastic Lymphoma Kinase (ALK)</span></div><div class="casAuthors">Cui, J. Jean; Tran-Dube, Michelle; Shen, Hong; Nambu, Mitchell; Kung, Pei-Pei; Pairish, Mason; Jia, Lei; Meng, Jerry; Funk, Lee; Botrous, Iriny; McTigue, Michele; Grodsky, Neil; Ryan, Kevin; Padrique, Ellen; Alton, Gordon; Timofeevski, Sergei; Yamazaki, Shinji; Li, Qiuhua; Zou, Helen; Christensen, James; Mroczkowski, Barbara; Bender, Steve; Kania, Robert S.; Edwards, Martin P.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">6342-6363</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Because of the crit. roles of aberrant signaling in cancer, both c-MET and ALK receptor tyrosine kinases are attractive oncol. targets for therapeutic intervention.  The cocrystal structure of 3 (PHA-665752), bound to c-MET kinase domain, revealed a novel ATP site environment, which served as the target to guide parallel, multiattribute drug design.  A novel 2-amino-5-aryl-3-benzyloxypyridine series was created to more effectively make the key interactions achieved with 3.  In the novel series, the 2-aminopyridine core allowed a 3-benzyloxy group to reach into the same pocket as the 2,6-dichlorophenyl group of 3 via a more direct vector and thus with a better ligand efficiency (LE).  Further optimization of the lead series generated the clin. candidate crizotinib (PF-02341066), which demonstrated potent in vitro and in vivo c-MET kinase and ALK inhibition, effective tumor growth inhibition, and good pharmaceutical properties.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHs_cKJ-U3t7Vg90H21EOLACvtfcHk0ljyVYxRoPmR4A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtVegtLrN&md5=dbab4c1b3e7c76180dbad04be2b6a474</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1021%2Fjm2007613&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm2007613%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DTran-Dub%25C3%25A9%26aufirst%3DM.%26aulast%3DShen%26aufirst%3DH.%26aulast%3DNambu%26aufirst%3DM.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DPairish%26aufirst%3DM.%26aulast%3DJia%26aufirst%3DL.%26aulast%3DMeng%26aufirst%3DJ.%26aulast%3DFunk%26aufirst%3DL.%26aulast%3DBotrous%26aufirst%3DI.%26aulast%3DMcTigue%26aufirst%3DM.%26aulast%3DGrodsky%26aufirst%3DN.%26aulast%3DRyan%26aufirst%3DK.%26aulast%3DPadrique%26aufirst%3DE.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DTimofeevski%26aufirst%3DS.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DZou%26aufirst%3DH.%26aulast%3DChristensen%26aufirst%3DJ.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DBender%26aufirst%3DS.%26aulast%3DKania%26aufirst%3DR.%2BS.%26aulast%3DEdwards%26aufirst%3DM.%2BP.%26atitle%3DStructure%2520based%2520drug%2520design%2520of%2520Crizotinib%2520%2528PF-02341066%2529%252C%2520a%2520potent%2520and%2520selective%2520dual%2520inhibitor%2520of%2520mesenchymal%25E2%2580%2593epithelial%2520transition%2520factor%2520%2528c-MET%2529%2520kinase%2520and%2520anaplastic%2520lymphoma%2520kinase%2520%2528ALK%2529%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2011%26volume%3D54%26spage%3D6342%26epage%3D6363%26doi%3D10.1021%2Fjm2007613" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shioda, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Classon, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maheswaran, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Choi, H. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Smith, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dowell, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ulkus, L. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuhlmann, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Greninger, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Genomic alterations of anaplastic lymphoma kinase may sensitize tumors to anaplastic lymphoma kinase inhibitors</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">68</span><span class="NLM_x">, </span> <span class="NLM_fpage">3389</span><span class="NLM_x">–</span> <span class="NLM_lpage">3395</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-07-6186</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-07-6186" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18451166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=68&publication_year=2008&pages=3389-3395&author=U.+McDermottauthor=A.+J.+Iafrateauthor=N.+S.+Grayauthor=T.+Shiodaauthor=M.+Classonauthor=S.+Maheswaranauthor=W.+Zhouauthor=H.+G.+Choiauthor=S.+L.+Smithauthor=L.+Dowellauthor=L.+E.+Ulkusauthor=G.+Kuhlmannauthor=P.+Greningerauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=J.+Settleman&title=Genomic+alterations+of+anaplastic+lymphoma+kinase+may+sensitize+tumors+to+anaplastic+lymphoma+kinase+inhibitors&doi=10.1158%2F0008-5472.CAN-07-6186"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Genomic Alterations of Anaplastic Lymphoma Kinase May Sensitize Tumors to Anaplastic Lymphoma Kinase Inhibitors</span></div><div class="casAuthors">McDermott, Ultan; Iafrate, A. John; Gray, Nathanael S.; Shioda, Toshi; Classon, Marie; Maheswaran, Shyamala; Zhou, Wenjun; Choi, Hwan Geun; Smith, Shannon L.; Dowell, Lori; Ulkus, Lindsey E.; Kuhlmann, Georgiana; Greninger, Patricia; Christensen, James G.; Haber, Daniel A.; Settleman, Jeffrey</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">68</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">3389-3395</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Selective kinase inhibitors have had a substantial impact on the field of medical oncol.  Whereas these agents can elicit dramatic clin. responses in some settings, their activity is generally limited to a subset of treated patients whose tumor cells harbor a specific genetic lesion.  We have established an automated platform for examg. the sensitivity to various molecularly targeted inhibitors across a large panel of human tumor-derived cell lines to identify addnl. genotype-correlated responses that may be clin. relevant.  Among the inhibitors tested in a panel of 602 cell lines derived from a variety of human cancers, we found that a selective inhibitor of the anaplastic lymphoma kinase (ALK) potently suppressed growth of a small subset of tumor cells.  This subset included lines derived from anaplastic large cell lymphomas, non-small-cell lung cancers, and neuroblastomas.  ALK is a receptor tyrosine kinase that was first identified as part of a protein fusion derived from a chromosomal translocation detected in the majority of anaplastic large cell lymphoma patients, and has recently been implicated as an oncogene in a small fraction of non-small-cell lung cancers and neuroblastomas.  Significantly, sensitivity in these cell lines was well correlated with specific ALK genomic rearrangements, including chromosomal translocations and gene amplification.  Moreover, in such cell lines, ALK kinase inhibition can lead to potent suppression of downstream survival signaling and an apoptotic response.  These findings suggest that a subset of lung cancers, lymphomas, and neuroblastomas that harbor genomic ALK alterations may be clin. responsive to pharmacol. ALK inhibition. [Cancer Res 2008;68(9):3389-95].</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqwtwwG7vhYTbVg90H21EOLACvtfcHk0lhcgwmT0Gb8PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXltlSlsbg%253D&md5=5168e6ce3ea650df3722dbd4f1aa53ea</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-07-6186&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-07-6186%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DShioda%26aufirst%3DT.%26aulast%3DClasson%26aufirst%3DM.%26aulast%3DMaheswaran%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DW.%26aulast%3DChoi%26aufirst%3DH.%2BG.%26aulast%3DSmith%26aufirst%3DS.%2BL.%26aulast%3DDowell%26aufirst%3DL.%26aulast%3DUlkus%26aufirst%3DL.%2BE.%26aulast%3DKuhlmann%26aufirst%3DG.%26aulast%3DGreninger%26aufirst%3DP.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DGenomic%2520alterations%2520of%2520anaplastic%2520lymphoma%2520kinase%2520may%2520sensitize%2520tumors%2520to%2520anaplastic%2520lymphoma%2520kinase%2520inhibitors%26jtitle%3DCancer%2520Res.%26date%3D2008%26volume%3D68%26spage%3D3389%26epage%3D3395%26doi%3D10.1158%2F0008-5472.CAN-07-6186" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group">Zou, H. Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Li, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Arango, M. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McDonnell, S. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yamazaki, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Koudriakova, T. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alton, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cui, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kung, P. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nambu, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Los, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bender, S. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mroczkowski, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span> </span><span class="NLM_article-title">An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">67</span><span class="NLM_x">, </span> <span class="NLM_fpage">4408</span><span class="NLM_x">–</span> <span class="NLM_lpage">4417</span><span class="refDoi"> DOI: 10.1158/0008-5472.CAN-06-4443</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F0008-5472.CAN-06-4443" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=17483355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2007&pages=4408-4417&author=H.+Y.+Zouauthor=Q.+Liauthor=J.+H.+Leeauthor=M.+E.+Arangoauthor=S.+R.+McDonnellauthor=S.+Yamazakiauthor=T.+B.+Koudriakovaauthor=G.+Altonauthor=J.+J.+Cuiauthor=P.+P.+Kungauthor=M.+D.+Nambuauthor=G.+Losauthor=S.+L.+Benderauthor=B.+Mroczkowskiauthor=J.+G.+Christensen&title=An+orally+available+small-molecule+inhibitor+of+c-Met%2C+PF-2341066%2C+exhibits+cytoreductive+antitumor+efficacy+through+antiproliferative+and+antiangiogenic+mechanisms&doi=10.1158%2F0008-5472.CAN-06-4443"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">An Orally Available Small-Molecule Inhibitor of c-Met, PF-2341066, Exhibits Cytoreductive Antitumor Efficacy through Antiproliferative and Antiangiogenic Mechanisms</span></div><div class="casAuthors">Zou, Helen Y.; Li, Qiuhua; Lee, Joseph H.; Arango, Maria E.; McDonnell, Scott R.; Yamazaki, Shinji; Koudriakova, Tatiana B.; Alton, Gordon; Cui, Jingrong J.; Kung, Pei-Pei; Nambu, Mitchell D.; Los, Gerrit; Bender, Steven L.; Mroczkowski, Barbara; Christensen, James G.</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Research</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">4408-4417</span>CODEN:
                <span class="NLM_cas:coden">CNREA8</span>;
        ISSN:<span class="NLM_cas:issn">0008-5472</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">The c-Met receptor tyrosine kinase and its ligand, hepatocyte growth factor (HGF), have been implicated in the progression of several human cancers and are attractive therapeutic targets.  PF-2341066 was identified as a potent, orally bioavailable, ATP-competitive small-mol. inhibitor of the catalytic activity of c-Met kinase.  PF-2341066 was selective for c-Met (and anaplastic lymphoma kinase) compared with a panel of >120 diverse tyrosine and serine-threonine kinases.  PF-2341066 potently inhibited c-Met phosphorylation and c-Met-dependent proliferation, migration, or invasion of human tumor cells in vitro (IC50 values, 5-20 nmol/L).  In addn., PF-2341066 potently inhibited HGF-stimulated endothelial cell survival or invasion and serum-stimulated tubulogenesis in vitro, suggesting that this agent also exhibits antiangiogenic properties.  PF-2341066 showed efficacy at well-tolerated doses, including marked cytoreductive antitumor activity, in several tumor models that expressed activated c-Met.  The antitumor efficacy of PF-2341066 was dose dependent and showed a strong correlation to inhibition of c-Met phosphorylation in vivo.  Near-maximal inhibition of c-Met activity for the full dosing interval was necessary to maximize the efficacy of PF-2341066.  Addnl. mechanism-of-action studies showed dose-dependent inhibition of c-Met-dependent signal transduction, tumor cell proliferation (Ki67), induction of apoptosis (caspase-3), and redn. of microvessel d. (CD31).  These results indicated that the antitumor activity of PF-2341066 may be mediated by direct effects on tumor cell growth or survival as well as antiangiogenic mechanisms.  Collectively, these results show the therapeutic potential of targeting c-Met with selective small-mol. inhibitors for the treatment of human cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrEAWtGPOBHC7Vg90H21EOLACvtfcHk0lhcgwmT0Gb8PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXltVyrsbg%253D&md5=798bf93e6cf8d5e9897e27485cba9002</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1158%2F0008-5472.CAN-06-4443&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F0008-5472.CAN-06-4443%26sid%3Dliteratum%253Aachs%26aulast%3DZou%26aufirst%3DH.%2BY.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DLee%26aufirst%3DJ.%2BH.%26aulast%3DArango%26aufirst%3DM.%2BE.%26aulast%3DMcDonnell%26aufirst%3DS.%2BR.%26aulast%3DYamazaki%26aufirst%3DS.%26aulast%3DKoudriakova%26aufirst%3DT.%2BB.%26aulast%3DAlton%26aufirst%3DG.%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26aulast%3DKung%26aufirst%3DP.%2BP.%26aulast%3DNambu%26aufirst%3DM.%2BD.%26aulast%3DLos%26aufirst%3DG.%26aulast%3DBender%26aufirst%3DS.%2BL.%26aulast%3DMroczkowski%26aufirst%3DB.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26atitle%3DAn%2520orally%2520available%2520small-molecule%2520inhibitor%2520of%2520c-Met%252C%2520PF-2341066%252C%2520exhibits%2520cytoreductive%2520antitumor%2520efficacy%2520through%2520antiproliferative%2520and%2520antiangiogenic%2520mechanisms%26jtitle%3DCancer%2520Res.%26date%3D2007%26volume%3D67%26spage%3D4408%26epage%3D4417%26doi%3D10.1158%2F0008-5472.CAN-06-4443" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group">Kwak, E. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bang, Y. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Maki, R. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dezube, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Varella-Garcia, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, W. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lynch, T. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fidias, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stubbs, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Engelman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sequist, L. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gandhi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mino-Kenudson, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, G. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ratain, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christensen, J. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haber, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salgia, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shapiro, G. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Clark, J. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iafrate, A. J.</span><span> </span><span class="NLM_article-title">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2010</span><span class="NLM_x">, </span> <span class="NLM_volume">363</span><span class="NLM_x">, </span> <span class="NLM_fpage">1693</span><span class="NLM_x">–</span> <span class="NLM_lpage">1703</span><span class="refDoi"> DOI: 10.1056/NEJMoa1006448</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1006448" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=20979469" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=363&publication_year=2010&pages=1693-1703&author=E.+L.+Kwakauthor=Y.+J.+Bangauthor=D.+R.+Camidgeauthor=A.+T.+Shawauthor=B.+Solomonauthor=R.+G.+Makiauthor=S.+H.+Ouauthor=B.+J.+Dezubeauthor=P.+A.+J%C3%A4nneauthor=D.+B.+Costaauthor=M.+Varella-Garciaauthor=W.+H.+Kimauthor=T.+J.+Lynchauthor=P.+Fidiasauthor=H.+Stubbsauthor=J.+A.+Engelmanauthor=L.+V.+Sequistauthor=W.+Tanauthor=L.+Gandhiauthor=M.+Mino-Kenudsonauthor=G.+C.+Weiauthor=S.+M.+Shreeveauthor=M.+J.+Ratainauthor=J.+Settlemanauthor=J.+G.+Christensenauthor=D.+A.+Haberauthor=K.+Wilnerauthor=R.+Salgiaauthor=G.+I.+Shapiroauthor=J.+W.+Clarkauthor=A.+J.+Iafrate&title=Anaplastic+lymphoma+kinase+inhibition+in+non-small-cell+lung+cancer&doi=10.1056%2FNEJMoa1006448"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer</span></div><div class="casAuthors">Kwak, Eunice L.; Bang, Yung-Jue; Camidge, Ross; Shaw, Alice T.; Solomon, Benjamin; Maki, Robert G.; Ou, Sai-Hong I.; Dezube, Bruce J.; Janne, Pasi A.; Costa, Daniel B.; Varella-Garcia, Marileila; Kim, Woo-Ho; Lynch, Thomas J.; Fidias, Panos; Stubbs, Hannah; Engelman, Jeffrey A.; Sequist, Lecia V.; Tan, WeiWei; Gandhi, Leena; Mino-Kenudson, Mari; Wei, Greg C.; Shreeve, Martin; Ratain, Mark J.; Settleman, Jeffrey; Christensen, James G.; Haber, Daniel A.; Wilner, Keith; Salgia, Ravi; Shapiro, Geoffrey I.; Clark, Jeffrey W.; Iafrate, A. John</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2010</span>),
    <span class="NLM_cas:volume">363</span>
        (<span class="NLM_cas:issue">18</span>),
    <span class="NLM_cas:pages">1693-1703</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">BACKGROUND: Oncogenic fusion genes consisting of EML4 and anaplastic lymphoma kinase (ALK) are present in a subgroup of non-small-cell lung cancers, representing 2 to 7% of such tumors.  The authors explored the therapeutic efficacy of inhibiting ALK in such tumors in an early-phase clin. trial of crizotinib (PF-02341066), an orally available small-mol. inhibitor of the ALK tyrosine kinase.  METHODS: After screening tumor samples from approx. 1500 patients with non-small-cell lung cancer for the presence of ALK rearrangements, the authors identified 82 patients with advanced ALK-pos. disease who were eligible for the clin. trial.  Most of the patients had received previous treatment.  These patients were enrolled in an expanded cohort study instituted after phase 1 dose escalation had established a recommended crizotinib dose of 250 mg twice daily in 28-day cycles.  Patients were assessed for adverse events and response to therapy.  RESULTS: Patients with ALK rearrangements tended to be younger than those without the rearrangements, and most of the patients had little or no exposure to tobacco and had adenocarcinomas.  At a mean treatment duration of 6.4 mo, the overall response rate was 57% (47 of 82 patients, with 46 confirmed partial responses and 1 confirmed complete response); 27 patients (33%) had stable disease.  A total of 63 of 82 patients (77%) were continuing to receive crizotinib at the time of data cutoff, and the estd. probability of 6-mo progression-free survival was 72%, with no median for the study reached.  The drug resulted in grade 1 or 2 (mild) gastrointestinal side effects.  CONCLUSIONS: The inhibition of ALK in lung tumors with the ALK rearrangement resulted in tumor shrinkage or stable disease in most patients.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoWDt_eL7Lyo7Vg90H21EOLACvtfcHk0ljsdzuhKSSipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtlKitL%252FO&md5=47440b9c944100295cca0f1859138d6b</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1006448&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1006448%26sid%3Dliteratum%253Aachs%26aulast%3DKwak%26aufirst%3DE.%2BL.%26aulast%3DBang%26aufirst%3DY.%2BJ.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DSolomon%26aufirst%3DB.%26aulast%3DMaki%26aufirst%3DR.%2BG.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DDezube%26aufirst%3DB.%2BJ.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DVarella-Garcia%26aufirst%3DM.%26aulast%3DKim%26aufirst%3DW.%2BH.%26aulast%3DLynch%26aufirst%3DT.%2BJ.%26aulast%3DFidias%26aufirst%3DP.%26aulast%3DStubbs%26aufirst%3DH.%26aulast%3DEngelman%26aufirst%3DJ.%2BA.%26aulast%3DSequist%26aufirst%3DL.%2BV.%26aulast%3DTan%26aufirst%3DW.%26aulast%3DGandhi%26aufirst%3DL.%26aulast%3DMino-Kenudson%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DG.%2BC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DRatain%26aufirst%3DM.%2BJ.%26aulast%3DSettleman%26aufirst%3DJ.%26aulast%3DChristensen%26aufirst%3DJ.%2BG.%26aulast%3DHaber%26aufirst%3DD.%2BA.%26aulast%3DWilner%26aufirst%3DK.%26aulast%3DSalgia%26aufirst%3DR.%26aulast%3DShapiro%26aufirst%3DG.%2BI.%26aulast%3DClark%26aufirst%3DJ.%2BW.%26aulast%3DIafrate%26aufirst%3DA.%2BJ.%26atitle%3DAnaplastic%2520lymphoma%2520kinase%2520inhibition%2520in%2520non-small-cell%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2010%26volume%3D363%26spage%3D1693%26epage%3D1703%26doi%3D10.1056%2FNEJMoa1006448" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, D. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nakagawa, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Seto, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crinó, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">De Pas, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Besse, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blackhall, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thomas, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">O’Byrne, K. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moro-Sibilot, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mok, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hirsh, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iyer, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tassell, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jänne, P. A.</span><span> </span><span class="NLM_article-title">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span> <span class="citation_source-journal">N. Engl. J. Med.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">368</span><span class="NLM_x">, </span> <span class="NLM_fpage">2385</span><span class="NLM_x">–</span> <span class="NLM_lpage">2394</span><span class="refDoi"> DOI: 10.1056/NEJMoa1214886</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1056%2FNEJMoa1214886" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23724913" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=368&publication_year=2013&pages=2385-2394&author=A.+T.+Shawauthor=D.+W.+Kimauthor=K.+Nakagawaauthor=T.+Setoauthor=L.+Crin%C3%B3author=M.+J.+Ahnauthor=T.+De+Pasauthor=B.+Besseauthor=B.+J.+Solomonauthor=F.+Blackhallauthor=Y.+L.+Wuauthor=M.+Thomasauthor=K.+J.+O%E2%80%99Byrneauthor=D.+Moro-Sibilotauthor=D.+R.+Camidgeauthor=T.+Mokauthor=V.+Hirshauthor=G.+J.+Rielyauthor=S.+Iyerauthor=V.+Tassellauthor=A.+Polliauthor=K.+D.+Wilnerauthor=P.+A.+J%C3%A4nne&title=Crizotinib+versus+chemotherapy+in+advanced+ALK-positive+lung+cancer&doi=10.1056%2FNEJMoa1214886"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib versus chemotherapy in advanced ALK-positive lung cancer</span></div><div class="casAuthors">Shaw, Alice T.; Kim, Dong-Wan; Nakagawa, Kazuhiko; Seto, Takashi; Crino, Lucio; Ahn, Myung-Ju; De Pas, Tommaso; Besse, Benjamin; Solomon, Benjamin J.; Blackhall, Fiona; Wu, Yi-Long; Thomas, Michael; O'Byrne, Kenneth J.; Moro-Sibilot, Denis; Camidge, D. Ross; Mok, Tony; Hirsh, Vera; Riely, Gregory J.; Iyer, Shrividya; Tassell, Vanessa; Polli, Anna; Wilner, Keith D.; Janne, Pasi A.</div><div class="citationInfo"><span class="NLM_cas:title">New England Journal of Medicine</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">368</span>
        (<span class="NLM_cas:issue">25</span>),
    <span class="NLM_cas:pages">2385-2394</span>CODEN:
                <span class="NLM_cas:coden">NEJMAG</span>;
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    
            (<span class="NLM_cas:orgname">Massachusetts Medical Society</span>)
        </div><div class="casAbstract">In single-group studies, chromosomal rearrangements of the anaplastic lymphoma kinase gene (ALK) have been assocd. with marked clin. responses to crizotinib, an oral tyrosine kinase inhibitor targeting ALK.  Whether crizotinib is superior to std. chemotherapy with respect to efficacy is unknown.  We conducted a phase 3, open-label trial comparing crizotinib with chemotherapy in 347 patients with locally advanced or metastatic ALK-pos. lung cancer who had received one prior platinum-based regimen.  Patients were randomly assigned to receive oral treatment with crizotinib (250 mg) twice daily or i.v. chemotherapy with either pemetrexed (500 mg per square meter of body-surface area) or docetaxel (75 mg per square meter) every 3 wk.  Patients in the chemotherapy group who had disease progression were permitted to cross over to crizotinib as part of a sep. study.  The primary end point was progression-free survival.  The median progression-free survival was 7.7 mo in the crizotinib group and 3.0 mo in the chemotherapy group (hazard ratio for progression or death with crizotinib, 0.49; 95% confidence interval [CI], 0.37 to 0.64; P<0.001).  The response rates were 65% (95% CI, 58 to 72) with crizotinib, as compared with 20% (95% CI, 14 to 26) with chemotherapy (P<0.001).  An interim anal. of overall survival showed no significant improvement with crizotinib as compared with chemotherapy (hazard ratio for death in the crizotinib group, 1.02; 95% CI, 0.68 to 1.54; P = 0.54).  Common adverse events assocd. with crizotinib were visual disorder, gastrointestinal side effects, and elevated liver aminotransferase levels, whereas common adverse events with chemotherapy were fatigue, alopecia, and dyspnea.  Patients reported greater redns. in symptoms of lung cancer and greater improvement in global quality of life with crizotinib than with chemotherapy.  Crizotinib is superior to std. chemotherapy in patients with previously treated, advanced non-small-cell lung cancer with ALK rearrangement.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrk62MsVCiljLVg90H21EOLACvtfcHk0ljsdzuhKSSipw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtVSnu7%252FM&md5=8c6f1a73472f87fa9a19ceac6fdbb132</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1056%2FNEJMoa1214886&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJMoa1214886%26sid%3Dliteratum%253Aachs%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DKim%26aufirst%3DD.%2BW.%26aulast%3DNakagawa%26aufirst%3DK.%26aulast%3DSeto%26aufirst%3DT.%26aulast%3DCrin%25C3%25B3%26aufirst%3DL.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DDe%2BPas%26aufirst%3DT.%26aulast%3DBesse%26aufirst%3DB.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DBlackhall%26aufirst%3DF.%26aulast%3DWu%26aufirst%3DY.%2BL.%26aulast%3DThomas%26aufirst%3DM.%26aulast%3DO%25E2%2580%2599Byrne%26aufirst%3DK.%2BJ.%26aulast%3DMoro-Sibilot%26aufirst%3DD.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DMok%26aufirst%3DT.%26aulast%3DHirsh%26aufirst%3DV.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DIyer%26aufirst%3DS.%26aulast%3DTassell%26aufirst%3DV.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DJ%25C3%25A4nne%26aufirst%3DP.%2BA.%26atitle%3DCrizotinib%2520versus%2520chemotherapy%2520in%2520advanced%2520ALK-positive%2520lung%2520cancer%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D2013%26volume%3D368%26spage%3D2385%26epage%3D2394%26doi%3D10.1056%2FNEJMoa1214886" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group">Sahu, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Prabhash, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Noronha, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Desai, S.</span><span> </span><span class="NLM_article-title">Crizotinib: A comprehensive review</span> <span class="citation_source-journal">South Asian J. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">2</span><span class="NLM_x">, </span> <span class="NLM_fpage">91</span><span class="NLM_x">–</span> <span class="NLM_lpage">97</span><span class="refDoi"> DOI: 10.4103/2278-330X.110506</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.4103%2F2278-330X.110506" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24455567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A280%3ADC%252BC2cflsFOhuw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2013&pages=91-97&author=A.+Sahuauthor=K.+Prabhashauthor=V.+Noronhaauthor=A.+Joshiauthor=S.+Desai&title=Crizotinib%3A+A+comprehensive+review&doi=10.4103%2F2278-330X.110506"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Crizotinib: A comprehensive review</span></div><div class="casAuthors">Sahu Arvind; Prabhash Kumar; Noronha Vanita; Joshi Amit; Desai Saral</div><div class="citationInfo"><span class="NLM_cas:title">South Asian journal of cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">91-7</span>
        ISSN:<span class="NLM_cas:issn">2278-330X</span>.
    </div><div class="casAbstract">Anaplastic lymphoma kinase (ALK) gene rearrangements are present in a small subset of non-small-cell lung cancers.  ALK-positivity confers sensitivity to small-molecule ALK kinase inhibitors, such as crizotinib.  The integration of crizotinib into standard treatment practice in NSCLC will rest on the widespread implementation of an effective screening system for newly diagnosed patients with NSCLC which is flexible enough to incorporate new targets as treatments are developed for them.  Phase I and II studies of crizotinib in ALK-positive lung cancer have demonstrated significant activity and impressive clinical benefit, which led to its early approval by USFDA in 2011.  Although crizotinib induces remissions and extends the lives of patients, there have been reports of emerging resistance to Crizotinib therapy.  In this review, we discuss the history, mechanism of action, uses, adverse effects, dose modifications and future challenges and opportunities for patients with ALK-positive lung cancers.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcR0KN9U3mPo0Nj_Vg2vObihfW6udTcc2eZ_zEKXPesvSLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC2cflsFOhuw%253D%253D&md5=672452a3d9d60dc8cc439f8d79e4f3b4</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=10.4103%2F2278-330X.110506&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4103%252F2278-330X.110506%26sid%3Dliteratum%253Aachs%26aulast%3DSahu%26aufirst%3DA.%26aulast%3DPrabhash%26aufirst%3DK.%26aulast%3DNoronha%26aufirst%3DV.%26aulast%3DJoshi%26aufirst%3DA.%26aulast%3DDesai%26aufirst%3DS.%26atitle%3DCrizotinib%253A%2520A%2520comprehensive%2520review%26jtitle%3DSouth%2520Asian%2520J.%2520Cancer%26date%3D2013%26volume%3D2%26spage%3D91%26epage%3D97%26doi%3D10.4103%2F2278-330X.110506" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group">Costa, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shaw, A. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ou, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Solomon, B. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riely, G. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahn, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shreeve, S. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Selaru, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Polli, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schnell, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wilner, K. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wiltshire, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Camidge, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Crinò, L.</span><span> </span><span class="NLM_article-title">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1881</span><span class="refDoi"> DOI: 10.1200/JCO.2014.59.0539</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2014.59.0539" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25624436" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2015&pages=1881&author=D.+B.+Costaauthor=A.+T.+Shawauthor=S.+H.+Ouauthor=B.+J.+Solomonauthor=G.+J.+Rielyauthor=M.+J.+Ahnauthor=C.+Zhouauthor=S.+M.+Shreeveauthor=P.+Selaruauthor=A.+Polliauthor=P.+Schnellauthor=K.+D.+Wilnerauthor=R.+Wiltshireauthor=D.+R.+Camidgeauthor=L.+Crin%C3%B2&title=Clinical+experience+with+crizotinib+in+patients+with+advanced+ALK-rearranged+non-small-cell+lung+cancer+and+brain+metastases&doi=10.1200%2FJCO.2014.59.0539"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit78R"><div class="casContent"><span class="casTitleNuber">78</span><div class="casTitle"><span class="NLM_cas:atitle">Clinical experience with crizotinib in patients with advanced ALK-rearranged non-small-cell lung cancer and brain metastases</span></div><div class="casAuthors">Costa, Daniel B.; Shaw, Alice T.; Ou, Sai-Hong I.; Solomon, Benjamin J.; Riely, Gregory J.; Ahn, Myung-Ju; Zhou, Caicun; Shreeve, S. Martin; Selaru, Paulina; Polli, Anna; Schnell, Patrick; Wilner, Keith D.; Wiltshire, Robin; Camidge, D. Ross; Crino, Lucio</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">1881-1888</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose Crizotinib is an oral kinase inhibitor approved for the treatment of ALK-rearranged non-small-cell lung cancer (NSCLC).  The clin. benefits of crizotinib in patients with brain metastases have not been previously studied.  Patients and Methods Patients with advanced ALK-rearranged NSCLC enrolled onto clin. trial PROFILE 1005 or 1007 (randomly assigned to crizotinib) were included in this retrospective anal.  Patients with asymptomatic brain metastases (nontarget or target lesions) were allowed to enroll.  Tumor assessments were evaluated every 6 wk using RECIST (version 1.1).  Results At baseline, 31% of patients (275 of 888) had asymptomatic brain metastases; 109 had received no prior and 166 had received prior brain radiotherapy as treatment.  Among patients with previously untreated asymptomatic brain metastases, the systemic disease control rate (DCR) at 12 wk was 63% (95% CI, 54% to 72%), the intracranial DCR was 56% (95% CI, 46% to 66%), and the median intracranial time to progression (TTP) was 7 mo (95% CI, 6.7 to 16.4).  Among patients with previously treated brain metastases, the systemic DCR was 65% (95% CI, 57% to 72%), the intracranial DCR was 62% (95% CI, 54% to 70%), and the median intracranial TTP was 13.2 mo (95% CI, 9.9 to not reached).  Patients with systemic disease control were also likely to experience intracranial disease control at 12 wk (correlation coeff., 0.7652; P <.001).  Among patients without baseline brain metastases who developed progressive disease (n = 253) after initiation of crizotinib, 20% were diagnosed with brain metastases.  Conclusion Crizotinib was assocd. with systemic and intracranial disease control in patients with ALK-rearranged NSCLC who were ALK inhibitor naive and had brain metastases.  However, progression of preexisting or development of new intracranial lesions while receiving therapy was a common manifestation of acquired resistance to crizotinib.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGokOoSZRSEa-bVg90H21EOLACvtfcHk0ljnRxenkGpxtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsFKmt7%252FM&md5=a398b73ebd0163c33c7805ffb17aabab</span></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1200%2FJCO.2014.59.0539&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2014.59.0539%26sid%3Dliteratum%253Aachs%26aulast%3DCosta%26aufirst%3DD.%2BB.%26aulast%3DShaw%26aufirst%3DA.%2BT.%26aulast%3DOu%26aufirst%3DS.%2BH.%26aulast%3DSolomon%26aufirst%3DB.%2BJ.%26aulast%3DRiely%26aufirst%3DG.%2BJ.%26aulast%3DAhn%26aufirst%3DM.%2BJ.%26aulast%3DZhou%26aufirst%3DC.%26aulast%3DShreeve%26aufirst%3DS.%2BM.%26aulast%3DSelaru%26aufirst%3DP.%26aulast%3DPolli%26aufirst%3DA.%26aulast%3DSchnell%26aufirst%3DP.%26aulast%3DWilner%26aufirst%3DK.%2BD.%26aulast%3DWiltshire%26aufirst%3DR.%26aulast%3DCamidge%26aufirst%3DD.%2BR.%26aulast%3DCrin%25C3%25B2%26aufirst%3DL.%26atitle%3DClinical%2520experience%2520with%2520crizotinib%2520in%2520patients%2520with%2520advanced%2520ALK-rearranged%2520non-small-cell%2520lung%2520cancer%2520and%2520brain%2520metastases%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2015%26volume%3D33%26spage%3D1881%26doi%3D10.1200%2FJCO.2014.59.0539" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group">Mahadevan, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cooke, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Riley, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Swart, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simons, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Della Croce, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wisner, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Iorio, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shakalya, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Garewal, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nagle, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bearss, D.</span><span> </span><span class="NLM_article-title">A novel tyrosine kinase switch is a mechanism of imatinib resistance in gastrointestinal stromal tumors</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2007</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">3909</span><span class="NLM_x">–</span> <span class="NLM_lpage">3919</span><span class="refDoi"> DOI: 10.1038/sj.onc.1210173</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1210173" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2007&pages=3909-3919&author=D.+Mahadevanauthor=L.+Cookeauthor=C.+Rileyauthor=R.+Swartauthor=B.+Simonsauthor=K.+Della+Croceauthor=L.+Wisnerauthor=M.+Iorioauthor=K.+Shakalyaauthor=H.+Garewalauthor=R.+Nagleauthor=D.+Bearss&title=A+novel+tyrosine+kinase+switch+is+a+mechanism+of+imatinib+resistance+in+gastrointestinal+stromal+tumors&doi=10.1038%2Fsj.onc.1210173"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1210173&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1210173%26sid%3Dliteratum%253Aachs%26aulast%3DMahadevan%26aufirst%3DD.%26aulast%3DCooke%26aufirst%3DL.%26aulast%3DRiley%26aufirst%3DC.%26aulast%3DSwart%26aufirst%3DR.%26aulast%3DSimons%26aufirst%3DB.%26aulast%3DDella%2BCroce%26aufirst%3DK.%26aulast%3DWisner%26aufirst%3DL.%26aulast%3DIorio%26aufirst%3DM.%26aulast%3DShakalya%26aufirst%3DK.%26aulast%3DGarewal%26aufirst%3DH.%26aulast%3DNagle%26aufirst%3DR.%26aulast%3DBearss%26aufirst%3DD.%26atitle%3DA%2520novel%2520tyrosine%2520kinase%2520switch%2520is%2520a%2520mechanism%2520of%2520imatinib%2520resistance%2520in%2520gastrointestinal%2520stromal%2520tumors%26jtitle%3DOncogene%26date%3D2007%26volume%3D26%26spage%3D3909%26epage%3D3919%26doi%3D10.1038%2Fsj.onc.1210173" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group">Asiedu, M. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Beauchamp-Perez, F. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ingle, J. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Behrens, M. D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radisky, D. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Knutson, K. L.</span><span> </span><span class="NLM_article-title">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">33</span><span class="NLM_x">, </span> <span class="NLM_fpage">1316</span><span class="NLM_x">–</span> <span class="NLM_lpage">1324</span><span class="refDoi"> DOI: 10.1038/onc.2013.57</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fonc.2013.57" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23474758" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=33&publication_year=2014&pages=1316-1324&author=M.+K.+Asieduauthor=F.+D.+Beauchamp-Perezauthor=J.+N.+Ingleauthor=M.+D.+Behrensauthor=D.+C.+Radiskyauthor=K.+L.+Knutson&title=AXL+induces+epithelial-to-mesenchymal+transition+and+regulates+the+function+of+breast+cancer+stem+cells&doi=10.1038%2Fonc.2013.57"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">AXL induces epithelial-to-mesenchymal transition and regulates the function of breast cancer stem cells</span></div><div class="casAuthors">Asiedu, M. K.; Beauchamp-Perez, F. D.; Ingle, J. N.; Behrens, M. D.; Radisky, D. C.; Knutson, K. L.</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">33</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">1316-1324</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Despite significant progress in the treatment of breast cancer, particularly through the use of targeted therapy, relapse and chemoresistance remain a major hindrance to the fight to minimize the burden of the disease.  It is becoming increasingly clear that a rare subpopulation of cells known as cancer stem cells (CSC), able to be generated through epithelial-to-mesenchymal transition (EMT) and capable of tumor initiation and self-renewal, contributes to treatment resistance and metastases.  This means that a more effective therapy should target both the chemoresistant CSCs and the proliferating epithelial cells that give rise to them to reverse EMT and to attenuate their conversion to CSCs.  Here, we demonstrate a novel function of AXL in acting upstream to induce EMT in normal and immortalized human mammary epithelial cells in an apparent pos. feedback loop mechanism and regulate breast CSC (BCSC) self-renewal and chemoresistance.  Downregulation of AXL using MP470 (Amuvatinib) reversed EMT in mesenchymal normal human mammary epithelial cells and murine BCSCs attenuating self-renewal and restored chemosensitivity of the BCSCs.  AXL expression was also found to be assocd. with the expression of stem cell genes, regulation of metastases genes, increased tumorigenicity and was important for BCSC invasion and migration.  Inactivation of AXL also led to the downregulation of nuclear factor-κB pathway and reduced tumor formation in vivo.  Taken together, our data suggest that targeted therapy against AXL, in combination with systemic therapies, has the potential to improve response to anticancer therapies and to reduce breast cancer recurrence and metastases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqR3FaG5OgnVrVg90H21EOLACvtfcHk0ljnRxenkGpxtA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXjslKlsb0%253D&md5=a30463cda3288fbc2c92d712f7ef43a8</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1038%2Fonc.2013.57&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fonc.2013.57%26sid%3Dliteratum%253Aachs%26aulast%3DAsiedu%26aufirst%3DM.%2BK.%26aulast%3DBeauchamp-Perez%26aufirst%3DF.%2BD.%26aulast%3DIngle%26aufirst%3DJ.%2BN.%26aulast%3DBehrens%26aufirst%3DM.%2BD.%26aulast%3DRadisky%26aufirst%3DD.%2BC.%26aulast%3DKnutson%26aufirst%3DK.%2BL.%26atitle%3DAXL%2520induces%2520epithelial-to-mesenchymal%2520transition%2520and%2520regulates%2520the%2520function%2520of%2520breast%2520cancer%2520stem%2520cells%26jtitle%3DOncogene%26date%3D2014%26volume%3D33%26spage%3D1316%26epage%3D1324%26doi%3D10.1038%2Fonc.2013.57" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group">Choy, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joshi-Hangal, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Oganesian, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fine, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rasmussen, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Collier, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kissling, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sahai, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Azab, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Redkar, S.</span><span> </span><span class="NLM_article-title">Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers</span> <span class="citation_source-journal">Cancer Chemother. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">70</span><span class="NLM_x">, </span> <span class="NLM_fpage">183</span><span class="NLM_x">–</span> <span class="NLM_lpage">190</span><span class="refDoi"> DOI: 10.1007/s00280-012-1821-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs00280-012-1821-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22349808" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XpsFajtrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=70&publication_year=2012&pages=183-190&author=G.+Choyauthor=R.+Joshi-Hangalauthor=A.+Oganesianauthor=G.+Fineauthor=S.+Rasmussenauthor=J.+Collierauthor=J.+Kisslingauthor=A.+Sahaiauthor=M.+Azabauthor=S.+Redkar&title=Safety%2C+tolerability%2C+and+pharmacokinetics+of+amuvatinib+from+three+phase+1+clinical+studies+in+healthy+volunteers&doi=10.1007%2Fs00280-012-1821-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Safety, tolerability, and pharmacokinetics of amuvatinib from three phase 1 clinical studies in healthy volunteers</span></div><div class="casAuthors">Choy, Gavin; Joshi-Hangal, Rajashree; Oganesian, Aram; Fine, Gil; Rasmussen, Scott; Collier, Joanne; Kissling, James; Sahai, Amarpal; Azab, Mohammad; Redkar, Sanjeev</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Chemotherapy and Pharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">70</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">183-190</span>CODEN:
                <span class="NLM_cas:coden">CCPHDZ</span>;
        ISSN:<span class="NLM_cas:issn">0344-5704</span>.
    
            (<span class="NLM_cas:orgname">Springer</span>)
        </div><div class="casAbstract">Purpose: Amuvatinib is a multi-targeted tyrosine kinase inhibitor with activity that also disrupts DNA damage repair through suppression of homologous recombination protein Rad51.  Amuvatinib dry-powder capsules (DPC) showed evidence of activity in early Phase 1 cancer studies but low systemic exposure.  The purposes of the studies were to investigate the cause of low exposure, develop, and test an alternative formulation with improved exposure, and establish the dose to be tested in future studies in cancer patients.  Methods: Three studies were conducted in a total of 58 healthy subjects: a food-effect study using amuvatinib DPC, a single-dose pharmacokinetic study comparing amuvatinib DPC to a new lipid-suspension capsules (LSC), and a multiple-dose pharmacokinetic study using amuvatinib LSC.  Results: A high-fat meal administered with amuvatinib DPC increased the rate and extent of absorption compared to the Fasted state, a 183 and 118% increase in the mean C max and AUC0-∞ of amuvatinib, resp.  The single-dose pharmacokinetics of amuvatinib LSC resulted in an approx. two-third-fold increased exposure (AUC) compared with amuvatinib DPC.  The multiple-dose pharmacokinetics of the amuvatinib LSC 300 mg administered every 8 h exhibited improved accumulation compared with the 12-h regimens and achieved presumed therapeutic level safely with no serious or severe adverse events reported.  No subject discontinued treatment due to an adverse event.  Conclusion: Amuvatinib LSC, 300 mg every 8 h, is being studied in cancer patients based on the improved exposure and similar safety profile to amuvatinib DPC.  A lipid-based formulation approach may be a useful tool for other low aq. sol. compds.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdrfzwPS5trbVg90H21EOLACvtfcHk0lhna5xKqqNePA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XpsFajtrs%253D&md5=4f53982982b318b548759783cfbb7a75</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1007%2Fs00280-012-1821-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00280-012-1821-2%26sid%3Dliteratum%253Aachs%26aulast%3DChoy%26aufirst%3DG.%26aulast%3DJoshi-Hangal%26aufirst%3DR.%26aulast%3DOganesian%26aufirst%3DA.%26aulast%3DFine%26aufirst%3DG.%26aulast%3DRasmussen%26aufirst%3DS.%26aulast%3DCollier%26aufirst%3DJ.%26aulast%3DKissling%26aufirst%3DJ.%26aulast%3DSahai%26aufirst%3DA.%26aulast%3DAzab%26aufirst%3DM.%26aulast%3DRedkar%26aufirst%3DS.%26atitle%3DSafety%252C%2520tolerability%252C%2520and%2520pharmacokinetics%2520of%2520amuvatinib%2520from%2520three%2520phase%25201%2520clinical%2520studies%2520in%2520healthy%2520volunteers%26jtitle%3DCancer%2520Chemother.%2520Pharmacol.%26date%3D2012%26volume%3D70%26spage%3D183%26epage%3D190%26doi%3D10.1007%2Fs00280-012-1821-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minson, K. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Glaros, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Newton, D. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC2025, a potent and orally bioavailable MER/FLT3 dual inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">7031</span><span class="NLM_x">–</span> <span class="NLM_lpage">7041</span><span class="refDoi"> DOI: 10.1021/jm500749d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm500749d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=7031-7041&author=W.+Zhangauthor=D.+DeRyckereauthor=D.+Hunterauthor=J.+Liuauthor=M.+A.+Stashkoauthor=K.+A.+Minsonauthor=C.+T.+Cummingsauthor=M.+Leeauthor=T.+G.+Glarosauthor=D.+L.+Newtonauthor=S.+Satherauthor=D.+Zhangauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC2025%2C+a+potent+and+orally+bioavailable+MER%2FFLT3+dual+inhibitor&doi=10.1021%2Fjm500749d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit82R"><div class="casContent"><span class="casTitleNuber">82</span><div class="casTitle"><span class="NLM_cas:atitle">UNC2025, a Potent and Orally Bioavailable MER/FLT3 Dual Inhibitor</span></div><div class="casAuthors">Zhang, Weihe; DeRyckere, Deborah; Hunter, Debra; Liu, Jing; Stashko, Michael A.; Minson, Katherine A.; Cummings, Christopher T.; Lee, Minjung; Glaros, Trevor G.; Newton, Dianne L.; Sather, Susan; Zhang, Dehui; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7031-7041</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">We previously reported a potent small mol. Mer tyrosine kinase inhibitor UNC1062.  However, its poor PK properties prevented further assessment in vivo.  We report here the sequential modification of UNC1062 to address DMPK properties and yield a new potent and highly orally bioavailable Mer inhibitor, 11, capable of inhibiting Mer phosphorylation in vivo, following oral dosing as demonstrated by pharmaco-dynamic (PD) studies examg. phospho-Mer in leukemic blasts from mouse bone marrow.  Kinome profiling vs. more than 300 kinases in vitro and cellular selectivity assessments demonstrate that 11 has similar subnanomolar activity against Flt3, an addnl. important target in acute myelogenous leukemia (AML), with pharmacol. useful selectivity vs. other kinases examd.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqIu8sRwBmPqrVg90H21EOLACvtfcHk0lhna5xKqqNePA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXht1agu7bN&md5=b3be89f194e6f5ea853d82aa67aea939</span></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1021%2Fjm500749d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm500749d%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DMinson%26aufirst%3DK.%2BA.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DGlaros%26aufirst%3DT.%2BG.%26aulast%3DNewton%26aufirst%3DD.%2BL.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC2025%252C%2520a%2520potent%2520and%2520orally%2520bioavailable%2520MER%252FFLT3%2520dual%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D7031%26epage%3D7041%26doi%3D10.1021%2Fjm500749d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deryckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jayakody, C. N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cheng, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">UNC1062, a new and potent Mer inhibitor</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">65</span><span class="NLM_x">, </span> <span class="NLM_fpage">83</span><span class="NLM_x">–</span> <span class="NLM_lpage">93</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2013.03.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ejmech.2013.03.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23693152" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=83-93&author=J.+Liuauthor=W.+Zhangauthor=M.+A.+Stashkoauthor=D.+Deryckereauthor=C.+T.+Cummingsauthor=D.+Hunterauthor=C.+Yangauthor=C.+N.+Jayakodyauthor=N.+Chengauthor=C.+Simpsonauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Kireevauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=UNC1062%2C+a+new+and+potent+Mer+inhibitor&doi=10.1016%2Fj.ejmech.2013.03.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">UNC1062, a new and potent Mer inhibitor</span></div><div class="casAuthors">Liu, Jing; Zhang, Weihe; Stashko, Michael A.; DeRyckere, Deborah; Cummings, Christopher T.; Hunter, Debra; Yang, Chao; Jayakody, Chatura N.; Cheng, Nancy; Simpson, Catherine; Norris-Drouin, Jacqueline; Sather, Susan; Kireev, Dmitri; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">83-93</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">Abnormal activation of Mer kinase has been implicated in the oncogenesis of many human cancers including acute lymphoblastic and myeloid leukemia, non-small cell lung cancer, and glioblastoma.  The authors have discovered a new family of small mol. Mer inhibitors, pyrazolopyrimidine sulfonamides, that potently inhibit the kinase activity of Mer.  Importantly, these compds. do not demonstrate significant hERG activity in the PatchXpress assay.  Through structure-activity relationship studies, UNC1062 was identified as a potent (IC50 = 1.1 nM) and selective Mer inhibitor.  When applied to live tumor cells, UNC1062 inhibited Mer phosphorylation and colony formation in soft agar.  Given the potential of Mer as a therapeutic target, UNC1062 is a promising candidate for further drug development.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrAMT5879KW7Vg90H21EOLACvtfcHk0lhna5xKqqNePA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFeltrvE&md5=fde1dd50f35af93a0e671932fb7c579d</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2013.03.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2013.03.035%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DCummings%26aufirst%3DC.%2BT.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DJayakody%26aufirst%3DC.%2BN.%26aulast%3DCheng%26aufirst%3DN.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DUNC1062%252C%2520a%2520new%2520and%2520potent%2520Mer%2520inhibitor%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D65%26spage%3D83%26epage%3D93%26doi%3D10.1016%2Fj.ejmech.2013.03.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group">Schlegel, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sambade, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Moschos, S. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tan, A. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Winges, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carson, C. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trembath, D. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tentler, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Eckhardt, S. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kuan, P. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hamilton, R. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Duncan, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miller, C. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nikolaishvili-Feinberg, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Midkiff, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shields, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span> </span><span class="NLM_article-title">MERTK receptor tyrosine kinase is a therapeutic target in melanoma</span> <span class="citation_source-journal">J. Clin. Invest.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">123</span><span class="NLM_x">, </span> <span class="NLM_fpage">2257</span><span class="NLM_x">–</span> <span class="NLM_lpage">2267</span><span class="refDoi"> DOI: 10.1172/JCI67816</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1172%2FJCI67816" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=123&publication_year=2013&pages=2257-2267&author=J.+Schlegelauthor=M.+J.+Sambadeauthor=S.+Satherauthor=S.+J.+Moschosauthor=A.+C.+Tanauthor=A.+Wingesauthor=D.+DeRyckereauthor=C.+C.+Carsonauthor=D.+G.+Trembathauthor=J.+J.+Tentlerauthor=S.+G.+Eckhardtauthor=P.+F.+Kuanauthor=R.+L.+Hamiltonauthor=L.+M.+Duncanauthor=C.+R.+Millerauthor=N.+Nikolaishvili-Feinbergauthor=B.+R.+Midkiffauthor=J.+Liuauthor=W.+Zhangauthor=C.+Yangauthor=X.+Wangauthor=S.+V.+Fryeauthor=H.+S.+Earpauthor=J.+M.+Shieldsauthor=D.+K.+Graham&title=MERTK+receptor+tyrosine+kinase+is+a+therapeutic+target+in+melanoma&doi=10.1172%2FJCI67816"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1172%2FJCI67816&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1172%252FJCI67816%26sid%3Dliteratum%253Aachs%26aulast%3DSchlegel%26aufirst%3DJ.%26aulast%3DSambade%26aufirst%3DM.%2BJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMoschos%26aufirst%3DS.%2BJ.%26aulast%3DTan%26aufirst%3DA.%2BC.%26aulast%3DWinges%26aufirst%3DA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DCarson%26aufirst%3DC.%2BC.%26aulast%3DTrembath%26aufirst%3DD.%2BG.%26aulast%3DTentler%26aufirst%3DJ.%2BJ.%26aulast%3DEckhardt%26aufirst%3DS.%2BG.%26aulast%3DKuan%26aufirst%3DP.%2BF.%26aulast%3DHamilton%26aufirst%3DR.%2BL.%26aulast%3DDuncan%26aufirst%3DL.%2BM.%26aulast%3DMiller%26aufirst%3DC.%2BR.%26aulast%3DNikolaishvili-Feinberg%26aufirst%3DN.%26aulast%3DMidkiff%26aufirst%3DB.%2BR.%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DWang%26aufirst%3DX.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DShields%26aufirst%3DJ.%2BM.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26atitle%3DMERTK%2520receptor%2520tyrosine%2520kinase%2520is%2520a%2520therapeutic%2520target%2520in%2520melanoma%26jtitle%3DJ.%2520Clin.%2520Invest.%26date%3D2013%26volume%3D123%26spage%3D2257%26epage%3D2267%26doi%3D10.1172%2FJCI67816" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group">Burbridge, M. F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bossard, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saunier, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fejes, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bruno, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Léonce, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ferry, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Da Violante, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bouzom, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cattan, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jacquet-Bescond, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Comoglio, P. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, B. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Boutin, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cordi, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ortuno, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pierré, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hickman, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cruzalegui, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Depil, S.</span><span> </span><span class="NLM_article-title">S49076 is a novel kinase inhibitor of MET, AXL, and FGFR with strong preclinical activity alone and in association with bevacizumab</span> <span class="citation_source-journal">Mol. Cancer Ther.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">1749</span><span class="NLM_x">–</span> <span class="NLM_lpage">1762</span><span class="refDoi"> DOI: 10.1158/1535-7163.MCT-13-0075</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1535-7163.MCT-13-0075" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=23804704" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2013&pages=1749-1762&author=M.+F.+Burbridgeauthor=C.+J.+Bossardauthor=C.+Saunierauthor=I.+Fejesauthor=A.+Brunoauthor=S.+L%C3%A9onceauthor=G.+Ferryauthor=G.+Da+Violanteauthor=F.+Bouzomauthor=V.+Cattanauthor=A.+Jacquet-Bescondauthor=P.+M.+Comoglioauthor=B.+P.+Lockhartauthor=J.+A.+Boutinauthor=A.+Cordiauthor=J.+C.+Ortunoauthor=A.+Pierr%C3%A9author=J.+A.+Hickmanauthor=F.+H.+Cruzaleguiauthor=S.+Depil&title=S49076+is+a+novel+kinase+inhibitor+of+MET%2C+AXL%2C+and+FGFR+with+strong+preclinical+activity+alone+and+in+association+with+bevacizumab&doi=10.1158%2F1535-7163.MCT-13-0075"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">S49076 Is a Novel Kinase Inhibitor of MET, AXL, and FGFR with Strong Preclinical Activity Alone and in Association with Bevacizumab</span></div><div class="casAuthors">Burbridge, Mike F.; Bossard, Celine J.; Saunier, Carine; Fejes, Imre; Bruno, Alain; Leonce, Stephane; Ferry, Gilles; Da Violante, Georges; Bouzom, Francois; Cattan, Valerie; Jacquet-Bescond, Anne; Comoglio, Paolo M.; Lockhart, Brian P.; Boutin, Jean A.; Cordi, Alex; Ortuno, Jean-Claude; Pierre, Alain; Hickman, John A.; Cruzalegui, Francisco H.; Depil, Stephane</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Cancer Therapeutics</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1749-1762</span>CODEN:
                <span class="NLM_cas:coden">MCTOCF</span>;
        ISSN:<span class="NLM_cas:issn">1535-7163</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Aberrant activity of the receptor tyrosine kinases MET, AXL, and FGFR1/2/3 has been assocd. with tumor progression in a wide variety of human malignancies, notably in instances of primary or acquired resistance to existing or emerging anticancer therapies.  This study describes the preclin. characterization of S49076, a novel, potent inhibitor of MET, AXL/MER, and FGFR1/2/3.  S49076 potently blocked cellular phosphorylation of MET, AXL, and FGFRs and inhibited downstream signaling in vitro and in vivo.  In cell models, S49076 inhibited the proliferation of MET- and FGFR2-dependent gastric cancer cells, blocked MET-driven migration of lung carcinoma cells, and inhibited colony formation of hepatocarcinoma cells expressing FGFR1/2 and AXL.  In tumor xenograft models, a good pharmacokinetic/pharmacodynamic relationship for MET and FGFR2 inhibition following oral administration of S49076 was established and correlated well with impact on tumor growth.  MET, AXL, and the FGFRs have all been implicated in resistance to VEGF/VEGFR inhibitors such as bevacizumab.  Accordingly, combination of S49076 with bevacizumab in colon carcinoma xenograft models led to near total inhibition of tumor growth.  Moreover, S49076 alone caused tumor growth arrest in bevacizumab-resistant tumors.  On the basis of these preclin. studies showing a favorable and novel pharmacol. profile of S49076, a phase I study is currently underway in patients with advanced solid tumors.  Mol Cancer Ther; 12(9); 1749-62. ©2013 AACR.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGodE4VwyiV-HrVg90H21EOLACvtfcHk0liUAV3cGasKJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtl2lur7O&md5=a53009f7a7b0601cf45598ca5b8775c2</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1158%2F1535-7163.MCT-13-0075&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1535-7163.MCT-13-0075%26sid%3Dliteratum%253Aachs%26aulast%3DBurbridge%26aufirst%3DM.%2BF.%26aulast%3DBossard%26aufirst%3DC.%2BJ.%26aulast%3DSaunier%26aufirst%3DC.%26aulast%3DFejes%26aufirst%3DI.%26aulast%3DBruno%26aufirst%3DA.%26aulast%3DL%25C3%25A9once%26aufirst%3DS.%26aulast%3DFerry%26aufirst%3DG.%26aulast%3DDa%2BViolante%26aufirst%3DG.%26aulast%3DBouzom%26aufirst%3DF.%26aulast%3DCattan%26aufirst%3DV.%26aulast%3DJacquet-Bescond%26aufirst%3DA.%26aulast%3DComoglio%26aufirst%3DP.%2BM.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DBoutin%26aufirst%3DJ.%2BA.%26aulast%3DCordi%26aufirst%3DA.%26aulast%3DOrtuno%26aufirst%3DJ.%2BC.%26aulast%3DPierr%25C3%25A9%26aufirst%3DA.%26aulast%3DHickman%26aufirst%3DJ.%2BA.%26aulast%3DCruzalegui%26aufirst%3DF.%2BH.%26aulast%3DDepil%26aufirst%3DS.%26atitle%3DS49076%2520is%2520a%2520novel%2520kinase%2520inhibitor%2520of%2520MET%252C%2520AXL%252C%2520and%2520FGFR%2520with%2520strong%2520preclinical%2520activity%2520alone%2520and%2520in%2520association%2520with%2520bevacizumab%26jtitle%3DMol.%2520Cancer%2520Ther.%26date%3D2013%26volume%3D12%26spage%3D1749%26epage%3D1762%26doi%3D10.1158%2F1535-7163.MCT-13-0075" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group">Blumenthal, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cortazar, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tang, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sridhara, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Murgo, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Justice, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazdur, R.</span><span> </span><span class="NLM_article-title">FDA approval summary: sunitinib for the treatment of progressive well-differentiated locally advanced or metastatic pancreatic neuroendocrine tumors</span> <span class="citation_source-journal">Oncologist</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">17</span><span class="NLM_x">, </span> <span class="NLM_fpage">1108</span><span class="NLM_x">–</span> <span class="NLM_lpage">1113</span><span class="refDoi"> DOI: 10.1634/theoncologist.2012-0044</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1634%2Ftheoncologist.2012-0044" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2012&pages=1108-1113&author=G.+M.+Blumenthalauthor=P.+Cortazarauthor=J.+Zhangauthor=S.+Tangauthor=R.+Sridharaauthor=A.+Murgoauthor=R.+Justiceauthor=R.+Pazdur&title=FDA+approval+summary%3A+sunitinib+for+the+treatment+of+progressive+well-differentiated+locally+advanced+or+metastatic+pancreatic+neuroendocrine+tumors&doi=10.1634%2Ftheoncologist.2012-0044"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.1634%2Ftheoncologist.2012-0044&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1634%252Ftheoncologist.2012-0044%26sid%3Dliteratum%253Aachs%26aulast%3DBlumenthal%26aufirst%3DG.%2BM.%26aulast%3DCortazar%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DJ.%26aulast%3DTang%26aufirst%3DS.%26aulast%3DSridhara%26aufirst%3DR.%26aulast%3DMurgo%26aufirst%3DA.%26aulast%3DJustice%26aufirst%3DR.%26aulast%3DPazdur%26aufirst%3DR.%26atitle%3DFDA%2520approval%2520summary%253A%2520sunitinib%2520for%2520the%2520treatment%2520of%2520progressive%2520well-differentiated%2520locally%2520advanced%2520or%2520metastatic%2520pancreatic%2520neuroendocrine%2520tumors%26jtitle%3DOncologist%26date%3D2012%26volume%3D17%26spage%3D1108%26epage%3D1113%26doi%3D10.1634%2Ftheoncologist.2012-0044" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group">Karaman, M. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gallant, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Atteridge, C. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Campbell, B. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chan, K. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Edeen, P. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Faraoni, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Floyd, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Milanov, Z. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morrison, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pritchard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">A quantitative analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">26</span><span class="NLM_x">, </span> <span class="NLM_fpage">127</span><span class="NLM_x">–</span> <span class="NLM_lpage">132</span><span class="refDoi"> DOI: 10.1038/nbt1358</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt1358" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=18183025" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=26&publication_year=2008&pages=127-132&author=M.+W.+Karamanauthor=S.+Herrgardauthor=D.+K.+Treiberauthor=P.+Gallantauthor=C.+E.+Atteridgeauthor=B.+T.+Campbellauthor=K.+W.+Chanauthor=P.+Ciceriauthor=M.+I.+Davisauthor=P.+T.+Edeenauthor=R.+Faraoniauthor=M.+Floydauthor=J.+P.+Huntauthor=D.+J.+Lockhartauthor=Z.+V.+Milanovauthor=M.+J.+Morrisonauthor=G.+Pallaresauthor=H.+K.+Patelauthor=S.+Pritchardauthor=L.+M.+Wodickaauthor=P.+P.+Zarrinkar&title=A+quantitative+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt1358"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">A quantitative analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Karaman, Mazen W.; Herrgard, Sanna; Treiber, Daniel K.; Gallant, Paul; Atteridge, Corey E.; Campbell, Brian T.; Chan, Katrina W.; Ciceri, Pietro; Davis, Mindy I.; Edeen, Philip T.; Faraoni, Raffaella; Floyd, Mark; Hunt, Jeremy P.; Lockhart, Daniel J.; Milanov, Zdravko V.; Morrison, Michael J.; Pallares, Gabriel; Patel, Hitesh K.; Pritchard, Stephanie; Wodicka, Lisa M.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">26</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">127-132</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Kinase inhibitors are a new class of therapeutics with a propensity to inhibit multiple targets.  The biol. consequences of multikinase activity are poorly defined, and an important step toward understanding the relationship between selectivity, efficacy and safety is the exploration of how inhibitors interact with the human kinome.  The authors present interaction maps for 38 kinase inhibitors across a panel of 317 kinases representing >50% of the predicted human protein kinome.  The data constitute the most comprehensive study of kinase inhibitor selectivity to date and reveal a wide diversity of interaction patterns.  To enable a global anal. of the results, the authors introduce the concept of a selectivity score as a general tool to quantify and differentiate the obsd. interaction patterns.  The authors further investigate the impact of panel size and find that small assay panels do not provide a robust measure of selectivity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpiArJSq2_lPrVg90H21EOLACvtfcHk0ljLblMm-1MlwQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFGlsQ%253D%253D&md5=346265d412853ced636ad4128ed8a76f</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1038%2Fnbt1358&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt1358%26sid%3Dliteratum%253Aachs%26aulast%3DKaraman%26aufirst%3DM.%2BW.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DGallant%26aufirst%3DP.%26aulast%3DAtteridge%26aufirst%3DC.%2BE.%26aulast%3DCampbell%26aufirst%3DB.%2BT.%26aulast%3DChan%26aufirst%3DK.%2BW.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DEdeen%26aufirst%3DP.%2BT.%26aulast%3DFaraoni%26aufirst%3DR.%26aulast%3DFloyd%26aufirst%3DM.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DMilanov%26aufirst%3DZ.%2BV.%26aulast%3DMorrison%26aufirst%3DM.%2BJ.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DPatel%26aufirst%3DH.%2BK.%26aulast%3DPritchard%26aufirst%3DS.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DA%2520quantitative%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2008%26volume%3D26%26spage%3D127%26epage%3D132%26doi%3D10.1038%2Fnbt1358" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group">Bhide, R. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y. Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Qian, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barbosa, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zheng, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, L. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barrish, J. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leavitt, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mathur, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Leith, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chao, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mortillo, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kukral, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fura, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vyas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">D’Arienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Derbin, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span> </span><span class="NLM_article-title">Discovery and preclinical studies of (R)-1-(4-(4-fluoro-2-methyl-1H-indol-5-yloxy)-X+36. 5- methylpyrrolo[2,1-f][1,2,4]triazin-6-yloxy)propan- 2-ol (BMS-540215), an in vivo active potent VEGFR-2 inhibitor</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">49</span><span class="NLM_x">, </span> <span class="NLM_fpage">2143</span><span class="NLM_x">–</span> <span class="NLM_lpage">2146</span><span class="refDoi"> DOI: 10.1021/jm051106d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm051106d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2006&pages=2143-2146&author=R.+S.+Bhideauthor=Z.+W.+Caiauthor=Y.+Z.+Zhangauthor=L.+Qianauthor=D.+Weiauthor=S.+Barbosaauthor=L.+J.+Lombardoauthor=R.+M.+Borzilleriauthor=X.+Zhengauthor=L.+I.+Wuauthor=J.+C.+Barrishauthor=S.+H.+Kimauthor=K.+Leavittauthor=A.+Mathurauthor=L.+Leithauthor=S.+Chaoauthor=B.+Wautletauthor=S.+Mortilloauthor=R.+Jeyaseelanauthor=D.+Kukralauthor=J.+T.+Huntauthor=A.+Kamathauthor=A.+Furaauthor=V.+Vyasauthor=P.+Maratheauthor=C.+D%E2%80%99Arienzoauthor=G.+Derbinauthor=J.+Fargnoli&title=Discovery+and+preclinical+studies+of+%28R%29-1-%284-%284-fluoro-2-methyl-1H-indol-5-yloxy%29-X%2B36.+5-+methylpyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazin-6-yloxy%29propan-+2-ol+%28BMS-540215%29%2C+an+in+vivo+active+potent+VEGFR-2+inhibitor&doi=10.1021%2Fjm051106d"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1021%2Fjm051106d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm051106d%26sid%3Dliteratum%253Aachs%26aulast%3DBhide%26aufirst%3DR.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DZhang%26aufirst%3DY.%2BZ.%26aulast%3DQian%26aufirst%3DL.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DBarbosa%26aufirst%3DS.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26aulast%3DZheng%26aufirst%3DX.%26aulast%3DWu%26aufirst%3DL.%2BI.%26aulast%3DBarrish%26aufirst%3DJ.%2BC.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLeavitt%26aufirst%3DK.%26aulast%3DMathur%26aufirst%3DA.%26aulast%3DLeith%26aufirst%3DL.%26aulast%3DChao%26aufirst%3DS.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DMortillo%26aufirst%3DS.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DKukral%26aufirst%3DD.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DFura%26aufirst%3DA.%26aulast%3DVyas%26aufirst%3DV.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DD%25E2%2580%2599Arienzo%26aufirst%3DC.%26aulast%3DDerbin%26aufirst%3DG.%26aulast%3DFargnoli%26aufirst%3DJ.%26atitle%3DDiscovery%2520and%2520preclinical%2520studies%2520of%2520%2528R%2529-1-%25284-%25284-fluoro-2-methyl-1H-indol-5-yloxy%2529-X%252B36.%25205-%2520methylpyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazin-6-yloxy%2529propan-%25202-ol%2520%2528BMS-540215%2529%252C%2520an%2520in%2520vivo%2520active%2520potent%2520VEGFR-2%2520inhibitor%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2006%26volume%3D49%26spage%3D2143%26epage%3D2146%26doi%3D10.1021%2Fjm051106d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nirschl, D. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Z.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huynh, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vaccaro, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Poss, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kellar, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wong, T. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Identification of pyrrolo[2,1-f][1,2,4]triazine-based inhibitors of Met kinase</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">1945</span><span class="NLM_x">–</span> <span class="NLM_lpage">1951</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.01.121</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bmcl.2008.01.121" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=1945-1951&author=G.+M.+Schroederauthor=X.+T.+Chenauthor=D.+K.+Williamsauthor=D.+S.+Nirschlauthor=Z.+W.+Caiauthor=D.+Weiauthor=J.+S.+Tokarskiauthor=Y.+Anauthor=J.+Sackauthor=Z.+Chenauthor=T.+Huynhauthor=W.+Vaccaroauthor=M.+Possauthor=B.+Wautletauthor=J.+Gullo-Brownauthor=K.+Kellarauthor=V.+Manneauthor=J.+T.+Huntauthor=T.+W.+Wongauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Identification+of+pyrrolo%5B2%2C1-f%5D%5B1%2C2%2C4%5Dtriazine-based+inhibitors+of+Met+kinase&doi=10.1016%2Fj.bmcl.2008.01.121"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.01.121&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.01.121%26sid%3Dliteratum%253Aachs%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DNirschl%26aufirst%3DD.%2BS.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%26aulast%3DChen%26aufirst%3DZ.%26aulast%3DHuynh%26aufirst%3DT.%26aulast%3DVaccaro%26aufirst%3DW.%26aulast%3DPoss%26aufirst%3DM.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DKellar%26aufirst%3DK.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DWong%26aufirst%3DT.%2BW.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DIdentification%2520of%2520pyrrolo%255B2%252C1-f%255D%255B1%252C2%252C4%255Dtriazine-based%2520inhibitors%2520of%2520Met%2520kinase%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D1945%26epage%3D1951%26doi%3D10.1016%2Fj.bmcl.2008.01.121" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schroeder, G. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cornelius, L. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, X. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of orally active pyrrolopyridine- and aminopyridine-based Met kinase inhibitors</span> <span class="citation_source-journal">Bioorg. Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">18</span><span class="NLM_x">, </span> <span class="NLM_fpage">3224</span><span class="NLM_x">–</span> <span class="NLM_lpage">3229</span><span class="refDoi"> DOI: 10.1016/j.bmcl.2008.04.047</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bmcl.2008.04.047" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3224-3229&author=Z.+W.+Caiauthor=D.+Weiauthor=G.+M.+Schroederauthor=L.+A.+Corneliusauthor=K.+Kimauthor=X.+T.+Chenauthor=R.+J.+Schmidtauthor=D.+K.+Williamsauthor=J.+S.+Tokarskiauthor=Y.+Anauthor=J.+S.+Sackauthor=V.+Manneauthor=A.+Kamathauthor=Y.+Zhangauthor=P.+Maratheauthor=J.+T.+Huntauthor=L.+J.+Lombardoauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+orally+active+pyrrolopyridine-+and+aminopyridine-based+Met+kinase+inhibitors&doi=10.1016%2Fj.bmcl.2008.04.047"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.04.047&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.04.047%26sid%3Dliteratum%253Aachs%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DSchroeder%26aufirst%3DG.%2BM.%26aulast%3DCornelius%26aufirst%3DL.%2BA.%26aulast%3DKim%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%2BT.%26aulast%3DSchmidt%26aufirst%3DR.%2BJ.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520orally%2520active%2520pyrrolopyridine-%2520and%2520aminopyridine-based%2520Met%2520kinase%2520inhibitors%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3224%26epage%3D3229%26doi%3D10.1016%2Fj.bmcl.2008.04.047" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group">Kim, K. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmidt, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cai, Z. W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wei, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lombardo, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Trainor, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Xie, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">An, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sack, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tokarski, J. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Darienzo, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kamath, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Marathe, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lippy, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jeyaseelan, R.,  Sr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wautlet, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Henley, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gullo-Brown, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Manne, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Fargnoli, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Borzilleri, R. M.</span><span> </span><span class="NLM_article-title">Discovery of pyrrolopyridine-pyridone based inhibitors of Met kinase: synthesis, X-ray crystallographic analysis, and biological activities</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2008</span><span class="NLM_x">, </span> <span class="NLM_volume">51</span><span class="NLM_x">, </span> <span class="NLM_fpage">5330</span><span class="NLM_x">–</span> <span class="NLM_lpage">5341</span><span class="refDoi"> DOI: 10.1021/jm800476q</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm800476q" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD1cXps1KnsL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=51&publication_year=2008&pages=5330-5341&author=K.+S.+Kimauthor=L.+Zhangauthor=R.+Schmidtauthor=Z.+W.+Caiauthor=D.+Weiauthor=D.+K.+Williamsauthor=L.+J.+Lombardoauthor=G.+L.+Trainorauthor=D.+Xieauthor=Y.+Zhangauthor=Y.+Anauthor=J.+S.+Sackauthor=J.+S.+Tokarskiauthor=C.+Darienzoauthor=A.+Kamathauthor=P.+Maratheauthor=Y.+Zhangauthor=J.+Lippyauthor=R.+Jeyaseelanauthor=B.+Wautletauthor=B.+Henleyauthor=J.+Gullo-Brownauthor=V.+Manneauthor=J.+T.+Huntauthor=J.+Fargnoliauthor=R.+M.+Borzilleri&title=Discovery+of+pyrrolopyridine-pyridone+based+inhibitors+of+Met+kinase%3A+synthesis%2C+X-ray+crystallographic+analysis%2C+and+biological+activities&doi=10.1021%2Fjm800476q"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Pyrrolopyridine-Pyridone Based Inhibitors of Met Kinase: Synthesis, X-ray Crystallographic Analysis, and Biological Activities</span></div><div class="casAuthors">Kim, Kyoung Soon; Zhang, Liping; Schmidt, Robert; Cai, Zhen-Wei; Wei, Donna; Williams, David K.; Lombardo, Louis J.; Trainor, George L.; Xie, Dianlin; Zhang, Yaquan; An, Yongmi; Sack, John S.; Tokarski, John S.; Darienzo, Celia; Kamath, Amrita; Marathe, Punit; Zhang, Yueping; Lippy, Jonathan; Jeyaseelan, Robert; Wautlet, Barri; Henley, Benjamin; Gullo-Brown, Johnni; Manne, Veeraswamy; Hunt, John T.; Fargnoli, Joseph; Borzilleri, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">51</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">5330-5341</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Conformationally constrained 2-pyridone analog 2 is a potent Met kinase inhibitor with an IC50 value of 1.8 nM.  Further SAR of the 2-pyridone based inhibitors of Met kinase led to potent 4-pyridone and pyridine N-oxide inhibitors such as 3 and 4.  The X-ray crystallog. data of the inhibitor 2 bound to the ATP binding site of Met kinase protein provided insight into the binding modes of these inhibitors, and the SAR of this series of analogs was rationalized.  Many of these analogs showed potent antiproliferative activities against the Met dependent GTL-16 gastric carcinoma cell line.  Compd. 2 also inhibited Flt-3 and VEGFR-2 kinases with IC50 values of 4 and 27 nM, resp.  It possesses a favorable pharmacokinetic profile in mice and demonstrates significant in vivo antitumor activity in the GTL-16 human gastric carcinoma xenograft model.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqyVhpyiMXT07Vg90H21EOLACvtfcHk0liBaTt5uByxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXps1KnsL8%253D&md5=ec5db4cd0ae460e569c5f728d221acf4</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=10.1021%2Fjm800476q&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm800476q%26sid%3Dliteratum%253Aachs%26aulast%3DKim%26aufirst%3DK.%2BS.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DSchmidt%26aufirst%3DR.%26aulast%3DCai%26aufirst%3DZ.%2BW.%26aulast%3DWei%26aufirst%3DD.%26aulast%3DWilliams%26aufirst%3DD.%2BK.%26aulast%3DLombardo%26aufirst%3DL.%2BJ.%26aulast%3DTrainor%26aufirst%3DG.%2BL.%26aulast%3DXie%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DAn%26aufirst%3DY.%26aulast%3DSack%26aufirst%3DJ.%2BS.%26aulast%3DTokarski%26aufirst%3DJ.%2BS.%26aulast%3DDarienzo%26aufirst%3DC.%26aulast%3DKamath%26aufirst%3DA.%26aulast%3DMarathe%26aufirst%3DP.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DLippy%26aufirst%3DJ.%26aulast%3DJeyaseelan%26aufirst%3DR.%26aulast%3DWautlet%26aufirst%3DB.%26aulast%3DHenley%26aufirst%3DB.%26aulast%3DGullo-Brown%26aufirst%3DJ.%26aulast%3DManne%26aufirst%3DV.%26aulast%3DHunt%26aufirst%3DJ.%2BT.%26aulast%3DFargnoli%26aufirst%3DJ.%26aulast%3DBorzilleri%26aufirst%3DR.%2BM.%26atitle%3DDiscovery%2520of%2520pyrrolopyridine-pyridone%2520based%2520inhibitors%2520of%2520Met%2520kinase%253A%2520synthesis%252C%2520X-ray%2520crystallographic%2520analysis%252C%2520and%2520biological%2520activities%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2008%26volume%3D51%26spage%3D5330%26epage%3D5341%26doi%3D10.1021%2Fjm800476q" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Salzberg, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kurtzberg, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Matsushima, G. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Keating, A. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lovell, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Williams, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dawson, T. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schell, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Anwar, A. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Snodgrass, H. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span> </span><span class="NLM_article-title">Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia</span> <span class="citation_source-journal">Clin. Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2006</span><span class="NLM_x">, </span> <span class="NLM_volume">12</span><span class="NLM_x">, </span> <span class="NLM_fpage">2662</span><span class="NLM_x">–</span> <span class="NLM_lpage">2669</span><span class="refDoi"> DOI: 10.1158/1078-0432.CCR-05-2208</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1078-0432.CCR-05-2208" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=16675557" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref92/cit92&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD28Xltlamsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=2662-2669&author=D.+K.+Grahamauthor=D.+B.+Salzbergauthor=J.+Kurtzbergauthor=S.+Satherauthor=G.+K.+Matsushimaauthor=A.+K.+Keatingauthor=X.+Liangauthor=M.+A.+Lovellauthor=S.+A.+Williamsauthor=T.+L.+Dawsonauthor=M.+J.+Schellauthor=A.+A.+Anwarauthor=H.+R.+Snodgrassauthor=H.+S.+Earp&title=Ectopic+expression+of+the+proto-oncogene+Mer+in+pediatric+T-cell+acute+lymphoblastic+leukemia&doi=10.1158%2F1078-0432.CCR-05-2208"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit92R"><div class="casContent"><span class="casTitleNuber">92</span><div class="casTitle"><span class="NLM_cas:atitle">Ectopic expression of the proto-oncogene Mer in pediatric T-cell acute lymphoblastic leukemia</span></div><div class="casAuthors">Graham, Douglas K.; Salzberg, Dana B.; Kurtzberg, Joanne; Sather, Susan; Matsushima, Glenn K.; Keating, Amy K.; Liang, Xiayuan; Lovell, Mark A.; Williams, Sara A.; Dawson, Thomas L.; Schell, Michael J.; Anwar, Adil A.; Snodgrass, H. Ralph; Earp, H. Shelton</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">2662-2669</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Purpose: The Mer receptor tyrosine kinase, cloned from a B-lymphoblastoid library, is the mammalian orthologue of the chicken retroviral oncogene v-eyk and sends antiapoptotic and transforming signals when activated.  To det. if Mer expression is ectopic in T-cell acute lymphoblastic leukemia (ALL) and potentially important in leukemogenesis, we analyzed Mer expression in normal human thymocytes and lymphocytes and in pediatric ALL patient samples.  Exptl. Design: Reverse transcription-PCR, flow cytometry, and immunohistochem. were used to det. expression of Mer in sorted human thymocyte populations, lymphocytes, and lymphocytes activated by phytohemagglutinin or phorbol 12-myristate 13-acetate/ionophore.  Mer expression in 34 T-cell ALL (T-ALL) patient samples was evaluated by reverse transcription-PCR, and Mer protein expression in a sep. cohort of 16 patient samples was assayed by flow cytometry and Western blot.  Results: Mer expression was absent in normal thymocytes or lymphocytes, and in T cells activated with phytohemagglutinin or phorbol 12-myristate 13-acetate/ionophore.  In contrast, Jurkat cells and T-ALL patient samples expressed unique 180 to 185 kDa Mer protein glycoforms.  Substantial Mer RNA levels were principally obsd. in a subset of T-ALL patient samples that expressed B220 (P = 0.004) but lacked surface expression of CD3 (P = 0.02) and CD4 (P = 0.006), a phenotypic profile consistent with immature lymphoblasts.  In addn., 8 of 16 T-ALL patient samples had Mer protein detected by flow cytometry and Western blot.  Conclusions: Transforming Mer signals may contribute to T-cell leukemogenesis, and abnormal Mer expression may be a novel therapeutic target in pediatric ALL therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr5MShoRa9blLVg90H21EOLACvtfcHk0liBaTt5uByxRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xltlamsrw%253D&md5=68f8310415b1984596118b40976cdd36</span></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=10.1158%2F1078-0432.CCR-05-2208&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1078-0432.CCR-05-2208%26sid%3Dliteratum%253Aachs%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DSalzberg%26aufirst%3DD.%2BB.%26aulast%3DKurtzberg%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DMatsushima%26aufirst%3DG.%2BK.%26aulast%3DKeating%26aufirst%3DA.%2BK.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DLovell%26aufirst%3DM.%2BA.%26aulast%3DWilliams%26aufirst%3DS.%2BA.%26aulast%3DDawson%26aufirst%3DT.%2BL.%26aulast%3DSchell%26aufirst%3DM.%2BJ.%26aulast%3DAnwar%26aufirst%3DA.%2BA.%26aulast%3DSnodgrass%26aufirst%3DH.%2BR.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26atitle%3DEctopic%2520expression%2520of%2520the%2520proto-oncogene%2520Mer%2520in%2520pediatric%2520T-cell%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DClin.%2520Cancer%2520Res.%26date%3D2006%26volume%3D12%26spage%3D2662%26epage%3D2669%26doi%3D10.1158%2F1078-0432.CCR-05-2208" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group">Gray, N. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thunnissen, A. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norman, T. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kwon, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Espinoza, F. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morgan, D. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Barnes, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">LeClerc, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Meijer, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kim, S. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lockhart, D. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultz, P. G.</span><span> </span><span class="NLM_article-title">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">1998</span><span class="NLM_x">, </span> <span class="NLM_volume">281</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">538</span><span class="refDoi"> DOI: 10.1126/science.281.5376.533</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscience.281.5376.533" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=9677190" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=281&publication_year=1998&pages=533-538&author=N.+S.+Grayauthor=L.+Wodickaauthor=A.+M.+Thunnissenauthor=T.+C.+Normanauthor=S.+Kwonauthor=F.+H.+Espinozaauthor=D.+O.+Morganauthor=G.+Barnesauthor=S.+LeClercauthor=L.+Meijerauthor=S.+H.+Kimauthor=D.+J.+Lockhartauthor=P.+G.+Schultz&title=Exploiting+chemical+libraries%2C+structure%2C+and+genomics+in+the+search+for+kinase+inhibitors&doi=10.1126%2Fscience.281.5376.533"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors</span></div><div class="casAuthors">Gray, Nathanael S.; Wodicka, Lisa; Thunnissen, Andy-Mark W. H.; Norman, Thea C.; Kwon, Soojin; Espinoza, F. Hernan; Morgan, David O.; Barnes, Georjana; LeClerc, Sophie; Meijer, Laurent; Kim, Sung-Hou; Lockhart, David J.; Schultz, Peter G.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, D. C.)</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">281</span>
        (<span class="NLM_cas:issue">5376</span>),
    <span class="NLM_cas:pages">533-538</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Selective protein kinase inhibitors were developed on the basis of the unexpected binding mode of 2,6,9-trisubstituted purines to the ATP-binding site of the human cyclin-dependent kinase 2 (CDK2).  By iterating chem. library synthesis and biol. screening, potent inhibitors of the human CDK2-cyclin A kinase complex and of Saccharomyces cerevisiae Cdc28p were identified.  The structural basis for the binding affinity and selectivity was detd. by anal. of a three-dimensional crystal structure of a CDK2-inhibitor complex.  The cellular effects of these compds. were characterized in mammalian cells and yeast.  In the latter case the effects were characterized on a genome-wide scale by monitoring changes in mRNA levels in treated cells with high-d. oligonucleotide probe arrays.  Purine libraries could provide useful tools for analyzing a variety of signaling and regulatory pathways and may led to the development of new therapeutics.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqRTOOPjk16tbVg90H21EOLACvtfcHk0lhIuFmUPW42ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXkvFCltr8%253D&md5=08b8debe4d05c1169c152ccd6676def8</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=10.1126%2Fscience.281.5376.533&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.281.5376.533%26sid%3Dliteratum%253Aachs%26aulast%3DGray%26aufirst%3DN.%2BS.%26aulast%3DWodicka%26aufirst%3DL.%26aulast%3DThunnissen%26aufirst%3DA.%2BM.%26aulast%3DNorman%26aufirst%3DT.%2BC.%26aulast%3DKwon%26aufirst%3DS.%26aulast%3DEspinoza%26aufirst%3DF.%2BH.%26aulast%3DMorgan%26aufirst%3DD.%2BO.%26aulast%3DBarnes%26aufirst%3DG.%26aulast%3DLeClerc%26aufirst%3DS.%26aulast%3DMeijer%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DLockhart%26aufirst%3DD.%2BJ.%26aulast%3DSchultz%26aufirst%3DP.%2BG.%26atitle%3DExploiting%2520chemical%2520libraries%252C%2520structure%252C%2520and%2520genomics%2520in%2520the%2520search%2520for%2520kinase%2520inhibitors%26jtitle%3DScience%26date%3D1998%26volume%3D281%26spage%3D533%26epage%3D538%26doi%3D10.1126%2Fscience.281.5376.533" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group">Huang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Finerty, P.,  Jr.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Walker, J. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Butler-Cole, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Vedadi, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schapira, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Parker, S. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Turk, B. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Thompson, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Dhe-Paganon, S.</span><span> </span><span class="NLM_article-title">Structural insights into the inhibited states of the Mer receptor tyrosine kinase</span> <span class="citation_source-journal">J. Struct. Biol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">165</span><span class="NLM_x">, </span> <span class="NLM_fpage">88</span><span class="NLM_x">–</span> <span class="NLM_lpage">96</span><span class="refDoi"> DOI: 10.1016/j.jsb.2008.10.003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.jsb.2008.10.003" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=165&publication_year=2009&pages=88-96&author=X.+Huangauthor=P.+Finertyauthor=J.+R.+Walkerauthor=C.+Butler-Coleauthor=M.+Vedadiauthor=M.+Schapiraauthor=S.+A.+Parkerauthor=B.+E.+Turkauthor=D.+A.+Thompsonauthor=S.+Dhe-Paganon&title=Structural+insights+into+the+inhibited+states+of+the+Mer+receptor+tyrosine+kinase&doi=10.1016%2Fj.jsb.2008.10.003"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.jsb.2008.10.003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.jsb.2008.10.003%26sid%3Dliteratum%253Aachs%26aulast%3DHuang%26aufirst%3DX.%26aulast%3DFinerty%26aufirst%3DP.%26aulast%3DWalker%26aufirst%3DJ.%2BR.%26aulast%3DButler-Cole%26aufirst%3DC.%26aulast%3DVedadi%26aufirst%3DM.%26aulast%3DSchapira%26aufirst%3DM.%26aulast%3DParker%26aufirst%3DS.%2BA.%26aulast%3DTurk%26aufirst%3DB.%2BE.%26aulast%3DThompson%26aufirst%3DD.%2BA.%26aulast%3DDhe-Paganon%26aufirst%3DS.%26atitle%3DStructural%2520insights%2520into%2520the%2520inhibited%2520states%2520of%2520the%2520Mer%2520receptor%2520tyrosine%2520kinase%26jtitle%3DJ.%2520Struct.%2520Biol.%26date%3D2009%26volume%3D165%26spage%3D88%26epage%3D96%26doi%3D10.1016%2Fj.jsb.2008.10.003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group">Liu, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yang, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Simpson, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Deryckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Deusen, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Korboukh, V. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Patel, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnson, G. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Discovery of novel small molecule Mer kinase inhibitors for the treatment of pediatric acute lymphoblastic leukemia</span> <span class="citation_source-journal">ACS Med. Chem. Lett.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">3</span><span class="NLM_x">, </span> <span class="NLM_fpage">129</span><span class="NLM_x">–</span> <span class="NLM_lpage">134</span><span class="refDoi"> DOI: 10.1021/ml200239k</span> </span><div class="citationLinks">[<a href="/doi/10.1021/ml200239k" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XktlOktw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2012&pages=129-134&author=J.+Liuauthor=C.+Yangauthor=C.+Simpsonauthor=D.+Deryckereauthor=A.+Van+Deusenauthor=M.+J.+Mileyauthor=D.+Kireevauthor=J.+Norris-Drouinauthor=S.+Satherauthor=D.+Hunterauthor=V.+K.+Korboukhauthor=H.+S.+Patelauthor=W.+P.+Janzenauthor=M.+Machiusauthor=G.+L.+Johnsonauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+novel+small+molecule+Mer+kinase+inhibitors+for+the+treatment+of+pediatric+acute+lymphoblastic+leukemia&doi=10.1021%2Fml200239k"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Small Molecule Mer Kinase Inhibitors for the Treatment of Pediatric Acute Lymphoblastic Leukemia</span></div><div class="casAuthors">Liu, Jing; Yang, Chao; Simpson, Catherine; DeRyckere, Deborah; Van Deusen, Amy; Miley, Michael J.; Kireev, Dmitri; Norris-Drouin, Jacqueline; Sather, Susan; Hunter, Debra; Korboukh, Victoria K.; Patel, Hari S.; Janzen, William P.; Machius, Mischa; Johnson, Gary L.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">ACS Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">129-134</span>CODEN:
                <span class="NLM_cas:coden">AMCLCT</span>;
        ISSN:<span class="NLM_cas:issn">1948-5875</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Ectopic Mer expression promotes pro-survival signaling and contributes to leukemogenesis and chemoresistance in childhood acute lymphoblastic leukemia (ALL).  Consequently, Mer kinase inhibitors may promote leukemic cell death and further act as chemosensitizers increasing efficacy and reducing toxicities of current ALL regimens.  We have applied a structure-based design approach to discover novel small mol. Mer kinase inhibitors.  Several pyrazolopyrimidine derivs. effectively inhibit Mer kinase activity at subnanomolar concns.  Furthermore, the lead compd. shows a promising selectivity profile against a panel of 72 kinases and has excellent pharmacokinetic properties.  We also describe the crystal structure of the complex between the lead compd. and Mer, opening new opportunities for further optimization and new template design.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgYt56zaMpS7Vg90H21EOLACvtfcHk0lhIuFmUPW42ew"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XktlOktw%253D%253D&md5=200b89e7e1ebb6e1008fa8324adc05d1</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1021%2Fml200239k&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fml200239k%26sid%3Dliteratum%253Aachs%26aulast%3DLiu%26aufirst%3DJ.%26aulast%3DYang%26aufirst%3DC.%26aulast%3DSimpson%26aufirst%3DC.%26aulast%3DDeryckere%26aufirst%3DD.%26aulast%3DVan%2BDeusen%26aufirst%3DA.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKorboukh%26aufirst%3DV.%2BK.%26aulast%3DPatel%26aufirst%3DH.%2BS.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJohnson%26aufirst%3DG.%2BL.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520novel%2520small%2520molecule%2520Mer%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520pediatric%2520acute%2520lymphoblastic%2520leukemia%26jtitle%3DACS%2520Med.%2520Chem.%2520Lett.%26date%3D2012%26volume%3D3%26spage%3D129%26epage%3D134%26doi%3D10.1021%2Fml200239k" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhang, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cummings, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kirkpatrick, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Pseudo-cyclization through intramolecular hydrogen bond enables discovery of pyridine substituted pyrimidines as new Mer kinase inhibitors</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9683</span><span class="NLM_x">–</span> <span class="NLM_lpage">9692</span><span class="refDoi"> DOI: 10.1021/jm401387j</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401387j" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslCgtbzF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9683-9692&author=W.+Zhangauthor=D.+Zhangauthor=M.+A.+Stashkoauthor=D.+DeRyckereauthor=D.+Hunterauthor=D.+Kireevauthor=M.+J.+Mileyauthor=C.+Cummingsauthor=M.+Leeauthor=J.+Norris-Drouinauthor=W.+M.+Stewartauthor=S.+Satherauthor=Y.+Zhouauthor=G.+Kirkpatrickauthor=M.+Machiusauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Pseudo-cyclization+through+intramolecular+hydrogen+bond+enables+discovery+of+pyridine+substituted+pyrimidines+as+new+Mer+kinase+inhibitors&doi=10.1021%2Fjm401387j"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">Pseudo-Cyclization through Intramolecular Hydrogen Bond Enables Discovery of Pyridine Substituted Pyrimidines as New Mer Kinase Inhibitors</span></div><div class="casAuthors">Zhang, Weihe; Zhang, Dehui; Stashko, Michael A.; DeRyckere, Deborah; Hunter, Debra; Kireev, Dmitri; Miley, Michael J.; Cummings, Christopher; Lee, Minjung; Norris-Drouin, Jacqueline; Stewart, Wendy M.; Sather, Susan; Zhou, Yingqiu; Kirkpatrick, Gregory; Machius, Mischa; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9683-9692</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Abnormal activation or overexpression of Mer receptor tyrosine kinase has been implicated in survival signaling and chemoresistance in many human cancers.  Consequently, Mer is a promising novel cancer therapeutic target.  A structure-based drug design approach using a pseudo-ring replacement strategy was developed and validated to discover a new family of pyridinepyrimidine analogs as potent Mer inhibitors.  Through SAR studies, compd. I (UNC2250) was identified as the lead compd. for further investigation based on high selectivity against other kinases and good pharmacokinetic properties.  When applied to live cells, I inhibited steady-state phosphorylation of endogenous Mer with an IC50 of 9.8 nM and blocked ligand-stimulated activation of a chimeric EGFR-Mer protein.  Treatment with I also resulted in decreased colony-forming potential in rhabdoid and NSCLC tumor cells, thereby demonstrating functional antitumor activity.  The results provide a rationale for further investigation of this compd. for therapeutic application in patients with cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq-jRMr-85lKbVg90H21EOLACvtfcHk0lgtnEvXCSX5fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslCgtbzF&md5=0a228cd34d0d23f8ade7443ca7fad8b8</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1021%2Fjm401387j&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401387j%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DZhang%26aufirst%3DD.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DCummings%26aufirst%3DC.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DW.%2BM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DKirkpatrick%26aufirst%3DG.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DPseudo-cyclization%2520through%2520intramolecular%2520hydrogen%2520bond%2520enables%2520discovery%2520of%2520pyridine%2520substituted%2520pyrimidines%2520as%2520new%2520Mer%2520kinase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9683%26epage%3D9692%26doi%3D10.1021%2Fjm401387j" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group">Zhang, W.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">McIver, A. L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stashko, M. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">DeRyckere, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Branchford, B. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunter, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kireev, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Miley, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Norris-Drouin, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stewart, W. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lee, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sather, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Di Paola, J. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Machius, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Janzen, W. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Earp, H. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Graham, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frye, S. V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, X.</span><span> </span><span class="NLM_article-title">Discovery of Mer specific tyrosine kinase inhibitors for the treatment and prevention of thrombosis</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">56</span><span class="NLM_x">, </span> <span class="NLM_fpage">9693</span><span class="NLM_x">–</span> <span class="NLM_lpage">9700</span><span class="refDoi"> DOI: 10.1021/jm4013888</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm4013888" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslOms7rK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=56&publication_year=2013&pages=9693-9700&author=W.+Zhangauthor=A.+L.+McIverauthor=M.+A.+Stashkoauthor=D.+DeRyckereauthor=B.+R.+Branchfordauthor=D.+Hunterauthor=D.+Kireevauthor=M.+J.+Mileyauthor=J.+Norris-Drouinauthor=W.+M.+Stewartauthor=M.+Leeauthor=S.+Satherauthor=Y.+Zhouauthor=J.+A.+Di+Paolaauthor=M.+Machiusauthor=W.+P.+Janzenauthor=H.+S.+Earpauthor=D.+K.+Grahamauthor=S.+V.+Fryeauthor=X.+Wang&title=Discovery+of+Mer+specific+tyrosine+kinase+inhibitors+for+the+treatment+and+prevention+of+thrombosis&doi=10.1021%2Fjm4013888"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">Discovery of Mer Specific Tyrosine Kinase Inhibitors for the Treatment and Prevention of Thrombosis</span></div><div class="casAuthors">Zhang, Weihe; McIver, Andrew L.; Stashko, Michael A.; DeRyckere, Deborah; Branchford, Brian R.; Hunter, Debra; Kireev, Dmitri; Miley, Michael J.; Norris-Drouin, Jacqueline; Stewart, Wendy M.; Lee, Minjung; Sather, Susan; Zhou, Yingqiu; Di Paola, Jorge A.; Machius, Mischa; Janzen, William P.; Earp, H. Shelton; Graham, Douglas K.; Frye, Stephen V.; Wang, Xiaodong</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">56</span>
        (<span class="NLM_cas:issue">23</span>),
    <span class="NLM_cas:pages">9693-9700</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The role of Mer kinase in regulating the second phase of platelet activation generates an opportunity to use Mer inhibitors for preventing thrombosis with diminished likelihood for bleeding as compared to current therapies.  Toward this end, we have discovered a novel, Mer kinase specific substituted-pyrimidine scaffold using a structure-based drug design and a pseudo ring replacement strategy.  The cocrystal structure of Mer with two compds. possessing distinct activity have been detd.  Subsequent SAR studies identified compd. I (UNC2881) as a lead compd. for in vivo evaluation.  When applied to live cells, I inhibits steady-state Mer kinase phosphorylation with an IC50 value of 22 nM.  Treatment with I is also sufficient to block EGF-mediated stimulation of a chimeric receptor contg. the intracellular domain of Mer fused to the extracellular domain of EGFR.  In addn., I potently inhibits collagen-induced platelet aggregation, suggesting that this class of inhibitors may have utility for prevention and/or treatment of pathol. thrombosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv1DOYha0vlLVg90H21EOLACvtfcHk0lgtnEvXCSX5fw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslOms7rK&md5=07f0b637d009061599c05caaf503372e</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1021%2Fjm4013888&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm4013888%26sid%3Dliteratum%253Aachs%26aulast%3DZhang%26aufirst%3DW.%26aulast%3DMcIver%26aufirst%3DA.%2BL.%26aulast%3DStashko%26aufirst%3DM.%2BA.%26aulast%3DDeRyckere%26aufirst%3DD.%26aulast%3DBranchford%26aufirst%3DB.%2BR.%26aulast%3DHunter%26aufirst%3DD.%26aulast%3DKireev%26aufirst%3DD.%26aulast%3DMiley%26aufirst%3DM.%2BJ.%26aulast%3DNorris-Drouin%26aufirst%3DJ.%26aulast%3DStewart%26aufirst%3DW.%2BM.%26aulast%3DLee%26aufirst%3DM.%26aulast%3DSather%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DY.%26aulast%3DDi%2BPaola%26aufirst%3DJ.%2BA.%26aulast%3DMachius%26aufirst%3DM.%26aulast%3DJanzen%26aufirst%3DW.%2BP.%26aulast%3DEarp%26aufirst%3DH.%2BS.%26aulast%3DGraham%26aufirst%3DD.%2BK.%26aulast%3DFrye%26aufirst%3DS.%2BV.%26aulast%3DWang%26aufirst%3DX.%26atitle%3DDiscovery%2520of%2520Mer%2520specific%2520tyrosine%2520kinase%2520inhibitors%2520for%2520the%2520treatment%2520and%2520prevention%2520of%2520thrombosis%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2013%26volume%3D56%26spage%3D9693%26epage%3D9700%26doi%3D10.1021%2Fjm4013888" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group">Singh, R.; Heckrodt, T. J.; Holland, S.</span><span> </span><span class="NLM_article-title">Polycyclic heteroaryl substituted triazoles useful as axl inhibitors</span>. Int. Patent WO 2010/005876 A2,<span class="NLM_x"> </span><span class="NLM_year">2010</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2010&author=R.+Singh&author=T.+J.+Heckrodt&author=S.+Holland&title=Polycyclic+heteroaryl+substituted+triazoles+useful+as+axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DSingh%26aufirst%3DR.%26atitle%3DPolycyclic%2520heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520axl%2520inhibitors%26date%3D2010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group">Wnuk-Lipinska, K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tiron, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gausdal, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sandal, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Frink, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hinz, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hellesøy, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ahmed, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Haugen, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Blø, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Micklem, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yule, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Minna, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zhou, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brekken, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lorens, J.</span><span> </span><span class="NLM_article-title">Abstract 1747: BGB324, a selective small molecule Axl kinase inhibitor to overcome EMT-associated drug resistance in carcinomas: Therapeutic rationale and early clinical studies</span> <span class="citation_source-journal">Cancer Res.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">74</span><span class="NLM_x">, </span> <span class="NLM_fpage">1747</span><span class="refDoi"> DOI: 10.1158/1538-7445.AM2014-1747</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1158%2F1538-7445.AM2014-1747" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=74&publication_year=2014&pages=1747&author=K.+Wnuk-Lipinskaauthor=C.+Tironauthor=G.+Gausdalauthor=T.+Sandalauthor=R.+Frinkauthor=S.+Hinzauthor=M.+Helles%C3%B8yauthor=L.+Ahmedauthor=H.+Haugenauthor=X.+Liangauthor=M.+Bl%C3%B8author=D.+Micklemauthor=M.+Yuleauthor=J.+Minnaauthor=L.+Zhouauthor=R.+Brekkenauthor=J.+Lorens&title=Abstract+1747%3A+BGB324%2C+a+selective+small+molecule+Axl+kinase+inhibitor+to+overcome+EMT-associated+drug+resistance+in+carcinomas%3A+Therapeutic+rationale+and+early+clinical+studies&doi=10.1158%2F1538-7445.AM2014-1747"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1158%2F1538-7445.AM2014-1747&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1158%252F1538-7445.AM2014-1747%26sid%3Dliteratum%253Aachs%26aulast%3DWnuk-Lipinska%26aufirst%3DK.%26aulast%3DTiron%26aufirst%3DC.%26aulast%3DGausdal%26aufirst%3DG.%26aulast%3DSandal%26aufirst%3DT.%26aulast%3DFrink%26aufirst%3DR.%26aulast%3DHinz%26aufirst%3DS.%26aulast%3DHelles%25C3%25B8y%26aufirst%3DM.%26aulast%3DAhmed%26aufirst%3DL.%26aulast%3DHaugen%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DX.%26aulast%3DBl%25C3%25B8%26aufirst%3DM.%26aulast%3DMicklem%26aufirst%3DD.%26aulast%3DYule%26aufirst%3DM.%26aulast%3DMinna%26aufirst%3DJ.%26aulast%3DZhou%26aufirst%3DL.%26aulast%3DBrekken%26aufirst%3DR.%26aulast%3DLorens%26aufirst%3DJ.%26atitle%3DAbstract%25201747%253A%2520BGB324%252C%2520a%2520selective%2520small%2520molecule%2520Axl%2520kinase%2520inhibitor%2520to%2520overcome%2520EMT-associated%2520drug%2520resistance%2520in%2520carcinomas%253A%2520Therapeutic%2520rationale%2520and%2520early%2520clinical%2520studies%26jtitle%3DCancer%2520Res.%26date%3D2014%26volume%3D74%26spage%3D1747%26doi%3D10.1158%2F1538-7445.AM2014-1747" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group">Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Ding, P.; Litvak, J.</span><span> </span><span class="NLM_article-title">Polycyclic heteroaryl substituted triazoles useful as Axl inhibitors</span>. Int. Patent US 8,741,898 B2,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=D.+Goff&author=J.+Zhang&author=R.+Singh&author=S.+Holland&author=J.+Yu&author=T.+J.+Heckrodt&author=P.+Ding&author=J.+Litvak&title=Polycyclic+heteroaryl+substituted+triazoles+useful+as+Axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DGoff%26aufirst%3DD.%26atitle%3DPolycyclic%2520heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520Axl%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref101"><div class="reference"><strong class="refLabel"><a href="#ref101" class="rightTabRefNumLink">101</a></strong><div class="NLM_citation" id="rightTab-cit101"><span><span class="NLM_contrib-group">Ding, P.; Goff, D.; Zhang, J.; Singh, R.; Holland, S.; Yu, J.; Heckrodt, T. J.; Litvak, J.</span><span> </span><span class="NLM_article-title"><i>N</i>3-Heteroaryl substituted triazoles and <i>N</i>5-heteroaryl substituted triazoles useful as axl inhibitors</span>. Int. Patent US 8,796,259 B2,<span class="NLM_x"> </span><span class="NLM_year">2014</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2014&author=P.+Ding&author=D.+Goff&author=J.+Zhang&author=R.+Singh&author=S.+Holland&author=J.+Yu&author=T.+J.+Heckrodt&author=J.+Litvak&title=N3-Heteroaryl+substituted+triazoles+and+N5-heteroaryl+substituted+triazoles+useful+as+axl+inhibitors"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit101&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dpatent%26sid%3Dliteratum%253Aachs%26aulast%3DDing%26aufirst%3DP.%26atitle%3DN3-Heteroaryl%2520substituted%2520triazoles%2520and%2520N5-heteroaryl%2520substituted%2520triazoles%2520useful%2520as%2520axl%2520inhibitors%26date%3D2014" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref102"><div class="reference"><strong class="refLabel"><a href="#ref102" class="rightTabRefNumLink">102</a></strong><div class="NLM_citation" id="rightTab-cit102"><span><span class="NLM_contrib-group">Robinson, D. R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wu, Y. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lin, S. F.</span><span> </span><span class="NLM_article-title">The protein tyrosine kinase family of the human genome</span> <span class="citation_source-journal">Oncogene</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2000</span><span class="NLM_x">, </span> <span class="NLM_volume">19</span><span class="NLM_x">, </span> <span class="NLM_fpage">5548</span><span class="NLM_x">–</span> <span class="NLM_lpage">5557</span><span class="refDoi"> DOI: 10.1038/sj.onc.1203957</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fsj.onc.1203957" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11114734" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref102/cit102&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2000&pages=5548-5557&author=D.+R.+Robinsonauthor=Y.+M.+Wuauthor=S.+F.+Lin&title=The+protein+tyrosine+kinase+family+of+the+human+genome&doi=10.1038%2Fsj.onc.1203957"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit102R"><div class="casContent"><span class="casTitleNuber">102</span><div class="casTitle"><span class="NLM_cas:atitle">The protein tyrosine kinase family of the human genome</span></div><div class="casAuthors">Robinson, Dan R.; Wu, Yi-Mi; Lin, Su-Fang</div><div class="citationInfo"><span class="NLM_cas:title">Oncogene</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">49</span>),
    <span class="NLM_cas:pages">5548-5557</span>CODEN:
                <span class="NLM_cas:coden">ONCNES</span>;
        ISSN:<span class="NLM_cas:issn">0950-9232</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">As the sequencing of the human genome is completed by the Human Genome Project, the anal. of this rich source of information will illuminate many areas in medicine and biol.  The protein tyrosine kinases are a large multigene family with particular relevance to many human diseases, including cancer.  A search of the human genome for tyrosine kinase coding elements identified several novel genes and enabled the creation of a nonredundant catalog of tyrosine kinase genes.  Ninety unique kinase genes can be identified in the human genome, along with five pseudogenes.  Of the 90 tyrosine kinases, 58 are receptor type, distributed into 20 subfamilies.  The 32 nonreceptor tyrosine kinases can be placed in 10 subfamilies.  Addnl., mouse orthologs can be identified for nearly all the human tyrosine kinases.  The completion of the human tyrosine kinase family tree provides a framework for further advances in biomedical science.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0KhPd82OXhLVg90H21EOLACvtfcHk0lhN8xN4pvpqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXosl2ntbs%253D&md5=007f1f4a2d4ada11c5c9ea77d586816d</span></div><a href="/servlet/linkout?suffix=cit102&amp;dbid=16384&amp;doi=10.1038%2Fsj.onc.1203957&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.onc.1203957%26sid%3Dliteratum%253Aachs%26aulast%3DRobinson%26aufirst%3DD.%2BR.%26aulast%3DWu%26aufirst%3DY.%2BM.%26aulast%3DLin%26aufirst%3DS.%2BF.%26atitle%3DThe%2520protein%2520tyrosine%2520kinase%2520family%2520of%2520the%2520human%2520genome%26jtitle%3DOncogene%26date%3D2000%26volume%3D19%26spage%3D5548%26epage%3D5557%26doi%3D10.1038%2Fsj.onc.1203957" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref103"><div class="reference"><strong class="refLabel"><a href="#ref103" class="rightTabRefNumLink">103</a></strong><div class="NLM_citation" id="rightTab-cit103"><span><span class="NLM_contrib-group">Suárez, R. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chevot, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cavagnino, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Saettel, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Radvanyi, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Piguel, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernard-Pierrot, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Stoven, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Legraverend, M.</span><span> </span><span class="NLM_article-title">Inhibitors of the TAM subfamily of tyrosine kinases: synthesis and biological evaluation</span> <span class="citation_source-journal">Eur. J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">61</span><span class="NLM_x">, </span> <span class="NLM_fpage">2</span><span class="NLM_x">–</span> <span class="NLM_lpage">25</span><span class="refDoi"> DOI: 10.1016/j.ejmech.2012.06.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ejmech.2012.06.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22749189" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref103/cit103&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXktFyit7k%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2013&pages=2-25&author=R.+M.+Su%C3%A1rezauthor=F.+Chevotauthor=A.+Cavagninoauthor=N.+Saettelauthor=F.+Radvanyiauthor=S.+Piguelauthor=I.+Bernard-Pierrotauthor=V.+Stovenauthor=M.+Legraverend&title=Inhibitors+of+the+TAM+subfamily+of+tyrosine+kinases%3A+synthesis+and+biological+evaluation&doi=10.1016%2Fj.ejmech.2012.06.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit103R"><div class="casContent"><span class="casTitleNuber">103</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibitors of the TAM subfamily of tyrosine kinases: Synthesis and biological evaluation</span></div><div class="casAuthors">Suarez, Rosa M.; Chevot, Franciane; Cavagnino, Andrea; Saettel, Nicolas; Radvanyi, Francois; Piguel, Sandrine; Bernard-Pierrot, Isabelle; Stoven, Veronique; Legraverend, Michel</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">2-25</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">The TAM subfamily of Receptor Tyrosine Kinases (RTKs) contains three human proteins of therapeutical interest, Axl, Mer, and Tyro3.  The authors' goal was to design a type II inhibitor specific for this family, i.e. able to interact with the allosteric pocket and with the hinge region of the kinase.  They report here the synthesis of several series of purine analogs of BMS-777607 (I).  The structural diversity of the designed inhibitors was expected to modify the interactions formed in the binding site and consequently to modulate their selectivity profiles.  The most potent inhibitor II exhibits Kds of 39, 42, 65 and 200 nM against Axl, Mer, Met and Tyro3 resp.  Anal. of the affinity of II for active and inactive forms of Abl1, an RTK protein that does not belong to the TAM subfamily, together with the binding modes of II predicted by docking studies, indicates that II displays some selectivity for the TAM family and may act as a type II inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrnvpVHBQMUl7Vg90H21EOLACvtfcHk0lhN8xN4pvpqdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXktFyit7k%253D&md5=1a0c1d34a4b95d425d7292befb502391</span></div><a href="/servlet/linkout?suffix=cit103&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2012.06.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2012.06.005%26sid%3Dliteratum%253Aachs%26aulast%3DSu%25C3%25A1rez%26aufirst%3DR.%2BM.%26aulast%3DChevot%26aufirst%3DF.%26aulast%3DCavagnino%26aufirst%3DA.%26aulast%3DSaettel%26aufirst%3DN.%26aulast%3DRadvanyi%26aufirst%3DF.%26aulast%3DPiguel%26aufirst%3DS.%26aulast%3DBernard-Pierrot%26aufirst%3DI.%26aulast%3DStoven%26aufirst%3DV.%26aulast%3DLegraverend%26aufirst%3DM.%26atitle%3DInhibitors%2520of%2520the%2520TAM%2520subfamily%2520of%2520tyrosine%2520kinases%253A%2520synthesis%2520and%2520biological%2520evaluation%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2013%26volume%3D61%26spage%3D2%26epage%3D25%26doi%3D10.1016%2Fj.ejmech.2012.06.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref104"><div class="reference"><strong class="refLabel"><a href="#ref104" class="rightTabRefNumLink">104</a></strong><div class="NLM_citation" id="rightTab-cit104"><span><span class="NLM_contrib-group">Cui, J. J.</span><span> </span><span class="NLM_article-title">Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress</span> <span class="citation_source-journal">J. Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">57</span><span class="NLM_x">, </span> <span class="NLM_fpage">4427</span><span class="NLM_x">–</span> <span class="NLM_lpage">4453</span><span class="refDoi"> DOI: 10.1021/jm401427c</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm401427c" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref104/cit104&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhvFWltbvE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=57&publication_year=2014&pages=4427-4453&author=J.+J.+Cui&title=Targeting+receptor+tyrosine+kinase+MET+in+cancer%3A+small+molecule+inhibitors+and+clinical+progress&doi=10.1021%2Fjm401427c"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit104R"><div class="casContent"><span class="casTitleNuber">104</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting Receptor Tyrosine Kinase MET in Cancer: Small Molecule Inhibitors and Clinical Progress</span></div><div class="casAuthors">Cui, J. Jean</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">57</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">4427-4453</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The HGF/MET signaling pathway is crit. in mediating a wide range of normal physiol. functions including embryol. development, wound healing, and tissue regeneration.  Aberrant activation of the pathway has frequently been found in human cancers via protein overexpression, mutation, gene amplification, and also paracrine or autocrine up-regulation.  In addn., the activation of HGF/MET signaling confers resistance to the effects of cancer treatments.  Therefore, inhibition of the HGF/MET signaling pathway has great potential for therapeutic intervention in cancer.  Currently, there are three approaches toward modulating HGF/MET signaling in human clin. studies of cancer: anti-HGF monoclonal antibodies, MET monoclonal antibodies, and small mol. MET inhibitors.  Preliminary clin. benefit from inhibition of HGF or MET has been reported.  This Perspective will provide an overview of the HGF/MET signaling pathway in cancer and then will review the development of small mol. MET inhibitors and their progress in clin. applications.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoARAsEnH4X5rVg90H21EOLACvtfcHk0lil6PUcItzO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhvFWltbvE&md5=534fd1c6fd8b83be41251d0d556903d1</span></div><a href="/servlet/linkout?suffix=cit104&amp;dbid=16384&amp;doi=10.1021%2Fjm401427c&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm401427c%26sid%3Dliteratum%253Aachs%26aulast%3DCui%26aufirst%3DJ.%2BJ.%26atitle%3DTargeting%2520receptor%2520tyrosine%2520kinase%2520MET%2520in%2520cancer%253A%2520small%2520molecule%2520inhibitors%2520and%2520clinical%2520progress%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2014%26volume%3D57%26spage%3D4427%26epage%3D4453%26doi%3D10.1021%2Fjm401427c" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref105"><div class="reference"><strong class="refLabel"><a href="#ref105" class="rightTabRefNumLink">105</a></strong><div class="NLM_citation" id="rightTab-cit105"><span><span class="NLM_contrib-group">Davis, M. I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hunt, J. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Herrgard, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ciceri, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wodicka, L. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pallares, G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hocker, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Treiber, D. K.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Zarrinkar, P. P.</span><span> </span><span class="NLM_article-title">Comprehensive analysis of kinase inhibitor selectivity</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2011</span><span class="NLM_x">, </span> <span class="NLM_volume">29</span><span class="NLM_x">, </span> <span class="NLM_fpage">1046</span><span class="NLM_x">–</span> <span class="NLM_lpage">1051</span><span class="refDoi"> DOI: 10.1038/nbt.1990</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt.1990" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22037378" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref105/cit105&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=29&publication_year=2011&pages=1046-1051&author=M.+I.+Davisauthor=J.+P.+Huntauthor=S.+Herrgardauthor=P.+Ciceriauthor=L.+M.+Wodickaauthor=G.+Pallaresauthor=M.+Hockerauthor=D.+K.+Treiberauthor=P.+P.+Zarrinkar&title=Comprehensive+analysis+of+kinase+inhibitor+selectivity&doi=10.1038%2Fnbt.1990"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit105R"><div class="casContent"><span class="casTitleNuber">105</span><div class="casTitle"><span class="NLM_cas:atitle">Comprehensive analysis of kinase inhibitor selectivity</span></div><div class="casAuthors">Davis, Mindy I.; Hunt, Jeremy P.; Herrgard, Sanna; Ciceri, Pietro; Wodicka, Lisa M.; Pallares, Gabriel; Hocker, Michael; Treiber, Daniel K.; Zarrinkar, Patrick P.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">29</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1046-1051</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">We tested the interaction of 72 kinase inhibitors with 442 kinases covering >80% of the human catalytic protein kinome.  Our data show that, as a class, type II inhibitors are more selective than type I inhibitors, but that there are important exceptions to this trend.  The data further illustrate that selective inhibitors have been developed against the majority of kinases targeted by the compds. tested.  Anal. of the interaction patterns reveals a class of 'group-selective' inhibitors broadly active against a single subfamily of kinases, but selective outside that subfamily.  The data set suggests compds. to use as tools to study kinases for which no dedicated inhibitors exist.  It also provides a foundation for further exploring kinase inhibitor biol. and toxicity, as well as for studying the structural basis of the obsd. interaction patterns.  Our findings will help to realize the direct enabling potential of genomics for drug development and basic research about cellular signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEZnKVs6Xt5rVg90H21EOLACvtfcHk0lil6PUcItzO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtlyisrrK&md5=67639f702cb48ffb2c60e9a250f0df5e</span></div><a href="/servlet/linkout?suffix=cit105&amp;dbid=16384&amp;doi=10.1038%2Fnbt.1990&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.1990%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DM.%2BI.%26aulast%3DHunt%26aufirst%3DJ.%2BP.%26aulast%3DHerrgard%26aufirst%3DS.%26aulast%3DCiceri%26aufirst%3DP.%26aulast%3DWodicka%26aufirst%3DL.%2BM.%26aulast%3DPallares%26aufirst%3DG.%26aulast%3DHocker%26aufirst%3DM.%26aulast%3DTreiber%26aufirst%3DD.%2BK.%26aulast%3DZarrinkar%26aufirst%3DP.%2BP.%26atitle%3DComprehensive%2520analysis%2520of%2520kinase%2520inhibitor%2520selectivity%26jtitle%3DNat.%2520Biotechnol.%26date%3D2011%26volume%3D29%26spage%3D1046%26epage%3D1051%26doi%3D10.1038%2Fnbt.1990" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref106"><div class="reference"><strong class="refLabel"><a href="#ref106" class="rightTabRefNumLink">106</a></strong><div class="NLM_citation" id="rightTab-cit106"><span><span class="NLM_contrib-group">Elisei, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schlumberger, M. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Müller, S. P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schöffski, P.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brose, M. S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Shah, M. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Licitra, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Jarzab, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Medvedev, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kreissl, M. C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Niederle, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cohen, E. E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wirth, L. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ali, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Hessel, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yaron, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ball, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Nelkin, B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sherman, S. I.</span><span> </span><span class="NLM_article-title">Cabozantinib in progressive medullary thyroid cancer</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">31</span><span class="NLM_x">, </span> <span class="NLM_fpage">3639</span><span class="NLM_x">–</span> <span class="NLM_lpage">3646</span><span class="refDoi"> DOI: 10.1200/JCO.2012.48.4659</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2012.48.4659" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24002501" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref106/cit106&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=31&publication_year=2013&pages=3639-3646&author=R.+Eliseiauthor=M.+J.+Schlumbergerauthor=S.+P.+M%C3%BCllerauthor=P.+Sch%C3%B6ffskiauthor=M.+S.+Broseauthor=M.+H.+Shahauthor=L.+Licitraauthor=B.+Jarzabauthor=V.+Medvedevauthor=M.+C.+Kreisslauthor=B.+Niederleauthor=E.+E.+Cohenauthor=L.+J.+Wirthauthor=H.+Aliauthor=C.+Hesselauthor=Y.+Yaronauthor=D.+Ballauthor=B.+Nelkinauthor=S.+I.+Sherman&title=Cabozantinib+in+progressive+medullary+thyroid+cancer&doi=10.1200%2FJCO.2012.48.4659"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit106R"><div class="casContent"><span class="casTitleNuber">106</span><div class="casTitle"><span class="NLM_cas:atitle">Cabozantinib in progressive medullary thyroid cancer</span></div><div class="casAuthors">Elisei, Rossella; Schlumberger, Martin J.; Mueller, Stefan P.; Schoffski, Patrick; Brose, Marcia S.; Shah, Manisha H.; Licitra, Lisa; Jarzab, Barbara; Medvedev, Viktor; Kreissl, Michael C.; Niederle, Bruno; Cohen, Ezra E. W.; Wirth, Lori J.; Ali, Haythem; Hessel, Colin; Yaron, Yifah; Ball, Douglas; Nelkin, Barry; Sherman, Steven I.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">31</span>
        (<span class="NLM_cas:issue">29</span>),
    <span class="NLM_cas:pages">3639-3646</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">Purpose: Cabozantinib, a tyrosine kinase inhibitor (TKI) of hepatocyte growth factor receptor (MET), vascular endothelial growth factor receptor 2, and rearranged during transfection (RET), demonstrated clin. activity in patients with medullary thyroid cancer (MTC) in phase I.  Patients and Methods: We conducted a double-blind, phase III trial comparing cabozantinib with placebo in 330 patients with documented radiog. progression of metastatic MTC.  Patients were randomly assigned (2:1) to cabozantinib (140 mg per day) or placebo.  The primary end point was progression-free survival (PFS).  Addnl. outcome measures included tumor response rate, overall survival, and safety.  Results: The estd. median PFS was 11.2 mo for cabozantinib vs. 4.0 mo for placebo (hazard ratio, 0.28; 95% CI, 0.19 to 0.40; P < .001).  Prolonged PFS with cabozantinib was obsd. across all subgroups including by age, prior TKI treatment, and RET mutation status (hereditary or sporadic).  Response rate was 28% for cabozantinib and 0% for placebo; responses were seen regardless of RET mutation status.  Kaplan-Meier ests. of patients alive and progression-free at 1 yr are 47.3% for cabozantinib and 7.2% for placebo.  Common cabozantinib-assocd. adverse events included diarrhea, palmar-plantar erythrodysesthesia, decreased wt. and appetite, nausea, and fatigue and resulted in dose redns. in 79% and holds in 65% of patients.  Adverse events led to treatment discontinuation in 16% of cabozantinib-treated patients and in 8% of placebo-treated patients.  Conclusion: Cabozantinib (140 mg per day) achieved a statistically significant improvement of PFS in patients with progressive metastatic MTC and represents an important new treatment option for patients with this rare disease.  This dose of cabozantinib was assocd. with significant but manageable toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoPCZeqoIzqYrVg90H21EOLACvtfcHk0lil6PUcItzO3g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsl2hsrbI&md5=83cd31614af02705f54ff533dbb64257</span></div><a href="/servlet/linkout?suffix=cit106&amp;dbid=16384&amp;doi=10.1200%2FJCO.2012.48.4659&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2012.48.4659%26sid%3Dliteratum%253Aachs%26aulast%3DElisei%26aufirst%3DR.%26aulast%3DSchlumberger%26aufirst%3DM.%2BJ.%26aulast%3DM%25C3%25BCller%26aufirst%3DS.%2BP.%26aulast%3DSch%25C3%25B6ffski%26aufirst%3DP.%26aulast%3DBrose%26aufirst%3DM.%2BS.%26aulast%3DShah%26aufirst%3DM.%2BH.%26aulast%3DLicitra%26aufirst%3DL.%26aulast%3DJarzab%26aufirst%3DB.%26aulast%3DMedvedev%26aufirst%3DV.%26aulast%3DKreissl%26aufirst%3DM.%2BC.%26aulast%3DNiederle%26aufirst%3DB.%26aulast%3DCohen%26aufirst%3DE.%2BE.%26aulast%3DWirth%26aufirst%3DL.%2BJ.%26aulast%3DAli%26aufirst%3DH.%26aulast%3DHessel%26aufirst%3DC.%26aulast%3DYaron%26aufirst%3DY.%26aulast%3DBall%26aufirst%3DD.%26aulast%3DNelkin%26aufirst%3DB.%26aulast%3DSherman%26aufirst%3DS.%2BI.%26atitle%3DCabozantinib%2520in%2520progressive%2520medullary%2520thyroid%2520cancer%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2013%26volume%3D31%26spage%3D3639%26epage%3D3646%26doi%3D10.1200%2FJCO.2012.48.4659" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref107"><div class="reference"><strong class="refLabel"><a href="#ref107" class="rightTabRefNumLink">107</a></strong><div class="NLM_citation" id="rightTab-cit107"><span><span class="NLM_contrib-group">De Smet, F.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Christopoulos, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Carmeliet, P.</span><span> </span><span class="NLM_article-title">Allosteric targeting of receptor tyrosine kinases</span> <span class="citation_source-journal">Nat. Biotechnol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2014</span><span class="NLM_x">, </span> <span class="NLM_volume">32</span><span class="NLM_x">, </span> <span class="NLM_fpage">1113</span><span class="NLM_x">–</span> <span class="NLM_lpage">1120</span><span class="refDoi"> DOI: 10.1038/nbt.3028</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnbt.3028" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25380447" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref107/cit107&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhs1Shu7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=32&publication_year=2014&pages=1113-1120&author=F.+De+Smetauthor=A.+Christopoulosauthor=P.+Carmeliet&title=Allosteric+targeting+of+receptor+tyrosine+kinases&doi=10.1038%2Fnbt.3028"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit107R"><div class="casContent"><span class="casTitleNuber">107</span><div class="casTitle"><span class="NLM_cas:atitle">Allosteric targeting of receptor tyrosine kinases</span></div><div class="casAuthors">De Smet, Frederik; Christopoulos, Arthur; Carmeliet, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Nature Biotechnology</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">32</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1113-1120</span>CODEN:
                <span class="NLM_cas:coden">NABIF9</span>;
        ISSN:<span class="NLM_cas:issn">1087-0156</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The drug discovery landscape has been transformed over the past decade by the discovery of allosteric modulators of all major mammalian receptor superfamilies.  Allosteric ligands are a rich potential source of drugs and drug targets with clear therapeutic advantages.  G protein-coupled receptors, ligand-gated ion channels and intracellular nuclear hormone receptors have all been targeted by allosteric modulators.  More recently, a receptor tyrosine kinase (RTK) has been targeted by an extracellular small-mol. allosteric modulator.  Allosteric mechanisms of structurally distinct mols. that target the various receptor families are more alike than originally anticipated and include selectivity, orthosteric probe dependence and pathway-biased signaling.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqhUEiFrNdlxrVg90H21EOLACvtfcHk0lh0Apl6egUYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhs1Shu7c%253D&md5=5dd8e5bf1d6578a418dce00686cd2334</span></div><a href="/servlet/linkout?suffix=cit107&amp;dbid=16384&amp;doi=10.1038%2Fnbt.3028&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnbt.3028%26sid%3Dliteratum%253Aachs%26aulast%3DDe%2BSmet%26aufirst%3DF.%26aulast%3DChristopoulos%26aufirst%3DA.%26aulast%3DCarmeliet%26aufirst%3DP.%26atitle%3DAllosteric%2520targeting%2520of%2520receptor%2520tyrosine%2520kinases%26jtitle%3DNat.%2520Biotechnol.%26date%3D2014%26volume%3D32%26spage%3D1113%26epage%3D1120%26doi%3D10.1038%2Fnbt.3028" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref108"><div class="reference"><strong class="refLabel"><a href="#ref108" class="rightTabRefNumLink">108</a></strong><div class="NLM_citation" id="rightTab-cit108"><span><span class="NLM_contrib-group">Carmi, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Mor, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Petronini, P. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Alfieri, R. R.</span><span> </span><span class="NLM_article-title">Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer</span> <span class="citation_source-journal">Biochem. Pharmacol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">84</span><span class="NLM_x">, </span> <span class="NLM_fpage">1388</span><span class="NLM_x">–</span> <span class="NLM_lpage">1399</span><span class="refDoi"> DOI: 10.1016/j.bcp.2012.07.031</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref108/cit108&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.bcp.2012.07.031" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=84&publication_year=2012&pages=1388-1399&author=C.+Carmiauthor=M.+Morauthor=P.+G.+Petroniniauthor=R.+R.+Alfieri&title=Clinical+perspectives+for+irreversible+tyrosine+kinase+inhibitors+in+cancer&doi=10.1016%2Fj.bcp.2012.07.031"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit108&amp;dbid=16384&amp;doi=10.1016%2Fj.bcp.2012.07.031&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bcp.2012.07.031%26sid%3Dliteratum%253Aachs%26aulast%3DCarmi%26aufirst%3DC.%26aulast%3DMor%26aufirst%3DM.%26aulast%3DPetronini%26aufirst%3DP.%2BG.%26aulast%3DAlfieri%26aufirst%3DR.%2BR.%26atitle%3DClinical%2520perspectives%2520for%2520irreversible%2520tyrosine%2520kinase%2520inhibitors%2520in%2520cancer%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2012%26volume%3D84%26spage%3D1388%26epage%3D1399%26doi%3D10.1016%2Fj.bcp.2012.07.031" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref109"><div class="reference"><strong class="refLabel"><a href="#ref109" class="rightTabRefNumLink">109</a></strong><div class="NLM_citation" id="rightTab-cit109"><span><span class="NLM_contrib-group">Lu, Q. X.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Lemke, G.</span><span> </span><span class="NLM_article-title">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span> <span class="citation_source-journal">Science</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2001</span><span class="NLM_x">, </span> <span class="NLM_volume">293</span><span class="NLM_x">, </span> <span class="NLM_fpage">306</span><span class="NLM_x">–</span> <span class="NLM_lpage">311</span><span class="refDoi"> DOI: 10.1126/science.1061663</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1126%2Fscience.1061663" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=11452127" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref109/cit109&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=293&publication_year=2001&pages=306-311&author=Q.+X.+Luauthor=G.+Lemke&title=Homeostatic+regulation+of+the+immune+system+by+receptor+tyrosine+kinases+of+the+Tyro+3+family&doi=10.1126%2Fscience.1061663"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit109R"><div class="casContent"><span class="casTitleNuber">109</span><div class="casTitle"><span class="NLM_cas:atitle">Homeostatic regulation of the immune system by receptor tyrosine kinases of the Tyro 3 family</span></div><div class="casAuthors">Lu, Qingxian; Lemke, Greg</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">293</span>
        (<span class="NLM_cas:issue">5528</span>),
    <span class="NLM_cas:pages">306-311</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">Receptor tyrosine kinases and their ligands mediate cell-cell communication and interaction in many organ systems, but have not been known to act in this capacity in the mature immune system.  The authors now provide genetic evidence that three closely related receptor tyrosine kinases, Tyro 3, Axl, and Mer, play an essential immunoregulatory role.  Mutant mice that lack these receptors develop a severe lymphoproliferative disorder accompanied by broad-spectrum autoimmunity.  These phenotypes are cell non-autonomous with respect to lymphocytes and result from the hyperactivation of antigen-presenting cells in which the three receptors are normally expressed.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrp8p8YELw6TLVg90H21EOLACvtfcHk0lh0Apl6egUYRA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXlt1ymsbY%253D&md5=7b6a3d91485e82fdb47f715331b1f310</span></div><a href="/servlet/linkout?suffix=cit109&amp;dbid=16384&amp;doi=10.1126%2Fscience.1061663&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1061663%26sid%3Dliteratum%253Aachs%26aulast%3DLu%26aufirst%3DQ.%2BX.%26aulast%3DLemke%26aufirst%3DG.%26atitle%3DHomeostatic%2520regulation%2520of%2520the%2520immune%2520system%2520by%2520receptor%2520tyrosine%2520kinases%2520of%2520the%2520Tyro%25203%2520family%26jtitle%3DScience%26date%3D2001%26volume%3D293%26spage%3D306%26epage%3D311%26doi%3D10.1126%2Fscience.1061663" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref110"><div class="reference"><strong class="refLabel"><a href="#ref110" class="rightTabRefNumLink">110</a></strong><div class="NLM_citation" id="rightTab-cit110"><span><span class="NLM_contrib-group">Bosurgi, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bernink, J. H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Delgado Cuevas, V.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gagliani, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Joannas, L.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schmid, E. T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Booth, C. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghosh, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rothlin, C. V.</span><span> </span><span class="NLM_article-title">Paradoxical role of the proto-oncogene Axl and Mer receptor tyrosine kinases in colon cancer</span> <span class="citation_source-journal">Proc. Natl. Acad. Sci. U. S. A.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">110</span><span class="NLM_x">, </span> <span class="NLM_fpage">13091</span><span class="NLM_x">–</span> <span class="NLM_lpage">13096</span><span class="refDoi"> DOI: 10.1073/pnas.1302507110</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref110/cit110&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1073%2Fpnas.1302507110" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2013&pages=13091-13096&author=L.+Bosurgiauthor=J.+H.+Berninkauthor=V.+Delgado+Cuevasauthor=N.+Gaglianiauthor=L.+Joannasauthor=E.+T.+Schmidauthor=C.+J.+Boothauthor=S.+Ghoshauthor=C.+V.+Rothlin&title=Paradoxical+role+of+the+proto-oncogene+Axl+and+Mer+receptor+tyrosine+kinases+in+colon+cancer&doi=10.1073%2Fpnas.1302507110"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit110&amp;dbid=16384&amp;doi=10.1073%2Fpnas.1302507110&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.1302507110%26sid%3Dliteratum%253Aachs%26aulast%3DBosurgi%26aufirst%3DL.%26aulast%3DBernink%26aufirst%3DJ.%2BH.%26aulast%3DDelgado%2BCuevas%26aufirst%3DV.%26aulast%3DGagliani%26aufirst%3DN.%26aulast%3DJoannas%26aufirst%3DL.%26aulast%3DSchmid%26aufirst%3DE.%2BT.%26aulast%3DBooth%26aufirst%3DC.%2BJ.%26aulast%3DGhosh%26aufirst%3DS.%26aulast%3DRothlin%26aufirst%3DC.%2BV.%26atitle%3DParadoxical%2520role%2520of%2520the%2520proto-oncogene%2520Axl%2520and%2520Mer%2520receptor%2520tyrosine%2520kinases%2520in%2520colon%2520cancer%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D2013%26volume%3D110%26spage%3D13091%26epage%3D13096%26doi%3D10.1073%2Fpnas.1302507110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref111"><div class="reference"><strong class="refLabel"><a href="#ref111" class="rightTabRefNumLink">111</a></strong><div class="NLM_citation" id="rightTab-cit111"><span><span class="NLM_contrib-group">Schmidt, T.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ben-Batalla, I.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Schultze, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Loges, S.</span><span> </span><span class="NLM_article-title">Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands</span> <span class="citation_source-journal">Cell. Mol. Life Sci.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">69</span><span class="NLM_x">, </span> <span class="NLM_fpage">1391</span><span class="NLM_x">–</span> <span class="NLM_lpage">1414</span><span class="refDoi"> DOI: 10.1007/s00018-011-0863-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1007%2Fs00018-011-0863-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22076650" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref111/cit111&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC38XlvFSntLc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=69&publication_year=2012&pages=1391-1414&author=T.+Schmidtauthor=I.+Ben-Batallaauthor=A.+Schultzeauthor=S.+Loges&title=Macrophage-tumor+crosstalk%3A+role+of+TAMR+tyrosine+kinase+receptors+and+of+their+ligands&doi=10.1007%2Fs00018-011-0863-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit111R"><div class="casContent"><span class="casTitleNuber">111</span><div class="casTitle"><span class="NLM_cas:atitle">Macrophage-tumor crosstalk: role of TAMR tyrosine kinase receptors and of their ligands</span></div><div class="casAuthors">Schmidt, Thomas; Ben-Batalla, Isabel; Schultze, Alexander; Loges, Sonja</div><div class="citationInfo"><span class="NLM_cas:title">Cellular and Molecular Life Sciences</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">69</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1391-1414</span>CODEN:
                <span class="NLM_cas:coden">CMLSFI</span>;
        ISSN:<span class="NLM_cas:issn">1420-682X</span>.
    
            (<span class="NLM_cas:orgname">Birkhaeuser Basel</span>)
        </div><div class="casAbstract">A review.  Ample clin. and preclin. evidence indicates that macrophages interact with tumor cells as well as with virtually all populations of host cells present in the tumor microenvironment.  This crosstalk can strongly promote malignancy, but also has in principle the potential to inhibit tumor growth.  Thus, it is of the utmost importance to improve our understanding of the mechanisms driving the pro- and antimalignant behavior of tumor-assocd. macrophages (TAMs) in order to develop better anticancer therapies.  In this review, we discuss the biol. consequences of reciprocal interactions between TAMs, cancer cells, endothelial cells, fibroblasts and other leukocyte subfractions within tumors.  It was recently elucidated that tumors specifically educate macrophages to secrete growth arrest-specific gene 6 (Gas6), the common ligand of the Tyro3, Axl, Mer receptor (TAMR) family.  In turn, Gas6 fosters tumor growth by promoting cancer cell proliferation.  Therefore, the Gas6-TAMR axis might represent a novel target for disrupting tumor-macrophage crosstalk.  We summarize here what is known about TAMR and their ligands in (human) cancer biol.  In order to shed more light on the role of macrophages in human cancer, we addnl. provide an overview of what is currently known about the prognostic impact of TAMs in human cancer.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqAp7eaxnYn_LVg90H21EOLACvtfcHk0lj3XeXBoKYYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XlvFSntLc%253D&md5=d6bcdd32f1c134285bdd70b07d4384b7</span></div><a href="/servlet/linkout?suffix=cit111&amp;dbid=16384&amp;doi=10.1007%2Fs00018-011-0863-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1007%252Fs00018-011-0863-7%26sid%3Dliteratum%253Aachs%26aulast%3DSchmidt%26aufirst%3DT.%26aulast%3DBen-Batalla%26aufirst%3DI.%26aulast%3DSchultze%26aufirst%3DA.%26aulast%3DLoges%26aufirst%3DS.%26atitle%3DMacrophage-tumor%2520crosstalk%253A%2520role%2520of%2520TAMR%2520tyrosine%2520kinase%2520receptors%2520and%2520of%2520their%2520ligands%26jtitle%3DCell.%2520Mol.%2520Life%2520Sci.%26date%3D2012%26volume%3D69%26spage%3D1391%26epage%3D1414%26doi%3D10.1007%2Fs00018-011-0863-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref112"><div class="reference"><strong class="refLabel"><a href="#ref112" class="rightTabRefNumLink">112</a></strong><div class="NLM_citation" id="rightTab-cit112"><span><span class="NLM_contrib-group">McDermott, U.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Settleman, J.</span><span> </span><span class="NLM_article-title">Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology</span> <span class="citation_source-journal">J. Clin. Oncol.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2009</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">5650</span><span class="NLM_x">–</span> <span class="NLM_lpage">5659</span><span class="refDoi"> DOI: 10.1200/JCO.2009.22.9054</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1200%2FJCO.2009.22.9054" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=19858389" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref112/cit112&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3cXhtVWit7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2009&pages=5650-5659&author=U.+McDermottauthor=J.+Settleman&title=Personalized+cancer+therapy+with+selective+kinase+inhibitors%3A+an+emerging+paradigm+in+medical+oncology&doi=10.1200%2FJCO.2009.22.9054"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit112R"><div class="casContent"><span class="casTitleNuber">112</span><div class="casTitle"><span class="NLM_cas:atitle">Personalized cancer therapy with selective kinase inhibitors: an emerging paradigm in medical oncology</span></div><div class="casAuthors">McDermott, Ultan; Settleman, Jeff</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Clinical Oncology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">5650-5659</span>CODEN:
                <span class="NLM_cas:coden">JCONDN</span>;
        ISSN:<span class="NLM_cas:issn">0732-183X</span>.
    
            (<span class="NLM_cas:orgname">American Society of Clinical Oncology</span>)
        </div><div class="casAbstract">A review.  Selective kinase inhibitors have emerged as an important class of anticancer agents, with demonstrated clin. efficacy and generally favorable toxicity profiles in several common disease settings where conventional treatments have previously provided only modest benefit.  Consequently, a substantial effort is now underway to identify addnl. therapeutically relevant kinase targets and to develop and test inhibitors of those proteins in a variety of human malignancies.  However, it has also become clear that the clin. benefit assocd. with these agents is typically limited to a subset of treated patients, who in many cases are defined by a specific genomic lesion within their tumor cells-frequently, an activating mutation within the gene encoding the target kinase.  This discovery has prompted efforts to stratify patients before treatment with kinase inhibitors based on specific genomic biomarkers, with the goal of optimizing clin. outcomes through the effective personalization of treatment (ie, matching the right patients with the right therapies).  With recent advances in our understanding of the relationship between tumor genotypes and cancer cell sensitivity to kinase inhibition, together with improved technologies for rapidly genotyping tumor biopsies for relevant lesions, the implementation of personalized cancer care with this exciting new class of inhibitors is now becoming a reality.  In this review, we summarize recent developments in this area, and we highlight some of the logistical challenges posed by this emerging paradigm in medical oncol.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq6rJzyK-uQbVg90H21EOLACvtfcHk0lj3XeXBoKYYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3cXhtVWit7c%253D&md5=d39ebdc45f21d3183dc26f5a2cf09be1</span></div><a href="/servlet/linkout?suffix=cit112&amp;dbid=16384&amp;doi=10.1200%2FJCO.2009.22.9054&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1200%252FJCO.2009.22.9054%26sid%3Dliteratum%253Aachs%26aulast%3DMcDermott%26aufirst%3DU.%26aulast%3DSettleman%26aufirst%3DJ.%26atitle%3DPersonalized%2520cancer%2520therapy%2520with%2520selective%2520kinase%2520inhibitors%253A%2520an%2520emerging%2520paradigm%2520in%2520medical%2520oncology%26jtitle%3DJ.%2520Clin.%2520Oncol.%26date%3D2009%26volume%3D27%26spage%3D5650%26epage%3D5659%26doi%3D10.1200%2FJCO.2009.22.9054" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref113"><div class="reference"><strong class="refLabel"><a href="#ref113" class="rightTabRefNumLink">113</a></strong><div class="NLM_citation" id="rightTab-cit113"><span><span class="NLM_contrib-group">Carragher, N. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Unciti-Broceta, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Cameron, D. A.</span><span> </span><span class="NLM_article-title">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span> <span class="citation_source-journal">Future Med. Chem.</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2012</span><span class="NLM_x">, </span> <span class="NLM_volume">4</span><span class="NLM_x">, </span> <span class="NLM_fpage">87</span><span class="NLM_x">–</span> <span class="NLM_lpage">105</span><span class="refDoi"> DOI: 10.4155/fmc.11.169</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.4155%2Ffmc.11.169" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=22168166" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref113/cit113&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2012&pages=87-105&author=N.+O.+Carragherauthor=A.+Unciti-Brocetaauthor=D.+A.+Cameron&title=Advancing+cancer+drug+discovery+towards+more+agile+development+of+targeted+combination+therapies&doi=10.4155%2Ffmc.11.169"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit113R"><div class="casContent"><span class="casTitleNuber">113</span><div class="casTitle"><span class="NLM_cas:atitle">Advancing cancer drug discovery towards more agile development of targeted combination therapies</span></div><div class="casAuthors">Carragher, Neil O.; Unciti-Broceta, Asier; Cameron, David A.</div><div class="citationInfo"><span class="NLM_cas:title">Future Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">87-105</span>CODEN:
                <span class="NLM_cas:coden">FMCUA7</span>;
        ISSN:<span class="NLM_cas:issn">1756-8919</span>.
    
            (<span class="NLM_cas:orgname">Future Science Ltd.</span>)
        </div><div class="casAbstract">A review.  Current drug-discovery strategies are typically target-centric'' and are based upon high-throughput screening of large chem. libraries against nominated targets and a selection of lead compds. with optimized on-target'' potency and selectivity profiles.  However, high attrition of targeted agents in clin. development suggest that combinations of targeted agents will be most effective in treating solid tumors if the biol. networks that permit cancer cells to subvert monotherapies are identified and retargeted.  Conventional drug-discovery and development strategies are suboptimal for the rational design and development of novel drug combinations.  In this article, we highlight a series of emerging technologies supporting a less reductionist, more agile, drug-discovery and development approach for the rational design, validation, prioritization and clin. development of novel drug combinations.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpKkliYmA82GLVg90H21EOLACvtfcHk0lj3XeXBoKYYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhs1ahtb%252FL&md5=d66f8996ad13dd84ce3667d527bc5516</span></div><a href="/servlet/linkout?suffix=cit113&amp;dbid=16384&amp;doi=10.4155%2Ffmc.11.169&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4155%252Ffmc.11.169%26sid%3Dliteratum%253Aachs%26aulast%3DCarragher%26aufirst%3DN.%2BO.%26aulast%3DUnciti-Broceta%26aufirst%3DA.%26aulast%3DCameron%26aufirst%3DD.%2BA.%26atitle%3DAdvancing%2520cancer%2520drug%2520discovery%2520towards%2520more%2520agile%2520development%2520of%2520targeted%2520combination%2520therapies%26jtitle%3DFuture%2520Med.%2520Chem.%26date%3D2012%26volume%3D4%26spage%3D87%26epage%3D105%26doi%3D10.4155%2Ffmc.11.169" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref114"><div class="reference"><strong class="refLabel"><a href="#ref114" class="rightTabRefNumLink">114</a></strong><div class="NLM_citation" id="rightTab-cit114"><span><span class="NLM_contrib-group">Holohan, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Van Schaeybroeck, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Longley, D. B.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Johnston, P. G.</span><span> </span><span class="NLM_article-title">Cancer drug resistance: an evolving paradigm</span> <span class="citation_source-journal">Nat. Rev. Cancer</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2013</span><span class="NLM_x">, </span> <span class="NLM_volume">13</span><span class="NLM_x">, </span> <span class="NLM_fpage">714</span><span class="NLM_x">–</span> <span class="NLM_lpage">726</span><span class="refDoi"> DOI: 10.1038/nrc3599</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1038%2Fnrc3599" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=24060863" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref114/cit114&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2013&pages=714-726&author=C.+Holohanauthor=S.+Van+Schaeybroeckauthor=D.+B.+Longleyauthor=P.+G.+Johnston&title=Cancer+drug+resistance%3A+an+evolving+paradigm&doi=10.1038%2Fnrc3599"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit114R"><div class="casContent"><span class="casTitleNuber">114</span><div class="casTitle"><span class="NLM_cas:atitle">Cancer drug resistance: an evolving paradigm</span></div><div class="casAuthors">Holohan, Caitriona; Van Schaeybroeck, Sandra; Longley, Daniel B.; Johnston, Patrick G.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Cancer</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">714-726</span>CODEN:
                <span class="NLM_cas:coden">NRCAC4</span>;
        ISSN:<span class="NLM_cas:issn">1474-175X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Resistance to chemotherapy and molecularly targeted therapies is a major problem facing current cancer research.  The mechanisms of resistance to 'classical' cytotoxic chemotherapeutics and to therapies that are designed to be selective for specific mol. targets share many features, such as alterations in the drug target, activation of prosurvival pathways and ineffective induction of cell death.  With the increasing arsenal of anticancer agents, improving preclin. models and the advent of powerful high-throughput screening techniques, there are now unprecedented opportunities to understand and overcome drug resistance through the clin. assessment of rational therapeutic drug combinations and the use of predictive biomarkers to enable patient stratification.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqrykBEUSgvv7Vg90H21EOLACvtfcHk0lj3XeXBoKYYww"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhsVyqurnE&md5=b497a823bbd968904ce1591b918d0679</span></div><a href="/servlet/linkout?suffix=cit114&amp;dbid=16384&amp;doi=10.1038%2Fnrc3599&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrc3599%26sid%3Dliteratum%253Aachs%26aulast%3DHolohan%26aufirst%3DC.%26aulast%3DVan%2BSchaeybroeck%26aufirst%3DS.%26aulast%3DLongley%26aufirst%3DD.%2BB.%26aulast%3DJohnston%26aufirst%3DP.%2BG.%26atitle%3DCancer%2520drug%2520resistance%253A%2520an%2520evolving%2520paradigm%26jtitle%3DNat.%2520Rev.%2520Cancer%26date%3D2013%26volume%3D13%26spage%3D714%26epage%3D726%26doi%3D10.1038%2Fnrc3599" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref115"><div class="reference"><strong class="refLabel"><a href="#ref115" class="rightTabRefNumLink">115</a></strong><div class="NLM_citation" id="rightTab-cit115"><span><span class="NLM_contrib-group">Elkabets, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pazarentzos, E.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Juric, D.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Sheng, Q.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Pelossof, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Brook, S.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Benzaken, A. O.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rodon, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Morse, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Yan, J. J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liu, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Das, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Chen, Y.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Tam, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Wang, H.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Liang, J.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Gurski, J. M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Kerr, D. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosell, R.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Teixidó, C.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Huang, A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Ghossein, R. A.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Rosen, N.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Bivona, T. G.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Scaltriti, M.</span><span class="NLM_x">; </span><span class="NLM_contrib-group">Baselga, J.</span><span> </span><span class="NLM_article-title">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span> <span class="citation_source-journal">Cancer Cell</span><span class="NLM_x"> </span><span class="NLM_year" style="font-weight: bold;">2015</span><span class="NLM_x">, </span> <span class="NLM_volume">27</span><span class="NLM_x">, </span> <span class="NLM_fpage">533</span><span class="NLM_x">–</span> <span class="NLM_lpage">546</span><span class="refDoi"> DOI: 10.1016/j.ccell.2015.03.010</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=10.1016%2Fj.ccell.2015.03.010" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=25873175" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref115/cit115&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;key=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2015&pages=533-546&author=M.+Elkabetsauthor=E.+Pazarentzosauthor=D.+Juricauthor=Q.+Shengauthor=R.+A.+Pelossofauthor=S.+Brookauthor=A.+O.+Benzakenauthor=J.+Rodonauthor=N.+Morseauthor=J.+J.+Yanauthor=M.+Liuauthor=R.+Dasauthor=Y.+Chenauthor=A.+Tamauthor=H.+Wangauthor=J.+Liangauthor=J.+M.+Gurskiauthor=D.+A.+Kerrauthor=R.+Rosellauthor=C.+Teixid%C3%B3author=A.+Huangauthor=R.+A.+Ghosseinauthor=N.+Rosenauthor=T.+G.+Bivonaauthor=M.+Scaltritiauthor=J.+Baselga&title=AXL+mediates+resistance+to+PI3K%CE%B1+inhibition+by+activating+the+EGFR%2FPKC%2FmTOR+axis+in+head+and+neck+and+esophageal+squamous+cell+carcinomas&doi=10.1016%2Fj.ccell.2015.03.010"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit115R"><div class="casContent"><span class="casTitleNuber">115</span><div class="casTitle"><span class="NLM_cas:atitle">AXL mediates resistance to PI3Kα inhibition by activating the EGFR/PKC/mTOR axis in head and neck and esophageal squamous cell carcinomas</span></div><div class="casAuthors">Elkabets, Moshe; Pazarentzos, Evangelos; Juric, Dejan; Sheng, Qing; Pelossof, Raphael A.; Brook, Samuel; Benzaken, Ana Oaknin; Rodon, Jordi; Morse, Natasha; Yan, Jenny Jiacheng; Liu, Manway; Das, Rita; Chen, Yan; Tam, Angela; Wang, Huiqin; Liang, Jinsheng; Gurski, Joseph M.; Kerr, Darcy A.; Rosell, Rafael; Teixido, Cristina; Huang, Alan; Ghossein, Ronald A.; Rosen, Neal; Bivona, Trever G.; Scaltriti, Maurizio; Baselga, Jose</div><div class="citationInfo"><span class="NLM_cas:title">Cancer Cell</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">533-546</span>CODEN:
                <span class="NLM_cas:coden">CCAECI</span>;
        ISSN:<span class="NLM_cas:issn">1535-6108</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Inc.</span>)
        </div><div class="casAbstract">Phosphoinositide-3-kinase (PI3K)-α inhibitors have shown clin. activity in squamous cell carcinomas (SCCs) of head and neck (H&N) bearing PIK3CA mutations or amplification.  Studying models of therapeutic resistance, we have obsd. that SCC cells that become refractory to PI3Kα inhibition maintain PI3K-independent activation of the mammalian target of rapamycin (mTOR).  This persistent mTOR activation is mediated by the tyrosine kinase receptor AXL.  AXL is overexpressed in resistant tumors from both lab. models and patients treated with the PI3Kα inhibitor BYL719.  AXL dimerizes with and phosphorylates epidermal growth factor receptor (EGFR), resulting in activation of phospholipase Cγ (PLCγ)-protein kinase C (PKC), which, in turn, activates mTOR.  Combined treatment with PI3Kα and either EGFR, AXL, or PKC inhibitors reverts this resistance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoLkH5_tNi2YrVg90H21EOLACvtfcHk0lig9Cb0fTVVaw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXmsFegt7Y%253D&md5=55b0362b0e32f0c305c5257aa66ecdc5</span></div><a href="/servlet/linkout?suffix=cit115&amp;dbid=16384&amp;doi=10.1016%2Fj.ccell.2015.03.010&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ccell.2015.03.010%26sid%3Dliteratum%253Aachs%26aulast%3DElkabets%26aufirst%3DM.%26aulast%3DPazarentzos%26aufirst%3DE.%26aulast%3DJuric%26aufirst%3DD.%26aulast%3DSheng%26aufirst%3DQ.%26aulast%3DPelossof%26aufirst%3DR.%2BA.%26aulast%3DBrook%26aufirst%3DS.%26aulast%3DBenzaken%26aufirst%3DA.%2BO.%26aulast%3DRodon%26aufirst%3DJ.%26aulast%3DMorse%26aufirst%3DN.%26aulast%3DYan%26aufirst%3DJ.%2BJ.%26aulast%3DLiu%26aufirst%3DM.%26aulast%3DDas%26aufirst%3DR.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DTam%26aufirst%3DA.%26aulast%3DWang%26aufirst%3DH.%26aulast%3DLiang%26aufirst%3DJ.%26aulast%3DGurski%26aufirst%3DJ.%2BM.%26aulast%3DKerr%26aufirst%3DD.%2BA.%26aulast%3DRosell%26aufirst%3DR.%26aulast%3DTeixid%25C3%25B3%26aufirst%3DC.%26aulast%3DHuang%26aufirst%3DA.%26aulast%3DGhossein%26aufirst%3DR.%2BA.%26aulast%3DRosen%26aufirst%3DN.%26aulast%3DBivona%26aufirst%3DT.%2BG.%26aulast%3DScaltriti%26aufirst%3DM.%26aulast%3DBaselga%26aufirst%3DJ.%26atitle%3DAXL%2520mediates%2520resistance%2520to%2520PI3K%25CE%25B1%2520inhibition%2520by%2520activating%2520the%2520EGFR%252FPKC%252FmTOR%2520axis%2520in%2520head%2520and%2520neck%2520and%2520esophageal%2520squamous%2520cell%2520carcinomas%26jtitle%3DCancer%2520Cell%26date%3D2015%26volume%3D27%26spage%3D533%26epage%3D546%26doi%3D10.1016%2Fj.ccell.2015.03.010" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.5b01273&amp;pbContext=%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.5b01273%3Bwgroup%3Astring%3AACHS+website+Group%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2016.59.issue-8%3Bwebsite%3Awebsite%3Aacspubs%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.5b01273" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                4MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"677abb64cf6e2388","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
